[
  {
    "id": "40580757",
    "title_en": "The effect of graphene oxide-polyethylene glycol on lung cell and treatment of sulforaphane.",
    "pub_date": "2026 Jan",
    "journal": "Talanta",
    "abstract_en": "This study explores the cytotoxic and biochemical effects of PEGylated graphene oxide (GO-PEG) nanoparticles, sulforaphane, and Raphanus sativus L. (black radish) juice on BEAS-2B human bronchial epithelial cells. Sulforaphane was extracted from radish juice through pH-adjusted aqueous treatment followed by organic solvent extraction, and quantified via high-performance liquid chromatography (HPLC) at 202Â nm, with a retention time of 11.0Â min. GO-PEG nanoparticles produced from graphites (50Â nm and 400Â nm) were tested at concentrations ranging from 50-225 Î¼gÂ mL<sup>-1</sup> and 100-1000 Î¼gÂ mL<sup>-1</sup> to have IC<sub>50</sub> values, respectively. Sulforaphane and black radish juice were also administered. The MTT assay revealed IC<sub>50</sub> values of 8.7Â Î¼gÂ mL<sup>-1</sup> for sulforaphane, 197.0 mgÂ mL<sup>-1</sup> for black radish juice, 175.8Â Î¼gÂ mL<sup>-1</sup> for GO-PEG (50Â nm), and 650.6Â Î¼gÂ mL<sup>-1</sup> for GO-PEG (400Â nm). Biochemical analyses showed that sulforaphane and radish juice decreased IL-6 levels and increased antioxidant enzyme activities (GSH-Px and CAT). These results highlight the therapeutic potential of GO-PEG, sulforaphane, and black radish juice for anti-inflammatory and antioxidant applications.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„é ˜åŸŸã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›å¤©ç„¶æˆåˆ†å¦‚è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½å°å‘¼å¸é“å¥åº·æœ‰æ­£é¢å½±éŸ¿ï¼Œé€™å°æ–¼é é˜²èˆ‡ç™¼ç‚ç›¸é—œçš„ç–¾ç—…ä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚é€™äº›æˆåˆ†çš„æŠ—æ°§åŒ–ç‰¹æ€§å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘ç´°èƒæå‚·ï¼Œé€²è€Œæ”¹å–„æ•´é«”å¥åº·ç‹€æ³ï¼Œç‰¹åˆ¥æ˜¯å°æ–¼å‘¼å¸ç³»çµ±çš„ä¿è­·ä½œç”¨ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨PEGåŒ–çŸ³å¢¨çƒ¯æ°§åŒ–ç‰©ï¼ˆGO-PEGï¼‰å¥ˆç±³é¡†ç²’ã€è˜¿è””ç¡«ç´ ä»¥åŠé»‘è˜¿è””æ±å°äººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒBEAS-2Bçš„ç´°èƒæ¯’æ€§å’Œç”ŸåŒ–æ•ˆæ‡‰ã€‚ç ”ç©¶è€…é—œå¿ƒé€™äº›ç‰©è³ªå¦‚ä½•å½±éŸ¿ç´°èƒçš„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„æ•ˆæœä¸Šï¼Œé€™å°æ–¼ç†è§£é€™äº›å¤©ç„¶æˆåˆ†åœ¨å‘¼å¸ç³»çµ±ç–¾ç—…ä¸­çš„æ½›åœ¨æ‡‰ç”¨éå¸¸é‡è¦ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†BEAS-2Bäººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒä½œç‚ºç ”ç©¶å°è±¡ï¼Œä¸¦å°ä¸åŒæ¿ƒåº¦çš„GO-PEGå¥ˆç±³é¡†ç²’ã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±é€²è¡Œæ¸¬è©¦ã€‚è˜¿è””ç¡«ç´ æ˜¯é€šéèª¿æ•´pHå€¼çš„æ°´è™•ç†å’Œæœ‰æ©Ÿæº¶åŠ‘æå–è€Œä¾†ï¼Œä¸¦ä½¿ç”¨é«˜æ•ˆæ¶²ç›¸è‰²è­œæ³•é€²è¡Œå®šé‡åˆ†æã€‚ç ”ç©¶ä¸­é‚„æ¸¬é‡äº†é€™äº›ç‰©è³ªå°ç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘çš„IC50å€¼ï¼Œé€™æœ‰åŠ©æ–¼è©•ä¼°å…¶ç´°èƒæ¯’æ€§ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½é™ä½IL-6çš„æ°´å¹³ï¼Œä¸¦æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼ˆå¦‚GSH-Pxå’ŒCATï¼‰ã€‚é€™äº›çµæœçªé¡¯äº†GO-PEGã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ‡‰ç”¨ä¸­çš„æ½›åœ¨ç™‚æ•ˆï¼Œé›–ç„¶ä¸èƒ½ä¿è­‰å®ƒå€‘ä¸€å®šèƒ½æ²»ç™’æˆ–æœ‰æ•ˆï¼Œä½†é€™äº›æˆåˆ†çš„ç ”ç©¶ç‚ºæœªä¾†çš„å¥åº·æ‡‰ç”¨æä¾›äº†æœ‰è¶£çš„æ–¹å‘ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„é ˜åŸŸã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›å¤©ç„¶æˆåˆ†å¦‚è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½å°å‘¼å¸é“å¥åº·æœ‰æ­£é¢å½±éŸ¿ï¼Œé€™å°æ–¼é é˜²èˆ‡ç™¼ç‚ç›¸é—œçš„ç–¾ç—…ä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚é€™äº›æˆåˆ†çš„æŠ—æ°§åŒ–ç‰¹æ€§å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘ç´°èƒæå‚·ï¼Œé€²è€Œæ”¹å–„æ•´é«”å¥åº·ç‹€æ³ï¼Œç‰¹åˆ¥æ˜¯å°æ–¼å‘¼å¸ç³»çµ±çš„ä¿è­·ä½œç”¨ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨PEGåŒ–çŸ³å¢¨çƒ¯æ°§åŒ–ç‰©ï¼ˆGO-PEGï¼‰å¥ˆç±³é¡†ç²’ã€è˜¿è””ç¡«ç´ ä»¥åŠé»‘è˜¿è””æ±å°äººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒBEAS-2Bçš„ç´°èƒæ¯’æ€§å’Œç”ŸåŒ–æ•ˆæ‡‰ã€‚ç ”ç©¶è€…é—œå¿ƒé€™äº›ç‰©è³ªå¦‚ä½•å½±éŸ¿ç´°èƒçš„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„æ•ˆæœä¸Šï¼Œé€™å°æ–¼ç†è§£é€™äº›å¤©ç„¶æˆåˆ†åœ¨å‘¼å¸ç³»çµ±ç–¾ç—…ä¸­çš„æ½›åœ¨æ‡‰ç”¨éå¸¸é‡è¦ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†BEAS-2Bäººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒä½œç‚ºç ”ç©¶å°è±¡ï¼Œä¸¦å°ä¸åŒæ¿ƒåº¦çš„GO-PEGå¥ˆç±³é¡†ç²’ã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±é€²è¡Œæ¸¬è©¦ã€‚è˜¿è””ç¡«ç´ æ˜¯é€šéèª¿æ•´pHå€¼çš„æ°´è™•ç†å’Œæœ‰æ©Ÿæº¶åŠ‘æå–è€Œä¾†ï¼Œä¸¦ä½¿ç”¨é«˜æ•ˆæ¶²ç›¸è‰²è­œæ³•é€²è¡Œå®šé‡åˆ†æã€‚ç ”ç©¶ä¸­é‚„æ¸¬é‡äº†é€™äº›ç‰©è³ªå°ç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘çš„IC50å€¼ï¼Œé€™æœ‰åŠ©æ–¼è©•ä¼°å…¶ç´°èƒæ¯’æ€§ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½é™ä½IL-6çš„æ°´å¹³ï¼Œä¸¦æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼ˆå¦‚GSH-Pxå’ŒCATï¼‰ã€‚é€™äº›çµæœçªé¡¯äº†GO-PEGã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ‡‰ç”¨ä¸­çš„æ½›åœ¨ç™‚æ•ˆï¼Œé›–ç„¶ä¸èƒ½ä¿è­‰å®ƒå€‘ä¸€å®šèƒ½æ²»ç™’æˆ–æœ‰æ•ˆï¼Œä½†é€™äº›æˆåˆ†çš„ç ”ç©¶ç‚ºæœªä¾†çš„å¥åº·æ‡‰ç”¨æä¾›äº†æœ‰è¶£çš„æ–¹å‘ã€‚",
    "fb_post": "æ ¹æ“šã€ŠTalantaã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ€ å¤§å®¶çŸ¥é“å—ï¼Ÿæœ‰äº›å¤©ç„¶æˆåˆ†å¯èƒ½å°æˆ‘å€‘çš„å‘¼å¸é“å¥åº·æœ‰å¹«åŠ©ï¼æœ€è¿‘ä¸€é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±çš„æ½›åŠ›ï¼Œè®“æˆ‘å€‘ä¸€èµ·ä¾†çœ‹çœ‹å§ï¼\n\né€™é …ç ”ç©¶ä¸»è¦é—œå¿ƒçš„æ˜¯é€™äº›æˆåˆ†å¦‚ä½•å½±éŸ¿æˆ‘å€‘çš„ç´°èƒå¥åº·ï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢ã€‚ç ”ç©¶è€…å€‘ä½¿ç”¨äº†äººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒï¼Œæ¸¬è©¦äº†ä¸åŒæ¿ƒåº¦çš„è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±ï¼Œé‚„æœ‰ä¸€ç¨®å«åšGO-PEGçš„å¥ˆç±³é¡†ç²’ã€‚ä»–å€‘æƒ³çŸ¥é“é€™äº›æˆåˆ†å°ç´°èƒçš„å½±éŸ¿æœ‰å¤šå¤§ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½æœ‰æ•ˆé™ä½ä¸€ç¨®å«åšIL-6çš„ç™¼ç‚æŒ‡æ¨™ï¼Œä¸¦æå‡æˆ‘å€‘é«”å…§çš„æŠ—æ°§åŒ–é…¶æ´»æ€§ï¼Œé€™å°æ–¼ä¿è­·æˆ‘å€‘çš„ç´°èƒå¥åº·æ˜¯éå¸¸é‡è¦çš„ï¼\n\nâœ¨ ç¸½çµå¹¾å€‹é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„å‘¼å¸é“å¥åº·ã€‚\n2. å®ƒå€‘èƒ½é™ä½ç™¼ç‚æŒ‡æ¨™ï¼Œä¸¦å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ã€‚\n3. é€™äº›å¤©ç„¶æˆåˆ†çš„ç ”ç©¶ç‚ºæœªä¾†å¥åº·æ‡‰ç”¨æä¾›äº†æœ‰è¶£çš„æ–¹å‘ï¼",
    "image_prompt": "Create a flat design infographic on a light background that illustrates the experimental process and main findings of a study on natural compounds like daikon sulforaphane and black radish juice. Include simple icons representing daikon and sulforaphane, human bronchial epithelial cells as the experimental subjects, and arrows or flow lines to show the steps of the experiment. Add a section that highlights the main results, such as the protective effects and changes observed in inflammation markers.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å‘¼å¸é“ç–¾ç—… Respiratory Diseases",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40580757/"
  },
  {
    "id": "40961586",
    "title_en": "Design, synthesis and biological evaluation of magnolol-sulforaphane hybrid analogues as potential therapeutics of triple-negative breast cancer.",
    "pub_date": "2025 Dec",
    "journal": "European journal of medicinal chemistry",
    "abstract_en": "Triple-negative breast cancer (TNBC) is an aggressive subtype that primarily relies on chemotherapy. Natural products like magnolol and sulforaphane, especially their synthetic hybrid, have shown promising antitumor activity. To develop more potent agents, we designed and synthesized 15 novel magnolol-sulforaphane hybrid analogues and evaluated their anticancer efficacy. Among them, compound 17a demonstrated the highest potency, exhibiting an average 7.4-fold increase in antiproliferative activity with IC<sub>50</sub> values ranging from 0.85Â Â±Â 0.04Â Î¼M to 1.34Â Â±Â 0.02Â Î¼M in TNBC cell lines compared to the parent hybrid CT1-3. In vitro, 17a significantly suppressed TNBC cell proliferation, colony formation, migration, and invasion while inducing apoptosis. In vivo, administration of 17a effectively inhibited tumor growth without apparent toxicity in an MDA-MB-231 xenograft model, as evidenced by normal organ morphology. Mechanistically, RNA sequencing revealed that 17a downregulated the nucleotide excision repair (NER) and NF-ÎºB pathways, suppressing expression of NER-related genes (ERCC2, POLE2, LIG1, GTF2H3, and DDB2) at mRNA and protein levels and inhibiting phosphorylation of IKKÎ± and p65. These findings position 17a as a potent therapeutic candidate for TNBC treatment, warranting further clinical investigation.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé‡å°ä¸‰é™°æ€§ä¹³ç™Œé€™ç¨®ä¾µç•¥æ€§å¼·çš„ç™Œç—‡é¡å‹ï¼Œå°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•æ˜¯éå¸¸é‡è¦çš„ã€‚ä¸‰é™°æ€§ä¹³ç™Œé€šå¸¸ä¾è³´åŒ–ç™‚ï¼Œä½†åŒ–ç™‚çš„æ•ˆæœæœ‰é™ï¼Œä¸”å¯èƒ½å¸¶ä¾†å‰¯ä½œç”¨ã€‚å› æ­¤ï¼Œé–‹ç™¼æ–°çš„å¤©ç„¶ç”¢å“æˆ–å…¶åˆæˆè¡ç”Ÿç‰©ï¼Œå¯èƒ½ç‚ºæ‚£è€…æä¾›æ›´æœ‰æ•ˆä¸”å‰¯ä½œç”¨è¼ƒå°çš„æ²»ç™‚é¸æ“‡ï¼Œé€™å°æ–¼æ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªå’Œæ²»ç™‚æ•ˆæœå…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯é‡å°ä¸‰é™°æ€§ä¹³ç™Œï¼ˆTNBCï¼‰é–‹ç™¼æ–°çš„æŠ—ç™Œè—¥ç‰©ã€‚ç ”ç©¶è€…å€‘é—œå¿ƒçš„æ˜¯å¦‚ä½•åˆ©ç”¨å¤©ç„¶ç”¢å“å¦‚æœ¨è˜­é…šå’Œè˜¿è””ç¡«ç´ ï¼Œå°¤å…¶æ˜¯å®ƒå€‘çš„åˆæˆæ··åˆç‰©ï¼Œä¾†æå‡æŠ—ç™Œæ•ˆæœã€‚é€éè¨­è¨ˆå’Œåˆæˆ15ç¨®æ–°çš„æœ¨è˜­é…š-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½æ‰¾åˆ°æ›´å…·æŠ—è…«ç˜¤æ´»æ€§çš„åŒ–åˆç‰©ï¼Œé€²è€Œç‚ºä¸‰é™°æ€§ä¹³ç™Œçš„æ²»ç™‚æä¾›æ–°çš„å¯èƒ½æ€§ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†15ç¨®æ–°çš„åŒ–åˆç‰©ï¼Œä¸¦è©•ä¼°å®ƒå€‘åœ¨ä¸‰é™°æ€§ä¹³ç™Œç´°èƒä¸­çš„æŠ—ç™Œæ•ˆæœã€‚å…·é«”ä¾†èªªï¼Œç ”ç©¶è€…æ¸¬è©¦äº†é€™äº›åŒ–åˆç‰©å°ç´°èƒå¢æ®–ã€é›†è½å½¢æˆã€é·ç§»å’Œä¾µè¥²çš„å½±éŸ¿ï¼Œä¸¦è§€å¯Ÿå®ƒå€‘æ˜¯å¦èƒ½èª˜å°ç´°èƒå‡‹äº¡ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„åœ¨å°é¼ æ¨¡å‹ä¸­é€²è¡Œäº†é«”å…§å¯¦é©—ï¼Œä»¥è©•ä¼°é€™äº›åŒ–åˆç‰©å°è…«ç˜¤ç”Ÿé•·çš„æŠ‘åˆ¶æ•ˆæœåŠå…¶æ¯’æ€§ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾æ˜¯ï¼ŒåŒ–åˆç‰©17aåœ¨æŠ—è…«ç˜¤æ´»æ€§æ–¹é¢è¡¨ç¾æœ€ä½³ï¼Œå°ä¸‰é™°æ€§ä¹³ç™Œç´°èƒçš„å¢æ®–æŠ‘åˆ¶æ•ˆæœé¡¯è‘—ï¼Œä¸¦ä¸”åœ¨å°é¼ æ¨¡å‹ä¸­æœ‰æ•ˆæŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸”æœªè¦‹æ˜é¡¯çš„æ¯’æ€§ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œ17aèƒ½å¤ ä¸‹èª¿èˆ‡æ ¸è‹·é…¸åˆ‡é™¤ä¿®å¾©å’ŒNF-ÎºBé€šè·¯ç›¸é—œçš„åŸºå› è¡¨é”ï¼Œé€™å¯èƒ½æ˜¯å…¶æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·çš„æ©Ÿåˆ¶ä¹‹ä¸€ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œ17aæ˜¯ä¸€å€‹æœ‰æ½›åŠ›çš„ä¸‰é™°æ€§ä¹³ç™Œæ²»ç™‚å€™é¸è—¥ç‰©ï¼Œå€¼å¾—é€²ä¸€æ­¥çš„è‡¨åºŠç ”ç©¶ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé‡å°ä¸‰é™°æ€§ä¹³ç™Œé€™ç¨®ä¾µç•¥æ€§å¼·çš„ç™Œç—‡é¡å‹ï¼Œå°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•æ˜¯éå¸¸é‡è¦çš„ã€‚ä¸‰é™°æ€§ä¹³ç™Œé€šå¸¸ä¾è³´åŒ–ç™‚ï¼Œä½†åŒ–ç™‚çš„æ•ˆæœæœ‰é™ï¼Œä¸”å¯èƒ½å¸¶ä¾†å‰¯ä½œç”¨ã€‚å› æ­¤ï¼Œé–‹ç™¼æ–°çš„å¤©ç„¶ç”¢å“æˆ–å…¶åˆæˆè¡ç”Ÿç‰©ï¼Œå¯èƒ½ç‚ºæ‚£è€…æä¾›æ›´æœ‰æ•ˆä¸”å‰¯ä½œç”¨è¼ƒå°çš„æ²»ç™‚é¸æ“‡ï¼Œé€™å°æ–¼æ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªå’Œæ²»ç™‚æ•ˆæœå…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯é‡å°ä¸‰é™°æ€§ä¹³ç™Œï¼ˆTNBCï¼‰é–‹ç™¼æ–°çš„æŠ—ç™Œè—¥ç‰©ã€‚ç ”ç©¶è€…å€‘é—œå¿ƒçš„æ˜¯å¦‚ä½•åˆ©ç”¨å¤©ç„¶ç”¢å“å¦‚æœ¨è˜­é…šå’Œè˜¿è””ç¡«ç´ ï¼Œå°¤å…¶æ˜¯å®ƒå€‘çš„åˆæˆæ··åˆç‰©ï¼Œä¾†æå‡æŠ—ç™Œæ•ˆæœã€‚é€éè¨­è¨ˆå’Œåˆæˆ15ç¨®æ–°çš„æœ¨è˜­é…š-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½æ‰¾åˆ°æ›´å…·æŠ—è…«ç˜¤æ´»æ€§çš„åŒ–åˆç‰©ï¼Œé€²è€Œç‚ºä¸‰é™°æ€§ä¹³ç™Œçš„æ²»ç™‚æä¾›æ–°çš„å¯èƒ½æ€§ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†15ç¨®æ–°çš„åŒ–åˆç‰©ï¼Œä¸¦è©•ä¼°å®ƒå€‘åœ¨ä¸‰é™°æ€§ä¹³ç™Œç´°èƒä¸­çš„æŠ—ç™Œæ•ˆæœã€‚å…·é«”ä¾†èªªï¼Œç ”ç©¶è€…æ¸¬è©¦äº†é€™äº›åŒ–åˆç‰©å°ç´°èƒå¢æ®–ã€é›†è½å½¢æˆã€é·ç§»å’Œä¾µè¥²çš„å½±éŸ¿ï¼Œä¸¦è§€å¯Ÿå®ƒå€‘æ˜¯å¦èƒ½èª˜å°ç´°èƒå‡‹äº¡ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„åœ¨å°é¼ æ¨¡å‹ä¸­é€²è¡Œäº†é«”å…§å¯¦é©—ï¼Œä»¥è©•ä¼°é€™äº›åŒ–åˆç‰©å°è…«ç˜¤ç”Ÿé•·çš„æŠ‘åˆ¶æ•ˆæœåŠå…¶æ¯’æ€§ã€‚\n\nä¸»è¦ç™¼ç¾æ˜¯ï¼ŒåŒ–åˆç‰©17aåœ¨æŠ—è…«ç˜¤æ´»æ€§æ–¹é¢è¡¨ç¾æœ€ä½³ï¼Œå°ä¸‰é™°æ€§ä¹³ç™Œç´°èƒçš„å¢æ®–æŠ‘åˆ¶æ•ˆæœé¡¯è‘—ï¼Œä¸¦ä¸”åœ¨å°é¼ æ¨¡å‹ä¸­æœ‰æ•ˆæŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸”æœªè¦‹æ˜é¡¯çš„æ¯’æ€§ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œ17aèƒ½å¤ ä¸‹èª¿èˆ‡æ ¸è‹·é…¸åˆ‡é™¤ä¿®å¾©å’ŒNF-ÎºBé€šè·¯ç›¸é—œçš„åŸºå› è¡¨é”ï¼Œé€™å¯èƒ½æ˜¯å…¶æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·çš„æ©Ÿåˆ¶ä¹‹ä¸€ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œ17aæ˜¯ä¸€å€‹æœ‰æ½›åŠ›çš„ä¸‰é™°æ€§ä¹³ç™Œæ²»ç™‚å€™é¸è—¥ç‰©ï¼Œå€¼å¾—é€²ä¸€æ­¥çš„è‡¨åºŠç ”ç©¶ã€‚",
    "fb_post": "æ ¹æ“šã€ŠEuropean journal of medicinal chemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é£²é£Ÿä¸­æœ‰äº›å¤©ç„¶æˆåˆ†å¯èƒ½å°æŠ—ç™Œç—‡æœ‰å¹«åŠ©ï¼\n\næœ€è¿‘æœ‰ä¸€é …æœ‰è¶£çš„ç ”ç©¶ï¼Œå°ˆæ³¨æ–¼ä¸€ç¨®ç‰¹åˆ¥çš„ç™Œç—‡â€”â€”ä¸‰é™°æ€§ä¹³ç™Œï¼ˆTNBCï¼‰ã€‚é€™ç¨®ç™Œç—‡å¾ˆé›£æ²»ç™‚ï¼Œå› ç‚ºå®ƒé€šå¸¸ä¾è³´åŒ–ç™‚ï¼Œè€ŒåŒ–ç™‚çš„æ•ˆæœæœ‰æ™‚ä¸å¦‚äººæ„ï¼Œé‚„å¯èƒ½å¸¶ä¾†å‰¯ä½œç”¨ã€‚å› æ­¤ï¼Œç§‘å­¸å®¶å€‘é–‹å§‹å°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•ï¼Œåƒæ˜¯åˆ©ç”¨å¤©ç„¶ç”¢å“ä¾†å¹«åŠ©ç—…æ‚£ã€‚\n\né€™é …ç ”ç©¶çš„åœ˜éšŠå°ˆæ³¨æ–¼å…©ç¨®å¤©ç„¶æˆåˆ†ï¼šæœ¨è˜­é…šå’Œè˜¿è””ç¡«ç´ ã€‚ä»–å€‘è¨­è¨ˆäº†15ç¨®æ–°çš„æ··åˆåŒ–åˆç‰©ï¼Œå¸Œæœ›èƒ½æ‰¾åˆ°å°æŠ—ä¸‰é™°æ€§ä¹³ç™Œçš„æœ‰æ•ˆé¸æ“‡ã€‚å¯¦é©—ä¸­ï¼Œä»–å€‘æ¸¬è©¦äº†é€™äº›åŒ–åˆç‰©å°ç™Œç´°èƒçš„å½±éŸ¿ï¼ŒåŒ…æ‹¬å®ƒå€‘æ˜¯å¦èƒ½æŠ‘åˆ¶ç´°èƒå¢æ®–å’Œèª˜å°ç´°èƒå‡‹äº¡ã€‚\n\nçµæœä»¤äººæŒ¯å¥®ï¼å…¶ä¸­ä¸€ç¨®åŒ–åˆç‰©ï¼ˆ17aï¼‰åœ¨æŠ—è…«ç˜¤æ´»æ€§æ–¹é¢è¡¨ç¾æœ€ä½³ï¼Œèƒ½æœ‰æ•ˆæŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸”åœ¨å°é¼ æ¨¡å‹ä¸­æœªè¦‹æ˜é¡¯æ¯’æ€§ã€‚é€™é¡¯ç¤º17aå¯èƒ½æ˜¯ä¸€å€‹æœ‰æ½›åŠ›çš„æ²»ç™‚é¸æ“‡ï¼Œå€¼å¾—é€²ä¸€æ­¥ç ”ç©¶ã€‚\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. ä¸‰é™°æ€§ä¹³ç™Œé›£ä»¥æ²»ç™‚ï¼Œå°‹æ‰¾æ–°æ–¹æ³•å¾ˆé‡è¦ã€‚\n2. ç ”ç©¶è€…è¨­è¨ˆäº†15ç¨®æ–°åŒ–åˆç‰©ï¼Œæ¢ç´¢å…¶æŠ—ç™Œæ•ˆæœã€‚\n3. åŒ–åˆç‰©17aåœ¨å¯¦é©—ä¸­é¡¯ç¤ºå‡ºè‰¯å¥½çš„æŠ—è…«ç˜¤æ´»æ€§ï¼Œæœªè¦‹æ¯’æ€§ã€‚",
    "image_prompt": "Create a flat design infographic illustrating the experimental process and main results of a study on natural compounds for cancer treatment. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like humans, animals, and cells. Use arrows or flow lines to indicate the steps of the experiment. Include a section labeled 'Main Results' highlighting protective effects or observed changes.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "ä¸‰é™°æ€§ä¹³ç™Œ Triple-negative Breast Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40961586/"
  },
  {
    "id": "41108925",
    "title_en": "Enhancing myocardial injury recovery: Nrf2 activation by sulforaphane regulates ferroptosis and oxidative stress in takotsubo-like models.",
    "pub_date": "2025 Dec",
    "journal": "International immunopharmacology",
    "abstract_en": "Takotsubo syndrome (TTS), once considered benign, can cause life-threatening myocardial injury. Although oxidative stress and ferroptosis are implicated in its pathogenesis, targeted therapies are not available for TTS. We demonstrate that sulforaphane (SFN), a natural Nrf2 activator, mitigates TTS-related injury in isoproterenol-induced rat models and AC16 cardiomyocytes. Isoproterenol induced ferroptosis and oxidative stress by impairing Nrf2 signaling. SFN treatment restored myocardial structure and function while enhancing antioxidant capacity, reducing mitochondrial damage, and suppressing ferroptosis markers. Additionally, similar to Fer-1 (a ferroptosis inhibitor), SFN reduced intracellular ferrous levels but uniquely activated Nrf2-driven endogenous defenses. Notably, Nrf2 inhibition abrogated the benefits of SFN in both in vitro and in vivo experiments. These findings highlight SFN as a dual-action therapeutic for TTS, simultaneously targeting oxidative stress and ferroptosis via Nrf2 activation. The therapeutic efficacy of SFN, combined with endogenous pathway modulation, underscores its translational potential for improving TTS outcomes.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé›–ç„¶ Takotsubo ç¶œåˆç—‡ï¼ˆTTSï¼‰éå»è¢«èªç‚ºæ˜¯è‰¯æ€§çš„ï¼Œä½†å¯¦éš›ä¸Šå®ƒå¯èƒ½å°è‡´å±åŠç”Ÿå‘½çš„å¿ƒè‚Œæå‚·ã€‚é€™æé†’æˆ‘å€‘ï¼Œå°æ–¼å¿ƒè‡Ÿå¥åº·çš„ä¿è­·ï¼Œç‰¹åˆ¥æ˜¯é‡å°æ°§åŒ–å£“åŠ›å’Œç´°èƒæ­»äº¡çš„ç ”ç©¶æ˜¯éå¸¸é‡è¦çš„ã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›å¤©ç„¶æˆåˆ†å¦‚è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•é€™ç¨®ç—…ç—‡çš„å½±éŸ¿ï¼Œæœªä¾†æˆ–è¨±å¯ä»¥æˆç‚ºé é˜²æˆ–æ²»ç™‚å¿ƒè‡Ÿç–¾ç—…çš„æ–°æ–¹å‘ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ Takotsubo ç¶œåˆç—‡ä¸­çš„æ½›åœ¨ç™‚æ•ˆã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ï¼Œé€™ç¨®å¤©ç„¶åŒ–åˆç‰©æ˜¯å¦èƒ½å¤ æ”¹å–„å› æ°§åŒ–å£“åŠ›å’Œç´°èƒæ­»äº¡æ‰€å¼•èµ·çš„å¿ƒè‚Œæå‚·ï¼Œä¸¦ä¸”å¸Œæœ›æ‰¾å‡ºå…¶ä½œç”¨æ©Ÿåˆ¶ã€‚é€™å°æ–¼é–‹ç™¼é‡å° TTS çš„æ–°ç™‚æ³•å…·æœ‰é‡è¦æ„ç¾©ï¼Œå› ç‚ºç›®å‰å°šç„¡é‡å°è©²ç—…ç—‡çš„ç‰¹å®šæ²»ç™‚æ–¹æ¡ˆã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å¤§é¼ æ¨¡å‹å’Œ AC16 å¿ƒè‚Œç´°èƒä¾†æ¨¡æ“¬ TTS çš„æƒ…æ³ã€‚å…·é«”ä¾†èªªï¼Œä»–å€‘ä½¿ç”¨ç•°ä¸™è…ä¸Šè…ºç´ ä¾†èª˜å°å¿ƒè‚Œçš„æ°§åŒ–å£“åŠ›å’Œç´°èƒæ­»äº¡ï¼Œç„¶å¾Œè§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ²»ç™‚æ•ˆæœã€‚ç ”ç©¶è€…è©•ä¼°äº†å¿ƒè‚Œçš„çµæ§‹å’ŒåŠŸèƒ½è®ŠåŒ–ï¼Œä¸¦æ¸¬é‡äº†æŠ—æ°§åŒ–èƒ½åŠ›åŠç´°èƒæ­»äº¡çš„æ¨™è¨˜ï¼Œä»¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ”¹å–„å¿ƒè‚Œçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œå¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œä¸¦æ¸›å°‘ç·šç²’é«”æå‚·åŠç´°èƒæ­»äº¡çš„æ¨™è¨˜ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½é™ä½ç´°èƒå…§çš„äºéµæ°´å¹³ï¼Œä¸¦å•Ÿå‹•å…§æºæ€§é˜²ç¦¦æ©Ÿåˆ¶ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼ŒæŠ‘åˆ¶ Nrf2 æœƒå‰Šå¼±è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆï¼Œé€™è¡¨æ˜ Nrf2 åœ¨å…¶ä½œç”¨ä¸­æ‰®æ¼”äº†é—œéµè§’è‰²ã€‚é€™äº›çµæœå¼·èª¿äº†è˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®é›™é‡ä½œç”¨ç™‚æ³•çš„æ½›åŠ›ï¼Œå¯èƒ½å°æ”¹å–„ TTS çš„çµæœæœ‰å¹«åŠ©ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé›–ç„¶ Takotsubo ç¶œåˆç—‡ï¼ˆTTSï¼‰éå»è¢«èªç‚ºæ˜¯è‰¯æ€§çš„ï¼Œä½†å¯¦éš›ä¸Šå®ƒå¯èƒ½å°è‡´å±åŠç”Ÿå‘½çš„å¿ƒè‚Œæå‚·ã€‚é€™æé†’æˆ‘å€‘ï¼Œå°æ–¼å¿ƒè‡Ÿå¥åº·çš„ä¿è­·ï¼Œç‰¹åˆ¥æ˜¯é‡å°æ°§åŒ–å£“åŠ›å’Œç´°èƒæ­»äº¡çš„ç ”ç©¶æ˜¯éå¸¸é‡è¦çš„ã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›å¤©ç„¶æˆåˆ†å¦‚è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•é€™ç¨®ç—…ç—‡çš„å½±éŸ¿ï¼Œæœªä¾†æˆ–è¨±å¯ä»¥æˆç‚ºé é˜²æˆ–æ²»ç™‚å¿ƒè‡Ÿç–¾ç—…çš„æ–°æ–¹å‘ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ Takotsubo ç¶œåˆç—‡ä¸­çš„æ½›åœ¨ç™‚æ•ˆã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ï¼Œé€™ç¨®å¤©ç„¶åŒ–åˆç‰©æ˜¯å¦èƒ½å¤ æ”¹å–„å› æ°§åŒ–å£“åŠ›å’Œç´°èƒæ­»äº¡æ‰€å¼•èµ·çš„å¿ƒè‚Œæå‚·ï¼Œä¸¦ä¸”å¸Œæœ›æ‰¾å‡ºå…¶ä½œç”¨æ©Ÿåˆ¶ã€‚é€™å°æ–¼é–‹ç™¼é‡å° TTS çš„æ–°ç™‚æ³•å…·æœ‰é‡è¦æ„ç¾©ï¼Œå› ç‚ºç›®å‰å°šç„¡é‡å°è©²ç—…ç—‡çš„ç‰¹å®šæ²»ç™‚æ–¹æ¡ˆã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å¤§é¼ æ¨¡å‹å’Œ AC16 å¿ƒè‚Œç´°èƒä¾†æ¨¡æ“¬ TTS çš„æƒ…æ³ã€‚å…·é«”ä¾†èªªï¼Œä»–å€‘ä½¿ç”¨ç•°ä¸™è…ä¸Šè…ºç´ ä¾†èª˜å°å¿ƒè‚Œçš„æ°§åŒ–å£“åŠ›å’Œç´°èƒæ­»äº¡ï¼Œç„¶å¾Œè§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ²»ç™‚æ•ˆæœã€‚ç ”ç©¶è€…è©•ä¼°äº†å¿ƒè‚Œçš„çµæ§‹å’ŒåŠŸèƒ½è®ŠåŒ–ï¼Œä¸¦æ¸¬é‡äº†æŠ—æ°§åŒ–èƒ½åŠ›åŠç´°èƒæ­»äº¡çš„æ¨™è¨˜ï¼Œä»¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ”¹å–„å¿ƒè‚Œçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œå¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œä¸¦æ¸›å°‘ç·šç²’é«”æå‚·åŠç´°èƒæ­»äº¡çš„æ¨™è¨˜ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½é™ä½ç´°èƒå…§çš„äºéµæ°´å¹³ï¼Œä¸¦å•Ÿå‹•å…§æºæ€§é˜²ç¦¦æ©Ÿåˆ¶ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼ŒæŠ‘åˆ¶ Nrf2 æœƒå‰Šå¼±è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆï¼Œé€™è¡¨æ˜ Nrf2 åœ¨å…¶ä½œç”¨ä¸­æ‰®æ¼”äº†é—œéµè§’è‰²ã€‚é€™äº›çµæœå¼·èª¿äº†è˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®é›™é‡ä½œç”¨ç™‚æ³•çš„æ½›åŠ›ï¼Œå¯èƒ½å°æ”¹å–„ TTS çš„çµæœæœ‰å¹«åŠ©ã€‚",
    "fb_post": "æ ¹æ“šã€ŠInternational immunopharmacologyã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæœ‰äº›å¤©ç„¶æˆåˆ†å¯èƒ½å°å¿ƒè‡Ÿå¥åº·æœ‰æ„æƒ³ä¸åˆ°çš„å¥½è™•ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼ä¸€ç¨®å«è˜¿è””ç¡«ç´ çš„å¤©ç„¶åŒ–åˆç‰©ï¼Œçœ‹çœ‹å®ƒèƒ½å¦å¹«åŠ©æ”¹å–„ Takotsubo ç¶œåˆç—‡ï¼ˆTTSï¼‰ï¼Œé€™æ˜¯ä¸€ç¨®å¯èƒ½å°è‡´å¿ƒè‡Ÿæå‚·çš„ç—…ç—‡ã€‚ç ”ç©¶è€…å€‘ç”¨å¤§é¼ å’Œå¿ƒè‚Œç´°èƒæ¨¡æ“¬ TTS çš„æƒ…æ³ï¼Œç„¶å¾Œè§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚ä»–å€‘ç™¼ç¾ï¼Œé€™ç¨®åŒ–åˆç‰©ä¸åƒ…èƒ½æ”¹å–„å¿ƒè‚Œçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œé‚„èƒ½å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œæ¸›å°‘ç´°èƒæ­»äº¡çš„æƒ…æ³ï¼é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºæœªä¾†å¿ƒè‡Ÿç–¾ç—…æ²»ç™‚çš„æ–°æ–¹å‘ã€‚  \n\nğŸ” ä¸»è¦ç™¼ç¾ï¼š  \n1. è˜¿è””ç¡«ç´ èƒ½æ”¹å–„å¿ƒè‚Œçµæ§‹èˆ‡åŠŸèƒ½  \n2. å¢åŠ æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œæ¸›å°‘ç´°èƒæå‚·  \n3. å¯èƒ½å•Ÿå‹•å…§æºæ€§é˜²ç¦¦æ©Ÿåˆ¶ï¼Œå¹«åŠ©å¿ƒè‡Ÿå¥åº·  \n\né€™é …ç ”ç©¶è®“æˆ‘å€‘å°å¿ƒè‡Ÿå¥åº·æœ‰äº†æ–°çš„èªè­˜ï¼ŒæœŸå¾…æœªä¾†èƒ½æœ‰æ›´å¤šç›¸é—œçš„ç ”ç©¶ï¼",
    "image_prompt": "Create a flat design infographic with a light background. Include symbols representing broccoli or daikon isothiocyanate. Simplified illustrations of experimental subjects like animals or cells. Use arrows or flow lines to indicate the experimental process. Add a section labeled 'Main Results' highlighting protective effects and changes observed in the study.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "Takotsubo ç¶œåˆç—‡ Takotsubo Syndrome",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41108925/"
  },
  {
    "id": "41340527",
    "title_en": "Metabolomics and Transcriptomics Analyses Reveal the Mechanisms of Sulforaphane Conversion and Adaptive Strategies in the Absence of Glucose by <i>Lactiplantibacillus plantarum</i>.",
    "pub_date": "2025 Dec",
    "journal": "Journal of agricultural and food chemistry",
    "abstract_en": "Sulforaphane is a beneficial but unstable bioactive compound that can be converted from glucoraphanin by <i>Lactiplantibacillus plantarum</i>. However, the sulforaphane conversion rate is low, and the conversion mechanism of <i>L. plantarum</i> remains unclear. This research utilized the adaptive laboratory evolution technology to enhance the sulforaphane conversion rate of <i>L. plantarum</i>. The results showed that an increase in the glucose replacement ratio significantly downregulated carbohydrate metabolism and upregulated amino acid metabolism. Transcriptomic analysis showed that the ALE-adapted strain significantly upregulated carbohydrate metabolism and amino acid metabolism. In the conversion pathway, glucoraphanin is imported into <i>L. plantarum</i> cells, and its glucose moiety is phosphorylated by bglF (the phosphate group may be derived from phosphoenolpyruvate via the phosphotransferase system). Subsequently, the S-glycosidic bond of phosphorylated glucoraphanin is hydrolyzed by bglA (6-phospho-Î²-glucosidase), followed by nonenzymatic rearrangement and sulfate elimination, ultimately yielding sulforaphane. This research can contribute to revealing the interaction mechanism between microorganisms and natural active substances.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ é€™ç¨®æœ‰ç›Šçš„ç”Ÿç‰©æ´»æ€§åŒ–åˆç‰©ã€‚è˜¿è””ç¡«ç´ ä¸»è¦ä¾†è‡ªé’èŠ±æ¤°èœï¼Œå°æ–¼ä¿ƒé€²å¥åº·å’Œé é˜²æŸäº›ç–¾ç—…å¯èƒ½æœ‰æ­£é¢å½±éŸ¿ã€‚ç„¶è€Œï¼Œè˜¿è””ç¡«ç´ çš„è½‰æ›ç‡è¼ƒä½ï¼Œé€™æ„å‘³è‘—æˆ‘å€‘éœ€è¦æ›´æœ‰æ•ˆçš„æ–¹æ³•ä¾†æé«˜å…¶ç”¢é‡ï¼Œä»¥ä¾¿èƒ½å¤ æ›´å¥½åœ°åˆ©ç”¨é€™ç¨®åŒ–åˆç‰©çš„æ½›åœ¨å¥½è™•ã€‚äº†è§£é€™äº›è½‰æ›éç¨‹çš„æ©Ÿåˆ¶ï¼Œå°‡æœ‰åŠ©æ–¼æœªä¾†çš„å¥åº·ç ”ç©¶å’Œæ‡‰ç”¨ï¼Œå°¤å…¶æ˜¯åœ¨ç‡Ÿé¤Šè£œå……å’Œç–¾ç—…é é˜²æ–¹é¢ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•æé«˜è˜¿è””ç¡«ç´ çš„è½‰æ›ç‡ï¼Œç‰¹åˆ¥æ˜¯é€šéåˆ©ç”¨ä¸€ç¨®åç‚ºLactiplantibacillus plantarumçš„ç´°èŒã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œé€™ç¨®ç´°èŒåœ¨å°‡é’èŠ±æ¤°èœä¸­çš„å‰é«”ç‰©è³ªï¼ˆå³è‘¡è„ç³–è‹·é…¸ï¼‰è½‰æ›ç‚ºè˜¿è””ç¡«ç´ çš„éç¨‹ä¸­ï¼Œè½‰æ›æ•ˆç‡ä½çš„åŸå› ä»¥åŠå¦‚ä½•æ”¹å–„é€™ä¸€éç¨‹ã€‚é€™ä¸åƒ…æ¶‰åŠåˆ°å¾®ç”Ÿç‰©çš„ä»£è¬æ©Ÿåˆ¶ï¼Œé‚„é—œä¹å¦‚ä½•æ›´æœ‰æ•ˆåœ°åˆ©ç”¨è‡ªç„¶ç•Œä¸­çš„æ´»æ€§ç‰©è³ªä¾†ä¿ƒé€²å¥åº·ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ä¾†å¢å¼·Lactiplantibacillus plantarumçš„è˜¿è””ç¡«ç´ è½‰æ›ç‡ã€‚ç ”ç©¶åœ˜éšŠè§€å¯Ÿäº†ä¸åŒçš„è‘¡è„ç³–æ›¿ä»£æ¯”ç‡å°ç´°èŒä»£è¬çš„å½±éŸ¿ï¼Œä¸¦é€²è¡Œäº†è½‰éŒ„çµ„åˆ†æï¼Œä»¥äº†è§£ç´°èŒåœ¨é©æ‡‰éç¨‹ä¸­ä»£è¬çš„è®ŠåŒ–ã€‚é€™äº›æ–¹æ³•å¹«åŠ©ç ”ç©¶è€…æ·±å…¥äº†è§£ç´°èŒå¦‚ä½•è™•ç†é’èŠ±æ¤°èœä¸­çš„è‘¡è„ç³–è‹·é…¸ï¼Œä¸¦æœ€çµ‚è½‰æ›ç‚ºè˜¿è””ç¡«ç´ çš„éç¨‹ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œç•¶è‘¡è„ç³–æ›¿ä»£æ¯”ç‡å¢åŠ æ™‚ï¼Œç´°èŒçš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬é¡¯è‘—ä¸‹é™ï¼Œè€Œæ°¨åŸºé…¸ä»£è¬å‰‡ä¸Šå‡ã€‚é€™è¡¨æ˜ç´°èŒåœ¨é©æ‡‰éç¨‹ä¸­å¯èƒ½æœƒæ”¹è®Šå…¶ä»£è¬è·¯å¾‘ï¼Œå¾è€Œæé«˜è˜¿è””ç¡«ç´ çš„ç”¢é‡ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„æ­ç¤ºäº†è˜¿è””ç¡«ç´ è½‰æ›éç¨‹ä¸­çš„ä¸€äº›é—œéµæ­¥é©Ÿï¼ŒåŒ…æ‹¬è‘¡è„ç³–è‹·é…¸çš„é€²å£ã€ç£·é…¸åŒ–å’Œæ°´è§£ç­‰ã€‚é€™äº›çµæœå°æ–¼æœªä¾†é€²ä¸€æ­¥äº†è§£å¾®ç”Ÿç‰©èˆ‡å¤©ç„¶æ´»æ€§ç‰©è³ªä¹‹é–“çš„ç›¸äº’ä½œç”¨æ©Ÿåˆ¶å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ é€™ç¨®æœ‰ç›Šçš„ç”Ÿç‰©æ´»æ€§åŒ–åˆç‰©ã€‚è˜¿è””ç¡«ç´ ä¸»è¦ä¾†è‡ªé’èŠ±æ¤°èœï¼Œå°æ–¼ä¿ƒé€²å¥åº·å’Œé é˜²æŸäº›ç–¾ç—…å¯èƒ½æœ‰æ­£é¢å½±éŸ¿ã€‚ç„¶è€Œï¼Œè˜¿è””ç¡«ç´ çš„è½‰æ›ç‡è¼ƒä½ï¼Œé€™æ„å‘³è‘—æˆ‘å€‘éœ€è¦æ›´æœ‰æ•ˆçš„æ–¹æ³•ä¾†æé«˜å…¶ç”¢é‡ï¼Œä»¥ä¾¿èƒ½å¤ æ›´å¥½åœ°åˆ©ç”¨é€™ç¨®åŒ–åˆç‰©çš„æ½›åœ¨å¥½è™•ã€‚äº†è§£é€™äº›è½‰æ›éç¨‹çš„æ©Ÿåˆ¶ï¼Œå°‡æœ‰åŠ©æ–¼æœªä¾†çš„å¥åº·ç ”ç©¶å’Œæ‡‰ç”¨ï¼Œå°¤å…¶æ˜¯åœ¨ç‡Ÿé¤Šè£œå……å’Œç–¾ç—…é é˜²æ–¹é¢ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•æé«˜è˜¿è””ç¡«ç´ çš„è½‰æ›ç‡ï¼Œç‰¹åˆ¥æ˜¯é€šéåˆ©ç”¨ä¸€ç¨®åç‚ºLactiplantibacillus plantarumçš„ç´°èŒã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œé€™ç¨®ç´°èŒåœ¨å°‡é’èŠ±æ¤°èœä¸­çš„å‰é«”ç‰©è³ªï¼ˆå³è‘¡è„ç³–è‹·é…¸ï¼‰è½‰æ›ç‚ºè˜¿è””ç¡«ç´ çš„éç¨‹ä¸­ï¼Œè½‰æ›æ•ˆç‡ä½çš„åŸå› ä»¥åŠå¦‚ä½•æ”¹å–„é€™ä¸€éç¨‹ã€‚é€™ä¸åƒ…æ¶‰åŠåˆ°å¾®ç”Ÿç‰©çš„ä»£è¬æ©Ÿåˆ¶ï¼Œé‚„é—œä¹å¦‚ä½•æ›´æœ‰æ•ˆåœ°åˆ©ç”¨è‡ªç„¶ç•Œä¸­çš„æ´»æ€§ç‰©è³ªä¾†ä¿ƒé€²å¥åº·ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ä¾†å¢å¼·Lactiplantibacillus plantarumçš„è˜¿è””ç¡«ç´ è½‰æ›ç‡ã€‚ç ”ç©¶åœ˜éšŠè§€å¯Ÿäº†ä¸åŒçš„è‘¡è„ç³–æ›¿ä»£æ¯”ç‡å°ç´°èŒä»£è¬çš„å½±éŸ¿ï¼Œä¸¦é€²è¡Œäº†è½‰éŒ„çµ„åˆ†æï¼Œä»¥äº†è§£ç´°èŒåœ¨é©æ‡‰éç¨‹ä¸­ä»£è¬çš„è®ŠåŒ–ã€‚é€™äº›æ–¹æ³•å¹«åŠ©ç ”ç©¶è€…æ·±å…¥äº†è§£ç´°èŒå¦‚ä½•è™•ç†é’èŠ±æ¤°èœä¸­çš„è‘¡è„ç³–è‹·é…¸ï¼Œä¸¦æœ€çµ‚è½‰æ›ç‚ºè˜¿è””ç¡«ç´ çš„éç¨‹ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œç•¶è‘¡è„ç³–æ›¿ä»£æ¯”ç‡å¢åŠ æ™‚ï¼Œç´°èŒçš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬é¡¯è‘—ä¸‹é™ï¼Œè€Œæ°¨åŸºé…¸ä»£è¬å‰‡ä¸Šå‡ã€‚é€™è¡¨æ˜ç´°èŒåœ¨é©æ‡‰éç¨‹ä¸­å¯èƒ½æœƒæ”¹è®Šå…¶ä»£è¬è·¯å¾‘ï¼Œå¾è€Œæé«˜è˜¿è””ç¡«ç´ çš„ç”¢é‡ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„æ­ç¤ºäº†è˜¿è””ç¡«ç´ è½‰æ›éç¨‹ä¸­çš„ä¸€äº›é—œéµæ­¥é©Ÿï¼ŒåŒ…æ‹¬è‘¡è„ç³–è‹·é…¸çš„é€²å£ã€ç£·é…¸åŒ–å’Œæ°´è§£ç­‰ã€‚é€™äº›çµæœå°æ–¼æœªä¾†é€²ä¸€æ­¥äº†è§£å¾®ç”Ÿç‰©èˆ‡å¤©ç„¶æ´»æ€§ç‰©è³ªä¹‹é–“çš„ç›¸äº’ä½œç”¨æ©Ÿåˆ¶å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "fb_post": "æ ¹æ“šã€ŠJournal of agricultural and food chemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“é’èŠ±æ¤°èœè£¡æœ‰ä¸€ç¨®ç¥å¥‡çš„æˆåˆ†å«è˜¿è””ç¡«ç´ å—ï¼Ÿé€™ç¨®ç‰©è³ªå¯èƒ½å°æˆ‘å€‘çš„å¥åº·æœ‰å¾ˆå¤§çš„å¹«åŠ©ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼å¦‚ä½•æé«˜è˜¿è””ç¡«ç´ çš„ç”¢é‡ï¼Œå°¤å…¶æ˜¯åˆ©ç”¨ä¸€ç¨®å«åšLactiplantibacillus plantarumçš„ç´°èŒä¾†é”æˆé€™å€‹ç›®æ¨™ã€‚ç ”ç©¶è€…å€‘æƒ³çŸ¥é“ï¼Œé€™ç¨®ç´°èŒåœ¨è½‰æ›é’èŠ±æ¤°èœä¸­çš„å‰é«”ç‰©è³ªï¼ˆè‘¡è„ç³–è‹·é…¸ï¼‰ç‚ºè˜¿è””ç¡«ç´ çš„éç¨‹ä¸­ï¼Œè½‰æ›æ•ˆç‡ä½çš„åŸå› ï¼Œä¸¦ä¸”å¸Œæœ›èƒ½æ”¹å–„é€™å€‹éç¨‹ã€‚  \n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶åœ˜éšŠä½¿ç”¨äº†ä¸€äº›å‰µæ–°çš„æŠ€è¡“ä¾†å¢å¼·é€™ç¨®ç´°èŒçš„è½‰æ›èƒ½åŠ›ã€‚ä»–å€‘è§€å¯Ÿä¸åŒçš„è‘¡è„ç³–æ›¿ä»£æ¯”ç‡å°ç´°èŒçš„å½±éŸ¿ï¼Œä¸¦åˆ†æç´°èŒåœ¨é©æ‡‰éç¨‹ä¸­çš„ä»£è¬è®ŠåŒ–ã€‚çµæœé¡¯ç¤ºï¼Œç•¶è‘¡è„ç³–çš„æ›¿ä»£æ¯”ç‡å¢åŠ æ™‚ï¼Œç´°èŒçš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬ä¸‹é™ï¼Œè€Œæ°¨åŸºé…¸ä»£è¬å‰‡ä¸Šå‡ï¼Œé€™å¯èƒ½æœ‰åŠ©æ–¼æé«˜è˜¿è””ç¡«ç´ çš„ç”¢é‡ã€‚  \n\né€™äº›ç™¼ç¾è®“æˆ‘å€‘æ›´äº†è§£å¾®ç”Ÿç‰©å¦‚ä½•èˆ‡å¤©ç„¶æ´»æ€§ç‰©è³ªäº’å‹•ï¼Œä¸¦ç‚ºæœªä¾†çš„å¥åº·ç ”ç©¶æä¾›äº†é‡è¦çš„ç·šç´¢ã€‚  \n\nğŸ” ä¸»è¦é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼å¥åº·ï¼Œä½†è½‰æ›ç‡è¼ƒä½ã€‚  \n2. åˆ©ç”¨Lactiplantibacillus plantarumç´°èŒå¯ä»¥æé«˜è½‰æ›æ•ˆç‡ã€‚  \n3. å¯¦é©—ç™¼ç¾ç´°èŒä»£è¬è·¯å¾‘çš„æ”¹è®Šèƒ½æå‡è˜¿è””ç¡«ç´ çš„ç”¢é‡ã€‚",
    "image_prompt": "Create an infographic that explains the experiment and main results of a study on increasing sulforaphane production from broccoli using Lactiplantibacillus plantarum bacteria. Include simple illustrations of broccoli and sulforaphane, a simplified representation of the bacteria, arrows or flow lines showing the experimental steps, and a section highlighting the main results, such as changes in metabolic pathways and increased sulforaphane yield. Use a flat design style with a light background and soft colors.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41340527/"
  },
  {
    "id": "41352012",
    "title_en": "Protection against deoxynivalenol (DON)-induced intestinal injury by sulforaphane via modulation of lysosomal function.",
    "pub_date": "2025 Dec",
    "journal": "Journal of hazardous materials",
    "abstract_en": "Deoxynivalenol (DON) is a prevalent mycotoxin commonly detected in both human and animal diets, representing a significant health risk. Sulforaphane (SFN), a bioactive compound from cruciferous vegetables known for its antioxidant. This study aimed to confirm SFN's protective effect against DON-induced intestinal injury and clarify its underlying molecular mechanism. In vivo, C57BL/6 male mice (nâ€¯=â€¯8/group) were treated with DON (2â€¯mg/kg BW) and SFN (10â€¯mg/kg BW) to assess the overall protective effects of SFN; in vitro, intestinal porcine epithelial cells (IPEC-J2) and pig intestinal organoids were treated with DON (1â€¯Î¼g/mL) and SFN (2â€¯Î¼M) to investigate the protective mechanism of SFN. Hematoxylin-eosin staining, western blot and flow cytometry were used to confirm the protective effects of SFN. RNA-seq, CETSA, ITDRF and non-targeted metabolomics was employed to investigate the mechanism of SFN supplementation. This study demonstrated that SFN significantly alleviated DON-induced intestinal toxicity: in vivo, SFN restored jejunal villus height/crypt depth and restored the balance of redox homeostasis (decreased MDA, LDH, SOD and CAT); in vitro, SFN lowered DON-induced cell apoptosis and ROS accumulation. Mechanistically, lysosomal function was critical for SFN's protection-SFN directly targeted ATP6AP1 to enhance lysosomal acidification Moreover, ATP supplementation further potentiated this acidification and SFN's cytoprotective effect. This study identified ATP6AP1-mediated lysosomal acidification as a novel mechanism for SFN to mitigate DON-induced intestinal injury. Therefore, investigating the crosstalk between the SFN-ATP6AP1 axis and gut microbiota warrants further investigation to elucidate a broader protective mechanism.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¸¸è¦‹çš„éœ‰èŒæ¯’ç´ è„«æ°§é›ªè…çƒ¯é†‡ï¼ˆDONï¼‰å°è…¸é“çš„å‚·å®³ã€‚é€™ç¨®æ¯’ç´ åœ¨æˆ‘å€‘çš„é£²é£Ÿä¸­ç›¸ç•¶æ™®éï¼Œå°äººé¡å’Œå‹•ç‰©çš„å¥åº·æ§‹æˆäº†é‡å¤§é¢¨éšªã€‚ç ”ç©¶é¡¯ç¤ºï¼Œä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„è˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—é€™ç¨®æ¯’ç´ å¼•èµ·çš„è…¸é“æå‚·ï¼Œé€™è®“æˆ‘å€‘å°å¦‚ä½•åˆ©ç”¨å¤©ç„¶é£Ÿæä¾†ä¿è­·è…¸é“å¥åº·æœ‰äº†æ–°çš„æ€è€ƒã€‚é€éäº†è§£è˜¿è””ç¡«ç´ çš„ä¿è­·æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„é é˜²å’Œæ²»ç™‚æ–¹æ³•ï¼Œæ¸›å°‘é€™é¡æ¯’ç´ å°å¥åº·çš„å½±éŸ¿ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è„«æ°§é›ªè…çƒ¯é†‡å¼•èµ·çš„è…¸é“æå‚·çš„ä¿è­·æ•ˆæœï¼Œä»¥åŠå…¶èƒŒå¾Œçš„åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›ç¢ºèªè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆæ¸›è¼•ç”±é€™ç¨®éœ‰èŒæ¯’ç´ é€ æˆçš„è…¸é“å‚·å®³ï¼Œä¸¦æ·±å…¥äº†è§£å…¶ä½œç”¨çš„ç”Ÿç‰©åŒ–å­¸éç¨‹ã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ çš„æ½›åœ¨å¥åº·ç›Šè™•ï¼Œä¹Ÿå¯èƒ½ç‚ºæœªä¾†çš„ç›¸é—œç ”ç©¶æä¾›åŸºç¤ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å°é¼ å’Œè±¬çš„è…¸é“ç´°èƒä¾†é€²è¡Œæ¸¬è©¦ã€‚å°é¼ å¯¦é©—ä¸­ï¼ŒC57BL/6é›„æ€§å°é¼ è¢«åˆ†ç‚ºå…©çµ„ï¼Œåˆ†åˆ¥æ¥å—è„«æ°§é›ªè…çƒ¯é†‡å’Œè˜¿è””ç¡«ç´ çš„è™•ç†ï¼Œä»¥è©•ä¼°è˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœã€‚åœ¨é«”å¤–å¯¦é©—ä¸­ï¼Œå‰‡ä½¿ç”¨è±¬è…¸é“ä¸Šçš®ç´°èƒå’Œè…¸é“å™¨å®˜é¡å™¨é€²è¡Œæ¸¬è©¦ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ çš„ä¿è­·æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…ä½¿ç”¨äº†å¤šç¨®æŠ€è¡“ï¼ŒåŒ…æ‹¬çµ„ç¹”æŸ“è‰²ã€è›‹ç™½è³ªæª¢æ¸¬å’Œæµå¼ç´°èƒè¡“ï¼Œä¾†ç¢ºèªè˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•è„«æ°§é›ªè…çƒ¯é†‡å¼•èµ·çš„è…¸é“æ¯’æ€§ã€‚åœ¨å°é¼ å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ æ¢å¾©äº†è…¸é“çµ¨æ¯›çš„é«˜åº¦å’Œè…ºé«”çš„æ·±åº¦ï¼Œä¸¦æ”¹å–„äº†æ°§åŒ–é‚„åŸå¹³è¡¡ã€‚åœ¨é«”å¤–å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ é™ä½äº†è„«æ°§é›ªè…çƒ¯é†‡å¼•èµ·çš„ç´°èƒå‡‹äº¡å’Œæ´»æ€§æ°§çš„ç©ç´¯ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ çš„ä¿è­·ä½œç”¨èˆ‡å…¶å°æº¶é…¶é«”åŠŸèƒ½çš„å½±éŸ¿æœ‰é—œï¼Œç‰¹åˆ¥æ˜¯å®ƒèƒ½ç›´æ¥ä½œç”¨æ–¼ATP6AP1ï¼Œä¿ƒé€²æº¶é…¶é«”çš„é…¸åŒ–ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éATP6AP1ä»‹å°çš„æº¶é…¶é«”é…¸åŒ–ä¾†æ¸›è¼•è…¸é“æå‚·ï¼Œæœªä¾†é‚„éœ€è¦é€²ä¸€æ­¥ç ”ç©¶å…¶èˆ‡è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„ç›¸äº’ä½œç”¨ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¸¸è¦‹çš„éœ‰èŒæ¯’ç´ è„«æ°§é›ªè…çƒ¯é†‡ï¼ˆDONï¼‰å°è…¸é“çš„å‚·å®³ã€‚é€™ç¨®æ¯’ç´ åœ¨æˆ‘å€‘çš„é£²é£Ÿä¸­ç›¸ç•¶æ™®éï¼Œå°äººé¡å’Œå‹•ç‰©çš„å¥åº·æ§‹æˆäº†é‡å¤§é¢¨éšªã€‚ç ”ç©¶é¡¯ç¤ºï¼Œä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„è˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—é€™ç¨®æ¯’ç´ å¼•èµ·çš„è…¸é“æå‚·ï¼Œé€™è®“æˆ‘å€‘å°å¦‚ä½•åˆ©ç”¨å¤©ç„¶é£Ÿæä¾†ä¿è­·è…¸é“å¥åº·æœ‰äº†æ–°çš„æ€è€ƒã€‚é€éäº†è§£è˜¿è””ç¡«ç´ çš„ä¿è­·æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„é é˜²å’Œæ²»ç™‚æ–¹æ³•ï¼Œæ¸›å°‘é€™é¡æ¯’ç´ å°å¥åº·çš„å½±éŸ¿ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è„«æ°§é›ªè…çƒ¯é†‡å¼•èµ·çš„è…¸é“æå‚·çš„ä¿è­·æ•ˆæœï¼Œä»¥åŠå…¶èƒŒå¾Œçš„åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›ç¢ºèªè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆæ¸›è¼•ç”±é€™ç¨®éœ‰èŒæ¯’ç´ é€ æˆçš„è…¸é“å‚·å®³ï¼Œä¸¦æ·±å…¥äº†è§£å…¶ä½œç”¨çš„ç”Ÿç‰©åŒ–å­¸éç¨‹ã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ çš„æ½›åœ¨å¥åº·ç›Šè™•ï¼Œä¹Ÿå¯èƒ½ç‚ºæœªä¾†çš„ç›¸é—œç ”ç©¶æä¾›åŸºç¤ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å°é¼ å’Œè±¬çš„è…¸é“ç´°èƒä¾†é€²è¡Œæ¸¬è©¦ã€‚å°é¼ å¯¦é©—ä¸­ï¼ŒC57BL/6é›„æ€§å°é¼ è¢«åˆ†ç‚ºå…©çµ„ï¼Œåˆ†åˆ¥æ¥å—è„«æ°§é›ªè…çƒ¯é†‡å’Œè˜¿è””ç¡«ç´ çš„è™•ç†ï¼Œä»¥è©•ä¼°è˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœã€‚åœ¨é«”å¤–å¯¦é©—ä¸­ï¼Œå‰‡ä½¿ç”¨è±¬è…¸é“ä¸Šçš®ç´°èƒå’Œè…¸é“å™¨å®˜é¡å™¨é€²è¡Œæ¸¬è©¦ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ çš„ä¿è­·æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…ä½¿ç”¨äº†å¤šç¨®æŠ€è¡“ï¼ŒåŒ…æ‹¬çµ„ç¹”æŸ“è‰²ã€è›‹ç™½è³ªæª¢æ¸¬å’Œæµå¼ç´°èƒè¡“ï¼Œä¾†ç¢ºèªè˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•è„«æ°§é›ªè…çƒ¯é†‡å¼•èµ·çš„è…¸é“æ¯’æ€§ã€‚åœ¨å°é¼ å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ æ¢å¾©äº†è…¸é“çµ¨æ¯›çš„é«˜åº¦å’Œè…ºé«”çš„æ·±åº¦ï¼Œä¸¦æ”¹å–„äº†æ°§åŒ–é‚„åŸå¹³è¡¡ã€‚åœ¨é«”å¤–å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ é™ä½äº†è„«æ°§é›ªè…çƒ¯é†‡å¼•èµ·çš„ç´°èƒå‡‹äº¡å’Œæ´»æ€§æ°§çš„ç©ç´¯ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ çš„ä¿è­·ä½œç”¨èˆ‡å…¶å°æº¶é…¶é«”åŠŸèƒ½çš„å½±éŸ¿æœ‰é—œï¼Œç‰¹åˆ¥æ˜¯å®ƒèƒ½ç›´æ¥ä½œç”¨æ–¼ATP6AP1ï¼Œä¿ƒé€²æº¶é…¶é«”çš„é…¸åŒ–ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éATP6AP1ä»‹å°çš„æº¶é…¶é«”é…¸åŒ–ä¾†æ¸›è¼•è…¸é“æå‚·ï¼Œæœªä¾†é‚„éœ€è¦é€²ä¸€æ­¥ç ”ç©¶å…¶èˆ‡è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„ç›¸äº’ä½œç”¨ã€‚",
    "fb_post": "æ ¹æ“šã€ŠJournal of hazardous materialsã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„è…¸é“ä¹Ÿæœƒå—åˆ°éœ‰èŒæ¯’ç´ çš„å¨è„…ï¼é€™æ¬¡çš„ç ”ç©¶å‘Šè¨´æˆ‘å€‘ï¼Œä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„è˜¿è””ç¡«ç´ ï¼Œå¯èƒ½æœ‰åŠ©æ–¼ä¿è­·è…¸é“å¥åº·ï¼ğŸ‘©â€ğŸ”¬\n\né€™é …ç ”ç©¶çš„é‡é»åœ¨æ–¼æ¢è¨è˜¿è””ç¡«ç´ å°ä¸€ç¨®å¸¸è¦‹çš„éœ‰èŒæ¯’ç´ â€”â€”è„«æ°§é›ªè…çƒ¯é†‡ï¼ˆDONï¼‰æ‰€é€ æˆçš„è…¸é“æå‚·çš„ä¿è­·æ•ˆæœã€‚ç ”ç©¶è€…å€‘ä½¿ç”¨å°é¼ å’Œè±¬çš„è…¸é“ç´°èƒé€²è¡Œå¯¦é©—ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ çš„ä½œç”¨ã€‚é€éå¤šç¨®æŠ€è¡“ï¼Œä»–å€‘ç¢ºèªäº†è˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•è„«æ°§é›ªè…çƒ¯é†‡å¼•èµ·çš„è…¸é“æ¯’æ€§ï¼Œç”šè‡³èƒ½æ”¹å–„è…¸é“çš„çµæ§‹å’ŒåŠŸèƒ½ï¼é€™è®“æˆ‘å€‘å°åˆ©ç”¨å¤©ç„¶é£Ÿæä¾†ä¿è­·è…¸é“å¥åº·æœ‰äº†æ–°çš„æ€è€ƒã€‚\n\nğŸ”é‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—éœ‰èŒæ¯’ç´ å°è…¸é“çš„å‚·å®³ã€‚\n2. å¯¦é©—é¡¯ç¤ºè˜¿è””ç¡«ç´ èƒ½æ”¹å–„è…¸é“çµæ§‹ã€‚\n3. ç ”ç©¶çµæœç‚ºæœªä¾†çš„å¥åº·ç ”ç©¶æä¾›äº†åŸºç¤ã€‚",
    "image_prompt": "Create a flat design infographic with a light background that explains the experiment and main findings of a study on the protective effects of sulforaphane from cruciferous vegetables against a common mycotoxin, deoxynivalenol (DON). Include simple icons representing broccoli or sulforaphane, simplified illustrations of experimental subjects such as mice and intestinal cells, arrows or flow lines indicating the experimental steps, and a section highlighting the main results like protective effects and changes observed in the intestine.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è…¸é“æå‚· Intestinal Injury",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41352012/"
  },
  {
    "id": "41341174",
    "title_en": "Sulforaphane attenuates oxidative stress, senescence, and ferroptosis induced by cigarette smoke extract <i>in vitro</i> and <i>in vivo via</i> upregulating the expression of SIRT1.",
    "pub_date": "2025 Dec",
    "journal": "Research in pharmaceutical sciences",
    "abstract_en": "Cigarette smoking induces lung toxicity by triggering oxidative stress, leading to apoptosis, ferroptosis, and senescence. Sulforaphane (SFN), a potent antioxidant, activates the SIRT1 pathway, enhancing cellular stress resistance and survival. This study aimed to evaluate the protective effects of SFN against cigarette smoke extract (CSE)-induced damage in human airway epithelial cells (BEAS-2B) and in mouse lungs, focusing on its role in upregulating SIRT1 expression. BEAS-2B cells were treated with CSE and SFN, and cell viability was assessed using the MTT assay. Cellular senescence was assessed using the SA-Î²-gal assay and the expression of genes associated with senescence (p16 and p21). The expression levels of SIRT1, senescence-associated secretory phenotype (SASP) cytokines (IL-1Î², IL-6, IL-8, TNF-Î±), GPX4, and SLC7A11 were quantified using qRT-PCR. Additionally, ROS production, GSH and MDA levels, and iron content were measured. An emphysema mouse model was induced by intraperitoneal administration of CSE (7.2 mg/kg) alone or in combination with SFN (10.2 mg/kg) over 28 days, and subsequent histopathological changes were evaluated. Our findings revealed that SFN co-treatment effectively mitigated CSE-induced cytotoxicity, senescence, and SASP cytokine secretion, as well as the pronounced emphysematous changes in lung tissues. Furthermore, SFN reversed CSE-induced downregulation of SIRT1 and upregulation of NF-ÎºB. Notably, SFN also inhibited CSE-induced ferroptosis by increasing GPX4 and SLC7A11 expression while reducing iron and MDA levels. The findings of the present study demonstrated that sulforaphane offers protective effects against CSE-induced toxicity by mitigating oxidative stress, ferroptosis, and cellular senescence.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å¸ç…™å°è‚ºéƒ¨é€ æˆçš„æå®³æ–¹é¢ã€‚å¸ç…™æœƒå¼•ç™¼æ°§åŒ–å£“åŠ›ï¼Œé€²è€Œå°è‡´ç´°èƒæ­»äº¡å’Œè€åŒ–ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¼·æ•ˆæŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼å¢å¼·ç´°èƒå°é€™äº›å£“åŠ›çš„æŠµæŠ—åŠ›ï¼Œå¾è€Œä¿è­·è‚ºéƒ¨å¥åº·ã€‚é€™å°æ–¼å¸ç…™è€…æˆ–é•·æœŸæ¥è§¸ç…™éœ§çš„äººä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹é‡è¦çš„å¥åº·æç¤ºï¼Œæé†’ä»–å€‘æ³¨æ„æŠ—æ°§åŒ–åŠ‘çš„æ”å–ï¼Œä¸¦è€ƒæ…®æ”¹å–„ç”Ÿæ´»æ–¹å¼ä»¥æ¸›å°‘å¸ç…™å¸¶ä¾†çš„å±å®³ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼é¦™ç…™ç…™éœ§æå–ç‰©å¼•èµ·çš„è‚ºéƒ¨æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶ç‰¹åˆ¥é—œæ³¨è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ä¸€ç¨®åç‚ºSIRT1çš„è›‹ç™½è³ªçš„è¡¨é”ï¼Œé€™ç¨®è›‹ç™½è³ªèˆ‡ç´°èƒçš„å£“åŠ›æŠµæŠ—å’Œå­˜æ´»æœ‰é—œã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ æ¸›å°‘é¦™ç…™ç…™éœ§å°äººé¡æ°£é“ä¸Šçš®ç´°èƒåŠå°é¼ è‚ºéƒ¨çš„æå®³ï¼Œä¸¦è©•ä¼°å…¶æ½›åœ¨çš„ä¿è­·æ©Ÿåˆ¶ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äººé¡æ°£é“ä¸Šçš®ç´°èƒï¼ˆBEAS-2Bï¼‰å’Œå°é¼ ä½œç‚ºç ”ç©¶å°è±¡ã€‚é¦–å…ˆï¼ŒBEAS-2Bç´°èƒè¢«è™•ç†é¦™ç…™ç…™éœ§æå–ç‰©å’Œè˜¿è””ç¡«ç´ ï¼Œç„¶å¾Œä½¿ç”¨MTTæ¸¬è©¦è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„ä½¿ç”¨SA-Î²-galæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„è€åŒ–æƒ…æ³ï¼Œä¸¦é€šéqRT-PCRé‡åŒ–èˆ‡è€åŒ–ç›¸é—œçš„åŸºå› è¡¨é”ã€‚å°æ–¼å°é¼ ï¼Œç ”ç©¶è€…å‰‡ä½¿ç”¨äº†èª˜å°è‚ºæ°£è…«çš„æ¨¡å‹ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ å°è‚ºéƒ¨çµ„ç¹”çš„å½±éŸ¿ï¼Œä¸¦è©•ä¼°å…¶çµ„ç¹”å­¸è®ŠåŒ–ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„å…±åŒè™•ç†æœ‰æ•ˆæ¸›å°‘äº†é¦™ç…™ç…™éœ§å¼•èµ·çš„ç´°èƒæ¯’æ€§ã€è€åŒ–å’Œç›¸é—œç´°èƒå› å­çš„åˆ†æ³Œï¼Œä¸¦æ”¹å–„äº†è‚ºéƒ¨çµ„ç¹”çš„æ°£è…«è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é€†è½‰é¦™ç…™ç…™éœ§å¼•èµ·çš„SIRT1ä¸‹èª¿å’ŒNF-ÎºBä¸Šèª¿ï¼Œä¸¦é€šéå¢åŠ GPX4å’ŒSLC7A11çš„è¡¨é”ä¾†æŠ‘åˆ¶éµæ­»äº¡ï¼ŒåŒæ™‚é™ä½éµå’ŒMDAçš„æ°´å¹³ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—é¦™ç…™ç…™éœ§å¼•èµ·çš„æ°§åŒ–å£“åŠ›ã€éµæ­»äº¡å’Œç´°èƒè€åŒ–å…·æœ‰ä¿è­·ä½œç”¨ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å¸ç…™å°è‚ºéƒ¨é€ æˆçš„æå®³æ–¹é¢ã€‚å¸ç…™æœƒå¼•ç™¼æ°§åŒ–å£“åŠ›ï¼Œé€²è€Œå°è‡´ç´°èƒæ­»äº¡å’Œè€åŒ–ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¼·æ•ˆæŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼å¢å¼·ç´°èƒå°é€™äº›å£“åŠ›çš„æŠµæŠ—åŠ›ï¼Œå¾è€Œä¿è­·è‚ºéƒ¨å¥åº·ã€‚é€™å°æ–¼å¸ç…™è€…æˆ–é•·æœŸæ¥è§¸ç…™éœ§çš„äººä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹é‡è¦çš„å¥åº·æç¤ºï¼Œæé†’ä»–å€‘æ³¨æ„æŠ—æ°§åŒ–åŠ‘çš„æ”å–ï¼Œä¸¦è€ƒæ…®æ”¹å–„ç”Ÿæ´»æ–¹å¼ä»¥æ¸›å°‘å¸ç…™å¸¶ä¾†çš„å±å®³ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼é¦™ç…™ç…™éœ§æå–ç‰©å¼•èµ·çš„è‚ºéƒ¨æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶ç‰¹åˆ¥é—œæ³¨è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ä¸€ç¨®åç‚ºSIRT1çš„è›‹ç™½è³ªçš„è¡¨é”ï¼Œé€™ç¨®è›‹ç™½è³ªèˆ‡ç´°èƒçš„å£“åŠ›æŠµæŠ—å’Œå­˜æ´»æœ‰é—œã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ æ¸›å°‘é¦™ç…™ç…™éœ§å°äººé¡æ°£é“ä¸Šçš®ç´°èƒåŠå°é¼ è‚ºéƒ¨çš„æå®³ï¼Œä¸¦è©•ä¼°å…¶æ½›åœ¨çš„ä¿è­·æ©Ÿåˆ¶ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äººé¡æ°£é“ä¸Šçš®ç´°èƒï¼ˆBEAS-2Bï¼‰å’Œå°é¼ ä½œç‚ºç ”ç©¶å°è±¡ã€‚é¦–å…ˆï¼ŒBEAS-2Bç´°èƒè¢«è™•ç†é¦™ç…™ç…™éœ§æå–ç‰©å’Œè˜¿è””ç¡«ç´ ï¼Œç„¶å¾Œä½¿ç”¨MTTæ¸¬è©¦è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„ä½¿ç”¨SA-Î²-galæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„è€åŒ–æƒ…æ³ï¼Œä¸¦é€šéqRT-PCRé‡åŒ–èˆ‡è€åŒ–ç›¸é—œçš„åŸºå› è¡¨é”ã€‚å°æ–¼å°é¼ ï¼Œç ”ç©¶è€…å‰‡ä½¿ç”¨äº†èª˜å°è‚ºæ°£è…«çš„æ¨¡å‹ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ å°è‚ºéƒ¨çµ„ç¹”çš„å½±éŸ¿ï¼Œä¸¦è©•ä¼°å…¶çµ„ç¹”å­¸è®ŠåŒ–ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„å…±åŒè™•ç†æœ‰æ•ˆæ¸›å°‘äº†é¦™ç…™ç…™éœ§å¼•èµ·çš„ç´°èƒæ¯’æ€§ã€è€åŒ–å’Œç›¸é—œç´°èƒå› å­çš„åˆ†æ³Œï¼Œä¸¦æ”¹å–„äº†è‚ºéƒ¨çµ„ç¹”çš„æ°£è…«è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é€†è½‰é¦™ç…™ç…™éœ§å¼•èµ·çš„SIRT1ä¸‹èª¿å’ŒNF-ÎºBä¸Šèª¿ï¼Œä¸¦é€šéå¢åŠ GPX4å’ŒSLC7A11çš„è¡¨é”ä¾†æŠ‘åˆ¶éµæ­»äº¡ï¼ŒåŒæ™‚é™ä½éµå’ŒMDAçš„æ°´å¹³ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—é¦™ç…™ç…™éœ§å¼•èµ·çš„æ°§åŒ–å£“åŠ›ã€éµæ­»äº¡å’Œç´°èƒè€åŒ–å…·æœ‰ä¿è­·ä½œç”¨ã€‚",
    "fb_post": "æ ¹æ“šã€ŠResearch in pharmaceutical sciencesã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿè˜¿è””ç¡«ç´ å¯èƒ½æ˜¯ä¿è­·æˆ‘å€‘è‚ºéƒ¨å¥åº·çš„å°è‹±é›„ï¼\n\næœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆé–€æ¢è¨äº†è˜¿è””ç¡«ç´ å°å¸ç…™é€ æˆçš„è‚ºéƒ¨æå®³çš„ä¿è­·ä½œç”¨ã€‚å¸ç…™æœƒè®“æˆ‘å€‘çš„è‚ºéƒ¨é­å—æ°§åŒ–å£“åŠ›ï¼Œé€™æœƒå°è‡´ç´°èƒæ­»äº¡å’Œè€åŒ–ï¼Œå°å¥åº·å½±éŸ¿ä¸å°ã€‚è€Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¼·æ•ˆçš„æŠ—æ°§åŒ–åŠ‘ï¼Œæˆ–è¨±èƒ½å¹«åŠ©æˆ‘å€‘æŠµæŠ—é€™äº›å£“åŠ›ã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç§‘å­¸å®¶å€‘ä½¿ç”¨äº†äººé¡çš„æ°£é“ç´°èƒå’Œå°é¼ ä¾†é€²è¡Œå¯¦é©—ã€‚ä»–å€‘ç™¼ç¾ï¼Œç•¶ç´°èƒæ¥è§¸åˆ°é¦™ç…™ç…™éœ§æå–ç‰©æ™‚ï¼ŒåŠ å…¥è˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆæ¸›å°‘ç´°èƒçš„æå‚·å’Œè€åŒ–ï¼Œé‚„èƒ½æ”¹å–„è‚ºéƒ¨çµ„ç¹”çš„ç‹€æ³ã€‚\n\né‚£éº¼ï¼Œé€™é …ç ”ç©¶å‘Šè¨´æˆ‘å€‘ä»€éº¼å‘¢ï¼Ÿ\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼ä¿è­·è‚ºéƒ¨ï¼Œç‰¹åˆ¥æ˜¯å°å¸ç…™è€…ã€‚\n2. å¢åŠ æŠ—æ°§åŒ–åŠ‘çš„æ”å–ï¼Œå¯èƒ½å°å¥åº·æœ‰ç›Šã€‚\n3. æ”¹å–„ç”Ÿæ´»æ–¹å¼ï¼Œæ¸›å°‘å¸ç…™çš„å±å®³ï¼Œå°æˆ‘å€‘çš„èº«é«”æœ‰å¾ˆå¤§å¹«åŠ©ï¼\n\nè®“æˆ‘å€‘ä¸€èµ·é—œå¿ƒè‚ºéƒ¨å¥åº·ï¼Œå¾é£²é£Ÿé–‹å§‹åšèµ·å§ï¼",
    "image_prompt": "Create a flat design infographic on the protective effects of sulforaphane against cigarette smoke damage. The image should have a light background with soft colors. Include simplified illustrations of broccoli or sulforaphane, human airway epithelial cells, and mice as experimental subjects. Use arrows or flow lines to indicate the experimental process. Add a section labeled 'Key Findings' that highlights the protective effects, such as reduced cell damage and improved lung tissue health.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚ºæ°£è…« Emphysema",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41341174/"
  },
  {
    "id": "41039785",
    "title_en": "Integrative Network Pharmacology and Proteomics Decipher the Immunomodulatory Mechanism of Sulforaphane Against Intrinsic Skin Aging.",
    "pub_date": "2025 Dec",
    "journal": "Molecular nutrition & food research",
    "abstract_en": "Skin aging is characterized by declines in structural functions, contributing to age-associated frailty. Sulforaphane (SFN), a natural anti-inflammatory substance, has been widely applied in multiple types of cancer therapies. However, its role in alleviating intrinsic skin aging remains to be elucidated. Integrative network pharmacology and proteomics were utilized to investigate the underlying mechanisms of SFN in intrinsic skin aging. Fifty-one anti-aging targets of SFN were identified, highlighting its promising regulatory impact on the aging process. Based on an 18-month-old natural aging mouse model, significant alleviation in skin structure, redox homeostasis, and immune cell composition was noted after 2 months of SFN supplementation. Additionally, proteomic analysis demonstrated that SFN reversed the proteomic profile of intrinsic skin aging, with 233 differentially expressed proteins (DEPs) identified in SFN-fed aging mice. Of note, the up-regulated DEPs were highly enriched in the apelin signaling pathway (pÂ =Â 0.010). Furthermore, immune cell infiltration and whole blood cell analysis revealed that SFN rescued T cells depletion in dermal tissue, which was strongly correlated with DEPs enriched in the SFN-activated apelin signaling pathway. SFN improves skin morphology and immune functions via activating the apelin signaling pathway, suggesting new prime targets in counteracting intrinsic skin aging.",
    "para1": "éš¨è‘—å¹´é½¡å¢é•·ï¼Œçš®è†šçš„çµæ§‹åŠŸèƒ½æœƒé€æ¼¸ä¸‹é™ï¼Œé€™å¯èƒ½å°è‡´èˆ‡å¹´é½¡ç›¸é—œçš„è™›å¼±ç¾è±¡ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶æŠ—ç™¼ç‚ç‰©è³ªåœ¨æ¸›ç·©å…§åœ¨çš®è†šè€åŒ–æ–¹é¢çš„æ½›åœ¨ä½œç”¨ï¼Œé€™å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦çš„å•Ÿç¤ºã€‚äº†è§£å¦‚ä½•é€éé£²é£Ÿæˆ–è£œå……å“ä¾†æ”¹å–„çš®è†šè€åŒ–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æå‡ç”Ÿæ´»å“è³ªï¼Œæ¸›å°‘èˆ‡å¹´é½¡ç›¸é—œçš„çš®è†šå•é¡Œï¼Œä¸¦ä¿ƒé€²æ•´é«”å¥åº·ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å…§åœ¨çš®è†šè€åŒ–ä¸­çš„ä½œç”¨åŠå…¶æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ï¼Œé€™ç¨®å¤©ç„¶ç‰©è³ªæ˜¯å¦èƒ½æœ‰æ•ˆæ”¹å–„çš®è†šçš„è€åŒ–ç¾è±¡ï¼Œä¸¦å¸Œæœ›æ­ç¤ºå…¶èƒŒå¾Œçš„ç”Ÿç‰©å­¸æ©Ÿåˆ¶ã€‚é€éé€™é …ç ”ç©¶ï¼Œç§‘å­¸å®¶å¸Œæœ›èƒ½æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†å°æŠ—çš®è†šè€åŒ–ï¼Œä¸¦æä¾›æœªä¾†ç›¸é—œæ²»ç™‚çš„ä¾æ“šã€‚",
    "para3": "ç ”ç©¶ä¸­ä½¿ç”¨äº†ä¸€ç¨®18å€‹æœˆå¤§çš„è‡ªç„¶è€åŒ–å°é¼ æ¨¡å‹ï¼Œä¾†æ¨¡æ“¬çš®è†šè€åŒ–çš„æƒ…æ³ã€‚ç ”ç©¶è€…å°é€™äº›å°é¼ é€²è¡Œäº†è˜¿è””ç¡«ç´ çš„è£œå……ï¼Œä¸¦è§€å¯Ÿå…¶å°çš®è†šçµæ§‹ã€æ°§åŒ–é‚„åŸå¹³è¡¡å’Œå…ç–«ç´°èƒçµ„æˆçš„å½±éŸ¿ã€‚é€éæ•´åˆæ€§ç¶²çµ¡è—¥ç†å­¸å’Œè›‹ç™½è³ªçµ„å­¸çš„æ–¹æ³•ï¼Œç ”ç©¶è€…è­˜åˆ¥äº†51å€‹èˆ‡æŠ—è€åŒ–ç›¸é—œçš„ç›®æ¨™ï¼Œä¸¦åˆ†æäº†è˜¿è””ç¡«ç´ å°é€™äº›ç›®æ¨™çš„èª¿æ§æ•ˆæœã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç¶“éå…©å€‹æœˆçš„è˜¿è””ç¡«ç´ è£œå……å¾Œï¼Œå°é¼ çš„çš®è†šçµæ§‹å’Œå…ç–«åŠŸèƒ½æœ‰é¡¯è‘—æ”¹å–„ã€‚è›‹ç™½è³ªçµ„å­¸åˆ†æé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é€†è½‰å…§åœ¨çš®è†šè€åŒ–çš„è›‹ç™½è³ªçµ„ç‰¹å¾µï¼Œä¸¦è­˜åˆ¥å‡º233å€‹å·®ç•°è¡¨é”çš„è›‹ç™½è³ªã€‚ç‰¹åˆ¥æ˜¯ï¼Œé€™äº›ä¸Šèª¿çš„è›‹ç™½è³ªåœ¨apelinä¿¡è™Ÿé€šè·¯ä¸­é«˜åº¦å¯Œé›†ï¼Œé¡¯ç¤ºè˜¿è””ç¡«ç´ å¯èƒ½é€éæ¿€æ´»è©²ä¿¡è™Ÿé€šè·¯ä¾†æ”¹å–„çš®è†šå½¢æ…‹å’Œå…ç–«åŠŸèƒ½ï¼Œé€™ç‚ºå°æŠ—å…§åœ¨çš®è†šè€åŒ–æä¾›äº†æ–°çš„ç ”ç©¶æ–¹å‘ã€‚",
    "explanation_zh": "éš¨è‘—å¹´é½¡å¢é•·ï¼Œçš®è†šçš„çµæ§‹åŠŸèƒ½æœƒé€æ¼¸ä¸‹é™ï¼Œé€™å¯èƒ½å°è‡´èˆ‡å¹´é½¡ç›¸é—œçš„è™›å¼±ç¾è±¡ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶æŠ—ç™¼ç‚ç‰©è³ªåœ¨æ¸›ç·©å…§åœ¨çš®è†šè€åŒ–æ–¹é¢çš„æ½›åœ¨ä½œç”¨ï¼Œé€™å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦çš„å•Ÿç¤ºã€‚äº†è§£å¦‚ä½•é€éé£²é£Ÿæˆ–è£œå……å“ä¾†æ”¹å–„çš®è†šè€åŒ–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æå‡ç”Ÿæ´»å“è³ªï¼Œæ¸›å°‘èˆ‡å¹´é½¡ç›¸é—œçš„çš®è†šå•é¡Œï¼Œä¸¦ä¿ƒé€²æ•´é«”å¥åº·ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å…§åœ¨çš®è†šè€åŒ–ä¸­çš„ä½œç”¨åŠå…¶æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ï¼Œé€™ç¨®å¤©ç„¶ç‰©è³ªæ˜¯å¦èƒ½æœ‰æ•ˆæ”¹å–„çš®è†šçš„è€åŒ–ç¾è±¡ï¼Œä¸¦å¸Œæœ›æ­ç¤ºå…¶èƒŒå¾Œçš„ç”Ÿç‰©å­¸æ©Ÿåˆ¶ã€‚é€éé€™é …ç ”ç©¶ï¼Œç§‘å­¸å®¶å¸Œæœ›èƒ½æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†å°æŠ—çš®è†šè€åŒ–ï¼Œä¸¦æä¾›æœªä¾†ç›¸é—œæ²»ç™‚çš„ä¾æ“šã€‚\n\nç ”ç©¶ä¸­ä½¿ç”¨äº†ä¸€ç¨®18å€‹æœˆå¤§çš„è‡ªç„¶è€åŒ–å°é¼ æ¨¡å‹ï¼Œä¾†æ¨¡æ“¬çš®è†šè€åŒ–çš„æƒ…æ³ã€‚ç ”ç©¶è€…å°é€™äº›å°é¼ é€²è¡Œäº†è˜¿è””ç¡«ç´ çš„è£œå……ï¼Œä¸¦è§€å¯Ÿå…¶å°çš®è†šçµæ§‹ã€æ°§åŒ–é‚„åŸå¹³è¡¡å’Œå…ç–«ç´°èƒçµ„æˆçš„å½±éŸ¿ã€‚é€éæ•´åˆæ€§ç¶²çµ¡è—¥ç†å­¸å’Œè›‹ç™½è³ªçµ„å­¸çš„æ–¹æ³•ï¼Œç ”ç©¶è€…è­˜åˆ¥äº†51å€‹èˆ‡æŠ—è€åŒ–ç›¸é—œçš„ç›®æ¨™ï¼Œä¸¦åˆ†æäº†è˜¿è””ç¡«ç´ å°é€™äº›ç›®æ¨™çš„èª¿æ§æ•ˆæœã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç¶“éå…©å€‹æœˆçš„è˜¿è””ç¡«ç´ è£œå……å¾Œï¼Œå°é¼ çš„çš®è†šçµæ§‹å’Œå…ç–«åŠŸèƒ½æœ‰é¡¯è‘—æ”¹å–„ã€‚è›‹ç™½è³ªçµ„å­¸åˆ†æé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é€†è½‰å…§åœ¨çš®è†šè€åŒ–çš„è›‹ç™½è³ªçµ„ç‰¹å¾µï¼Œä¸¦è­˜åˆ¥å‡º233å€‹å·®ç•°è¡¨é”çš„è›‹ç™½è³ªã€‚ç‰¹åˆ¥æ˜¯ï¼Œé€™äº›ä¸Šèª¿çš„è›‹ç™½è³ªåœ¨apelinä¿¡è™Ÿé€šè·¯ä¸­é«˜åº¦å¯Œé›†ï¼Œé¡¯ç¤ºè˜¿è””ç¡«ç´ å¯èƒ½é€éæ¿€æ´»è©²ä¿¡è™Ÿé€šè·¯ä¾†æ”¹å–„çš®è†šå½¢æ…‹å’Œå…ç–«åŠŸèƒ½ï¼Œé€™ç‚ºå°æŠ—å…§åœ¨çš®è†šè€åŒ–æä¾›äº†æ–°çš„ç ”ç©¶æ–¹å‘ã€‚",
    "fb_post": "æ ¹æ“šã€ŠMolecular nutrition & food researchã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œâœ¨ä½ çŸ¥é“å—ï¼Ÿéš¨è‘—å¹´é½¡å¢é•·ï¼Œæˆ‘å€‘çš„çš®è†šæœƒé€æ¼¸è®Šå¾—è„†å¼±ï¼Œé€™æ˜¯ç‚ºä»€éº¼å¾ˆå¤šäººé–‹å§‹é—œå¿ƒçš®è†šä¿é¤Šçš„åŸå› ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶æ¢è¨äº†ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„å¤©ç„¶ç‰©è³ªï¼Œçœ‹çœ‹å®ƒèƒ½ä¸èƒ½å¹«åŠ©æˆ‘å€‘å°æŠ—çš®è†šè€åŒ–ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿çš®è†šçš„è€åŒ–éç¨‹ã€‚ç ”ç©¶è€…å€‘ä½¿ç”¨18å€‹æœˆå¤§çš„å°é¼ ä¾†æ¨¡æ“¬çš®è†šè€åŒ–ï¼Œä¸¦è®“é€™äº›å°é¼ æ”å–è˜¿è””ç¡«ç´ ï¼Œè§€å¯Ÿå®ƒå°çš®è†šçµæ§‹å’Œå…ç–«ç³»çµ±çš„å½±éŸ¿ã€‚çµæœé¡¯ç¤ºï¼Œç¶“éå…©å€‹æœˆçš„è£œå……å¾Œï¼Œå°é¼ çš„çš®è†šæ˜é¡¯æ”¹å–„ï¼Œç”šè‡³æœ‰åŠ©æ–¼æå‡å…ç–«åŠŸèƒ½ï¼\n\né€™é …ç ”ç©¶ä¸åƒ…æ­ç¤ºäº†è˜¿è””ç¡«ç´ çš„æ½›åŠ›ï¼Œé‚„è®“æˆ‘å€‘çœ‹åˆ°äº†æœªä¾†å°æŠ—çš®è†šè€åŒ–çš„æ–°æ–¹å‘ã€‚\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›ç·©çš®è†šè€åŒ–ã€‚\n2. ç ”ç©¶é¡¯ç¤ºçš®è†šçµæ§‹å’Œå…ç–«åŠŸèƒ½éƒ½æœ‰æ”¹å–„ã€‚\n3. é€™ç‚ºæœªä¾†çš„çš®è†šä¿é¤Šæä¾›äº†æ–°çš„æ€è·¯ï¼",
    "image_prompt": "Create a flat design infographic that explains the experimental method and main results of a study on sulforaphane. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like mice or cells, arrows or flow lines showing the experimental steps, and a section labeled 'Main Results' highlighting protective effects or changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41039785/"
  },
  {
    "id": "41027171",
    "title_en": "Multi-omics analysis of gut-liver axis reveals the mechanism by which sulforaphane alleviates liver injury in Cyprinus carpio exposed to triphenyltin.",
    "pub_date": "2025 Dec",
    "journal": "Comparative biochemistry and physiology. Part D, Genomics & proteomics",
    "abstract_en": "This study investigates the protective effects of sulforaphane (SFN) against triphenyltin (TPT)-induced hepatotoxicity, immune dysfunction and gut microbiota dysbiosis in Cyprinus carpio. Cyprinus carpio were divided into three groups and exposed for 8Â weeks, including control, 10Â Î¼g/L TPT and 10Â Î¼g/L TPTÂ +Â 10Â mg/kg SFN group. This result showed that TPT exposure induced significantly (PÂ <Â 0.05) hepatotoxicity, evidenced by increasing hepatic total bile acid (TBA) and total cholesterol levels, while upregulating Hsp70/90 and downregulating lysozyme gene expression. SFN supplementation reduced TBA accumulation, normalized Hsp90 and lysozyme expression, mitigating TPT-induced lipid dysregulation and immunosuppression. Transcriptomic analysis revealed that TPT exposure activated lipid metabolism pathways (PPAR signaling and cholesterol metabolism), but suppressed immune-related pathways. SFN supplementation restored metabolic homeostasis by enriching glucose and amino acid metabolism pathways and activating AMPK signaling, while also modulating the expression of key genes (PLIN1, ME1, CPT1B). The microbiota composition were changed in SFNÂ +Â TPT, including the increased of beneficial Fusobacteriota and Cetobacterium, and the decreased of pathogenic Proteobacteria and Aeromonas. The gut transcriptome dysregulation were restored in SFNÂ +Â TPT by enhancing immune pathways in Toll-like/NOD-like receptors. The significant correlations linked were found in gut microbes (Kaistia, Vagococcus) to hepatic/intestinal gene expression in SFNÂ +Â TPT. Overall, these findings elucidate novel mechanisms underlying TPT-induced immunotoxicity in liver and intestine and demonstrate the protective role of SFN, providing a theoretical foundation for its application in toxicity mitigation strategies.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°è‚è‡Ÿå¥åº·å’Œå…ç–«ç³»çµ±çš„ä¿è­·ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—ç”±ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæ¯’æ€§å’Œå…ç–«åŠŸèƒ½éšœç¤™ï¼Œé€™å°æ–¼å°‹æ‰¾å¤©ç„¶ç‰©è³ªä¾†æ”¹å–„å¥åº·ç‹€æ³å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚é€™äº›ç™¼ç¾å¯èƒ½å¹«åŠ©æˆ‘å€‘ç†è§£å¦‚ä½•åˆ©ç”¨é£²é£Ÿä¸­çš„å¤©ç„¶æˆåˆ†ä¾†ä¿è­·èº«é«”å…å—ç’°å¢ƒæ¯’ç´ çš„å½±éŸ¿ï¼Œé€²è€Œä¿ƒé€²å¥åº·å’Œé é˜²ç–¾ç—…ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ä¸‰è‹¯éŒ«èª˜å°çš„è‚è‡Ÿæ¯’æ€§ã€å…ç–«åŠŸèƒ½éšœç¤™åŠè…¸é“å¾®ç”Ÿç‰©å¤±èª¿çš„ä¿è­·æ•ˆæœã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œä¸‰è‹¯éŒ«é€™ç¨®ç’°å¢ƒæ±¡æŸ“ç‰©å¦‚ä½•å½±éŸ¿é­šé¡çš„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯å°è‚è‡Ÿå’Œå…ç–«ç³»çµ±çš„å½±éŸ¿ï¼Œä»¥åŠè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ æ¸›è¼•é€™äº›ä¸è‰¯å½±éŸ¿ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…é¸æ“‡äº†é¯‰é­šä½œç‚ºç ”ç©¶å°è±¡ï¼Œå°‡å…¶åˆ†ç‚ºä¸‰çµ„ï¼Œåˆ†åˆ¥ç‚ºå°ç…§çµ„ã€10å¾®å…‹/å‡çš„ä¸‰è‹¯éŒ«çµ„ï¼Œä»¥åŠ10å¾®å…‹/å‡çš„ä¸‰è‹¯éŒ«åŠ 10æ¯«å…‹/å…¬æ–¤çš„è˜¿è””ç¡«ç´ çµ„ã€‚é€™äº›é­šåœ¨ç‚ºæœŸ8é€±çš„å¯¦é©—ä¸­æ¥å—ä¸åŒçš„è™•ç†ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†è‚è‡Ÿçš„ç”ŸåŒ–æŒ‡æ¨™ã€å…ç–«åŸºå› è¡¨é”ä»¥åŠè…¸é“å¾®ç”Ÿç‰©çš„è®ŠåŒ–ï¼Œä»¥è©•ä¼°è˜¿è””ç¡«ç´ çš„ä¿è­·ä½œç”¨ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œä¸‰è‹¯éŒ«çš„æš´éœ²ç¢ºå¯¦å¼•èµ·äº†è‚è‡Ÿæ¯’æ€§ï¼Œä¸¦å½±éŸ¿äº†å…ç–«ç³»çµ±å’Œè…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆã€‚ç„¶è€Œï¼Œè˜¿è””ç¡«ç´ çš„è£œå……èƒ½å¤ æ¸›å°‘è‚è‡Ÿä¸­çš„è†½é¹½ç©ç´¯ï¼Œä¸¦æ¢å¾©å…ç–«ç›¸é—œåŸºå› çš„è¡¨é”ï¼Œé¡¯ç¤ºå‡ºå…¶åœ¨æ”¹å–„ä»£è¬å¹³è¡¡å’Œè…¸é“å¥åº·æ–¹é¢çš„æ½›åŠ›ã€‚æ­¤å¤–ï¼Œè…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆä¹Ÿå› è˜¿è””ç¡«ç´ çš„è£œå……è€Œç™¼ç”Ÿäº†è®ŠåŒ–ï¼Œé€™äº›çµæœç‚ºæœªä¾†åœ¨æ¯’æ€§ç·©è§£ç­–ç•¥ä¸­çš„æ‡‰ç”¨æä¾›äº†ç†è«–åŸºç¤ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°è‚è‡Ÿå¥åº·å’Œå…ç–«ç³»çµ±çš„ä¿è­·ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—ç”±ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæ¯’æ€§å’Œå…ç–«åŠŸèƒ½éšœç¤™ï¼Œé€™å°æ–¼å°‹æ‰¾å¤©ç„¶ç‰©è³ªä¾†æ”¹å–„å¥åº·ç‹€æ³å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚é€™äº›ç™¼ç¾å¯èƒ½å¹«åŠ©æˆ‘å€‘ç†è§£å¦‚ä½•åˆ©ç”¨é£²é£Ÿä¸­çš„å¤©ç„¶æˆåˆ†ä¾†ä¿è­·èº«é«”å…å—ç’°å¢ƒæ¯’ç´ çš„å½±éŸ¿ï¼Œé€²è€Œä¿ƒé€²å¥åº·å’Œé é˜²ç–¾ç—…ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ä¸‰è‹¯éŒ«èª˜å°çš„è‚è‡Ÿæ¯’æ€§ã€å…ç–«åŠŸèƒ½éšœç¤™åŠè…¸é“å¾®ç”Ÿç‰©å¤±èª¿çš„ä¿è­·æ•ˆæœã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œä¸‰è‹¯éŒ«é€™ç¨®ç’°å¢ƒæ±¡æŸ“ç‰©å¦‚ä½•å½±éŸ¿é­šé¡çš„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯å°è‚è‡Ÿå’Œå…ç–«ç³»çµ±çš„å½±éŸ¿ï¼Œä»¥åŠè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ æ¸›è¼•é€™äº›ä¸è‰¯å½±éŸ¿ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…é¸æ“‡äº†é¯‰é­šä½œç‚ºç ”ç©¶å°è±¡ï¼Œå°‡å…¶åˆ†ç‚ºä¸‰çµ„ï¼Œåˆ†åˆ¥ç‚ºå°ç…§çµ„ã€10å¾®å…‹/å‡çš„ä¸‰è‹¯éŒ«çµ„ï¼Œä»¥åŠ10å¾®å…‹/å‡çš„ä¸‰è‹¯éŒ«åŠ 10æ¯«å…‹/å…¬æ–¤çš„è˜¿è””ç¡«ç´ çµ„ã€‚é€™äº›é­šåœ¨ç‚ºæœŸ8é€±çš„å¯¦é©—ä¸­æ¥å—ä¸åŒçš„è™•ç†ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†è‚è‡Ÿçš„ç”ŸåŒ–æŒ‡æ¨™ã€å…ç–«åŸºå› è¡¨é”ä»¥åŠè…¸é“å¾®ç”Ÿç‰©çš„è®ŠåŒ–ï¼Œä»¥è©•ä¼°è˜¿è””ç¡«ç´ çš„ä¿è­·ä½œç”¨ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œä¸‰è‹¯éŒ«çš„æš´éœ²ç¢ºå¯¦å¼•èµ·äº†è‚è‡Ÿæ¯’æ€§ï¼Œä¸¦å½±éŸ¿äº†å…ç–«ç³»çµ±å’Œè…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆã€‚ç„¶è€Œï¼Œè˜¿è””ç¡«ç´ çš„è£œå……èƒ½å¤ æ¸›å°‘è‚è‡Ÿä¸­çš„è†½é¹½ç©ç´¯ï¼Œä¸¦æ¢å¾©å…ç–«ç›¸é—œåŸºå› çš„è¡¨é”ï¼Œé¡¯ç¤ºå‡ºå…¶åœ¨æ”¹å–„ä»£è¬å¹³è¡¡å’Œè…¸é“å¥åº·æ–¹é¢çš„æ½›åŠ›ã€‚æ­¤å¤–ï¼Œè…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆä¹Ÿå› è˜¿è””ç¡«ç´ çš„è£œå……è€Œç™¼ç”Ÿäº†è®ŠåŒ–ï¼Œé€™äº›çµæœç‚ºæœªä¾†åœ¨æ¯’æ€§ç·©è§£ç­–ç•¥ä¸­çš„æ‡‰ç”¨æä¾›äº†ç†è«–åŸºç¤ã€‚",
    "fb_post": "æ ¹æ“šã€ŠComparative biochemistry and physiology. Part D, Genomics & proteomicsã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿè˜¿è””ä¸åªæ˜¯ç¾å‘³çš„è”¬èœï¼Œå®ƒçš„æˆåˆ†è˜¿è””ç¡«ç´ å¯èƒ½å°æˆ‘å€‘çš„å¥åº·æœ‰å¾ˆå¤§å¹«åŠ©å“¦ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å°æŠ—ç’°å¢ƒæ±¡æŸ“ç‰©ä¸‰è‹¯éŒ«é€ æˆçš„è‚è‡Ÿå‚·å®³å’Œå…ç–«ç³»çµ±å•é¡Œï¼Œé€™å°æˆ‘å€‘çš„å¥åº·æ„ç¾©é‡å¤§ï¼\n\né€™é …ç ”ç©¶ç‰¹åˆ¥é—œæ³¨ä¸‰è‹¯éŒ«å°é­šé¡çš„å½±éŸ¿ï¼Œå°¤å…¶æ˜¯å®ƒå¦‚ä½•æå®³è‚è‡Ÿå’Œå…ç–«ç³»çµ±ã€‚ç ”ç©¶è€…é¸æ“‡äº†é¯‰é­šé€²è¡Œå¯¦é©—ï¼Œå°‡å®ƒå€‘åˆ†ç‚ºä¸‰çµ„ï¼Œåˆ†åˆ¥æ˜¯å°ç…§çµ„ã€ä¸‰è‹¯éŒ«çµ„ï¼Œä»¥åŠä¸‰è‹¯éŒ«åŠ ä¸Šè˜¿è””ç¡«ç´ çš„çµ„åˆ¥ï¼ŒæŒçºŒè§€å¯Ÿ8é€±ã€‚\n\nçµæœé¡¯ç¤ºï¼Œä¸‰è‹¯éŒ«ç¢ºå¯¦æœƒå°è‡´è‚è‡Ÿå—æå’Œå…ç–«ç³»çµ±åŠŸèƒ½ä¸‹é™ï¼Œä½†æ·»åŠ è˜¿è””ç¡«ç´ å¾Œï¼Œè‚è‡Ÿä¸­çš„è†½é¹½ç©ç´¯æ¸›å°‘ï¼Œå…ç–«ç›¸é—œåŸºå› çš„è¡¨é”ä¹Ÿæ¢å¾©æ­£å¸¸ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ åœ¨æ”¹å–„å¥åº·æ–¹é¢çš„æ½›åŠ›ï¼\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼ä¿è­·è‚è‡Ÿå’Œå…ç–«ç³»çµ±ã€‚\n2. ä¸‰è‹¯éŒ«æœƒå½±éŸ¿é­šé¡çš„å¥åº·ï¼Œä½†è˜¿è””ç¡«ç´ èƒ½ç·©è§£é€™äº›å½±éŸ¿ã€‚\n3. é€™äº›ç™¼ç¾ç‚ºæœªä¾†ä½¿ç”¨å¤©ç„¶æˆåˆ†æ”¹å–„å¥åº·æä¾›äº†æ–°æ–¹å‘ï¼",
    "image_prompt": "Create a flat design infographic that explains the experiment and main findings of a study on the protective effects of sulforaphane from radishes against toxicity induced by tributyltin. Include simplified illustrations of radishes or sulforaphane, a fish as the experimental subject, arrows or flow lines indicating the experimental steps, and a section highlighting the main results such as the protective effects on liver health and immune function.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚è‡Ÿæ¯’æ€§ Hepatotoxicity",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41027171/"
  },
  {
    "id": "40714240",
    "title_en": "Gut microbiota-related glutathione metabolism is key mechanism for sulforaphane ameliorating ulcerative colitis.",
    "pub_date": "2025 Dec",
    "journal": "The Journal of nutritional biochemistry",
    "abstract_en": "Gut barrier dysfunction is associated with dysbiosis of the gut microbiota and its metabolites, which is closely linked to the pathogenesis of ulcerative colitis (UC). Recent studies have demonstrated that Sulforaphane (SFN) exerts beneficial effects on UC. However, the role of the gut microbiota and microbial metabolism in the anti-UC mechanisms of SFN remains inadequately understood. In this study, we observed that SFN administration significantly improved the pathological phenotype, restored gut barrier integrity, and reduced colon inflammation in dextran sulfate sodium (DSS)-induced colitis mice. Gut microbiota analysis illustrated that SFN administration rebalances the alterations in gut microbiota composition, including genera such as Turicibacter, Lactobacillus and Bacteroides, in DSS-induced mice. Furthermore, untargeted metabolomics analysis indicated that the levels of microbial arachidonic acid metabolism, as well as the metabolism of alanine, aspartate, and glutamate, and glutathione metabolism in the gastrointestinal tract, were significantly altered in DSS-induced mice. Interestingly, SFN treatment significantly restore the alterations in glutathione metabolism and the levels of associated metabolites. Additionally, we observed that the MAPK/NF-ÎºB signaling pathway, regulated by glutathione metabolism, was inhibited in the colon of DSS-induced mice following SFN treatment. Collectively, these results suggest that SFN can alleviate DSS-induced colitis in mice by restoring dysregulated gut microbiota and glutathione metabolism, thereby modulating the MAPK/NF-ÎºB signaling pathway, enhancing intestinal barrier function and reducing colonic inflammation. Importantly, our findings elucidate a novel mechanism by which SFN improves gut barrier function, highlighting its potential to advance the development of SFN-derived therapeutics for the clinical management of colitis.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè…¸é“å±éšœåŠŸèƒ½çš„æ”¹å–„å¯èƒ½æœ‰åŠ©æ–¼é é˜²å’Œç·©è§£æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®å½±éŸ¿è…¸é“çš„æ…¢æ€§ç–¾ç—…ï¼Œèˆ‡è…¸é“å¾®ç”Ÿç‰©å¤±èª¿æœ‰é—œã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿æ•´è…¸é“å¾®ç”Ÿç‰©çµ„å’Œæ”¹å–„è…¸é“å±éšœåŠŸèƒ½ï¼Œä¾†æ¸›å°‘è…¸é“ç™¼ç‚ï¼Œé€™å°æ–¼æœªä¾†çš„æ²»ç™‚æ–¹æ³•é–‹ç™¼å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…¸é“å¾®ç”Ÿç‰©çµ„å’Œå¾®ç”Ÿç‰©ä»£è¬ã€‚ç ”ç©¶äººå“¡é—œæ³¨çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„ç”±ç¡«é…¸å³æ—‹ç³–é…ï¼ˆDSSï¼‰èª˜å°çš„çµè…¸ç‚å°é¼ çš„è…¸é“å¥åº·ï¼Œä¸¦ä¸”å¸Œæœ›äº†è§£å…¶èƒŒå¾Œçš„æ©Ÿåˆ¶ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶äººå“¡ä½¿ç”¨äº†DSSèª˜å°çš„çµè…¸ç‚å°é¼ ä½œç‚ºç ”ç©¶å°è±¡ï¼Œä¸¦çµ¦äºˆé€™äº›å°é¼ è˜¿è””ç¡«ç´ é€²è¡Œæ²»ç™‚ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬è§€å¯Ÿå°é¼ çš„ç—…ç†è¡¨ç¾ã€è…¸é“å±éšœå®Œæ•´æ€§åŠçµè…¸ç™¼ç‚æƒ…æ³ï¼Œä¸¦é€²è¡Œè…¸é“å¾®ç”Ÿç‰©çµ„çš„åˆ†æå’Œä»£è¬çµ„å­¸çš„ç ”ç©¶ï¼Œä»¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ”¹å–„DSSèª˜å°çš„å°é¼ çš„ç—…ç†è¡¨ç¾ï¼Œæ¢å¾©è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œä¸¦æ¸›å°‘çµè…¸çš„ç™¼ç‚ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ çš„æ²»ç™‚é‚„èƒ½èª¿æ•´è…¸é“å¾®ç”Ÿç‰©çµ„çš„çµ„æˆï¼Œä¸¦é¡¯è‘—æ”¹è®Šèˆ‡è…¸é“ä»£è¬ç›¸é—œçš„ç‰©è³ªï¼Œç‰¹åˆ¥æ˜¯è°·èƒ±ç”˜è‚½çš„ä»£è¬ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿ç¯€è…¸é“å¾®ç”Ÿç‰©çµ„å’Œä»£è¬ä¾†æ”¹å–„è…¸é“åŠŸèƒ½ï¼Œä¸¦æ¸›å°‘ç™¼ç‚åæ‡‰ï¼Œç‚ºæ½°ç˜æ€§çµè…¸ç‚çš„æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè…¸é“å±éšœåŠŸèƒ½çš„æ”¹å–„å¯èƒ½æœ‰åŠ©æ–¼é é˜²å’Œç·©è§£æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®å½±éŸ¿è…¸é“çš„æ…¢æ€§ç–¾ç—…ï¼Œèˆ‡è…¸é“å¾®ç”Ÿç‰©å¤±èª¿æœ‰é—œã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿æ•´è…¸é“å¾®ç”Ÿç‰©çµ„å’Œæ”¹å–„è…¸é“å±éšœåŠŸèƒ½ï¼Œä¾†æ¸›å°‘è…¸é“ç™¼ç‚ï¼Œé€™å°æ–¼æœªä¾†çš„æ²»ç™‚æ–¹æ³•é–‹ç™¼å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…¸é“å¾®ç”Ÿç‰©çµ„å’Œå¾®ç”Ÿç‰©ä»£è¬ã€‚ç ”ç©¶äººå“¡é—œæ³¨çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„ç”±ç¡«é…¸å³æ—‹ç³–é…ï¼ˆDSSï¼‰èª˜å°çš„çµè…¸ç‚å°é¼ çš„è…¸é“å¥åº·ï¼Œä¸¦ä¸”å¸Œæœ›äº†è§£å…¶èƒŒå¾Œçš„æ©Ÿåˆ¶ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶äººå“¡ä½¿ç”¨äº†DSSèª˜å°çš„çµè…¸ç‚å°é¼ ä½œç‚ºç ”ç©¶å°è±¡ï¼Œä¸¦çµ¦äºˆé€™äº›å°é¼ è˜¿è””ç¡«ç´ é€²è¡Œæ²»ç™‚ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬è§€å¯Ÿå°é¼ çš„ç—…ç†è¡¨ç¾ã€è…¸é“å±éšœå®Œæ•´æ€§åŠçµè…¸ç™¼ç‚æƒ…æ³ï¼Œä¸¦é€²è¡Œè…¸é“å¾®ç”Ÿç‰©çµ„çš„åˆ†æå’Œä»£è¬çµ„å­¸çš„ç ”ç©¶ï¼Œä»¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ”¹å–„DSSèª˜å°çš„å°é¼ çš„ç—…ç†è¡¨ç¾ï¼Œæ¢å¾©è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œä¸¦æ¸›å°‘çµè…¸çš„ç™¼ç‚ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ çš„æ²»ç™‚é‚„èƒ½èª¿æ•´è…¸é“å¾®ç”Ÿç‰©çµ„çš„çµ„æˆï¼Œä¸¦é¡¯è‘—æ”¹è®Šèˆ‡è…¸é“ä»£è¬ç›¸é—œçš„ç‰©è³ªï¼Œç‰¹åˆ¥æ˜¯è°·èƒ±ç”˜è‚½çš„ä»£è¬ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿ç¯€è…¸é“å¾®ç”Ÿç‰©çµ„å’Œä»£è¬ä¾†æ”¹å–„è…¸é“åŠŸèƒ½ï¼Œä¸¦æ¸›å°‘ç™¼ç‚åæ‡‰ï¼Œç‚ºæ½°ç˜æ€§çµè…¸ç‚çš„æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "fb_post": "æ ¹æ“šã€ŠThe Journal of nutritional biochemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿè˜¿è””è£¡é¢æœ‰ç¨®ç¥å¥‡çš„æˆåˆ†å«è˜¿è””ç¡«ç´ ï¼Œå¯èƒ½å°è…¸é“å¥åº·æœ‰å¹«åŠ©å“¦ï¼é€™ç¯‡ç ”ç©¶å°ˆé–€æ¢è¨è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰ä¸­çš„ä½œç”¨ï¼Œé€™æ˜¯ä¸€ç¨®å½±éŸ¿è…¸é“çš„æ…¢æ€§ç–¾ç—…ï¼Œè·Ÿè…¸é“è£¡çš„å¾®ç”Ÿç‰©æœ‰é—œã€‚ ç ”ç©¶åœ˜éšŠç”¨å°é¼ é€²è¡Œå¯¦é©—ï¼Œçœ‹çœ‹è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„å› ç¡«é…¸å³æ—‹ç³–é…ï¼ˆDSSï¼‰é€ æˆçš„çµè…¸ç‚ã€‚ ä»–å€‘è§€å¯Ÿäº†å°é¼ çš„è…¸é“å¥åº·ç‹€æ³ï¼ŒåŒ…æ‹¬ç—…ç†è®ŠåŒ–å’Œè…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œé‚„åˆ†æäº†è…¸é“å¾®ç”Ÿç‰©çš„è®ŠåŒ–ã€‚ çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æ”¹å–„å°é¼ çš„ç—…ç†è¡¨ç¾ï¼Œé‚„èƒ½æ¢å¾©è…¸é“çš„å±éšœåŠŸèƒ½ä¸¦æ¸›å°‘ç™¼ç‚ï¼è€Œä¸”ï¼Œå®ƒé‚„èª¿æ•´äº†è…¸é“è£¡çš„å¾®ç”Ÿç‰©çµ„ï¼Œå½±éŸ¿äº†èˆ‡è…¸é“ä»£è¬æœ‰é—œçš„ç‰©è³ªï¼Œåƒæ˜¯è°·èƒ±ç”˜è‚½çš„ä»£è¬ã€‚é€™äº›ç™¼ç¾ç‚ºæ½°ç˜æ€§çµè…¸ç‚çš„æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ï¼\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å±éšœï¼Œæ¸›å°‘ç™¼ç‚ã€‚\n2. èƒ½èª¿æ•´è…¸é“å¾®ç”Ÿç‰©çµ„çš„çµ„æˆã€‚\n3. å¯èƒ½å°æ½°ç˜æ€§çµè…¸ç‚çš„æ²»ç™‚æœ‰æ–°å•Ÿç¤ºï¼",
    "image_prompt": "Create a flat design infographic explaining the experiment and main results of the study on glucosinolate in ulcerative colitis. Use a light background with soft colors. Include symbols representing broccoli or glucosinolate, simplified illustrations of experimental subjects like mice or cells, arrows or flow lines indicating the experimental steps, and a section labeled 'Main Results' highlighting protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ½°ç˜æ€§çµè…¸ç‚ Ulcerative Colitis",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40714240/"
  },
  {
    "id": "41291551",
    "title_en": "Nanoliposome-mediated delivery of sulforaphane suppresses Ehrlich ascites carcinoma growth and improves liver integrity and therapeutic outcomes in a murine model.",
    "pub_date": "2025 Nov",
    "journal": "BMC cancer",
    "abstract_en": "The anticancer activity of sulforaphane (SFN) involves multiple signaling pathways, but its mechanism against Ehrlich Ascites Carcinoma (EAC) in mice remains unclear. This study evaluated the antitumor efficacy of SFN-loaded nanoliposomes (SFN-NLPs). Ninety female Swiss albino mice were allocated into six groups: (1) untreated control, (2) SFN alone (50Â mg/kg/day, orally), (3) SFN-NLPs alone (50Â mg/kg/day, orally), (4) EAC-bearing mice (2.5â€‰Ã—â€‰10â¶ cells, intraperitoneally), (5) EACâ€‰+â€‰SFN, and (6) EACâ€‰+â€‰SFN-NLPs. with treatment lasting 20 days in tumor-bearing groups. SFN-NLPs significantly reduced EAC tumor volume, viable cell count, and tumor marker levels, while prolonging survival more effectively than free SFN. SFN-NLPs modulated key molecular pathways by suppressing inflammatory gene expression (NF-ÎºB, COX-2) and shifting the balance toward apoptosis via upregulation of TP53 and Bax and concomitant downregulation of Bcl-2. Regarding liver integrity, SFN-NLPs significantly reduced DNA fragmentation and hepatic oxidative stress, while modulating systemic inflammation through reductions in total leukocyte count, TNF-Î±, and C-reactive protein. In addition, SFN-NLPs conferred superior protection against both histopathological and ultrastructural liver damage. Furthermore, molecular docking analysis suggested plausible interactions of SFN with proteins associated with antioxidant defense, inflammation regulation, and apoptosis, indicating a potential modulatory role. In conclusion, nanoformulated SFN enhances stability, augments efficacy, and facilitates sustained release and bioavailability, thereby strengthening its antitumor, anti-inflammatory, antioxidant, and pro-apoptotic effects in EAC-bearing mice. These findings highlight the potential of SFN-NLPs to suppress tumor growth by modulating inflammatory and apoptotic gene expression while preserving liver integrity.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™Œæ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¾é’èŠ±æ¤°èœä¸­æå–çš„åŒ–åˆç‰©ï¼Œå·²çŸ¥å…·æœ‰æŠ—ç™Œç‰¹æ€§ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨å°é¼ é«”å…§å°è…«ç˜¤çš„å½±éŸ¿ï¼Œä¸¦ä¸”ä½¿ç”¨äº†ç´ç±³è„‚è³ªé«”çš„å½¢å¼ä¾†æé«˜å…¶æ•ˆæœã€‚é€™æ¨£çš„ç ”ç©¶å¯èƒ½ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„æ€è·¯ï¼Œå°¤å…¶æ˜¯å¦‚ä½•åˆ©ç”¨å¤©ç„¶æˆåˆ†ä¾†æ¸›å°‘è…«ç˜¤ç”Ÿé•·å’Œæ”¹å–„èº«é«”å¥åº·ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯è©•ä¼°è˜¿è””ç¡«ç´ è² è¼‰ç´ç±³è„‚è³ªé«”ï¼ˆSFN-NLPsï¼‰å°å°é¼ Ehrlichè…¹æ°´ç™Œï¼ˆEACï¼‰çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ åœ¨å°é¼ é«”å…§çš„æŠ—ç™Œæ©Ÿåˆ¶ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…«ç˜¤çš„ç”Ÿé•·å’Œå°é¼ çš„ç”Ÿå­˜ç‡ã€‚é€™é …ç ”ç©¶ä¸åƒ…æ¢è¨äº†è˜¿è””ç¡«ç´ çš„ç›´æ¥æ•ˆæœï¼Œé‚„è€ƒå¯Ÿäº†å…¶åœ¨ç´ç±³è„‚è³ªé«”å½¢å¼ä¸‹çš„æ½›åœ¨å„ªå‹¢ã€‚",
    "para3": "å¯¦é©—ä¸­ä½¿ç”¨äº†90éš»é›Œæ€§ç‘å£«ç™½é¼ ï¼Œå°‡å®ƒå€‘åˆ†æˆå…­çµ„é€²è¡Œä¸åŒçš„è™•ç†ã€‚é€™äº›çµ„åˆ¥åŒ…æ‹¬æœªè™•ç†çš„å°ç…§çµ„ã€å–®ç¨ä½¿ç”¨è˜¿è””ç¡«ç´ çš„çµ„åˆ¥ã€å–®ç¨ä½¿ç”¨è˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çš„çµ„åˆ¥ï¼Œä»¥åŠå¸¶æœ‰EACè…«ç˜¤çš„å°é¼ çµ„åˆ¥ã€‚æ²»ç™‚æŒçºŒäº†20å¤©ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†è…«ç˜¤é«”ç©ã€å­˜æ´»ç‡ä»¥åŠç›¸é—œçš„ç”Ÿç‰©æ¨™è¨˜ç‰©ã€‚é€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶è€…èƒ½å¤ æ¯”è¼ƒä¸åŒè™•ç†æ–¹å¼çš„æ•ˆæœï¼Œä¸¦äº†è§£è˜¿è””ç¡«ç´ åœ¨æŠ—è…«ç˜¤æ–¹é¢çš„æ½›åŠ›ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”åœ¨æ¸›å°‘EACè…«ç˜¤é«”ç©ã€æ´»ç´°èƒæ•¸é‡å’Œè…«ç˜¤æ¨™è¨˜ç‰©æ°´å¹³æ–¹é¢ï¼Œæ¯”å–®ç¨ä½¿ç”¨è˜¿è””ç¡«ç´ æ›´æœ‰æ•ˆã€‚æ­¤å¤–ï¼Œé€™ç¨®ç´ç±³å½¢å¼çš„è˜¿è””ç¡«ç´ é‚„èƒ½æ”¹å–„å°é¼ çš„è‚è‡Ÿå¥åº·ï¼Œæ¸›å°‘DNAæ–·è£‚å’Œæ°§åŒ–å£“åŠ›ï¼Œä¸¦èª¿ç¯€å…¨èº«ç‚ç—‡åæ‡‰ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œç´ç±³åŒ–çš„è˜¿è””ç¡«ç´ å¯èƒ½åœ¨æŠ—è…«ç˜¤ã€æŠ—ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢å…·æœ‰æ›´å¼·çš„æ•ˆæœï¼Œä¸¦ä¸”æœ‰åŠ©æ–¼æ”¹å–„å°é¼ çš„æ•´é«”å¥åº·ç‹€æ³ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™Œæ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¾é’èŠ±æ¤°èœä¸­æå–çš„åŒ–åˆç‰©ï¼Œå·²çŸ¥å…·æœ‰æŠ—ç™Œç‰¹æ€§ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨å°é¼ é«”å…§å°è…«ç˜¤çš„å½±éŸ¿ï¼Œä¸¦ä¸”ä½¿ç”¨äº†ç´ç±³è„‚è³ªé«”çš„å½¢å¼ä¾†æé«˜å…¶æ•ˆæœã€‚é€™æ¨£çš„ç ”ç©¶å¯èƒ½ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„æ€è·¯ï¼Œå°¤å…¶æ˜¯å¦‚ä½•åˆ©ç”¨å¤©ç„¶æˆåˆ†ä¾†æ¸›å°‘è…«ç˜¤ç”Ÿé•·å’Œæ”¹å–„èº«é«”å¥åº·ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯è©•ä¼°è˜¿è””ç¡«ç´ è² è¼‰ç´ç±³è„‚è³ªé«”ï¼ˆSFN-NLPsï¼‰å°å°é¼ Ehrlichè…¹æ°´ç™Œï¼ˆEACï¼‰çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ åœ¨å°é¼ é«”å…§çš„æŠ—ç™Œæ©Ÿåˆ¶ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…«ç˜¤çš„ç”Ÿé•·å’Œå°é¼ çš„ç”Ÿå­˜ç‡ã€‚é€™é …ç ”ç©¶ä¸åƒ…æ¢è¨äº†è˜¿è””ç¡«ç´ çš„ç›´æ¥æ•ˆæœï¼Œé‚„è€ƒå¯Ÿäº†å…¶åœ¨ç´ç±³è„‚è³ªé«”å½¢å¼ä¸‹çš„æ½›åœ¨å„ªå‹¢ã€‚\n\nå¯¦é©—ä¸­ä½¿ç”¨äº†90éš»é›Œæ€§ç‘å£«ç™½é¼ ï¼Œå°‡å®ƒå€‘åˆ†æˆå…­çµ„é€²è¡Œä¸åŒçš„è™•ç†ã€‚é€™äº›çµ„åˆ¥åŒ…æ‹¬æœªè™•ç†çš„å°ç…§çµ„ã€å–®ç¨ä½¿ç”¨è˜¿è””ç¡«ç´ çš„çµ„åˆ¥ã€å–®ç¨ä½¿ç”¨è˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çš„çµ„åˆ¥ï¼Œä»¥åŠå¸¶æœ‰EACè…«ç˜¤çš„å°é¼ çµ„åˆ¥ã€‚æ²»ç™‚æŒçºŒäº†20å¤©ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†è…«ç˜¤é«”ç©ã€å­˜æ´»ç‡ä»¥åŠç›¸é—œçš„ç”Ÿç‰©æ¨™è¨˜ç‰©ã€‚é€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶è€…èƒ½å¤ æ¯”è¼ƒä¸åŒè™•ç†æ–¹å¼çš„æ•ˆæœï¼Œä¸¦äº†è§£è˜¿è””ç¡«ç´ åœ¨æŠ—è…«ç˜¤æ–¹é¢çš„æ½›åŠ›ã€‚\n\nä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”åœ¨æ¸›å°‘EACè…«ç˜¤é«”ç©ã€æ´»ç´°èƒæ•¸é‡å’Œè…«ç˜¤æ¨™è¨˜ç‰©æ°´å¹³æ–¹é¢ï¼Œæ¯”å–®ç¨ä½¿ç”¨è˜¿è””ç¡«ç´ æ›´æœ‰æ•ˆã€‚æ­¤å¤–ï¼Œé€™ç¨®ç´ç±³å½¢å¼çš„è˜¿è””ç¡«ç´ é‚„èƒ½æ”¹å–„å°é¼ çš„è‚è‡Ÿå¥åº·ï¼Œæ¸›å°‘DNAæ–·è£‚å’Œæ°§åŒ–å£“åŠ›ï¼Œä¸¦èª¿ç¯€å…¨èº«ç‚ç—‡åæ‡‰ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œç´ç±³åŒ–çš„è˜¿è””ç¡«ç´ å¯èƒ½åœ¨æŠ—è…«ç˜¤ã€æŠ—ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢å…·æœ‰æ›´å¼·çš„æ•ˆæœï¼Œä¸¦ä¸”æœ‰åŠ©æ–¼æ”¹å–„å°é¼ çš„æ•´é«”å¥åº·ç‹€æ³ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBMC cancerã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“é’èŠ±æ¤°èœè£¡æœ‰ä¸€ç¨®ç¥å¥‡çš„æˆåˆ†å«è˜¿è””ç¡«ç´ å—ï¼Ÿæœ€è¿‘æœ‰ç ”ç©¶ç™¼ç¾ï¼Œé€™å€‹æˆåˆ†å¯èƒ½å°æŠ—ç™Œæœ‰å¾ˆå¤§çš„å¹«åŠ©ï¼\n\né€™é …ç ”ç©¶ä¸»è¦åœ¨æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿å°é¼ çš„è…«ç˜¤ç”Ÿé•·ã€‚ç§‘å­¸å®¶å€‘ç”¨äº†ä¸€ç¨®ç‰¹åˆ¥çš„æŠ€è¡“ï¼Œå°‡è˜¿è””ç¡«ç´ åŒ…è£¹åœ¨ç´ç±³è„‚è³ªé«”è£¡ï¼Œé€™æ¨£å¯ä»¥è®“å®ƒæ›´æœ‰æ•ˆåœ°ç™¼æ®ä½œç”¨ã€‚ä»–å€‘æŠŠ90éš»å°é¼ åˆ†æˆä¸åŒçµ„åˆ¥ï¼Œè§€å¯Ÿå®ƒå€‘åœ¨æ¥å—ä¸åŒè™•ç†å¾Œçš„è…«ç˜¤è®ŠåŒ–å’Œå­˜æ´»æƒ…æ³ã€‚\n\nç¶“é20å¤©çš„å¯¦é©—ï¼Œç ”ç©¶çµæœè®“äººæŒ¯å¥®ï¼ç´ç±³è„‚è³ªé«”å½¢å¼çš„è˜¿è””ç¡«ç´ ä¸åƒ…æœ‰æ•ˆæ¸›å°‘äº†è…«ç˜¤çš„å¤§å°ï¼Œé‚„æ”¹å–„äº†å°é¼ çš„è‚è‡Ÿå¥åº·ï¼Œä¸¦æ¸›å°‘äº†èº«é«”çš„æ°§åŒ–å£“åŠ›å’Œç‚ç—‡åæ‡‰ã€‚\n\né€™äº›ç™¼ç¾æˆ–è¨±èƒ½ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚å¸¶ä¾†æ–°çš„æ€è·¯ï¼Œè®“æˆ‘å€‘æ›´å¥½åœ°åˆ©ç”¨å¤©ç„¶æˆåˆ†ä¾†å°æŠ—ç–¾ç—…ï¼\n\nâœ¨ ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å°æŠ—è…«ç˜¤æœ‰æ½›åŠ›ã€‚\n2. ç´ç±³è„‚è³ªé«”æå‡äº†è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚\n3. å¯èƒ½æ”¹å–„æ•´é«”å¥åº·ç‹€æ³ï¼",
    "image_prompt": "Create a simple and informative illustration explaining the experimental method and main results of a study on sulforaphane (SFN) from broccoli. Use a flat design style with a white or light-colored background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like mice or cells, arrows or flow lines to indicate the experimental steps, and a section highlighting 'Main Results' such as protective effects or changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è…¹æ°´ç™Œ Ehrlich Ascites Carcinoma",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41291551/"
  },
  {
    "id": "41135276",
    "title_en": "Sulforaphane targets STAT3-CKMT2-AS1 to suppress gastric cancer via PSMB8 downregulation and AIMP1 stabilization.",
    "pub_date": "2025 Nov",
    "journal": "Phytomedicine : international journal of phytotherapy and phytopharmacology",
    "abstract_en": "Gastric cancer (GC) remains one of the most formidable threats to human health with limited therapeutic options. Sulforaphane (SFN), a natural isothiocyanate, exhibits antitumor activity; however, its molecular mechanisms of action in GC remain unclear. To investigate the mechanism of action of SFN in gastric cancer. The antitumor effects of SFN were comprehensively assessed in vitro and in vivo, followed by sequencing analysis to identify the targeted lncRNA. Subsequently, the mechanical verification experiments were carried out to determine the upstream and downstream regulatory components involved in the STAT3-CKMT2-AS1 regulatory axis. We demonstrated that SFN strongly inhibits GC. SFN downregulated the expression of the lncRNA CKMT2-AS1. Elevated expression levels of CKMT2-AS1 in human GC tissues are correlated with poor patient survival rates. Knockdown of CKMT2-AS1 significantly inhibited GC proliferation and migration both in vivo and in vitro, whereas CKMT2-AS1 overexpression enhanced malignant phenotypes. Mechanistically, we identified STAT3 as the transcriptional activator driving CKMT2-AS1 expression, with SFN directly binding to, and inhibiting, STAT3 phosphorylation to decrease its transcriptional activity. Interestingly, cytoplasmic CKMT2-AS1 competitively adsorbs miR-451a, leading to the expression of PSMB8, ultimately promoting the progression of the malignant phenotype of GC. Moreover, we discovered that CKMT2-AS1 directly binds to the RNA-binding protein (RBP) AIMP1, promoting ubiquitination-mediated degradation of AIMP1 protein via the proteasomal pathway. The highly expressed AIMP1 protein, in turn, inhibits the phosphorylation of the PI3K/AKT signaling pathway, which is hyperactivated in virtually all solid tumors. Our findings not only elucidate a novel SFN-mediated tumor-suppressive mechanism via the STAT3/CKMT2-AS1 regulatory axis, but also validate CKMT2-AS1 as a promising therapeutic target for GC intervention.",
    "para1": "èƒƒç™Œæ˜¯ä¸€ç¨®å°äººé¡å¥åº·æ§‹æˆé‡å¤§å¨è„…çš„ç–¾ç—…ï¼Œç›®å‰çš„æ²»ç™‚é¸æ“‡æœ‰é™ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ï¼Œæˆ–è¨±èƒ½é–‹ç™¼å‡ºæ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•ï¼Œå¹«åŠ©æ”¹å–„æ‚£è€…çš„ç”Ÿå­˜ç‡å’Œç”Ÿæ´»å“è³ªã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„æŠ—è…«ç˜¤ä½œç”¨åŠå…¶åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„è¡Œç‚ºï¼Œç‰¹åˆ¥æ˜¯å®ƒå°æŸäº›é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰çš„èª¿æ§ä½œç”¨ã€‚é€™äº›lncRNAåœ¨ç™Œç—‡çš„ç™¼å±•ä¸­å¯èƒ½æ‰®æ¼”é‡è¦è§’è‰²ï¼Œå› æ­¤äº†è§£å®ƒå€‘çš„ä½œç”¨å°æ–¼ç™Œç—‡æ²»ç™‚è‡³é—œé‡è¦ã€‚",
    "para3": "ç ”ç©¶åœ˜éšŠé€²è¡Œäº†ä¸€ç³»åˆ—çš„å¯¦é©—ï¼ŒåŒ…æ‹¬é«”å¤–å’Œé«”å…§çš„æ¸¬è©¦ï¼Œä»¥å…¨é¢è©•ä¼°è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ç ”ç©¶è€…é‚„é€²è¡Œäº†åŸºå› æ¸¬åºåˆ†æï¼Œä»¥è­˜åˆ¥èˆ‡è˜¿è””ç¡«ç´ ä½œç”¨ç›¸é—œçš„ç›®æ¨™lncRNAã€‚æ¥è‘—ï¼Œä»–å€‘é€²è¡Œäº†æ©Ÿåˆ¶é©—è­‰å¯¦é©—ï¼Œä»¥ç¢ºå®šåœ¨STAT3-CKMT2-AS1èª¿æ§è»¸ä¸­ï¼Œä¸Šæ¸¸å’Œä¸‹æ¸¸çš„èª¿æ§æˆåˆ†ï¼Œå¾è€Œæ·±å…¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¼·çƒˆæŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œä¸¦é™ä½lncRNA CKMT2-AS1çš„è¡¨é”ã€‚CKMT2-AS1åœ¨èƒƒç™Œçµ„ç¹”ä¸­çš„é«˜è¡¨é”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡è¼ƒä½æœ‰é—œã€‚ç•¶CKMT2-AS1è¢«æŠ‘åˆ¶æ™‚ï¼Œèƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»é¡¯è‘—æ¸›å°‘ï¼Œè€ŒCKMT2-AS1çš„éåº¦è¡¨é”å‰‡æœƒåŠ åŠ‡ç™Œç—‡çš„æƒ¡æ€§ç‰¹å¾µã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾STAT3æ˜¯é©…å‹•CKMT2-AS1è¡¨é”çš„è½‰éŒ„æ¿€æ´»å› å­ï¼Œè˜¿è””ç¡«ç´ èƒ½ç›´æ¥çµåˆä¸¦æŠ‘åˆ¶STAT3çš„ç£·é…¸åŒ–ï¼Œé€²è€Œé™ä½å…¶è½‰éŒ„æ´»æ€§ï¼Œé€™äº›ç™¼ç¾ç‚ºèƒƒç™Œçš„æ²»ç™‚æä¾›äº†æ–°çš„æ½›åœ¨é¶é»ã€‚",
    "explanation_zh": "èƒƒç™Œæ˜¯ä¸€ç¨®å°äººé¡å¥åº·æ§‹æˆé‡å¤§å¨è„…çš„ç–¾ç—…ï¼Œç›®å‰çš„æ²»ç™‚é¸æ“‡æœ‰é™ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ï¼Œæˆ–è¨±èƒ½é–‹ç™¼å‡ºæ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•ï¼Œå¹«åŠ©æ”¹å–„æ‚£è€…çš„ç”Ÿå­˜ç‡å’Œç”Ÿæ´»å“è³ªã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„æŠ—è…«ç˜¤ä½œç”¨åŠå…¶åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„è¡Œç‚ºï¼Œç‰¹åˆ¥æ˜¯å®ƒå°æŸäº›é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰çš„èª¿æ§ä½œç”¨ã€‚é€™äº›lncRNAåœ¨ç™Œç—‡çš„ç™¼å±•ä¸­å¯èƒ½æ‰®æ¼”é‡è¦è§’è‰²ï¼Œå› æ­¤äº†è§£å®ƒå€‘çš„ä½œç”¨å°æ–¼ç™Œç—‡æ²»ç™‚è‡³é—œé‡è¦ã€‚\n\nç ”ç©¶åœ˜éšŠé€²è¡Œäº†ä¸€ç³»åˆ—çš„å¯¦é©—ï¼ŒåŒ…æ‹¬é«”å¤–å’Œé«”å…§çš„æ¸¬è©¦ï¼Œä»¥å…¨é¢è©•ä¼°è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ç ”ç©¶è€…é‚„é€²è¡Œäº†åŸºå› æ¸¬åºåˆ†æï¼Œä»¥è­˜åˆ¥èˆ‡è˜¿è””ç¡«ç´ ä½œç”¨ç›¸é—œçš„ç›®æ¨™lncRNAã€‚æ¥è‘—ï¼Œä»–å€‘é€²è¡Œäº†æ©Ÿåˆ¶é©—è­‰å¯¦é©—ï¼Œä»¥ç¢ºå®šåœ¨STAT3-CKMT2-AS1èª¿æ§è»¸ä¸­ï¼Œä¸Šæ¸¸å’Œä¸‹æ¸¸çš„èª¿æ§æˆåˆ†ï¼Œå¾è€Œæ·±å…¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¼·çƒˆæŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œä¸¦é™ä½lncRNA CKMT2-AS1çš„è¡¨é”ã€‚CKMT2-AS1åœ¨èƒƒç™Œçµ„ç¹”ä¸­çš„é«˜è¡¨é”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡è¼ƒä½æœ‰é—œã€‚ç•¶CKMT2-AS1è¢«æŠ‘åˆ¶æ™‚ï¼Œèƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»é¡¯è‘—æ¸›å°‘ï¼Œè€ŒCKMT2-AS1çš„éåº¦è¡¨é”å‰‡æœƒåŠ åŠ‡ç™Œç—‡çš„æƒ¡æ€§ç‰¹å¾µã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾STAT3æ˜¯é©…å‹•CKMT2-AS1è¡¨é”çš„è½‰éŒ„æ¿€æ´»å› å­ï¼Œè˜¿è””ç¡«ç´ èƒ½ç›´æ¥çµåˆä¸¦æŠ‘åˆ¶STAT3çš„ç£·é…¸åŒ–ï¼Œé€²è€Œé™ä½å…¶è½‰éŒ„æ´»æ€§ï¼Œé€™äº›ç™¼ç¾ç‚ºèƒƒç™Œçš„æ²»ç™‚æä¾›äº†æ–°çš„æ½›åœ¨é¶é»ã€‚",
    "fb_post": "æ ¹æ“šã€ŠPhytomedicine : international journal of phytotherapy and phytopharmacologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é¤æ¡Œä¸Šæœ‰ä¸€ç¨®ç¥ç§˜çš„æˆåˆ†ï¼Œå¯èƒ½å°æŠ—èƒƒç™Œï¼é€™é …ç ”ç©¶å°ˆæ³¨æ–¼ã€Œè˜¿è””ç¡«ç´ ã€ï¼Œå®ƒå¯èƒ½æˆç‚ºèƒƒç™Œæ²»ç™‚çš„æ–°å¸Œæœ›ã€‚ç ”ç©¶è€…å€‘æƒ³äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒï¼Œç‰¹åˆ¥æ˜¯å®ƒå°æŸäº›é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰çš„èª¿æ§ä½œç”¨ã€‚é€™äº›lncRNAåœ¨ç™Œç—‡ç™¼å±•ä¸­æ‰®æ¼”é‡è¦è§’è‰²ï¼Œäº†è§£å®ƒå€‘çš„åŠŸèƒ½å°æ²»ç™‚ç™Œç—‡è‡³é—œé‡è¦ã€‚\n\nç ”ç©¶åœ˜éšŠé€²è¡Œäº†å¤šç¨®å¯¦é©—ï¼ŒåŒ…æ‹¬åœ¨å¯¦é©—å®¤ä¸­çš„ç´°èƒæ¸¬è©¦å’Œå‹•ç‰©æ¸¬è©¦ï¼Œä¾†å…¨é¢è©•ä¼°è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ä»–å€‘é‚„åˆ†æäº†åŸºå› ï¼Œä»¥æ‰¾å‡ºèˆ‡è˜¿è””ç¡«ç´ ç›¸é—œçš„ç›®æ¨™lncRNAï¼Œä¸¦é€²ä¸€æ­¥æ¢è¨å…¶ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¼·çƒˆæŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œä¸¦é™ä½ä¸€ç¨®åç‚ºCKMT2-AS1çš„lncRNAè¡¨é”ï¼Œé€™ç¨®lncRNAåœ¨èƒƒç™Œæ‚£è€…ä¸­èˆ‡è¼ƒä½çš„ç”Ÿå­˜ç‡æœ‰é—œã€‚ç•¶CKMT2-AS1è¢«æŠ‘åˆ¶æ™‚ï¼Œèƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»æ˜é¡¯æ¸›å°‘ï¼Œé€™ç‚ºèƒƒç™Œçš„æ²»ç™‚æä¾›äº†æ–°çš„æ½›åœ¨é¶é»ï¼\n\nğŸ” ç ”ç©¶é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æŠ‘åˆ¶èƒƒç™Œç´°èƒç”Ÿé•·ã€‚\n2. CKMT2-AS1çš„è¡¨é”èˆ‡èƒƒç™Œçš„æƒ¡æ€§ç‰¹å¾µæœ‰é—œã€‚\n3. STAT3æ˜¯ä¸€å€‹é‡è¦çš„èª¿æ§å› å­ï¼Œè˜¿è””ç¡«ç´ èƒ½æŠ‘åˆ¶å…¶æ´»æ€§ã€‚",
    "image_prompt": "Create a flat design infographic explaining the experimental methods and main results of a study on the anti-cancer effects of sulforaphane found in foods like broccoli and radishes. Include simple icons representing sulforaphane, experimental subjects like cells or animals, and arrows or flow lines to indicate the steps of the experiment. Add a section that summarizes the main results, such as protective effects and changes observed in cancer cells.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "èƒƒç™Œ Gastric Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41135276/"
  },
  {
    "id": "41275316",
    "title_en": "Investigating the clinical efficacy, safety and molecular mechanism of sulforaphane in autism spectrum disorder: an integrated study combining meta-analysis, network pharmacology, and computational biology.",
    "pub_date": "2025 Nov",
    "journal": "BMC pharmacology & toxicology",
    "abstract_en": "Sulforaphane, a natural antioxidant rich in cruciferous vegetables, has emerged as a promising dietary supplement for autism spectrum disorder (ASD). However, its therapeutic efficacy remains controversial, and the pharmacological mechanisms are not fully elucidated. Eligible randomized controlled trials were retrieved from PubMed, Web of Science, Embase, and Cochrane Library databases. Review Manager 5.4 was used for meta-analysis and bias risk assessment. Network pharmacology, Mendelian randomization, GEO data analyses, molecular docking, and molecular dynamics simulation were employed to explore the mechanisms of sulforaphane in ASD. Six trials involving 333 participants were included in the meta-analysis. Pooled results demonstrated that both 4-5 weeks and 8-10 weeks of sulforaphane supplementation significantly decreased the scores on the Social Responsiveness Scale compared to placebo controls. No significant difference was observed in the incidence of adverse events. Network pharmacology identified 10 core targets of sulforaphane in ASD, including AKT1, EGFR, HSP90AA1, SRC, CASP3, STAT1, MAPK1, MMP9, MAPK8, and JAK2. These targets were implicated in the PI3K-Akt signaling pathway, MAPK signaling pathway, Chemokine signaling pathway, Chemical carcinogenesis - reactive oxygen species, TNF signaling pathway, Th17 cell differentiation, mTOR signaling pathway, and IL-17 signaling pathway. Mendelian randomization further revealed an inverse association between STAT1 levels and ASD risk. GEO transcriptomic data provided independent validation for the network pharmacology predictions. The binding energies between sulforaphane and the top 10 core targets are all â‰¤ -4.0Â kcal/mol. Molecular dynamics simulations further validated the stable interaction between MMP-9 and sulforaphane. Sulforaphane may serve as an efficacious and safe adjunctive therapy for ASD, mediated by its anti-oxidant and anti-inflammatory effects along with the modulation of autophagy. CRD42025635045.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¤©ç„¶æŠ—æ°§åŒ–åŠ‘ï¼Œä¸»è¦å­˜åœ¨æ–¼åå­—èŠ±ç§‘è”¬èœä¸­ï¼Œè¿‘å¹´ä¾†è¢«èªç‚ºå¯èƒ½å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰æœ‰å¹«åŠ©ã€‚é›–ç„¶æœ‰äº›ç ”ç©¶é¡¯ç¤ºå®ƒå¯èƒ½æœ‰æ½›åœ¨çš„ç™‚æ•ˆï¼Œä½†ç›®å‰å°æ–¼å®ƒçš„ç™‚æ•ˆä»å­˜åœ¨çˆ­è­°ï¼Œä¸”å…¶è—¥ç†æ©Ÿåˆ¶å°šæœªå®Œå…¨æ˜ç­ã€‚å› æ­¤ï¼Œäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œå°æ–¼æœªä¾†çš„å¥åº·ä¿ƒé€²å’Œç–¾ç—…é é˜²å¯èƒ½å…·æœ‰é‡è¦æ„ç¾©ï¼Œç‰¹åˆ¥æ˜¯åœ¨è‡ªé–‰ç—‡çš„è¼”åŠ©æ²»ç™‚æ–¹é¢ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›é€šéç³»çµ±æ€§å›é¡§å’Œåˆ†æç¾æœ‰çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œä¾†è©•ä¼°è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆåŠå…¶å¯èƒ½çš„ä½œç”¨æ©Ÿåˆ¶ã€‚è‡ªé–‰ç—‡è­œç³»éšœç¤™æ˜¯ä¸€ç¨®å½±éŸ¿ç¤¾äº¤äº’å‹•å’Œæºé€šèƒ½åŠ›çš„ç¥ç¶“ç™¼å±•éšœç¤™ï¼Œå°æ‚£è€…åŠå…¶å®¶åº­é€ æˆé‡å¤§å½±éŸ¿ï¼Œå› æ­¤å°‹æ‰¾æœ‰æ•ˆçš„è¼”åŠ©ç™‚æ³•æ˜¯ç•¶å‰çš„ç ”ç©¶é‡é»ã€‚",
    "para3": "ç ”ç©¶è€…å¾å¤šå€‹è³‡æ–™åº«ä¸­æª¢ç´¢ç¬¦åˆæ¢ä»¶çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œä¸¦ä½¿ç”¨Review Manager 5.4é€²è¡Œçµ±è¨ˆåˆ†æå’Œåå€šé¢¨éšªè©•ä¼°ã€‚æœ€çµ‚ç´å…¥äº†å…­é …è©¦é©—ï¼Œå…±æœ‰333ååƒèˆ‡è€…ã€‚ç ”ç©¶ä¸­ï¼Œåƒèˆ‡è€…æ¥å—äº†ç‚ºæœŸ4-5é€±å’Œ8-10é€±çš„è˜¿è””ç¡«ç´ è£œå……ï¼Œä¸¦èˆ‡å®‰æ…°åŠ‘çµ„é€²è¡Œæ¯”è¼ƒã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„é‹ç”¨äº†ç¶²çµ¡è—¥ç†å­¸ã€å­Ÿå¾·çˆ¾éš¨æ©ŸåŒ–ã€GEOæ•¸æ“šåˆ†æã€åˆ†å­å°æ¥å’Œåˆ†å­å‹•åŠ›å­¸æ¨¡æ“¬ç­‰æ–¹æ³•ï¼Œä¾†æ¢è¨è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œèˆ‡å®‰æ…°åŠ‘çµ„ç›¸æ¯”ï¼Œæ¥å—è˜¿è””ç¡«ç´ è£œå……çš„åƒèˆ‡è€…åœ¨ç¤¾äº¤åæ‡‰é‡è¡¨ä¸Šçš„å¾—åˆ†é¡¯è‘—é™ä½ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½å°æ”¹å–„è‡ªé–‰ç—‡çš„ç¤¾äº¤è¡Œç‚ºæœ‰ä¸€å®šçš„å¹«åŠ©ã€‚æ­¤å¤–ï¼Œç ”ç©¶ä¸­ä¸¦æœªè§€å¯Ÿåˆ°é¡¯è‘—çš„å‰¯ä½œç”¨ç™¼ç”Ÿç‡ã€‚ç¶²çµ¡è—¥ç†å­¸åˆ†æç¢ºå®šäº†è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„åå€‹æ ¸å¿ƒé¶é»ï¼Œé€™äº›é¶é»èˆ‡å¤šæ¢ä¿¡è™Ÿé€šè·¯æœ‰é—œï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ å¯èƒ½é€šéæŠ—æ°§åŒ–å’ŒæŠ—ç‚ä½œç”¨ä»¥åŠè‡ªå™¬èª¿ç¯€ä¾†ç™¼æ®å…¶æ•ˆæœã€‚é€™äº›çµæœç‚ºè˜¿è””ç¡«ç´ ä½œç‚ºè‡ªé–‰ç—‡è¼”åŠ©ç™‚æ³•çš„æ½›åŠ›æä¾›äº†æ”¯æŒï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶ç™‚æ•ˆã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¤©ç„¶æŠ—æ°§åŒ–åŠ‘ï¼Œä¸»è¦å­˜åœ¨æ–¼åå­—èŠ±ç§‘è”¬èœä¸­ï¼Œè¿‘å¹´ä¾†è¢«èªç‚ºå¯èƒ½å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰æœ‰å¹«åŠ©ã€‚é›–ç„¶æœ‰äº›ç ”ç©¶é¡¯ç¤ºå®ƒå¯èƒ½æœ‰æ½›åœ¨çš„ç™‚æ•ˆï¼Œä½†ç›®å‰å°æ–¼å®ƒçš„ç™‚æ•ˆä»å­˜åœ¨çˆ­è­°ï¼Œä¸”å…¶è—¥ç†æ©Ÿåˆ¶å°šæœªå®Œå…¨æ˜ç­ã€‚å› æ­¤ï¼Œäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œå°æ–¼æœªä¾†çš„å¥åº·ä¿ƒé€²å’Œç–¾ç—…é é˜²å¯èƒ½å…·æœ‰é‡è¦æ„ç¾©ï¼Œç‰¹åˆ¥æ˜¯åœ¨è‡ªé–‰ç—‡çš„è¼”åŠ©æ²»ç™‚æ–¹é¢ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›é€šéç³»çµ±æ€§å›é¡§å’Œåˆ†æç¾æœ‰çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œä¾†è©•ä¼°è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆåŠå…¶å¯èƒ½çš„ä½œç”¨æ©Ÿåˆ¶ã€‚è‡ªé–‰ç—‡è­œç³»éšœç¤™æ˜¯ä¸€ç¨®å½±éŸ¿ç¤¾äº¤äº’å‹•å’Œæºé€šèƒ½åŠ›çš„ç¥ç¶“ç™¼å±•éšœç¤™ï¼Œå°æ‚£è€…åŠå…¶å®¶åº­é€ æˆé‡å¤§å½±éŸ¿ï¼Œå› æ­¤å°‹æ‰¾æœ‰æ•ˆçš„è¼”åŠ©ç™‚æ³•æ˜¯ç•¶å‰çš„ç ”ç©¶é‡é»ã€‚\n\nç ”ç©¶è€…å¾å¤šå€‹è³‡æ–™åº«ä¸­æª¢ç´¢ç¬¦åˆæ¢ä»¶çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œä¸¦ä½¿ç”¨Review Manager 5.4é€²è¡Œçµ±è¨ˆåˆ†æå’Œåå€šé¢¨éšªè©•ä¼°ã€‚æœ€çµ‚ç´å…¥äº†å…­é …è©¦é©—ï¼Œå…±æœ‰333ååƒèˆ‡è€…ã€‚ç ”ç©¶ä¸­ï¼Œåƒèˆ‡è€…æ¥å—äº†ç‚ºæœŸ4-5é€±å’Œ8-10é€±çš„è˜¿è””ç¡«ç´ è£œå……ï¼Œä¸¦èˆ‡å®‰æ…°åŠ‘çµ„é€²è¡Œæ¯”è¼ƒã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„é‹ç”¨äº†ç¶²çµ¡è—¥ç†å­¸ã€å­Ÿå¾·çˆ¾éš¨æ©ŸåŒ–ã€GEOæ•¸æ“šåˆ†æã€åˆ†å­å°æ¥å’Œåˆ†å­å‹•åŠ›å­¸æ¨¡æ“¬ç­‰æ–¹æ³•ï¼Œä¾†æ¢è¨è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œèˆ‡å®‰æ…°åŠ‘çµ„ç›¸æ¯”ï¼Œæ¥å—è˜¿è””ç¡«ç´ è£œå……çš„åƒèˆ‡è€…åœ¨ç¤¾äº¤åæ‡‰é‡è¡¨ä¸Šçš„å¾—åˆ†é¡¯è‘—é™ä½ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½å°æ”¹å–„è‡ªé–‰ç—‡çš„ç¤¾äº¤è¡Œç‚ºæœ‰ä¸€å®šçš„å¹«åŠ©ã€‚æ­¤å¤–ï¼Œç ”ç©¶ä¸­ä¸¦æœªè§€å¯Ÿåˆ°é¡¯è‘—çš„å‰¯ä½œç”¨ç™¼ç”Ÿç‡ã€‚ç¶²çµ¡è—¥ç†å­¸åˆ†æç¢ºå®šäº†è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„åå€‹æ ¸å¿ƒé¶é»ï¼Œé€™äº›é¶é»èˆ‡å¤šæ¢ä¿¡è™Ÿé€šè·¯æœ‰é—œï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ å¯èƒ½é€šéæŠ—æ°§åŒ–å’ŒæŠ—ç‚ä½œç”¨ä»¥åŠè‡ªå™¬èª¿ç¯€ä¾†ç™¼æ®å…¶æ•ˆæœã€‚é€™äº›çµæœç‚ºè˜¿è””ç¡«ç´ ä½œç‚ºè‡ªé–‰ç—‡è¼”åŠ©ç™‚æ³•çš„æ½›åŠ›æä¾›äº†æ”¯æŒï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶ç™‚æ•ˆã€‚",
    "fb_post": "æ ¹æ“šã€ŠBMC pharmacology & toxicologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿè˜¿è””ç¡«ç´ ä¸åƒ…æ˜¯è”¬èœä¸­çš„å¤©ç„¶æŠ—æ°§åŒ–åŠ‘ï¼Œæœ€è¿‘é‚„è¢«é—œæ³¨å°è‡ªé–‰ç—‡çš„æ½›åœ¨å½±éŸ¿ï¼é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¹«åŠ©è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰çš„æœ‹å‹å€‘ã€‚ç ”ç©¶è€…å€‘å¾å¤šå€‹è³‡æ–™åº«ä¸­æ‰¾åˆ°äº†ä¸€äº›éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œæœ€çµ‚ç´å…¥äº†å…­é …ï¼Œå…±æœ‰333ä½åƒèˆ‡è€…ã€‚ä»–å€‘æ¥å—äº†è˜¿è””ç¡«ç´ çš„è£œå……ï¼Œä¸¦èˆ‡å®‰æ…°åŠ‘çµ„é€²è¡Œæ¯”è¼ƒã€‚ ç ”ç©¶çµæœé¡¯ç¤ºï¼Œæ¥å—è˜¿è””ç¡«ç´ çš„åƒèˆ‡è€…åœ¨ç¤¾äº¤åæ‡‰ä¸Šæœ‰é¡¯è‘—æ”¹å–„ï¼Œé€™æ„å‘³è‘—è˜¿è””ç¡«ç´ å¯èƒ½å°ç¤¾äº¤è¡Œç‚ºæœ‰å¹«åŠ©ï¼è€Œä¸”ï¼Œç ”ç©¶ä¸­æ²’æœ‰ç™¼ç¾é¡¯è‘—çš„å‰¯ä½œç”¨ã€‚é€™äº›ç™¼ç¾è®“æˆ‘å€‘å°è˜¿è””ç¡«ç´ ä½œç‚ºè‡ªé–‰ç—‡è¼”åŠ©ç™‚æ³•çš„æ½›åŠ›å……æ»¿æœŸå¾…ï¼Œä½†ä»éœ€è¦æ›´å¤šç ”ç©¶ä¾†ç¢ºèªå®ƒçš„ç™‚æ•ˆã€‚ ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æ”¹å–„è‡ªé–‰ç—‡çš„ç¤¾äº¤è¡Œç‚ºã€‚\n2. ç ”ç©¶ä¸­æœªè§€å¯Ÿåˆ°é¡¯è‘—å‰¯ä½œç”¨ã€‚\n3. ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªç™‚æ•ˆã€‚",
    "image_prompt": "Create an infographic that explains the experiment and main results of the study on sulforaphane and autism. Use a flat design style with a white or light-colored background and soft color palette. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects (like people or cells), arrows or flow lines showing the steps of the experiment, and a section labeled 'Main Results' highlighting the protective effects observed.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "è‡ªé–‰ç—‡è­œç³»éšœç¤™ Autism Spectrum Disorder",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41275316/"
  },
  {
    "id": "41265122",
    "title_en": "Synergistic strategies of sulforaphane biosynthesis and functional properties in broccoli sprouts powder obtained from sucrose stress modulation coupled with vacuum freeze-drying.",
    "pub_date": "2025 Nov",
    "journal": "Food chemistry",
    "abstract_en": "This study investigated methionine-sucrose stress treatments on glucoraphanin biosynthesis in broccoli sprouts and the impact of vacuum freeze-drying (VFD) on sprout powder quality. Results showed that sucrose treatment elevated glucoraphanin content by 316.30Â % in 4-day sprouts compared to the control (9.72Â mg/g), accompanied by increases of 42.65Â % in total isothiocyanates (ITCs) and 70.00Â % in anthocyanins. The treatment enhanced myrosinase activity and upregulated osmotic regulators. PCA confirmed that sucrose stress optimized the nutritional quality of broccoli sprouts and exhibited potential in sulforaphane enrichment. The VFD broccoli sprout powder exhibited high retention of sulforaphane (6.00Â mg/g dw) and total ITCs (7.00Â mg/g dw), with optimal water-holding capacity, oil-holding capacity, and swelling capacity. The sulforaphane extract exhibited significant antimicrobial activity against E. coli (16.00Â mm inhibition zone) and Staphylococcus aureus (10.02Â mm). The synergistic application of sucrose stress and VFD presents a promising approach for developing functional foods.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›æœ‰è¶£çš„å•Ÿç¤ºã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éç‰¹å®šçš„è™•ç†æ–¹æ³•ï¼Œå¯ä»¥æå‡é’èŠ±æ¤°èœèŠ½ä¸­çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ çš„å«é‡ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®è¢«èªç‚ºæœ‰åŠ©æ–¼æŠ—æ°§åŒ–å’ŒæŠ—èŒçš„åŒ–åˆç‰©ï¼Œé€™å¯èƒ½å°å¢å¼·å…ç–«ç³»çµ±å’Œé é˜²æŸäº›ç–¾ç—…æœ‰å¹«åŠ©ã€‚é€™æ„å‘³è‘—ï¼Œé€éæ”¹è®Šé’èŠ±æ¤°èœèŠ½çš„ç”Ÿé•·æ¢ä»¶ï¼Œå¯èƒ½èƒ½å¤ è£½é€ å‡ºæ›´æœ‰ç›Šå¥åº·çš„é£Ÿå“ï¼Œé€²è€Œä¿ƒé€²äººå€‘çš„æ•´é«”å¥åº·ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†å°é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–è‹·çš„åˆæˆå½±éŸ¿ï¼Œä»¥åŠçœŸç©ºå†·å‡ä¹¾ç‡¥å°èŠ½ç²‰å“è³ªçš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯å¦‚ä½•é€éç‰¹å®šçš„è™•ç†æ–¹æ³•ä¾†æå‡é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šåƒ¹å€¼ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ çš„å«é‡ï¼Œé€™å°æ–¼é–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°é’èŠ±æ¤°èœèŠ½é€²è¡Œäº†ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†ï¼Œä¸¦è§€å¯Ÿå…¶å°è‘¡è„ç³–è‹·åˆæˆçš„å½±éŸ¿ã€‚å¯¦é©—ä¸­ä½¿ç”¨äº†4å¤©å¤§çš„é’èŠ±æ¤°èœèŠ½ï¼Œä¸¦èˆ‡å°ç…§çµ„é€²è¡Œæ¯”è¼ƒã€‚ç ”ç©¶è€…é‚„é€²è¡Œäº†çœŸç©ºå†·å‡ä¹¾ç‡¥ï¼Œä»¥è©•ä¼°èŠ½ç²‰çš„å“è³ªï¼ŒåŒ…æ‹¬æ°´åˆ†ä¿æŒèƒ½åŠ›å’Œæ²¹è„‚ä¿æŒèƒ½åŠ›ç­‰æŒ‡æ¨™ï¼Œå¾è€Œäº†è§£é€™äº›è™•ç†æ–¹æ³•å°é’èŠ±æ¤°èœèŠ½ç‡Ÿé¤Šæˆåˆ†çš„å½±éŸ¿ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè”—ç³–è™•ç†ä½¿é’èŠ±æ¤°èœèŠ½ä¸­çš„è‘¡è„ç³–è‹·å«é‡æé«˜äº†316.30%ï¼ŒåŒæ™‚ç¸½ç•°ç¡«æ°°é…¸é¹½å’ŒèŠ±é’ç´ çš„å«é‡ä¹Ÿæœ‰é¡¯è‘—å¢åŠ ã€‚æ­¤å¤–ï¼Œé€™ç¨®è™•ç†é‚„æå‡äº†é…µç´ æ´»æ€§ï¼Œä¸¦ä¿ƒé€²äº†æ»²é€èª¿ç¯€å› å­çš„ä¸Šèª¿ã€‚çœŸç©ºå†·å‡ä¹¾ç‡¥çš„é’èŠ±æ¤°èœèŠ½ç²‰ä¿ç•™äº†é«˜å«é‡çš„è˜¿è””ç¡«ç´ å’Œç¸½ç•°ç¡«æ°°é…¸é¹½ï¼Œä¸¦å±•ç¾å‡ºè‰¯å¥½çš„æ°´åˆ†å’Œæ²¹è„‚ä¿æŒèƒ½åŠ›ã€‚è˜¿è””ç¡«ç´ æå–ç‰©å°å¤§è…¸æ¡¿èŒå’Œé‡‘é»ƒè‰²è‘¡è„çƒèŒå…·æœ‰é¡¯è‘—çš„æŠ—èŒæ´»æ€§ï¼Œé€™äº›çµæœé¡¯ç¤ºå‡ºè”—ç³–å£“åŠ›å’ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„çµåˆå¯èƒ½æ˜¯ä¸€ç¨®é–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“çš„æœ‰æ•ˆæ–¹æ³•ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›æœ‰è¶£çš„å•Ÿç¤ºã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éç‰¹å®šçš„è™•ç†æ–¹æ³•ï¼Œå¯ä»¥æå‡é’èŠ±æ¤°èœèŠ½ä¸­çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ çš„å«é‡ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®è¢«èªç‚ºæœ‰åŠ©æ–¼æŠ—æ°§åŒ–å’ŒæŠ—èŒçš„åŒ–åˆç‰©ï¼Œé€™å¯èƒ½å°å¢å¼·å…ç–«ç³»çµ±å’Œé é˜²æŸäº›ç–¾ç—…æœ‰å¹«åŠ©ã€‚é€™æ„å‘³è‘—ï¼Œé€éæ”¹è®Šé’èŠ±æ¤°èœèŠ½çš„ç”Ÿé•·æ¢ä»¶ï¼Œå¯èƒ½èƒ½å¤ è£½é€ å‡ºæ›´æœ‰ç›Šå¥åº·çš„é£Ÿå“ï¼Œé€²è€Œä¿ƒé€²äººå€‘çš„æ•´é«”å¥åº·ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†å°é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–è‹·çš„åˆæˆå½±éŸ¿ï¼Œä»¥åŠçœŸç©ºå†·å‡ä¹¾ç‡¥å°èŠ½ç²‰å“è³ªçš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯å¦‚ä½•é€éç‰¹å®šçš„è™•ç†æ–¹æ³•ä¾†æå‡é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šåƒ¹å€¼ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ çš„å«é‡ï¼Œé€™å°æ–¼é–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°é’èŠ±æ¤°èœèŠ½é€²è¡Œäº†ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†ï¼Œä¸¦è§€å¯Ÿå…¶å°è‘¡è„ç³–è‹·åˆæˆçš„å½±éŸ¿ã€‚å¯¦é©—ä¸­ä½¿ç”¨äº†4å¤©å¤§çš„é’èŠ±æ¤°èœèŠ½ï¼Œä¸¦èˆ‡å°ç…§çµ„é€²è¡Œæ¯”è¼ƒã€‚ç ”ç©¶è€…é‚„é€²è¡Œäº†çœŸç©ºå†·å‡ä¹¾ç‡¥ï¼Œä»¥è©•ä¼°èŠ½ç²‰çš„å“è³ªï¼ŒåŒ…æ‹¬æ°´åˆ†ä¿æŒèƒ½åŠ›å’Œæ²¹è„‚ä¿æŒèƒ½åŠ›ç­‰æŒ‡æ¨™ï¼Œå¾è€Œäº†è§£é€™äº›è™•ç†æ–¹æ³•å°é’èŠ±æ¤°èœèŠ½ç‡Ÿé¤Šæˆåˆ†çš„å½±éŸ¿ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè”—ç³–è™•ç†ä½¿é’èŠ±æ¤°èœèŠ½ä¸­çš„è‘¡è„ç³–è‹·å«é‡æé«˜äº†316.30%ï¼ŒåŒæ™‚ç¸½ç•°ç¡«æ°°é…¸é¹½å’ŒèŠ±é’ç´ çš„å«é‡ä¹Ÿæœ‰é¡¯è‘—å¢åŠ ã€‚æ­¤å¤–ï¼Œé€™ç¨®è™•ç†é‚„æå‡äº†é…µç´ æ´»æ€§ï¼Œä¸¦ä¿ƒé€²äº†æ»²é€èª¿ç¯€å› å­çš„ä¸Šèª¿ã€‚çœŸç©ºå†·å‡ä¹¾ç‡¥çš„é’èŠ±æ¤°èœèŠ½ç²‰ä¿ç•™äº†é«˜å«é‡çš„è˜¿è””ç¡«ç´ å’Œç¸½ç•°ç¡«æ°°é…¸é¹½ï¼Œä¸¦å±•ç¾å‡ºè‰¯å¥½çš„æ°´åˆ†å’Œæ²¹è„‚ä¿æŒèƒ½åŠ›ã€‚è˜¿è””ç¡«ç´ æå–ç‰©å°å¤§è…¸æ¡¿èŒå’Œé‡‘é»ƒè‰²è‘¡è„çƒèŒå…·æœ‰é¡¯è‘—çš„æŠ—èŒæ´»æ€§ï¼Œé€™äº›çµæœé¡¯ç¤ºå‡ºè”—ç³–å£“åŠ›å’ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„çµåˆå¯èƒ½æ˜¯ä¸€ç¨®é–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“çš„æœ‰æ•ˆæ–¹æ³•ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFood chemistryã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ€ å°å°é’èŠ±æ¤°èœèŠ½ï¼Œç«Ÿç„¶è—è‘—å¤§å¤§çš„å¥åº·ç§˜å¯†ï¼ä½ çŸ¥é“å—ï¼Ÿæœ€è¿‘ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œé€éç‰¹å®šçš„è™•ç†æ–¹æ³•ï¼Œæˆ‘å€‘å¯ä»¥è®“é’èŠ±æ¤°èœèŠ½ä¸­çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œå°¤å…¶æ˜¯è˜¿è””ç¡«ç´ çš„å«é‡å¤§å¹…æå‡ï¼\n\né€™é …ç ”ç©¶ä¸»è¦é—œå¿ƒçš„æ˜¯å¦‚ä½•é€éç‰¹æ®Šçš„å£“åŠ›è™•ç†ä¾†å¢åŠ é’èŠ±æ¤°èœèŠ½ä¸­çš„è‘¡è„ç³–è‹·ï¼Œé€™æ˜¯ä¸€ç¨®æœ‰åŠ©æ–¼å¥åº·çš„åŒ–åˆç‰©ã€‚ç ”ç©¶è€…å€‘ç”¨4å¤©å¤§çš„é’èŠ±æ¤°èœèŠ½é€²è¡Œäº†å¯¦é©—ï¼Œä¸¦æ¯”è¼ƒäº†ä¸åŒè™•ç†æ–¹æ³•å°èŠ½ç²‰å“è³ªçš„å½±éŸ¿ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè”—ç³–è™•ç†è®“é’èŠ±æ¤°èœèŠ½ä¸­çš„è‘¡è„ç³–è‹·å«é‡æé«˜äº†316.30%ï¼Œè€Œä¸”é‚„æå‡äº†å…¶ä»–æœ‰ç›Šæˆåˆ†çš„å«é‡ï¼é€™æ¨£çš„è™•ç†ä¸åƒ…è®“èŠ½ç²‰ä¿ç•™äº†é«˜å«é‡çš„è˜¿è””ç¡«ç´ ï¼Œé‚„å±•ç¾å‡ºè‰¯å¥½çš„æ°´åˆ†å’Œæ²¹è„‚ä¿æŒèƒ½åŠ›ï¼Œç”šè‡³å°æŸäº›ç´°èŒæœ‰æŠ—èŒæ•ˆæœå‘¢ï¼\n\nğŸ” ä¸»è¦ç™¼ç¾ï¼š\n1. è”—ç³–è™•ç†æå‡é’èŠ±æ¤°èœèŠ½çš„è‘¡è„ç³–è‹·å«é‡ã€‚\n2. çœŸç©ºå†·å‡ä¹¾ç‡¥ä¿ç•™äº†é«˜å«é‡çš„è˜¿è””ç¡«ç´ ã€‚\n3. è˜¿è””ç¡«ç´ å°å¤§è…¸æ¡¿èŒå’Œé‡‘é»ƒè‰²è‘¡è„çƒèŒæœ‰æŠ—èŒæ´»æ€§ã€‚\n\né€™äº›çµæœè®“æˆ‘å€‘çœ‹åˆ°ï¼Œé€éç§‘å­¸çš„æ–¹æ³•ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½é–‹ç™¼å‡ºæ›´æœ‰ç›Šå¥åº·çš„é£Ÿå“ï¼Œè®“ç”Ÿæ´»æ›´ç¾å¥½ï¼",
    "image_prompt": "Create an infographic that explains the experiment and main results of a study on broccoli sprouts. The infographic should have a flat design style on a white or light background with soft colors. Include symbols for broccoli and sulforaphane. Simplified illustrations of the experimental subjects, such as humans or cells, should be present. Use arrows or flow lines to indicate the steps of the experiment. Include a section labeled 'Main Results' highlighting key findings like increased protective effects and changes in nutrient levels.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41265122/"
  },
  {
    "id": "41159773",
    "title_en": "Sulforaphane-Loaded Hydrogel Prolongs Fully MHC-Mismatched Skin Allograft Survival.",
    "pub_date": "2025 Nov",
    "journal": "ACS applied bio materials",
    "abstract_en": "Despite immunosuppression, acute rejection (AR) is still a common setback among transplantation patients and is a risk factor for graft survival. Sulforaphane (SFN), a phytochemical present in crucifers, has been shown to have anti-inflammatory and immunoregulatory properties, yet its influences on immune cell activation as well as in graft survival are still unknown. Thus, the aim was to evaluate SFN's effect, and to improve efficacy, efficiency, and availability, it was incorporated into thermosensitive polymeric hydrogels, to prevent AR in skin transplant (Tx) model mice. A thermosensitive hydrogel containing SFN (0.1%) and hyaluronic acid (HA) (0.5%) dispersed in a poloxamer matrix (PL407 at 20% w/v) was developed (GS-PL407 20%, HA and SFN) and characterized as a liquid-viscous hydrogel. The fully MHC-incompatible skin Tx procedure was performed by using donor skin Balb/c mice, transplanted into C57BL/6 recipient mice. The cytotoxicity test of GS was performed using in vitro assays with bone marrow-derived dendritic cells (BMDC). Treatment of BMDC with GS for 24 h presents no cytotoxicity. Untreated allograft mice present 100% of graft loss at day 9 post Tx. Remarkably, subcutaneous GS injection every 3 days promoted 80% of allograft survival for more than 14 days when compared with untreated recipients (<i>p</i> < 0.001). Histological analysis showed a lower level of inflammatory cells in the skin Tx of GS-treated mice. Flow cytometry analysis of draining lymph nodes at day 5 post Tx revealed that GS treatment reduced the frequency of DC and subtypes and function of the CD4<sup>+</sup> T cells. In vitro GS-treated lipopolysaccharide-activated BMDC present less activation of costimulatory markers. Taken together, GS treatment reduced immune cell activation, postponing AR onset and prolonging allograft survival in Tx animals. This strategy highlights the role of SFN as a promising candidate for further studies in organ transplantation experiments and being tested combined with current immunosuppression protocols.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å™¨å®˜ç§»æ¤çš„é ˜åŸŸã€‚å™¨å®˜ç§»æ¤å¾Œï¼Œæ‚£è€…å¸¸å¸¸æœƒé¢è‡¨æ€¥æ€§æ’æ–¥åæ‡‰çš„é¢¨éšªï¼Œé€™æœƒå½±éŸ¿ç§»æ¤å™¨å®˜çš„å­˜æ´»ç‡ã€‚ç ”ç©¶ä¸­æåˆ°çš„è˜¿è””ç¡«ç´ ï¼Œé€™ç¨®å­˜åœ¨æ–¼åå­—èŠ±ç§‘æ¤ç‰©ä¸­çš„æ¤ç‰©åŒ–å­¸ç‰©è³ªï¼Œå…·æœ‰æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€çš„ç‰¹æ€§ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„ç§»æ¤å¾Œçš„å…ç–«åæ‡‰ï¼Œå¾è€Œæé«˜å™¨å®˜çš„å­˜æ´»ç‡ã€‚é€™æ„å‘³è‘—ï¼Œé€éé€²ä¸€æ­¥çš„ç ”ç©¶ï¼Œè˜¿è””ç¡«ç´ æœ‰æ½›åŠ›æˆç‚ºç§»æ¤æ‚£è€…çš„ä¸€ç¨®è¼”åŠ©ç™‚æ³•ï¼Œå¹«åŠ©ä»–å€‘æ›´å¥½åœ°æ‡‰å°æ’æ–¥åæ‡‰çš„æŒ‘æˆ°ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼æ€¥æ€§æ’æ–¥åæ‡‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªå¦‚ä½•å½±éŸ¿å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œä»¥åŠå®ƒåœ¨ç§»æ¤å™¨å®˜å­˜æ´»ä¸­çš„ä½œç”¨ã€‚å„˜ç®¡è˜¿è””ç¡«ç´ å·²çŸ¥å…·æœ‰æŠ—ç™¼ç‚çš„ç‰¹æ€§ï¼Œä½†å…¶å…·é«”çš„å…ç–«èª¿ç¯€æ•ˆæœä»ç„¶ä¸æ˜ï¼Œå› æ­¤é€™é …ç ”ç©¶æ—¨åœ¨å¡«è£œé€™ä¸€çŸ¥è­˜ç©ºç™½ï¼Œä¸¦å°‹æ‰¾æ”¹å–„ç§»æ¤çµæœçš„æ½›åœ¨æ–¹æ³•ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å°é¼ ä½œç‚ºæ¨¡å‹ï¼Œç‰¹åˆ¥æ˜¯å°‡è˜¿è””ç¡«ç´ èˆ‡ç†±æ•èšåˆç‰©æ°´å‡è† çµåˆï¼Œä»¥æé«˜å…¶ç™‚æ•ˆå’Œå¯ç”¨æ€§ã€‚é€™ç¨®æ°´å‡è† ä¸­å«æœ‰0.1%çš„è˜¿è””ç¡«ç´ å’Œ0.5%çš„é€æ˜è³ªé…¸ï¼Œä¸¦åœ¨èšæ°§ä¹™çƒ¯åŸºè³ªä¸­åˆ†æ•£ã€‚ç ”ç©¶è€…é€²è¡Œäº†çš®è†šç§»æ¤æ‰‹è¡“ï¼Œå°‡ä¾›é«”å°é¼ çš„çš®è†šç§»æ¤åˆ°æ¥å—è€…å°é¼ èº«ä¸Šï¼Œä¸¦é€²è¡Œäº†ç´°èƒæ¯’æ€§æ¸¬è©¦ï¼Œä»¥è©•ä¼°æ°´å‡è† çš„å®‰å…¨æ€§å’Œæœ‰æ•ˆæ€§ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œä½¿ç”¨è˜¿è””ç¡«ç´ çš„æ°´å‡è† å¯ä»¥é¡¯è‘—æé«˜ç§»æ¤çš®è†šçš„å­˜æ´»ç‡ã€‚èˆ‡æœªæ¥å—æ²»ç™‚çš„å°é¼ ç›¸æ¯”ï¼Œæ¥å—æ°´å‡è† æ²»ç™‚çš„å°é¼ åœ¨14å¤©å…§æœ‰80%çš„ç§»æ¤å­˜æ´»ç‡ã€‚æ­¤å¤–ï¼Œçµ„ç¹”å­¸åˆ†æé¡¯ç¤ºï¼Œæ¥å—æ²»ç™‚çš„å°é¼ çš®è†šä¸­çš„ç™¼ç‚ç´°èƒæ•¸é‡è¼ƒå°‘ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½æ¸›å°‘äº†å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œå»¶ç·©äº†æ€¥æ€§æ’æ–¥åæ‡‰çš„ç™¼ç”Ÿã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨å™¨å®˜ç§»æ¤ä¸­å¯èƒ½æ˜¯ä¸€å€‹æœ‰å‰æ™¯çš„ç ”ç©¶æ–¹å‘ï¼Œå€¼å¾—é€²ä¸€æ­¥æ¢ç´¢ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å™¨å®˜ç§»æ¤çš„é ˜åŸŸã€‚å™¨å®˜ç§»æ¤å¾Œï¼Œæ‚£è€…å¸¸å¸¸æœƒé¢è‡¨æ€¥æ€§æ’æ–¥åæ‡‰çš„é¢¨éšªï¼Œé€™æœƒå½±éŸ¿ç§»æ¤å™¨å®˜çš„å­˜æ´»ç‡ã€‚ç ”ç©¶ä¸­æåˆ°çš„è˜¿è””ç¡«ç´ ï¼Œé€™ç¨®å­˜åœ¨æ–¼åå­—èŠ±ç§‘æ¤ç‰©ä¸­çš„æ¤ç‰©åŒ–å­¸ç‰©è³ªï¼Œå…·æœ‰æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€çš„ç‰¹æ€§ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„ç§»æ¤å¾Œçš„å…ç–«åæ‡‰ï¼Œå¾è€Œæé«˜å™¨å®˜çš„å­˜æ´»ç‡ã€‚é€™æ„å‘³è‘—ï¼Œé€éé€²ä¸€æ­¥çš„ç ”ç©¶ï¼Œè˜¿è””ç¡«ç´ æœ‰æ½›åŠ›æˆç‚ºç§»æ¤æ‚£è€…çš„ä¸€ç¨®è¼”åŠ©ç™‚æ³•ï¼Œå¹«åŠ©ä»–å€‘æ›´å¥½åœ°æ‡‰å°æ’æ–¥åæ‡‰çš„æŒ‘æˆ°ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼æ€¥æ€§æ’æ–¥åæ‡‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªå¦‚ä½•å½±éŸ¿å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œä»¥åŠå®ƒåœ¨ç§»æ¤å™¨å®˜å­˜æ´»ä¸­çš„ä½œç”¨ã€‚å„˜ç®¡è˜¿è””ç¡«ç´ å·²çŸ¥å…·æœ‰æŠ—ç™¼ç‚çš„ç‰¹æ€§ï¼Œä½†å…¶å…·é«”çš„å…ç–«èª¿ç¯€æ•ˆæœä»ç„¶ä¸æ˜ï¼Œå› æ­¤é€™é …ç ”ç©¶æ—¨åœ¨å¡«è£œé€™ä¸€çŸ¥è­˜ç©ºç™½ï¼Œä¸¦å°‹æ‰¾æ”¹å–„ç§»æ¤çµæœçš„æ½›åœ¨æ–¹æ³•ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å°é¼ ä½œç‚ºæ¨¡å‹ï¼Œç‰¹åˆ¥æ˜¯å°‡è˜¿è””ç¡«ç´ èˆ‡ç†±æ•èšåˆç‰©æ°´å‡è† çµåˆï¼Œä»¥æé«˜å…¶ç™‚æ•ˆå’Œå¯ç”¨æ€§ã€‚é€™ç¨®æ°´å‡è† ä¸­å«æœ‰0.1%çš„è˜¿è””ç¡«ç´ å’Œ0.5%çš„é€æ˜è³ªé…¸ï¼Œä¸¦åœ¨èšæ°§ä¹™çƒ¯åŸºè³ªä¸­åˆ†æ•£ã€‚ç ”ç©¶è€…é€²è¡Œäº†çš®è†šç§»æ¤æ‰‹è¡“ï¼Œå°‡ä¾›é«”å°é¼ çš„çš®è†šç§»æ¤åˆ°æ¥å—è€…å°é¼ èº«ä¸Šï¼Œä¸¦é€²è¡Œäº†ç´°èƒæ¯’æ€§æ¸¬è©¦ï¼Œä»¥è©•ä¼°æ°´å‡è† çš„å®‰å…¨æ€§å’Œæœ‰æ•ˆæ€§ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œä½¿ç”¨è˜¿è””ç¡«ç´ çš„æ°´å‡è† å¯ä»¥é¡¯è‘—æé«˜ç§»æ¤çš®è†šçš„å­˜æ´»ç‡ã€‚èˆ‡æœªæ¥å—æ²»ç™‚çš„å°é¼ ç›¸æ¯”ï¼Œæ¥å—æ°´å‡è† æ²»ç™‚çš„å°é¼ åœ¨14å¤©å…§æœ‰80%çš„ç§»æ¤å­˜æ´»ç‡ã€‚æ­¤å¤–ï¼Œçµ„ç¹”å­¸åˆ†æé¡¯ç¤ºï¼Œæ¥å—æ²»ç™‚çš„å°é¼ çš®è†šä¸­çš„ç™¼ç‚ç´°èƒæ•¸é‡è¼ƒå°‘ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½æ¸›å°‘äº†å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œå»¶ç·©äº†æ€¥æ€§æ’æ–¥åæ‡‰çš„ç™¼ç”Ÿã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨å™¨å®˜ç§»æ¤ä¸­å¯èƒ½æ˜¯ä¸€å€‹æœ‰å‰æ™¯çš„ç ”ç©¶æ–¹å‘ï¼Œå€¼å¾—é€²ä¸€æ­¥æ¢ç´¢ã€‚",
    "fb_post": "æ ¹æ“šã€ŠACS applied bio materialsã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæœ‰ä¸€ç¨®ä¾†è‡ªé’èŠ±èœçš„ç¥å¥‡æˆåˆ†ï¼Œå¯èƒ½å°å™¨å®˜ç§»æ¤æœ‰å¹«åŠ©ï¼æœ€è¿‘çš„ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ï¼ˆé€™æ˜¯ä¸€ç¨®åœ¨åå­—èŠ±ç§‘æ¤ç‰©ä¸­æ‰¾åˆ°çš„æ¤ç‰©åŒ–å­¸ç‰©è³ªï¼‰å¯èƒ½èƒ½æ”¹å–„ç§»æ¤å¾Œçš„å…ç–«åæ‡‰ï¼Œè®“å™¨å®˜å­˜æ´»ç‡æ›´é«˜ã€‚  \n  \né€™é …ç ”ç©¶ä¸»è¦æ¢è¨äº†è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿å…ç–«ç´°èƒï¼Œç‰¹åˆ¥æ˜¯åœ¨æ€¥æ€§æ’æ–¥åæ‡‰çš„æƒ…æ³ä¸‹ã€‚ç ”ç©¶è€…å€‘ä½¿ç”¨å°é¼ ä½œç‚ºå¯¦é©—å°è±¡ï¼Œå°‡è˜¿è””ç¡«ç´ èˆ‡ä¸€ç¨®ç‰¹æ®Šçš„æ°´å‡è† çµåˆï¼Œé€²è¡Œäº†çš®è†šç§»æ¤æ‰‹è¡“ï¼Œä¸¦è§€å¯Ÿæ°´å‡è† çš„æ•ˆæœã€‚  \n  \nçµæœé¡¯ç¤ºï¼Œä½¿ç”¨è˜¿è””ç¡«ç´ çš„æ°´å‡è† çš„å°é¼ åœ¨14å¤©å…§æœ‰80%çš„ç§»æ¤å­˜æ´»ç‡ï¼Œä¸¦ä¸”ç™¼ç¾æ¥å—æ²»ç™‚çš„å°é¼ çš®è†šä¸­çš„ç™¼ç‚ç´°èƒæ•¸é‡è¼ƒå°‘ï¼Œé€™æ„å‘³è‘—è˜¿è””ç¡«ç´ å¯èƒ½å¹«åŠ©æ¸›å°‘å…ç–«ç³»çµ±çš„éåº¦åæ‡‰ã€‚  \n  \né€™é …ç ”ç©¶å‘Šè¨´æˆ‘å€‘ï¼š  \n- è˜¿è””ç¡«ç´ å¯èƒ½å°ç§»æ¤æ‚£è€…æœ‰æ½›åœ¨çš„å¥½è™•  \n- é€²ä¸€æ­¥ç ”ç©¶æˆ–è¨±èƒ½ç™¼ç¾æ›´å¤šæ”¹å–„ç§»æ¤çµæœçš„æ–¹æ³•  \n- å¥åº·é£²é£Ÿä¸­åŒ…å«åå­—èŠ±ç§‘è”¬èœï¼Œæˆ–è¨±èƒ½å°æˆ‘å€‘çš„å…ç–«ç³»çµ±æœ‰æ­£é¢å½±éŸ¿ï¼",
    "image_prompt": "Create a flat design infographic explaining an experiment involving sulforaphane. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like mice or cells, arrows or flow lines to show the experimental steps, and a section highlighting key results such as increased survival rates or reduced inflammation.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ€¥æ€§æ’æ–¥åæ‡‰ Acute Rejection",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41159773/"
  },
  {
    "id": "41196460",
    "title_en": "Sulforaphane: a natural organosulfur having potential to modulate apoptosis and survival signalling in cancer.",
    "pub_date": "2025 Nov",
    "journal": "Discover oncology",
    "abstract_en": "Owing to its ever-growing range of pharmacological advantages, sulforaphane, an isothiocyanate from cruciferous vegetables such as broccoli, is becoming increasingly popular. This review aims to provide a thorough understanding and a current update on the application of sulforaphane in cancer treatment. Sulforaphane interacts with many signaling molecules that control various pathways in malignant cells, including angiogenesis, apoptosis, cell cycle arrest, metastasis, and inflammation pathways. This review examines the effects of this isothiocyanate on inflammatory mediators, caspases, MMPs, cytokines, and the proteins Bax and Bcl-2. Furthermore, the advantages of nanotechnology and synergistic effects in sulforaphane applications are also reviewed. As per evidence, sulforaphane is a shining example of how ethno-pharmacological expertise can be used to create modern medications.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œå› å…¶æ½›åœ¨çš„è—¥ç†å„ªå‹¢è€Œå—åˆ°è¶Šä¾†è¶Šå¤šçš„é—œæ³¨ã€‚é€™é …ç ”ç©¶æä¾›äº†å°è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­æ‡‰ç”¨çš„æ·±å…¥ç†è§£ï¼Œå¯èƒ½ç‚ºå¥åº·ä¿ƒé€²å’Œç–¾ç—…é é˜²å¸¶ä¾†æ–°çš„å•Ÿç¤ºã€‚éš¨è‘—å°é€™ç¨®åŒ–åˆç‰©çš„ç ”ç©¶ä¸æ–·å¢å¤šï¼Œäº†è§£å…¶å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œç™¼å±•ï¼Œå°æ–¼æœªä¾†çš„æ²»ç™‚ç­–ç•¥å¯èƒ½å…·æœ‰é‡è¦æ„ç¾©ã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼æå‡æˆ‘å€‘å°ç™Œç—‡çš„èªè­˜ï¼Œä¹Ÿå¯èƒ½ä¿ƒé€²æ–°ç™‚æ³•çš„ç™¼å±•ã€‚",
    "para2": "é€™ç¯‡ç ”ç©¶çš„ä¸»é¡Œæ˜¯è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ‡‰ç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•èˆ‡ç™Œç´°èƒä¸­çš„å¤šç¨®ä¿¡è™Ÿåˆ†å­äº’å‹•ï¼Œä¸¦å½±éŸ¿ç™Œç´°èƒçš„ä¸åŒç”Ÿç‰©å­¸éç¨‹ï¼Œä¾‹å¦‚è¡€ç®¡ç”Ÿæˆã€ç´°èƒå‡‹äº¡ã€ç´°èƒé€±æœŸåœæ»¯ã€è½‰ç§»å’Œç‚ç—‡ç­‰é€”å¾‘ã€‚é€™äº›å•é¡Œçš„æ¢è¨ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£ç™Œç—‡çš„ç™¼å±•æ©Ÿåˆ¶ï¼Œä¹Ÿå¯èƒ½ç‚ºé–‹ç™¼æ–°çš„æ²»ç™‚æ–¹æ³•æä¾›ä¾æ“šã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…å›é¡§äº†è˜¿è””ç¡«ç´ å°å¤šç¨®ç”Ÿç‰©æ¨™è¨˜ç‰©çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬ç‚ç—‡ä»‹è³ªã€åŠèƒ±å¤©å†¬é…¶ã€åŸºè³ªé‡‘å±¬è›‹ç™½é…¶ã€ç´°èƒå› å­ä»¥åŠBaxå’ŒBcl-2ç­‰è›‹ç™½è³ªã€‚é€™æ˜¯ä¸€é …æ–‡ç»å›é¡§ï¼Œæ—¨åœ¨æ•´åˆç¾æœ‰çš„ç ”ç©¶çµæœï¼Œä¸¦æ¢è¨è˜¿è””ç¡«ç´ çš„æ‡‰ç”¨æ½›åŠ›ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„è€ƒå¯Ÿäº†ç´ç±³æŠ€è¡“å’Œå”åŒæ•ˆæ‡‰åœ¨è˜¿è””ç¡«ç´ æ‡‰ç”¨ä¸­çš„å„ªå‹¢ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„ç ”ç©¶æä¾›æ–°çš„æ–¹å‘ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨èª¿æ§ç™Œç´°èƒçš„å¤šå€‹ç”Ÿç‰©å­¸é€”å¾‘ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ï¼Œä¸¦ä¸”å…¶åœ¨æŠ—ç‚å’Œä¿ƒé€²ç´°èƒå‡‹äº¡æ–¹é¢çš„æ½›åŠ›å€¼å¾—é€²ä¸€æ­¥æ¢ç´¢ã€‚é›–ç„¶ç›®å‰çš„è­‰æ“šè¡¨æ˜è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­å…·æœ‰è‰¯å¥½çš„æ‡‰ç”¨å‰æ™¯ï¼Œä½†ä»éœ€æ›´å¤šçš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”çš„ç™‚æ•ˆå’Œæ©Ÿåˆ¶ã€‚å› æ­¤ï¼Œé€™é …ç ”ç©¶ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›äº†é‡è¦çš„åƒè€ƒã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œå› å…¶æ½›åœ¨çš„è—¥ç†å„ªå‹¢è€Œå—åˆ°è¶Šä¾†è¶Šå¤šçš„é—œæ³¨ã€‚é€™é …ç ”ç©¶æä¾›äº†å°è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­æ‡‰ç”¨çš„æ·±å…¥ç†è§£ï¼Œå¯èƒ½ç‚ºå¥åº·ä¿ƒé€²å’Œç–¾ç—…é é˜²å¸¶ä¾†æ–°çš„å•Ÿç¤ºã€‚éš¨è‘—å°é€™ç¨®åŒ–åˆç‰©çš„ç ”ç©¶ä¸æ–·å¢å¤šï¼Œäº†è§£å…¶å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œç™¼å±•ï¼Œå°æ–¼æœªä¾†çš„æ²»ç™‚ç­–ç•¥å¯èƒ½å…·æœ‰é‡è¦æ„ç¾©ã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼æå‡æˆ‘å€‘å°ç™Œç—‡çš„èªè­˜ï¼Œä¹Ÿå¯èƒ½ä¿ƒé€²æ–°ç™‚æ³•çš„ç™¼å±•ã€‚\n\né€™ç¯‡ç ”ç©¶çš„ä¸»é¡Œæ˜¯è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ‡‰ç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•èˆ‡ç™Œç´°èƒä¸­çš„å¤šç¨®ä¿¡è™Ÿåˆ†å­äº’å‹•ï¼Œä¸¦å½±éŸ¿ç™Œç´°èƒçš„ä¸åŒç”Ÿç‰©å­¸éç¨‹ï¼Œä¾‹å¦‚è¡€ç®¡ç”Ÿæˆã€ç´°èƒå‡‹äº¡ã€ç´°èƒé€±æœŸåœæ»¯ã€è½‰ç§»å’Œç‚ç—‡ç­‰é€”å¾‘ã€‚é€™äº›å•é¡Œçš„æ¢è¨ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£ç™Œç—‡çš„ç™¼å±•æ©Ÿåˆ¶ï¼Œä¹Ÿå¯èƒ½ç‚ºé–‹ç™¼æ–°çš„æ²»ç™‚æ–¹æ³•æä¾›ä¾æ“šã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…å›é¡§äº†è˜¿è””ç¡«ç´ å°å¤šç¨®ç”Ÿç‰©æ¨™è¨˜ç‰©çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬ç‚ç—‡ä»‹è³ªã€åŠèƒ±å¤©å†¬é…¶ã€åŸºè³ªé‡‘å±¬è›‹ç™½é…¶ã€ç´°èƒå› å­ä»¥åŠBaxå’ŒBcl-2ç­‰è›‹ç™½è³ªã€‚é€™æ˜¯ä¸€é …æ–‡ç»å›é¡§ï¼Œæ—¨åœ¨æ•´åˆç¾æœ‰çš„ç ”ç©¶çµæœï¼Œä¸¦æ¢è¨è˜¿è””ç¡«ç´ çš„æ‡‰ç”¨æ½›åŠ›ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„è€ƒå¯Ÿäº†ç´ç±³æŠ€è¡“å’Œå”åŒæ•ˆæ‡‰åœ¨è˜¿è””ç¡«ç´ æ‡‰ç”¨ä¸­çš„å„ªå‹¢ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„ç ”ç©¶æä¾›æ–°çš„æ–¹å‘ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨èª¿æ§ç™Œç´°èƒçš„å¤šå€‹ç”Ÿç‰©å­¸é€”å¾‘ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ï¼Œä¸¦ä¸”å…¶åœ¨æŠ—ç‚å’Œä¿ƒé€²ç´°èƒå‡‹äº¡æ–¹é¢çš„æ½›åŠ›å€¼å¾—é€²ä¸€æ­¥æ¢ç´¢ã€‚é›–ç„¶ç›®å‰çš„è­‰æ“šè¡¨æ˜è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­å…·æœ‰è‰¯å¥½çš„æ‡‰ç”¨å‰æ™¯ï¼Œä½†ä»éœ€æ›´å¤šçš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”çš„ç™‚æ•ˆå’Œæ©Ÿåˆ¶ã€‚å› æ­¤ï¼Œé€™é …ç ”ç©¶ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›äº†é‡è¦çš„åƒè€ƒã€‚",
    "fb_post": "æ ¹æ“šã€ŠDiscover oncologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“é’èŠ±æ¤°èœè£¡çš„è˜¿è””ç¡«ç´ å—ï¼Ÿé€™ç¨®ç¥å¥‡çš„åŒ–åˆç‰©æœ€è¿‘å¼•èµ·äº†ç§‘å­¸å®¶çš„æ³¨æ„ï¼Œå› ç‚ºå®ƒå¯èƒ½åœ¨ç™Œç—‡æ²»ç™‚ä¸­æ‰®æ¼”é‡è¦è§’è‰²ï¼\n\né€™é …ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„è¡Œç‚ºã€‚ç ”ç©¶äººå“¡æ¢è¨äº†å®ƒå¦‚ä½•èˆ‡ç™Œç´°èƒä¸­çš„ä¿¡è™Ÿåˆ†å­äº’å‹•ï¼Œä¸¦å½±éŸ¿åƒè¡€ç®¡ç”Ÿæˆï¼ˆæ–°è¡€ç®¡çš„å½¢æˆï¼‰ã€ç´°èƒå‡‹äº¡ï¼ˆç´°èƒæ­»äº¡ï¼‰ã€ç´°èƒé€±æœŸï¼ˆç´°èƒç”Ÿé•·çš„éç¨‹ï¼‰ã€è½‰ç§»ï¼ˆç™Œç´°èƒæ“´æ•£ï¼‰å’Œç‚ç—‡ç­‰ç”Ÿç‰©éç¨‹ã€‚é€™äº›ç™¼ç¾ä¸åƒ…å¹«åŠ©æˆ‘å€‘ç†è§£ç™Œç—‡çš„ç™¼å±•ï¼Œé‚„å¯èƒ½ç‚ºæœªä¾†çš„æ–°ç™‚æ³•æä¾›éˆæ„Ÿã€‚\n\nåœ¨ç ”ç©¶ä¸­ï¼Œç§‘å­¸å®¶å€‘å›é¡§äº†è˜¿è””ç¡«ç´ å°å¤šç¨®ç”Ÿç‰©æ¨™è¨˜ç‰©çš„å½±éŸ¿ï¼Œä¸¦è€ƒæ…®äº†ç´ç±³æŠ€è¡“çš„æ‡‰ç”¨ï¼Œé€™å¯èƒ½æœƒé–‹å•Ÿæ–°çš„ç ”ç©¶æ–¹å‘ã€‚\n\nä»¥ä¸‹æ˜¯å¹¾å€‹å€¼å¾—æ³¨æ„çš„é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ åœ¨èª¿æ§ç™Œç´°èƒçš„å¤šå€‹ç”Ÿç‰©å­¸é€”å¾‘ä¸­æ‰®æ¼”é‡è¦è§’è‰²ã€‚\n2. å®ƒåœ¨æŠ—ç‚å’Œä¿ƒé€²ç´°èƒå‡‹äº¡æ–¹é¢å±•ç¾å‡ºæ½›åŠ›ã€‚\n3. é›–ç„¶åˆæ­¥çµæœä»¤äººé¼“èˆï¼Œä½†ä»éœ€æ›´å¤šç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”ç™‚æ•ˆå’Œæ©Ÿåˆ¶ã€‚\n\nè®“æˆ‘å€‘ä¸€èµ·æœŸå¾…æœªä¾†çš„ç™¼å±•å§ï¼",
    "image_prompt": "Create a flat design infographic on a light background that explains the experiment and main results of a study on sulforaphane. Include simple icons representing broccoli and sulforaphane, along with simplified illustrations of experimental subjects like humans or cells. Use arrows or flow lines to indicate the experimental steps. Include a section labeled 'Main Results' highlighting protective effects and changes observed in the study.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç™Œç—‡ Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41196460/"
  },
  {
    "id": "41184790",
    "title_en": "Efficacy and safety of sulforaphane in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.",
    "pub_date": "2025 Nov",
    "journal": "BMC psychiatry",
    "abstract_en": "Sulforaphane, an isothiocyanate derived from cruciferous vegetables (e.g., broccoli sprouts), has been explored for its antioxidant and anti-inflammatory properties. This is the first systematic review and meta-analysis to explore the therapeutic potentials of sulforaphane in schizophrenia. We searched PubMed, Scopus, Web of Science, and Cochrane Central for studies from inception to April 2025. We included randomized controlled trials (RCTs) evaluating the efficacy of sulforaphane in schizophrenia. The primary outcomes were changes in the Positive and Negative Syndrome Scale (PANSS) total and its subscales. Secondary outcomes included cognitive measures, metabolic markers, and safety. Four RCTs with 369 schizophrenia patients were included. Sulforaphane did not significantly improve PANSS total or positive symptom scores at the latest follow-up (ranging from 24 weeks to 18 weeks) or at a consistent 12-week time point. However, a modest improvement in negative symptoms was found at 12 week- time point (MD= -1.06; 95% CI: -1.95 to -0.16; pâ€‰=â€‰0.02), which was not maintained at the latest follow-up. General psychopathology scores improved significantly (MD= -1.5; 95% CI: -2.78 to -0.23; pâ€‰=â€‰0.02). No cognitive benefits were observed. Sulforaphane led to significant reductions in metabolic markers, including LDL, triglycerides, and cholesterol. Discontinuation rates were lower in the sulforaphane group (RRâ€‰=â€‰0.68; 95% CI: 0.49 to 0.95; pâ€‰=â€‰0.02). The study provides initial insights into sulforaphane's potential therapeutic effects in schizophrenia, showing modest improvements in general psychopathology and negative symptoms, with favorable metabolic changes and lower discontinuation rates. Due to limited data and heterogeneity, the study findings should be interpreted with caution. Not applicable.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç²¾ç¥å¥åº·æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœï¼ˆå¦‚é’èŠ±æ¤°èœï¼‰çš„åŒ–åˆç‰©ï¼Œéå»å·²ç¶“è¢«ç ”ç©¶å…¶æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ç‰¹æ€§ã€‚é€™é …ç³»çµ±æ€§å›é¡§å’Œçµ±åˆåˆ†æå°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ²»ç™‚ä¸­çš„æ½›åŠ›ï¼Œé€™å°æ–¼å°‹æ‰¾æ–°ç™‚æ³•çš„ç ”ç©¶è€…å’Œæ‚£è€…ä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…ä¸­çš„ç™‚æ•ˆã€‚ç ”ç©¶è€…å€‘å¸Œæœ›äº†è§£é€™ç¨®åŒ–åˆç‰©æ˜¯å¦èƒ½æ”¹å–„ç²¾ç¥åˆ†è£‚ç—‡çš„ç—‡ç‹€ï¼Œç‰¹åˆ¥æ˜¯ä½¿ç”¨æ¨™æº–çš„è©•ä¼°å·¥å…·ä¾†æ¸¬é‡æ‚£è€…çš„å¿ƒç†ç‹€æ…‹ã€‚é€™æ˜¯ç¬¬ä¸€å€‹ç³»çµ±æ€§å›é¡§å’Œçµ±åˆåˆ†æï¼Œå°ˆé–€é‡å°è˜¿è””ç¡«ç´ åœ¨æ­¤ç–¾ç—…ä¸­çš„æ‡‰ç”¨ï¼Œé€™é¡¯ç¤ºå‡ºè©²é ˜åŸŸçš„ç ”ç©¶ä»åœ¨ç™¼å±•ä¸­ã€‚",
    "para3": "ç ”ç©¶åœ˜éšŠå¾å¤šå€‹è³‡æ–™åº«ä¸­æœå°‹ç›¸é—œæ–‡ç»ï¼Œä¸¦ç´å…¥äº†éš¨æ©Ÿå°ç…§è©¦é©—ï¼ˆRCTï¼‰ï¼Œé€™äº›è©¦é©—è©•ä¼°äº†è˜¿è””ç¡«ç´ å°ç²¾ç¥åˆ†è£‚ç—‡çš„ç™‚æ•ˆã€‚æœ€çµ‚ï¼Œç ”ç©¶ç´å…¥äº†å››é …RCTï¼Œæ¶‰åŠ369åç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…ã€‚ä¸»è¦çš„è©•ä¼°æŒ‡æ¨™æ˜¯ç²¾ç¥ç—…ç—‡ç‹€çš„è®ŠåŒ–ï¼ŒåŒ…æ‹¬é™½æ€§å’Œé™°æ€§ç—‡ç‹€çš„è©•åˆ†ï¼Œæ­¤å¤–é‚„è©•ä¼°äº†èªçŸ¥åŠŸèƒ½ã€ä»£è¬æŒ‡æ¨™å’Œå®‰å…¨æ€§ç­‰æ¬¡è¦çµæœã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æœ€æ–°çš„éš¨è¨ªä¸­ä¸¦æœªé¡¯è‘—æ”¹å–„ç¸½é«”ç—‡ç‹€æˆ–é™½æ€§ç—‡ç‹€çš„è©•åˆ†ï¼Œä½†åœ¨12é€±çš„æ™‚é–“é»ä¸Šï¼Œé™°æ€§ç—‡ç‹€æœ‰è¼•å¾®æ”¹å–„ã€‚ä¸€èˆ¬ç²¾ç¥ç—…ç†å­¸çš„è©•åˆ†ä¹Ÿé¡¯ç¤ºå‡ºé¡¯è‘—æ”¹å–„ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ å°ä»£è¬æŒ‡æ¨™æœ‰é¡¯è‘—çš„æ­£é¢å½±éŸ¿ï¼Œå¦‚é™ä½ä½å¯†åº¦è„‚è›‹ç™½ã€ä¸‰é…¸ç”˜æ²¹è„‚å’Œè†½å›ºé†‡ï¼Œä¸”åœ¨è˜¿è””ç¡«ç´ çµ„çš„ä¸­æ­¢ç‡è¼ƒä½ã€‚å„˜ç®¡å¦‚æ­¤ï¼Œç”±æ–¼æ•¸æ“šæœ‰é™ä¸”å­˜åœ¨ç•°è³ªæ€§ï¼Œé€™äº›çµæœéœ€è¬¹æ…è§£è®€ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç²¾ç¥å¥åº·æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœï¼ˆå¦‚é’èŠ±æ¤°èœï¼‰çš„åŒ–åˆç‰©ï¼Œéå»å·²ç¶“è¢«ç ”ç©¶å…¶æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ç‰¹æ€§ã€‚é€™é …ç³»çµ±æ€§å›é¡§å’Œçµ±åˆåˆ†æå°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ²»ç™‚ä¸­çš„æ½›åŠ›ï¼Œé€™å°æ–¼å°‹æ‰¾æ–°ç™‚æ³•çš„ç ”ç©¶è€…å’Œæ‚£è€…ä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…ä¸­çš„ç™‚æ•ˆã€‚ç ”ç©¶è€…å€‘å¸Œæœ›äº†è§£é€™ç¨®åŒ–åˆç‰©æ˜¯å¦èƒ½æ”¹å–„ç²¾ç¥åˆ†è£‚ç—‡çš„ç—‡ç‹€ï¼Œç‰¹åˆ¥æ˜¯ä½¿ç”¨æ¨™æº–çš„è©•ä¼°å·¥å…·ä¾†æ¸¬é‡æ‚£è€…çš„å¿ƒç†ç‹€æ…‹ã€‚é€™æ˜¯ç¬¬ä¸€å€‹ç³»çµ±æ€§å›é¡§å’Œçµ±åˆåˆ†æï¼Œå°ˆé–€é‡å°è˜¿è””ç¡«ç´ åœ¨æ­¤ç–¾ç—…ä¸­çš„æ‡‰ç”¨ï¼Œé€™é¡¯ç¤ºå‡ºè©²é ˜åŸŸçš„ç ”ç©¶ä»åœ¨ç™¼å±•ä¸­ã€‚\n\nç ”ç©¶åœ˜éšŠå¾å¤šå€‹è³‡æ–™åº«ä¸­æœå°‹ç›¸é—œæ–‡ç»ï¼Œä¸¦ç´å…¥äº†éš¨æ©Ÿå°ç…§è©¦é©—ï¼ˆRCTï¼‰ï¼Œé€™äº›è©¦é©—è©•ä¼°äº†è˜¿è””ç¡«ç´ å°ç²¾ç¥åˆ†è£‚ç—‡çš„ç™‚æ•ˆã€‚æœ€çµ‚ï¼Œç ”ç©¶ç´å…¥äº†å››é …RCTï¼Œæ¶‰åŠ369åç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…ã€‚ä¸»è¦çš„è©•ä¼°æŒ‡æ¨™æ˜¯ç²¾ç¥ç—…ç—‡ç‹€çš„è®ŠåŒ–ï¼ŒåŒ…æ‹¬é™½æ€§å’Œé™°æ€§ç—‡ç‹€çš„è©•åˆ†ï¼Œæ­¤å¤–é‚„è©•ä¼°äº†èªçŸ¥åŠŸèƒ½ã€ä»£è¬æŒ‡æ¨™å’Œå®‰å…¨æ€§ç­‰æ¬¡è¦çµæœã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æœ€æ–°çš„éš¨è¨ªä¸­ä¸¦æœªé¡¯è‘—æ”¹å–„ç¸½é«”ç—‡ç‹€æˆ–é™½æ€§ç—‡ç‹€çš„è©•åˆ†ï¼Œä½†åœ¨12é€±çš„æ™‚é–“é»ä¸Šï¼Œé™°æ€§ç—‡ç‹€æœ‰è¼•å¾®æ”¹å–„ã€‚ä¸€èˆ¬ç²¾ç¥ç—…ç†å­¸çš„è©•åˆ†ä¹Ÿé¡¯ç¤ºå‡ºé¡¯è‘—æ”¹å–„ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ å°ä»£è¬æŒ‡æ¨™æœ‰é¡¯è‘—çš„æ­£é¢å½±éŸ¿ï¼Œå¦‚é™ä½ä½å¯†åº¦è„‚è›‹ç™½ã€ä¸‰é…¸ç”˜æ²¹è„‚å’Œè†½å›ºé†‡ï¼Œä¸”åœ¨è˜¿è””ç¡«ç´ çµ„çš„ä¸­æ­¢ç‡è¼ƒä½ã€‚å„˜ç®¡å¦‚æ­¤ï¼Œç”±æ–¼æ•¸æ“šæœ‰é™ä¸”å­˜åœ¨ç•°è³ªæ€§ï¼Œé€™äº›çµæœéœ€è¬¹æ…è§£è®€ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBMC psychiatryã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“é’èŠ±æ¤°èœè£¡çš„è˜¿è””ç¡«ç´ ï¼Œå¯èƒ½å°ç²¾ç¥å¥åº·æœ‰å¹«åŠ©å—ï¼Ÿé€™æ˜¯ä¸€é …æœ‰è¶£çš„ç ”ç©¶ï¼Œå°ˆé–€æ¢è¨é€™ç¨®åŒ–åˆç‰©åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ²»ç™‚ä¸­çš„æ½›åŠ›ã€‚ç ”ç©¶è€…å€‘æƒ³äº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…çš„ç—‡ç‹€ï¼Œä¸¦ä½¿ç”¨æ¨™æº–å·¥å…·ä¾†è©•ä¼°å¿ƒç†ç‹€æ…‹ã€‚é€™æ˜¯ç¬¬ä¸€å€‹é‡å°é€™å€‹ä¸»é¡Œçš„ç³»çµ±æ€§å›é¡§ï¼Œé¡¯ç¤ºå‡ºé€™æ–¹é¢çš„ç ”ç©¶ä»åœ¨æŒçºŒé€²è¡Œä¸­ã€‚  \n\nç ”ç©¶åœ˜éšŠå¾å¤šå€‹è³‡æ–™åº«ä¸­æœå°‹è³‡æ–™ï¼Œç´å…¥äº†å››é …éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œæ¶‰åŠ369åæ‚£è€…ã€‚ä»–å€‘ä¸»è¦è§€å¯Ÿç²¾ç¥ç—…ç—‡ç‹€çš„è®ŠåŒ–ï¼Œé‚„æœ‰èªçŸ¥åŠŸèƒ½å’Œä»£è¬æŒ‡æ¨™ç­‰ã€‚çµæœé¡¯ç¤ºï¼Œé›–ç„¶è˜¿è””ç¡«ç´ åœ¨æ”¹å–„ç¸½é«”ç—‡ç‹€æ–¹é¢ä¸¦ä¸é¡¯è‘—ï¼Œä½†åœ¨é™°æ€§ç—‡ç‹€ä¸Šæœ‰è¼•å¾®æ”¹å–„ï¼Œä¸¦ä¸”å°ä»£è¬æŒ‡æ¨™å¦‚è†½å›ºé†‡æœ‰æ­£é¢å½±éŸ¿ã€‚  \n\né€™è£¡æœ‰å¹¾å€‹é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½å°ç²¾ç¥åˆ†è£‚ç—‡çš„é™°æ€§ç—‡ç‹€æœ‰è¼•å¾®æ”¹å–„ã€‚  \n2. å°ä»£è¬æŒ‡æ¨™æœ‰é¡¯è‘—æ­£é¢å½±éŸ¿ï¼Œå¦‚é™ä½è†½å›ºé†‡ã€‚  \n3. ç ”ç©¶çµæœä»éœ€è¬¹æ…è§£è®€ï¼Œå› ç‚ºæ•¸æ“šæœ‰é™ã€‚",
    "image_prompt": "Create an infographic that explains the experimental method and main results of a study on sulforaphane, a compound found in broccoli. Use a flat design style with a white or light-colored background and soft color palette. Include symbols representing broccoli and sulforaphane, simplified illustrations of experimental subjects like people or cells, arrows or flow lines to indicate the experimental steps, and a section highlighting the main results such as protective effects or changes in symptoms.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç²¾ç¥åˆ†è£‚ç—‡ Schizophrenia",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41184790/"
  },
  {
    "id": "40992247",
    "title_en": "Assessing the transplacental passage and breastmilk levels of broccoli sprout-derived sulforaphane.",
    "pub_date": "2025 Nov",
    "journal": "Placenta",
    "abstract_en": "Preeclampsia is characterised by hypertension with maternal end-organ dysfunction and/or fetal growth restriction. Sulforaphane, an antioxidant found in broccoli sprouts, has potential as a future therapeutic. With its ability to attenuate the injurious impacts of endothelial dysfunction in vitro, sulforaphane is uniquely positioned to protect against the harmful effects of preeclampsia. However, the transferability of sulforaphane from mother to fetus/baby remains unknown in humans. Uncomplicated pregnant patients (nÂ =Â 8) scheduled for elective caesarean sections (>37 weeks gestation) provided written and informed consent. A single oral dose of EnduraCell, a broccoli sprout extract (equivalent to 21Â mg of sulforaphane), was administered prior to caesarean section. Baseline blood pressure, blood and urine were collected and again at time of operation, alongside umbilical cord blood (vein and artery) and placental samples. 2-4 days post-delivery, a second dose was administered. Two hours later, maternal bloods and breast milk were collected. Samples were processed and analysed by liquid-chromatography mass-spectrometry to measure sulforaphane. Besides an increase in peripheral diastolic blood pressure on the day of caesarean section (pÂ =Â 0.028), there were no changes in maternal blood pressure or heart rate after ingestion of EnduraCell. Sulforaphane was found in maternal serum (70.10Â ng/mlÂ Â±Â 11.90), umbilical cord blood (vein: 25.18Â ng/mLÂ Â±Â 3.11, artery: 18.81Â ng/mLÂ Â±Â 2.36), urine (5726.00Â ng/mLÂ Â±Â 1175.00), placental tissue (10.99Â ng/mgÂ Â±Â 2.11) and breast milk (1.33Â ng/mLÂ Â±Â 2.29). Sulforaphane is present in the umbilical cord and breast milk, providing the world's first evidence of sulforaphane maternal-fetal transfer in humans, and opening avenues for future research into relevant fetal implications.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°å¦Šå¨ é«˜è¡€å£“ç—‡ï¼ˆå³å¦Šå¨ æ¯’è¡€ç—‡ï¼‰æœ‰æ½›åœ¨çš„ä¿è­·ä½œç”¨ã€‚å¦Šå¨ é«˜è¡€å£“ç—‡æ˜¯ä¸€ç¨®æœƒå½±éŸ¿å­•å©¦å’Œèƒå…’å¥åº·çš„ç–¾ç—…ï¼Œé€šå¸¸ä¼´éš¨è‘—é«˜è¡€å£“å’Œå…¶ä»–å™¨å®˜åŠŸèƒ½éšœç¤™ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ¸›è¼•å…§çš®åŠŸèƒ½éšœç¤™çš„æå®³ï¼Œé€™æ„å‘³è‘—å®ƒå¯èƒ½æœ‰åŠ©æ–¼é™ä½å¦Šå¨ é«˜è¡€å£“ç—‡çš„é¢¨éšªï¼Œé€²è€Œæ”¹å–„æ¯å¬°å¥åº·ã€‚ç„¶è€Œï¼Œé€™é …ç ”ç©¶çš„çµæœä»éœ€é€²ä¸€æ­¥é©—è­‰ï¼Œä»¥ç¢ºå®šè˜¿è””ç¡«ç´ çš„å¯¦éš›æ•ˆæœåŠå…¶åœ¨è‡¨åºŠä¸Šçš„æ‡‰ç”¨æ½›åŠ›ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ä¸­çš„æ½›åœ¨ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒæ˜¯å¦èƒ½å¤ å¾æ¯é«”è½‰ç§»åˆ°èƒå…’æˆ–å¬°å…’ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®æŠ—æ°§åŒ–åŠ‘åœ¨å­•å©¦é«”å…§çš„è¡Œç‚ºï¼Œä»¥åŠå®ƒæ˜¯å¦èƒ½å¤ é€šéè‡å¸¶è¡€å’Œæ¯ä¹³å‚³éçµ¦èƒå…’ã€‚é€™æ˜¯ä¸€å€‹é‡è¦çš„å•é¡Œï¼Œå› ç‚ºå¦‚æœè˜¿è””ç¡«ç´ èƒ½å¤ æˆåŠŸè½‰ç§»ï¼Œå°‡ç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›æ–°çš„æ–¹å‘ï¼Œå°¤å…¶æ˜¯åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡çš„é é˜²å’Œæ²»ç™‚ä¸Šã€‚",
    "para3": "é€™é …ç ”ç©¶çš„å¯¦é©—å°è±¡æ˜¯å…«ä½è¨ˆåŠƒé€²è¡Œå‰–è…¹ç”¢çš„å¥åº·å­•å©¦ï¼Œé€™äº›å­•å©¦çš„æ‡·å­•é€±æ•¸å‡è¶…é37é€±ã€‚ç ”ç©¶è€…åœ¨æ‰‹è¡“å‰çµ¦äºˆé€™äº›å­•å©¦ä¸€åŠ‘å£æœçš„é’èŠ±æ¤°èœèƒå–ç‰©ï¼Œé€™ç›¸ç•¶æ–¼21æ¯«å…‹çš„è˜¿è””ç¡«ç´ ã€‚æ‰‹è¡“ç•¶å¤©ï¼Œç ”ç©¶äººå“¡æ”¶é›†äº†å­•å©¦çš„åŸºç·šè¡€å£“ã€è¡€æ¶²å’Œå°¿æ¶²æ¨£æœ¬ï¼Œä¸¦åœ¨æ‰‹è¡“éç¨‹ä¸­æ”¶é›†è‡å¸¶è¡€å’Œèƒç›¤æ¨£æœ¬ã€‚ç”¢å¾Œ2åˆ°4å¤©ï¼Œå­•å©¦å†æ¬¡æœç”¨è˜¿è””ç¡«ç´ ï¼Œä¸¦åœ¨å…©å°æ™‚å¾Œæ”¶é›†æ¯é«”è¡€æ¶²å’Œæ¯ä¹³æ¨£æœ¬ï¼Œé€™äº›æ¨£æœ¬éš¨å¾Œé€²è¡Œäº†æ¶²ç›¸è‰²è­œè³ªè­œåˆ†æï¼Œä»¥æ¸¬é‡è˜¿è””ç¡«ç´ çš„å«é‡ã€‚",
    "para4": "ç ”ç©¶çš„ä¸»è¦ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨æ¯é«”è¡€æ¸…ã€è‡å¸¶è¡€ã€å°¿æ¶²ã€èƒç›¤çµ„ç¹”å’Œæ¯ä¹³ä¸­å‡æœ‰æª¢æ¸¬åˆ°ï¼Œé€™æ˜¯å…¨çƒé¦–æ¬¡è­‰å¯¦è˜¿è””ç¡«ç´ èƒ½å¤ åœ¨æ¯é«”èˆ‡èƒå…’ä¹‹é–“è½‰ç§»çš„è­‰æ“šã€‚é›–ç„¶åœ¨å‰–è…¹ç”¢ç•¶å¤©ï¼Œå­•å©¦çš„å‘¨é‚Šèˆ’å¼µå£“æœ‰æ‰€ä¸Šå‡ï¼Œä½†åœ¨æœç”¨è˜¿è””ç¡«ç´ å¾Œï¼Œæ¯é«”çš„è¡€å£“å’Œå¿ƒç‡ä¸¦æœªå‡ºç¾é¡¯è‘—è®ŠåŒ–ã€‚é€™äº›çµæœç‚ºæœªä¾†ç ”ç©¶è˜¿è””ç¡«ç´ å°èƒå…’çš„å½±éŸ¿æä¾›äº†æ–°çš„ç ”ç©¶æ–¹å‘ï¼Œä¸¦å¯èƒ½å°å¦Šå¨ é«˜è¡€å£“ç—‡çš„æ²»ç™‚æœ‰é‡è¦æ„ç¾©ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°å¦Šå¨ é«˜è¡€å£“ç—‡ï¼ˆå³å¦Šå¨ æ¯’è¡€ç—‡ï¼‰æœ‰æ½›åœ¨çš„ä¿è­·ä½œç”¨ã€‚å¦Šå¨ é«˜è¡€å£“ç—‡æ˜¯ä¸€ç¨®æœƒå½±éŸ¿å­•å©¦å’Œèƒå…’å¥åº·çš„ç–¾ç—…ï¼Œé€šå¸¸ä¼´éš¨è‘—é«˜è¡€å£“å’Œå…¶ä»–å™¨å®˜åŠŸèƒ½éšœç¤™ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ¸›è¼•å…§çš®åŠŸèƒ½éšœç¤™çš„æå®³ï¼Œé€™æ„å‘³è‘—å®ƒå¯èƒ½æœ‰åŠ©æ–¼é™ä½å¦Šå¨ é«˜è¡€å£“ç—‡çš„é¢¨éšªï¼Œé€²è€Œæ”¹å–„æ¯å¬°å¥åº·ã€‚ç„¶è€Œï¼Œé€™é …ç ”ç©¶çš„çµæœä»éœ€é€²ä¸€æ­¥é©—è­‰ï¼Œä»¥ç¢ºå®šè˜¿è””ç¡«ç´ çš„å¯¦éš›æ•ˆæœåŠå…¶åœ¨è‡¨åºŠä¸Šçš„æ‡‰ç”¨æ½›åŠ›ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ä¸­çš„æ½›åœ¨ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒæ˜¯å¦èƒ½å¤ å¾æ¯é«”è½‰ç§»åˆ°èƒå…’æˆ–å¬°å…’ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®æŠ—æ°§åŒ–åŠ‘åœ¨å­•å©¦é«”å…§çš„è¡Œç‚ºï¼Œä»¥åŠå®ƒæ˜¯å¦èƒ½å¤ é€šéè‡å¸¶è¡€å’Œæ¯ä¹³å‚³éçµ¦èƒå…’ã€‚é€™æ˜¯ä¸€å€‹é‡è¦çš„å•é¡Œï¼Œå› ç‚ºå¦‚æœè˜¿è””ç¡«ç´ èƒ½å¤ æˆåŠŸè½‰ç§»ï¼Œå°‡ç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›æ–°çš„æ–¹å‘ï¼Œå°¤å…¶æ˜¯åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡çš„é é˜²å’Œæ²»ç™‚ä¸Šã€‚\n\né€™é …ç ”ç©¶çš„å¯¦é©—å°è±¡æ˜¯å…«ä½è¨ˆåŠƒé€²è¡Œå‰–è…¹ç”¢çš„å¥åº·å­•å©¦ï¼Œé€™äº›å­•å©¦çš„æ‡·å­•é€±æ•¸å‡è¶…é37é€±ã€‚ç ”ç©¶è€…åœ¨æ‰‹è¡“å‰çµ¦äºˆé€™äº›å­•å©¦ä¸€åŠ‘å£æœçš„é’èŠ±æ¤°èœèƒå–ç‰©ï¼Œé€™ç›¸ç•¶æ–¼21æ¯«å…‹çš„è˜¿è””ç¡«ç´ ã€‚æ‰‹è¡“ç•¶å¤©ï¼Œç ”ç©¶äººå“¡æ”¶é›†äº†å­•å©¦çš„åŸºç·šè¡€å£“ã€è¡€æ¶²å’Œå°¿æ¶²æ¨£æœ¬ï¼Œä¸¦åœ¨æ‰‹è¡“éç¨‹ä¸­æ”¶é›†è‡å¸¶è¡€å’Œèƒç›¤æ¨£æœ¬ã€‚ç”¢å¾Œ2åˆ°4å¤©ï¼Œå­•å©¦å†æ¬¡æœç”¨è˜¿è””ç¡«ç´ ï¼Œä¸¦åœ¨å…©å°æ™‚å¾Œæ”¶é›†æ¯é«”è¡€æ¶²å’Œæ¯ä¹³æ¨£æœ¬ï¼Œé€™äº›æ¨£æœ¬éš¨å¾Œé€²è¡Œäº†æ¶²ç›¸è‰²è­œè³ªè­œåˆ†æï¼Œä»¥æ¸¬é‡è˜¿è””ç¡«ç´ çš„å«é‡ã€‚\n\nç ”ç©¶çš„ä¸»è¦ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨æ¯é«”è¡€æ¸…ã€è‡å¸¶è¡€ã€å°¿æ¶²ã€èƒç›¤çµ„ç¹”å’Œæ¯ä¹³ä¸­å‡æœ‰æª¢æ¸¬åˆ°ï¼Œé€™æ˜¯å…¨çƒé¦–æ¬¡è­‰å¯¦è˜¿è””ç¡«ç´ èƒ½å¤ åœ¨æ¯é«”èˆ‡èƒå…’ä¹‹é–“è½‰ç§»çš„è­‰æ“šã€‚é›–ç„¶åœ¨å‰–è…¹ç”¢ç•¶å¤©ï¼Œå­•å©¦çš„å‘¨é‚Šèˆ’å¼µå£“æœ‰æ‰€ä¸Šå‡ï¼Œä½†åœ¨æœç”¨è˜¿è””ç¡«ç´ å¾Œï¼Œæ¯é«”çš„è¡€å£“å’Œå¿ƒç‡ä¸¦æœªå‡ºç¾é¡¯è‘—è®ŠåŒ–ã€‚é€™äº›çµæœç‚ºæœªä¾†ç ”ç©¶è˜¿è””ç¡«ç´ å°èƒå…’çš„å½±éŸ¿æä¾›äº†æ–°çš„ç ”ç©¶æ–¹å‘ï¼Œä¸¦å¯èƒ½å°å¦Šå¨ é«˜è¡€å£“ç—‡çš„æ²»ç™‚æœ‰é‡è¦æ„ç¾©ã€‚",
    "fb_post": "æ ¹æ“šã€ŠPlacentaã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿè˜¿è””ç¡«ç´ å¯èƒ½å°å­•å©¦çš„é«˜è¡€å£“æœ‰å¹«åŠ©ï¼é€™é …æ–°ç ”ç©¶è®“æˆ‘å€‘å°å¦Šå¨ é«˜è¡€å£“ç—‡ï¼ˆä¹Ÿå°±æ˜¯å¦Šå¨ æ¯’è¡€ç—‡ï¼‰æœ‰äº†æ›´å¤šäº†è§£ã€‚é€™ç¨®ç—…ç—‡æœƒå½±éŸ¿å­•å©¦å’Œèƒå…’çš„å¥åº·ï¼Œé€šå¸¸ä¼´éš¨è‘—é«˜è¡€å£“å’Œå…¶ä»–å•é¡Œã€‚\n\nç ”ç©¶è€…å€‘æ¢è¨äº†è˜¿è””ç¡«ç´ é€™ç¨®æŠ—æ°§åŒ–åŠ‘åœ¨å­•å©¦é«”å…§çš„è¡¨ç¾ï¼Œç‰¹åˆ¥æ˜¯å®ƒæ˜¯å¦èƒ½å¾æ¯é«”è½‰ç§»åˆ°èƒå…’æˆ–å¬°å…’ã€‚ä»–å€‘é¸æ“‡äº†å…«ä½å¥åº·å­•å©¦ï¼Œçµ¦å¥¹å€‘å£æœé’èŠ±æ¤°èœèƒå–ç‰©ï¼Œä¸¦åœ¨å‰–è…¹ç”¢æ™‚æ”¶é›†äº†å„ç¨®æ¨£æœ¬ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨å­•å©¦çš„è¡€æ¶²ã€è‡å¸¶è¡€ã€å°¿æ¶²å’Œæ¯ä¹³ä¸­éƒ½æœ‰æª¢æ¸¬åˆ°ï¼é€™æ˜¯å…¨çƒé¦–æ¬¡è­‰å¯¦è˜¿è””ç¡«ç´ èƒ½åœ¨æ¯è¦ªå’Œèƒå…’ä¹‹é–“è½‰ç§»çš„è­‰æ“šã€‚é›–ç„¶å­•å©¦åœ¨æ‰‹è¡“ç•¶å¤©çš„è¡€å£“æœ‰äº›ä¸Šå‡ï¼Œä½†æœç”¨è˜¿è””ç¡«ç´ å¾Œï¼Œæ²’æœ‰é¡¯è‘—è®ŠåŒ–ã€‚\n\né€™äº›çµæœç‚ºæœªä¾†ç ”ç©¶è˜¿è””ç¡«ç´ å°èƒå…’å½±éŸ¿æä¾›äº†æ–°çš„æ–¹å‘ï¼Œä¸¦å¯èƒ½å°å¦Šå¨ é«˜è¡€å£“ç—‡çš„æ²»ç™‚æœ‰é‡è¦æ„ç¾©ã€‚\n\nğŸ”‘ é‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼é™ä½å¦Šå¨ é«˜è¡€å£“ç—‡çš„é¢¨éšªã€‚\n2. ç ”ç©¶è­‰å¯¦è˜¿è””ç¡«ç´ èƒ½åœ¨æ¯é«”èˆ‡èƒå…’ä¹‹é–“è½‰ç§»ã€‚\n3. æœªä¾†çš„ç ”ç©¶å¯èƒ½æœƒæ¢ç´¢å®ƒå°æ¯å¬°å¥åº·çš„æ›´å¤šå½±éŸ¿ã€‚",
    "image_prompt": "Create an infographic explaining the experiment of the study on sulforaphane and its effects on pregnancy hypertension. Include simple illustrations of broccoli and sulforaphane, simplified representations of human subjects, arrows or flow lines indicating the steps of the experiment, and a section highlighting the main results such as protective effects and changes observed. Use a flat design style with a white or light-colored background and soft color palette.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å¦Šå¨ é«˜è¡€å£“ç—‡ Preeclampsia",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40992247/"
  },
  {
    "id": "40633511",
    "title_en": "Synthesis and biological evaluation of Sulforaphane derivatives with dual functions: Ischemia-reperfusion injury protection and antitumor effects.",
    "pub_date": "2025 Nov",
    "journal": "Bioorganic & medicinal chemistry",
    "abstract_en": "Reperfusion therapy for the treatment of acute myocardial infarction (AMI) often leads to ischemia-reperfusion (I/R) injuries, characterized by excessive ROS. Sulforaphane (SFN) homologous, known for their anti-inflammatory and antioxidant properties, activate the nuclear factor-erythroid 2-related factor 2 (Nrf2) pathway and reduce mitochondrial ROS but are limited by poor stability and short half-life. SFN derivatives were synthesized through structural modifications of the dithiocarbamate and thiourea moieties at the isothiocyanate group, aiming to enhance stability and maintain therapeutic efficacy. Compound 3g emerged as a promising candidate, demonstrating superior protection against hypoxia-reoxygenation (H/R) injury in cardiac microvascular endothelial cells (CMECs) and exhibiting good antitumor activity. Specifically, 3g reduced ROS levels by 24.5Â % (compared to nifedipine at 17.8Â %), increased NO production to 48.0Â Î¼M (vs. 44.0Â Î¼M), lowered TNF-Î± secretion to 22.6Â pg/mL (vs. 23.9Â pg/mL). Concurrently, 3g showed potent antiproliferative activity (IC<sub>50</sub>Â =Â 7.5Â Î¼M), with 3.8-fold greater potency than 5-fluorouracil (IC<sub>50</sub>Â =Â 28.2Â Î¼M). Stability studies showed enhanced resistance in both protic and aprotic solvents. Density functional theory (DFT) was applied to characterize the molecular properties of the optimal compounds. Molecular docking and ADMET analysis revealed that aromatic substitution and sulfur oxidation significantly improved Nrf2/Keap1 pathway targeting, highlighting the derivative's potential for stability and therapeutic efficacy. These findings suggest that 3g is a promising candidate for treating I/R-induced injury and oxidative stress-related cardiovascular conditions.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¿ƒè¡€ç®¡å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›æ–°çš„è¦‹è§£ã€‚æ€¥æ€§å¿ƒè‚Œæ¢—å¡ï¼ˆAMIï¼‰æ‚£è€…åœ¨æ¥å—å†çŒæ³¨æ²»ç™‚å¾Œï¼Œå¸¸å¸¸æœƒé¢è‡¨ç¼ºè¡€å†çŒæ³¨æå‚·ï¼Œé€™ç¨®æå‚·èˆ‡éé‡çš„æ´»æ€§æ°§ï¼ˆROSï¼‰æœ‰é—œã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›åŒ–åˆç‰©å¦‚è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©ï¼Œå…·æœ‰æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„ç‰¹æ€§ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘é€™äº›æå‚·ï¼Œå¾è€Œæ”¹å–„å¿ƒè¡€ç®¡å¥åº·ã€‚é€™æ„å‘³è‘—ï¼Œé€éé€™äº›åŒ–åˆç‰©çš„æ‡‰ç”¨ï¼Œæœªä¾†æœ‰æ©Ÿæœƒæ¸›å°‘å¿ƒè¡€ç®¡ç–¾ç—…çš„é¢¨éšªï¼Œä¸¦æ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©åœ¨æ€¥æ€§å¿ƒè‚Œæ¢—å¡å¾Œçš„ç¼ºè¡€å†çŒæ³¨æå‚·ä¸­çš„æ½›åœ¨ç™‚æ•ˆã€‚ç ”ç©¶è€…é—œæ³¨é€™äº›è¡ç”Ÿç‰©å¦‚ä½•é€éæ¿€æ´»ç‰¹å®šçš„ç”Ÿç‰©é€”å¾‘ä¾†æ¸›å°‘å¿ƒè‡Ÿç´°èƒçš„æå‚·ï¼Œä¸¦åŒæ™‚è©•ä¼°å®ƒå€‘çš„æŠ—è…«ç˜¤æ´»æ€§ã€‚é€™ä¸åƒ…æ¶‰åŠå¿ƒè‡Ÿå¥åº·ï¼Œé‚„å»¶ä¼¸åˆ°ç™Œç—‡æ²»ç™‚çš„å¯èƒ½æ€§ï¼Œé¡¯ç¤ºå‡ºé€™äº›åŒ–åˆç‰©çš„å¤šé‡æ‡‰ç”¨æ½›åŠ›ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†å¤šç¨®è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©ï¼Œç‰¹åˆ¥æ˜¯é€šéå°äºŒç¡«ä»£æ°¨åŸºç”²é…¸é¹½å’Œç¡«è„²åŸºåœ˜é€²è¡Œçµæ§‹ä¿®é£¾ï¼Œä»¥æé«˜å…¶ç©©å®šæ€§å’Œç™‚æ•ˆã€‚å¯¦é©—å°è±¡ä¸»è¦æ˜¯å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒï¼Œç ”ç©¶è€…è©•ä¼°äº†é€™äº›åŒ–åˆç‰©åœ¨ç¼ºæ°§å†æ°§åˆæå‚·ä¸­çš„ä¿è­·æ•ˆæœã€‚é€éä¸€ç³»åˆ—çš„å¯¦é©—ï¼Œç ”ç©¶è€…æ¸¬é‡äº†æ´»æ€§æ°§çš„æ°´å¹³ã€æ°®æ°§åŒ–ç‰©çš„ç”¢ç”Ÿä»¥åŠç™¼ç‚å› å­çš„åˆ†æ³Œï¼Œä¸¦é€²è¡Œäº†ç©©å®šæ€§æ¸¬è©¦å’Œåˆ†å­ç‰¹æ€§åˆ†æã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼ŒåŒ–åˆç‰©3gåœ¨æ¸›å°‘æ´»æ€§æ°§æ°´å¹³å’Œå¢åŠ æ°®æ°§åŒ–ç‰©ç”¢ç”Ÿæ–¹é¢è¡¨ç¾å‡ºè‰²ï¼Œä¸¦ä¸”åœ¨æŠ—è…«ç˜¤æ´»æ€§ä¸Šä¹Ÿé¡¯ç¤ºå‡ºæ¯”å‚³çµ±è—¥ç‰©æ›´å¼·çš„æ•ˆæœã€‚å…·é«”ä¾†èªªï¼Œ3gèƒ½å°‡æ´»æ€§æ°§æ°´å¹³é™ä½24.5%ï¼Œä¸¦é¡¯è‘—æé«˜æ°®æ°§åŒ–ç‰©çš„ç”¢ç”Ÿã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œ3gåœ¨æ²»ç™‚ç¼ºè¡€å†çŒæ³¨æå‚·åŠèˆ‡æ°§åŒ–å£“åŠ›ç›¸é—œçš„å¿ƒè¡€ç®¡ç–¾ç—…æ–¹é¢ï¼Œå…·æœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ï¼Œé›–ç„¶ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶ç™‚æ•ˆã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¿ƒè¡€ç®¡å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›æ–°çš„è¦‹è§£ã€‚æ€¥æ€§å¿ƒè‚Œæ¢—å¡ï¼ˆAMIï¼‰æ‚£è€…åœ¨æ¥å—å†çŒæ³¨æ²»ç™‚å¾Œï¼Œå¸¸å¸¸æœƒé¢è‡¨ç¼ºè¡€å†çŒæ³¨æå‚·ï¼Œé€™ç¨®æå‚·èˆ‡éé‡çš„æ´»æ€§æ°§ï¼ˆROSï¼‰æœ‰é—œã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›åŒ–åˆç‰©å¦‚è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©ï¼Œå…·æœ‰æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„ç‰¹æ€§ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘é€™äº›æå‚·ï¼Œå¾è€Œæ”¹å–„å¿ƒè¡€ç®¡å¥åº·ã€‚é€™æ„å‘³è‘—ï¼Œé€éé€™äº›åŒ–åˆç‰©çš„æ‡‰ç”¨ï¼Œæœªä¾†æœ‰æ©Ÿæœƒæ¸›å°‘å¿ƒè¡€ç®¡ç–¾ç—…çš„é¢¨éšªï¼Œä¸¦æ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©åœ¨æ€¥æ€§å¿ƒè‚Œæ¢—å¡å¾Œçš„ç¼ºè¡€å†çŒæ³¨æå‚·ä¸­çš„æ½›åœ¨ç™‚æ•ˆã€‚ç ”ç©¶è€…é—œæ³¨é€™äº›è¡ç”Ÿç‰©å¦‚ä½•é€éæ¿€æ´»ç‰¹å®šçš„ç”Ÿç‰©é€”å¾‘ä¾†æ¸›å°‘å¿ƒè‡Ÿç´°èƒçš„æå‚·ï¼Œä¸¦åŒæ™‚è©•ä¼°å®ƒå€‘çš„æŠ—è…«ç˜¤æ´»æ€§ã€‚é€™ä¸åƒ…æ¶‰åŠå¿ƒè‡Ÿå¥åº·ï¼Œé‚„å»¶ä¼¸åˆ°ç™Œç—‡æ²»ç™‚çš„å¯èƒ½æ€§ï¼Œé¡¯ç¤ºå‡ºé€™äº›åŒ–åˆç‰©çš„å¤šé‡æ‡‰ç”¨æ½›åŠ›ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†å¤šç¨®è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©ï¼Œç‰¹åˆ¥æ˜¯é€šéå°äºŒç¡«ä»£æ°¨åŸºç”²é…¸é¹½å’Œç¡«è„²åŸºåœ˜é€²è¡Œçµæ§‹ä¿®é£¾ï¼Œä»¥æé«˜å…¶ç©©å®šæ€§å’Œç™‚æ•ˆã€‚å¯¦é©—å°è±¡ä¸»è¦æ˜¯å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒï¼Œç ”ç©¶è€…è©•ä¼°äº†é€™äº›åŒ–åˆç‰©åœ¨ç¼ºæ°§å†æ°§åˆæå‚·ä¸­çš„ä¿è­·æ•ˆæœã€‚é€éä¸€ç³»åˆ—çš„å¯¦é©—ï¼Œç ”ç©¶è€…æ¸¬é‡äº†æ´»æ€§æ°§çš„æ°´å¹³ã€æ°®æ°§åŒ–ç‰©çš„ç”¢ç”Ÿä»¥åŠç™¼ç‚å› å­çš„åˆ†æ³Œï¼Œä¸¦é€²è¡Œäº†ç©©å®šæ€§æ¸¬è©¦å’Œåˆ†å­ç‰¹æ€§åˆ†æã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼ŒåŒ–åˆç‰©3gåœ¨æ¸›å°‘æ´»æ€§æ°§æ°´å¹³å’Œå¢åŠ æ°®æ°§åŒ–ç‰©ç”¢ç”Ÿæ–¹é¢è¡¨ç¾å‡ºè‰²ï¼Œä¸¦ä¸”åœ¨æŠ—è…«ç˜¤æ´»æ€§ä¸Šä¹Ÿé¡¯ç¤ºå‡ºæ¯”å‚³çµ±è—¥ç‰©æ›´å¼·çš„æ•ˆæœã€‚å…·é«”ä¾†èªªï¼Œ3gèƒ½å°‡æ´»æ€§æ°§æ°´å¹³é™ä½24.5%ï¼Œä¸¦é¡¯è‘—æé«˜æ°®æ°§åŒ–ç‰©çš„ç”¢ç”Ÿã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œ3gåœ¨æ²»ç™‚ç¼ºè¡€å†çŒæ³¨æå‚·åŠèˆ‡æ°§åŒ–å£“åŠ›ç›¸é—œçš„å¿ƒè¡€ç®¡ç–¾ç—…æ–¹é¢ï¼Œå…·æœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ï¼Œé›–ç„¶ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶ç™‚æ•ˆã€‚",
    "fb_post": "æ ¹æ“šã€ŠBioorganic & medicinal chemistryã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿåƒè˜¿è””ä¸åƒ…èƒ½è®“ä½ çš„é¤æ¡Œæ›´è±å¯Œï¼Œé‚„å¯èƒ½å°å¿ƒè‡Ÿå¥åº·æœ‰å¹«åŠ©ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™ç¨®åŒ–åˆç‰©å°æ–¼å¿ƒè¡€ç®¡å¥åº·çš„æ½›åœ¨å¥½è™•ï¼Œè®“äººè€³ç›®ä¸€æ–°ï¼\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨æ€¥æ€§å¿ƒè‚Œæ¢—å¡ï¼ˆAMIï¼‰æ‚£è€…åœ¨æ¥å—æ²»ç™‚å¾Œï¼Œå¯èƒ½æœƒé¢è‡¨çš„ä¸€ç¨®æå‚·ï¼Œé€™ç¨®æå‚·èˆ‡éé‡çš„æ´»æ€§æ°§æœ‰é—œã€‚ç ”ç©¶è€…å€‘ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©å…·æœ‰æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„ç‰¹æ€§ï¼Œæˆ–è¨±èƒ½å¹«åŠ©æ¸›å°‘é€™äº›æå‚·ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç§‘å­¸å®¶å€‘åˆæˆäº†å¤šç¨®è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©ï¼Œä¸¦æ¸¬è©¦å®ƒå€‘å°å¿ƒè‡Ÿç´°èƒçš„ä¿è­·æ•ˆæœã€‚ä»–å€‘ç™¼ç¾æŸå€‹ç‰¹å®šçš„åŒ–åˆç‰©åœ¨é™ä½æ´»æ€§æ°§æ°´å¹³å’Œæé«˜æ°®æ°§åŒ–ç‰©ï¼ˆæœ‰åŠ©æ–¼è¡€ç®¡æ“´å¼µçš„ç‰©è³ªï¼‰æ–¹é¢è¡¨ç¾å„ªç•°ï¼Œé‚„é¡¯ç¤ºå‡ºæ¯”å‚³çµ±è—¥ç‰©æ›´å¼·çš„æŠ—è…«ç˜¤æ´»æ€§ã€‚\n\né€™é …ç ”ç©¶çš„çµæœè®“äººæŒ¯å¥®ï¼Œä½†ä»éœ€è¦æ›´å¤šçš„ç ”ç©¶ä¾†ç¢ºèªé€™äº›åŒ–åˆç‰©çš„ç™‚æ•ˆã€‚ \n\nğŸ” ç¸½çµä¸€ä¸‹ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„å¿ƒè¡€ç®¡å¥åº·ã€‚\n2. ç‰¹å®šè¡ç”Ÿç‰©åœ¨æ¸›å°‘å¿ƒè‡Ÿæå‚·å’ŒæŠ—è…«ç˜¤æ–¹é¢è¡¨ç¾å‡ºè‰²ã€‚\n3. é€™äº›ç™¼ç¾ç‚ºæœªä¾†å¿ƒè‡Ÿç–¾ç—…çš„æ²»ç™‚æä¾›äº†æ–°çš„å¯èƒ½æ€§ï¼",
    "image_prompt": "Create an infographic that explains the experimental methods and main results of a study on the potential benefits of a compound called sulforaphane. The design should include a simple illustration of broccoli or a radish to symbolize sulforaphane, simplified icons representing experimental subjects like human cells, and arrows or flow lines indicating the experimental steps. Include a section labeled 'Main Results' that highlights key findings, such as protective effects and changes in reactive oxygen levels.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å¿ƒè‚Œæ¢—å¡ Myocardial Infarction",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40633511/"
  },
  {
    "id": "40617372",
    "title_en": "Antioxidant effect of esculin and sulforaphane in zebrafish larvae: A comparative study.",
    "pub_date": "2025 Nov",
    "journal": "Comparative biochemistry and physiology. Toxicology & pharmacology : CBP",
    "abstract_en": "Antioxidants are crucial for maintaining cellular redox homeostasis by neutralizing free radicals, including reactive oxygen species (ROS). Nuclear factor erythroid-2-related factor 2 (Nrf2) is a transcription factor that activates various cytoprotective genes to counteract oxidative damage. The present study aimed to compare the antioxidant potential of natural phytochemicals, esculin (ESC), and sulforaphane (SFN) in zebrafish larvae, focusing on Nrf2 activation. Zebrafish larvae were treated with ESC (100Â Î¼M) and SFN (40Â Î¼M) along with control for 6Â h. The levels of ROS, lipid peroxidation (LPO), nitric oxide (NO), glutathione S-transferase (GST), glutathione peroxidase (GPx), catalase (CAT), and reduced glutathione (GSH) were measured. Further, RT-PCR and Western blotting methods were employed to determine the antioxidant genes and protein levels, respectively. In addition, Nrf2 localization within the cell was assessed using nuclear/cytosolic fractionation assay and wholemount immunohistochemistry method. Our results demonstrate that ESC treatment significantly increased antioxidant enzyme activities (GST, GPx, CAT), similar to the effects observed with SFN. Further, ESC enhanced the mRNA levels of antioxidant genes expression, such as nrf2, gstp1, hmox1a, prdx1, nqo1, gss, gsr, sqstm1, hsp90aa1.2 than SFN. Antioxidant proteins Nrf2, Gstp1, Cat, and Sod2 were upregulated in the ESC-treated groups. Subsequently, nuclear localization of Nrf2 was detected in both SFN- and ESC-treated groups, confirming Nrf2 translocation into the nucleus. Our findings suggest that ESC possesses potent antioxidant activity as SFN in 72-hpf zebrafish larvae through the Keap1-Nrf2 signaling pathway.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—æ°§åŒ–åŠ‘çš„ä½œç”¨ä¸Šã€‚æŠ—æ°§åŒ–åŠ‘èƒ½å¤ ä¸­å’Œè‡ªç”±åŸºï¼Œé€™å°æ–¼ç¶­æŒç´°èƒçš„å¥åº·è‡³é—œé‡è¦ã€‚ç•¶ç´°èƒå—åˆ°æ°§åŒ–å£“åŠ›æ™‚ï¼Œå¯èƒ½æœƒå°è‡´å„ç¨®å¥åº·å•é¡Œï¼Œå› æ­¤äº†è§£å¦‚ä½•å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œå°æ–¼é é˜²ç›¸é—œç–¾ç—…æœ‰è‘—é‡è¦çš„æ„ç¾©ã€‚é€™é …ç ”ç©¶æ¢ç´¢äº†å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æŠ—æ°§åŒ–æ½›åŠ›ï¼Œå¯èƒ½ç‚ºæœªä¾†çš„å¥åº·ä¿ƒé€²ç­–ç•¥æä¾›æ–°çš„æ–¹å‘ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¯”è¼ƒå…©ç¨®å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªï¼Œåˆ†åˆ¥æ˜¯è˜¿è””ç¡«ç´ å’Œesculinï¼Œåœ¨æ–‘é¦¬é­šå¹¼é«”ä¸­çš„æŠ—æ°§åŒ–æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘å°æ–¼Nrf2é€™ç¨®è½‰éŒ„å› å­çš„æ¿€æ´»æ•ˆæœã€‚Nrf2æ˜¯ä¸€ç¨®èƒ½å¤ å•Ÿå‹•å¤šç¨®ç´°èƒä¿è­·åŸºå› çš„å› å­ï¼Œå°æŠ—æ°§åŒ–æå‚·ã€‚ç ”ç©¶è€…å¸Œæœ›é€éé€™é …ç ”ç©¶ï¼Œäº†è§£é€™å…©ç¨®åŒ–åˆç‰©åœ¨æŠ—æ°§åŒ–æ–¹é¢çš„å·®ç•°å’Œæ½›åŠ›ï¼Œé€²ä¸€æ­¥æ­ç¤ºå®ƒå€‘å°ç´°èƒå¥åº·çš„å½±éŸ¿ã€‚",
    "para3": "å¯¦é©—ä¸­ä½¿ç”¨äº†72å°æ™‚çš„æ–‘é¦¬é­šå¹¼é«”ä½œç‚ºç ”ç©¶å°è±¡ï¼Œä¸¦å°‡å…¶åˆ†ç‚ºä¸åŒçµ„åˆ¥ï¼Œåˆ†åˆ¥æ¥å—esculinï¼ˆ100Î¼Mï¼‰å’Œè˜¿è””ç¡«ç´ ï¼ˆ40Î¼Mï¼‰çš„è™•ç†ï¼ŒæŒçºŒ6å°æ™‚ã€‚ç ”ç©¶è€…æ¸¬é‡äº†å¤šç¨®æŒ‡æ¨™ï¼ŒåŒ…æ‹¬æ´»æ€§æ°§ï¼ˆROSï¼‰ã€è„‚è³ªéæ°§åŒ–ï¼ˆLPOï¼‰ã€ä¸€æ°§åŒ–æ°®ï¼ˆNOï¼‰ã€ä»¥åŠå¹¾ç¨®æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ã€‚æ­¤å¤–ï¼Œé‚„ä½¿ç”¨äº†RT-PCRå’Œè¥¿æ–¹å°è·¡æ³•ä¾†æª¢æ¸¬æŠ—æ°§åŒ–åŸºå› å’Œè›‹ç™½è³ªçš„è¡¨é”ï¼Œä¸¦é€šéç´°èƒæ ¸/ç´°èƒè³ªåˆ†é›¢å’Œå…¨èº«å…ç–«çµ„ç¹”åŒ–å­¸æ–¹æ³•ä¾†è©•ä¼°Nrf2åœ¨ç´°èƒå…§çš„å®šä½ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œesculinè™•ç†é¡¯è‘—æé«˜äº†æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œèˆ‡è˜¿è””ç¡«ç´ çš„æ•ˆæœç›¸ä¼¼ã€‚æ­¤å¤–ï¼Œesculiné‚„ä¿ƒé€²äº†å¤šç¨®æŠ—æ°§åŒ–åŸºå› çš„mRNAè¡¨é”ï¼Œé¡¯ç¤ºå‡ºå…¶åœ¨æŠ—æ°§åŒ–æ–¹é¢çš„æ½›åŠ›ã€‚ç ”ç©¶ä¸­è§€å¯Ÿåˆ°Nrf2åœ¨esculinå’Œè˜¿è””ç¡«ç´ è™•ç†çµ„ä¸­å‡æœ‰æ ¸å…§å®šä½ï¼Œé€™è¡¨æ˜Nrf2æˆåŠŸè½‰ç§»åˆ°ç´°èƒæ ¸ä¸­ã€‚é€™äº›çµæœæš—ç¤ºesculinåœ¨æ–‘é¦¬é­šå¹¼é«”ä¸­å…·æœ‰å¼·å¤§çš„æŠ—æ°§åŒ–æ´»æ€§ï¼Œèˆ‡è˜¿è””ç¡«ç´ ç›¸ç•¶ï¼Œä¸¦é€éKeap1-Nrf2ä¿¡è™Ÿé€šè·¯ç™¼æ®ä½œç”¨ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—æ°§åŒ–åŠ‘çš„ä½œç”¨ä¸Šã€‚æŠ—æ°§åŒ–åŠ‘èƒ½å¤ ä¸­å’Œè‡ªç”±åŸºï¼Œé€™å°æ–¼ç¶­æŒç´°èƒçš„å¥åº·è‡³é—œé‡è¦ã€‚ç•¶ç´°èƒå—åˆ°æ°§åŒ–å£“åŠ›æ™‚ï¼Œå¯èƒ½æœƒå°è‡´å„ç¨®å¥åº·å•é¡Œï¼Œå› æ­¤äº†è§£å¦‚ä½•å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œå°æ–¼é é˜²ç›¸é—œç–¾ç—…æœ‰è‘—é‡è¦çš„æ„ç¾©ã€‚é€™é …ç ”ç©¶æ¢ç´¢äº†å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æŠ—æ°§åŒ–æ½›åŠ›ï¼Œå¯èƒ½ç‚ºæœªä¾†çš„å¥åº·ä¿ƒé€²ç­–ç•¥æä¾›æ–°çš„æ–¹å‘ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¯”è¼ƒå…©ç¨®å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªï¼Œåˆ†åˆ¥æ˜¯è˜¿è””ç¡«ç´ å’Œesculinï¼Œåœ¨æ–‘é¦¬é­šå¹¼é«”ä¸­çš„æŠ—æ°§åŒ–æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘å°æ–¼Nrf2é€™ç¨®è½‰éŒ„å› å­çš„æ¿€æ´»æ•ˆæœã€‚Nrf2æ˜¯ä¸€ç¨®èƒ½å¤ å•Ÿå‹•å¤šç¨®ç´°èƒä¿è­·åŸºå› çš„å› å­ï¼Œå°æŠ—æ°§åŒ–æå‚·ã€‚ç ”ç©¶è€…å¸Œæœ›é€éé€™é …ç ”ç©¶ï¼Œäº†è§£é€™å…©ç¨®åŒ–åˆç‰©åœ¨æŠ—æ°§åŒ–æ–¹é¢çš„å·®ç•°å’Œæ½›åŠ›ï¼Œé€²ä¸€æ­¥æ­ç¤ºå®ƒå€‘å°ç´°èƒå¥åº·çš„å½±éŸ¿ã€‚\n\nå¯¦é©—ä¸­ä½¿ç”¨äº†72å°æ™‚çš„æ–‘é¦¬é­šå¹¼é«”ä½œç‚ºç ”ç©¶å°è±¡ï¼Œä¸¦å°‡å…¶åˆ†ç‚ºä¸åŒçµ„åˆ¥ï¼Œåˆ†åˆ¥æ¥å—esculinï¼ˆ100Î¼Mï¼‰å’Œè˜¿è””ç¡«ç´ ï¼ˆ40Î¼Mï¼‰çš„è™•ç†ï¼ŒæŒçºŒ6å°æ™‚ã€‚ç ”ç©¶è€…æ¸¬é‡äº†å¤šç¨®æŒ‡æ¨™ï¼ŒåŒ…æ‹¬æ´»æ€§æ°§ï¼ˆROSï¼‰ã€è„‚è³ªéæ°§åŒ–ï¼ˆLPOï¼‰ã€ä¸€æ°§åŒ–æ°®ï¼ˆNOï¼‰ã€ä»¥åŠå¹¾ç¨®æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ã€‚æ­¤å¤–ï¼Œé‚„ä½¿ç”¨äº†RT-PCRå’Œè¥¿æ–¹å°è·¡æ³•ä¾†æª¢æ¸¬æŠ—æ°§åŒ–åŸºå› å’Œè›‹ç™½è³ªçš„è¡¨é”ï¼Œä¸¦é€šéç´°èƒæ ¸/ç´°èƒè³ªåˆ†é›¢å’Œå…¨èº«å…ç–«çµ„ç¹”åŒ–å­¸æ–¹æ³•ä¾†è©•ä¼°Nrf2åœ¨ç´°èƒå…§çš„å®šä½ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œesculinè™•ç†é¡¯è‘—æé«˜äº†æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œèˆ‡è˜¿è””ç¡«ç´ çš„æ•ˆæœç›¸ä¼¼ã€‚æ­¤å¤–ï¼Œesculiné‚„ä¿ƒé€²äº†å¤šç¨®æŠ—æ°§åŒ–åŸºå› çš„mRNAè¡¨é”ï¼Œé¡¯ç¤ºå‡ºå…¶åœ¨æŠ—æ°§åŒ–æ–¹é¢çš„æ½›åŠ›ã€‚ç ”ç©¶ä¸­è§€å¯Ÿåˆ°Nrf2åœ¨esculinå’Œè˜¿è””ç¡«ç´ è™•ç†çµ„ä¸­å‡æœ‰æ ¸å…§å®šä½ï¼Œé€™è¡¨æ˜Nrf2æˆåŠŸè½‰ç§»åˆ°ç´°èƒæ ¸ä¸­ã€‚é€™äº›çµæœæš—ç¤ºesculinåœ¨æ–‘é¦¬é­šå¹¼é«”ä¸­å…·æœ‰å¼·å¤§çš„æŠ—æ°§åŒ–æ´»æ€§ï¼Œèˆ‡è˜¿è””ç¡«ç´ ç›¸ç•¶ï¼Œä¸¦é€éKeap1-Nrf2ä¿¡è™Ÿé€šè·¯ç™¼æ®ä½œç”¨ã€‚",
    "fb_post": "æ ¹æ“šã€ŠComparative biochemistry and physiology. Toxicology & pharmacology : CBPã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„èº«é«”è£¡æœ‰ä¸€ç¨®å«åšæŠ—æ°§åŒ–åŠ‘çš„å¥½æ±è¥¿ï¼Œèƒ½å¹«åŠ©æˆ‘å€‘æŠµæŠ—å£çš„è‡ªç”±åŸºï¼Œä¿è­·ç´°èƒå¥åº·ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼å…©ç¨®å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªï¼šè˜¿è””ç¡«ç´ å’Œesculinï¼Œæƒ³çœ‹çœ‹å®ƒå€‘åœ¨æŠ—æ°§åŒ–æ–¹é¢çš„è¡¨ç¾å¦‚ä½•ã€‚ é€™é …ç ”ç©¶ä½¿ç”¨äº†72å°æ™‚å¤§çš„æ–‘é¦¬é­šå¹¼é«”ï¼Œå°‡å®ƒå€‘åˆ†æˆä¸åŒçµ„åˆ¥ï¼Œåˆ†åˆ¥çµ¦äºˆesculinå’Œè˜¿è””ç¡«ç´ ï¼ŒæŒçºŒ6å°æ™‚ã€‚ç ”ç©¶è€…å€‘æ¸¬é‡äº†å¤šç¨®æŒ‡æ¨™ï¼ŒåŒ…æ‹¬æ´»æ€§æ°§å’ŒæŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œé‚„æª¢æŸ¥äº†é€™äº›ç‰©è³ªå°ç´°èƒçš„å½±éŸ¿ã€‚ çµæœé¡¯ç¤ºï¼Œesculinçš„æŠ—æ°§åŒ–æ•ˆæœç›¸ç•¶ä¸éŒ¯ï¼Œç”šè‡³ä¿ƒé€²äº†è¨±å¤šæŠ—æ°§åŒ–åŸºå› çš„è¡¨é”ï¼é€™æ„å‘³è‘—esculinå’Œè˜¿è””ç¡«ç´ éƒ½èƒ½æœ‰æ•ˆå•Ÿå‹•ç´°èƒçš„ä¿è­·æ©Ÿåˆ¶ï¼Œå¹«åŠ©æˆ‘å€‘æŠµæŠ—æ°§åŒ–æå‚·ã€‚ ğŸ¥¦âœ¨ ç¸½çµä¸€ä¸‹ï¼š 1. æŠ—æ°§åŒ–åŠ‘å°æˆ‘å€‘çš„ç´°èƒå¥åº·éå¸¸é‡è¦ï¼ 2. è˜¿è””ç¡«ç´ å’Œesculinéƒ½æ˜¯å€¼å¾—é—œæ³¨çš„å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªã€‚ 3. é€™é …ç ”ç©¶æˆ–è¨±èƒ½ç‚ºæœªä¾†çš„å¥åº·ç­–ç•¥æä¾›æ–°æ–¹å‘ã€‚",
    "image_prompt": "Create a flat design infographic with a light background. Include simplified illustrations of broccoli or daikon sulforaphane, and a simplified representation of zebrafish or cells as experimental subjects. Use arrows or flow lines to indicate the experimental process. Include a section labeled 'Main Results' highlighting antioxidant effects or changes observed in the study.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40617372/"
  },
  {
    "id": "40533430",
    "title_en": "Monovalent glycoconjugates of sulforaphane prevent inflammation induced by lipopolysaccharide in human dendritic cells by inhibiting NF-Ä¸B signalling pathway.",
    "pub_date": "2025 Nov",
    "journal": "British journal of pharmacology",
    "abstract_en": "Sulforaphane (SFN) has notable health benefits but faces challenges due to its poor solubility and delivery. This study investigates SFN-glycoconjugates effects on lipopolysaccharide (LPS)-induced inflammation in dendritic cells (DCs). With the aiming to enhance their therapeutic potential against inflammatory diseases. Novel monovalent SFN-glycoconjugates with mannose (Man) and fucose (0Fuc) were developed and tested for their anti-inflammatory and immune-modulatory properties in DCs from healthy donors under chronic LPS exposure. By leveraging therapeutic strategies, SFN-glycoconjugates significantly improved the solubility and bioavailability of SFN, thereby overcoming the limitations of traditional delivery methods. Monocyte-derived DCs were treated with SFN-glycoconjugates and subsequently exposed to a chronic inflammatory environment induced by LPS. Our results showed that SFN-glycoconjugates enhance effectiveness in suppressing inflammation by targeting the p65 NF-ÎºB pathway, without affecting MAPK signalling. SFN-glycoconjugates induce a tolerogenic immune response, characterized by increased IL-10 production and enhanced regulatory T- and B-cell proliferation. These effects surpass those of p65 NF-ÎºB inhibition alone, highlighting a distinct and potent regulatory mechanism independent of MAPK pathways. The integration of food therapeutic strategies not only enhances the stability and delivery of bioactive compounds but also broadens their potential applications in functional foods and therapeutic approaches. In particular, SFN-glycoconjugates represent a promising option as biologically active compounds for inflammatory diseases, offering enhanced anti-inflammatory and immunomodulatory effects through optimized delivery systems and the activation of specific molecular pathways.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å…·æœ‰é¡¯è‘—å¥åº·ç›Šè™•çš„åŒ–åˆç‰©ï¼Œä½†ç”±æ–¼å…¶æº¶è§£æ€§å·®å’Œå‚³éå›°é›£ï¼Œé™åˆ¶äº†å®ƒçš„æ‡‰ç”¨ã€‚é€éæ”¹è‰¯çš„å‚³éç³»çµ±ï¼Œé€™é …ç ”ç©¶æ¢ç´¢äº†è˜¿è””ç¡«ç´ èˆ‡å…¶ä»–åˆ†å­çµåˆå¾Œï¼Œå¦‚ä½•å¢å¼·å…¶åœ¨æŠ—ç™¼ç‚ç–¾ç—…ä¸­çš„æ½›åŠ›ï¼Œé€™å°æ–¼æœªä¾†çš„å¥åº·ç®¡ç†å’Œç–¾ç—…é é˜²å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©å°æ–¼ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„ç™¼ç‚åæ‡‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¦‚ä½•æ”¹å–„è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©å¯ç”¨æ€§å’Œæº¶è§£æ€§ï¼Œä¸¦é€²ä¸€æ­¥äº†è§£é€™äº›çµåˆç‰©åœ¨æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€æ–¹é¢çš„æ•ˆæœã€‚é€™äº›ç ”ç©¶çµæœå¯èƒ½ç‚ºæ²»ç™‚æ…¢æ€§ç™¼ç‚ç›¸é—œç–¾ç—…æä¾›æ–°çš„æ€è·¯ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨ä¾†è‡ªå¥åº·æè´ˆè€…çš„æ¨¹çªç´°èƒï¼Œä¸¦å°‡å…¶æš´éœ²æ–¼æ…¢æ€§LPSå¼•èµ·çš„ç™¼ç‚ç’°å¢ƒä¸­ã€‚ç ”ç©¶è€…é–‹ç™¼äº†æ–°å‹çš„å–®åƒ¹è˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©ï¼Œä¸¦æ¸¬è©¦å…¶åœ¨æ¨¹çªç´°èƒä¸­çš„æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€ç‰¹æ€§ã€‚é€™äº›çµåˆç‰©çš„è¨­è¨ˆæ—¨åœ¨æé«˜è˜¿è””ç¡«ç´ çš„ç©©å®šæ€§å’Œå‚³éæ•ˆç‡ï¼Œå¾è€Œå…‹æœå‚³çµ±æ–¹æ³•çš„é™åˆ¶ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©åœ¨æŠ‘åˆ¶ç™¼ç‚æ–¹é¢çš„æ•ˆæœé¡¯è‘—ï¼Œç‰¹åˆ¥æ˜¯é€šéé‡å°p65 NF-ÎºBé€”å¾‘ä¾†å¯¦ç¾ï¼Œè€Œä¸å½±éŸ¿MAPKä¿¡è™Ÿé€šè·¯ã€‚æ­¤å¤–ï¼Œé€™äº›çµåˆç‰©èƒ½å¤ èª˜å°è€å—æ€§å…ç–«åæ‡‰ï¼Œå¢åŠ IL-10çš„ç”¢ç”Ÿï¼Œä¸¦ä¿ƒé€²èª¿ç¯€æ€§Tç´°èƒå’ŒBç´°èƒçš„å¢æ®–ã€‚é€™äº›æ•ˆæœè¶…éäº†å–®ç´”æŠ‘åˆ¶p65 NF-ÎºBçš„æ•ˆæœï¼Œé¡¯ç¤ºå‡ºä¸€ç¨®ç¨ç‰¹ä¸”å¼·æ•ˆçš„èª¿ç¯€æ©Ÿåˆ¶ï¼Œç‚ºæœªä¾†åœ¨åŠŸèƒ½æ€§é£Ÿå“å’Œæ²»ç™‚æ–¹æ³•ä¸­çš„æ‡‰ç”¨æä¾›äº†æ–°çš„å¯èƒ½æ€§ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å…·æœ‰é¡¯è‘—å¥åº·ç›Šè™•çš„åŒ–åˆç‰©ï¼Œä½†ç”±æ–¼å…¶æº¶è§£æ€§å·®å’Œå‚³éå›°é›£ï¼Œé™åˆ¶äº†å®ƒçš„æ‡‰ç”¨ã€‚é€éæ”¹è‰¯çš„å‚³éç³»çµ±ï¼Œé€™é …ç ”ç©¶æ¢ç´¢äº†è˜¿è””ç¡«ç´ èˆ‡å…¶ä»–åˆ†å­çµåˆå¾Œï¼Œå¦‚ä½•å¢å¼·å…¶åœ¨æŠ—ç™¼ç‚ç–¾ç—…ä¸­çš„æ½›åŠ›ï¼Œé€™å°æ–¼æœªä¾†çš„å¥åº·ç®¡ç†å’Œç–¾ç—…é é˜²å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©å°æ–¼ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„ç™¼ç‚åæ‡‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¦‚ä½•æ”¹å–„è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©å¯ç”¨æ€§å’Œæº¶è§£æ€§ï¼Œä¸¦é€²ä¸€æ­¥äº†è§£é€™äº›çµåˆç‰©åœ¨æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€æ–¹é¢çš„æ•ˆæœã€‚é€™äº›ç ”ç©¶çµæœå¯èƒ½ç‚ºæ²»ç™‚æ…¢æ€§ç™¼ç‚ç›¸é—œç–¾ç—…æä¾›æ–°çš„æ€è·¯ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨ä¾†è‡ªå¥åº·æè´ˆè€…çš„æ¨¹çªç´°èƒï¼Œä¸¦å°‡å…¶æš´éœ²æ–¼æ…¢æ€§LPSå¼•èµ·çš„ç™¼ç‚ç’°å¢ƒä¸­ã€‚ç ”ç©¶è€…é–‹ç™¼äº†æ–°å‹çš„å–®åƒ¹è˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©ï¼Œä¸¦æ¸¬è©¦å…¶åœ¨æ¨¹çªç´°èƒä¸­çš„æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€ç‰¹æ€§ã€‚é€™äº›çµåˆç‰©çš„è¨­è¨ˆæ—¨åœ¨æé«˜è˜¿è””ç¡«ç´ çš„ç©©å®šæ€§å’Œå‚³éæ•ˆç‡ï¼Œå¾è€Œå…‹æœå‚³çµ±æ–¹æ³•çš„é™åˆ¶ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©åœ¨æŠ‘åˆ¶ç™¼ç‚æ–¹é¢çš„æ•ˆæœé¡¯è‘—ï¼Œç‰¹åˆ¥æ˜¯é€šéé‡å°p65 NF-ÎºBé€”å¾‘ä¾†å¯¦ç¾ï¼Œè€Œä¸å½±éŸ¿MAPKä¿¡è™Ÿé€šè·¯ã€‚æ­¤å¤–ï¼Œé€™äº›çµåˆç‰©èƒ½å¤ èª˜å°è€å—æ€§å…ç–«åæ‡‰ï¼Œå¢åŠ IL-10çš„ç”¢ç”Ÿï¼Œä¸¦ä¿ƒé€²èª¿ç¯€æ€§Tç´°èƒå’ŒBç´°èƒçš„å¢æ®–ã€‚é€™äº›æ•ˆæœè¶…éäº†å–®ç´”æŠ‘åˆ¶p65 NF-ÎºBçš„æ•ˆæœï¼Œé¡¯ç¤ºå‡ºä¸€ç¨®ç¨ç‰¹ä¸”å¼·æ•ˆçš„èª¿ç¯€æ©Ÿåˆ¶ï¼Œç‚ºæœªä¾†åœ¨åŠŸèƒ½æ€§é£Ÿå“å’Œæ²»ç™‚æ–¹æ³•ä¸­çš„æ‡‰ç”¨æä¾›äº†æ–°çš„å¯èƒ½æ€§ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBritish journal of pharmacologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿè˜¿è””ç¡«ç´ ä¸åƒ…åƒ…æ˜¯é£Ÿç‰©ä¸­çš„ä¸€ç¨®æˆåˆ†ï¼Œå®ƒé‚„å¯èƒ½æˆç‚ºæˆ‘å€‘æŠ—ç™¼ç‚çš„å¥½å¹«æ‰‹ï¼é€™ç¯‡ç ”ç©¶è®“æˆ‘å€‘å°è˜¿è””ç¡«ç´ æœ‰äº†æ–°çš„èªè­˜ï¼Œç‰¹åˆ¥æ˜¯åœ¨å°æŠ—ç™¼ç‚æ–¹é¢çš„æ½›åŠ›ã€‚ç ”ç©¶è€…å€‘é—œæ³¨çš„æ˜¯å¦‚ä½•è®“è˜¿è””ç¡«ç´ æ›´å®¹æ˜“è¢«èº«é«”å¸æ”¶ï¼Œä¸¦ä¸”æœ‰æ•ˆåœ°ç™¼æ®å®ƒçš„ä½œç”¨ã€‚ä»–å€‘é€éæ”¹è‰¯çš„æ–¹å¼ï¼Œå°‡è˜¿è””ç¡«ç´ èˆ‡å…¶ä»–åˆ†å­çµåˆï¼Œé€™æ¨£ä¸€ä¾†ï¼Œå°±èƒ½æå‡å®ƒåœ¨æŠ—ç™¼ç‚ç–¾ç—…ä¸­çš„æ•ˆæœã€‚  \n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å¥åº·æè´ˆè€…çš„æ¨¹çªç´°èƒï¼Œä¸¦åœ¨ä¸€å€‹æ¨¡æ“¬ç™¼ç‚çš„ç’°å¢ƒä¸­é€²è¡Œæ¸¬è©¦ã€‚ä»–å€‘ç™¼ç¾ï¼Œé€™äº›æ–°å‹çš„è˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©åœ¨æŠ‘åˆ¶ç™¼ç‚æ–¹é¢è¡¨ç¾å¾—ç›¸ç•¶å‡ºè‰²ï¼Œå°¤å…¶æ˜¯é‡å°ç‰¹å®šçš„ä¿¡è™Ÿé€šè·¯ï¼Œä¸¦ä¸”é‚„èƒ½ä¿ƒé€²å…ç–«ç³»çµ±çš„å¥åº·åæ‡‰ã€‚  \n\nğŸ” ç¸½çµä¸€ä¸‹é€™é …ç ”ç©¶çš„é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ èˆ‡å…¶ä»–åˆ†å­çµåˆå¾Œï¼Œèƒ½æå‡å…¶æŠ—ç™¼ç‚æ•ˆæœã€‚  \n2. é€™äº›çµåˆç‰©èƒ½ä¿ƒé€²å…ç–«ç³»çµ±çš„å¥åº·åæ‡‰ï¼Œå¢åŠ æœ‰ç›Šçš„å…ç–«å› å­ã€‚  \n3. ç ”ç©¶çµæœç‚ºæœªä¾†åœ¨å¥åº·ç®¡ç†å’Œç–¾ç—…é é˜²æä¾›äº†æ–°çš„æ€è·¯ï¼",
    "image_prompt": "Create a flat design infographic that explains the experiment and main results of the study on sulforaphane. Include simple illustrations of broccoli or a symbol representing sulforaphane, simplified representations of human cells or dendritic cells as experimental subjects, and arrows or flow lines indicating the experimental steps. Add a section that highlights the main results, such as protective effects or changes observed in the immune response.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç™¼ç‚æ€§ç–¾ç—… Inflammatory Diseases",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40533430/"
  },
  {
    "id": "41171476",
    "title_en": "Online solid-phase extraction of glucoraphanin and sulforaphane from non-edible plants based on amino acid-functionalized covalent organic frameworks.",
    "pub_date": "2025 Oct",
    "journal": "Mikrochimica acta",
    "abstract_en": "Glucoraphanin (GR) and sulforaphane (SFN) are sulfur-containing compounds with diverse medicinal applications. However, cruciferous vegetables are a single source of GR and SFN, which limits development and utilization in natural resources. Herein, amino acid covalent organic framework (COF-Cys) was synthesized via click reactions and employed as an adsorbent in online solid-phase extraction (online SPE) to determine GR and SFN in non-edible plant samples. The adsorption mechanism was analyzed using density functional theory, revealing that adsorption occurred via electrostatic interaction and hydrogen bonding. Under the optimum conditions, good linearity (4-2500Â ng/mL; R<sup>2</sup>â€‰=â€‰0.9922 and 0.9968) and lower limits of detection (1.0Â ng/mL and 0.6Â ng/mL) were observed. GR and SFN were found in 18 non-edible plant samples, and recoveries of spiked samples were 89.1-109.3% with RSDâ€‰â‰¤â€‰6.9%. The COF-Cys-online SPE-UPLC-MS/MS approach displays great potential for application to detect GR and SFN in non-edible plants and provide valuable support for the development of functional products.",
    "para1": "é€™é …ç ”ç©¶å¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦å•Ÿç¤ºï¼Œå› ç‚ºè˜¿è””ç¡«ç´ å’Œå…¶å‰é«”åŒ–åˆç‰©åœ¨è¨±å¤šé†«ç™‚æ‡‰ç”¨ä¸­é¡¯ç¤ºå‡ºæ½›åŠ›ã€‚é€™äº›åŒ–åˆç‰©ä¸»è¦ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœï¼Œå¦‚é’èŠ±æ¤°èœï¼Œç„¶è€Œï¼Œé€™ä¹Ÿé™åˆ¶äº†å®ƒå€‘çš„é–‹ç™¼å’Œåˆ©ç”¨ã€‚å› æ­¤ï¼Œæ¢ç´¢å…¶ä»–æ¤ç‰©ä¾†æºçš„è˜¿è””ç¡«ç´ å’Œå…¶å‰é«”åŒ–åˆç‰©ï¼Œå¯èƒ½ç‚ºæœªä¾†çš„å¥åº·ç”¢å“é–‹ç™¼æä¾›æ–°çš„æ–¹å‘ï¼Œä¸¦æœ‰åŠ©æ–¼æå‡æˆ‘å€‘å°é€™äº›åŒ–åˆç‰©çš„èªè­˜ï¼Œé€²è€Œä¿ƒé€²å¥åº·å’Œé é˜²ç–¾ç—…çš„å¯èƒ½æ€§ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•å¾éå¯é£Ÿç”¨æ¤ç‰©ä¸­æª¢æ¸¬è˜¿è””ç¡«ç´ å’Œå…¶å‰é«”åŒ–åˆç‰©â€”â€”è‘¡è„ç³–è˜¿è””ç¡«ç´ ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•æœ‰æ•ˆåœ°å¾é€™äº›éå¯é£Ÿç”¨æ¤ç‰©ä¸­æå–å’Œæª¢æ¸¬é€™äº›æœ‰ç›Šçš„åŒ–åˆç‰©ï¼Œä¸¦è©•ä¼°å…¶åœ¨ä¸åŒæ¤ç‰©æ¨£æœ¬ä¸­çš„å­˜åœ¨æƒ…æ³ã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼æ“´å¤§æˆ‘å€‘å°é€™äº›åŒ–åˆç‰©çš„ä¾†æºäº†è§£ï¼Œé‚„å¯èƒ½ä¿ƒé€²å…¶åœ¨åŠŸèƒ½æ€§ç”¢å“ä¸­çš„æ‡‰ç”¨ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†ä¸€ç¨®æ°¨åŸºé…¸å…±åƒ¹æœ‰æ©Ÿæ¡†æ¶ï¼ˆCOF-Cysï¼‰ï¼Œä¸¦å°‡å…¶ç”¨ä½œåœ¨ç·šå›ºç›¸èƒå–çš„å¸é™„åŠ‘ï¼Œä»¥æª¢æ¸¬éå¯é£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­çš„è‘¡è„ç³–è˜¿è””ç¡«ç´ å’Œè˜¿è””ç¡«ç´ ã€‚ç ”ç©¶è€…ä½¿ç”¨å¯†åº¦æ³›å‡½ç†è«–åˆ†æäº†å¸é™„æ©Ÿåˆ¶ï¼Œç™¼ç¾å¸é™„ä¸»è¦æ˜¯é€ééœé›»ä½œç”¨å’Œæ°«éµé€²è¡Œçš„ã€‚åœ¨æœ€ä½³æ¢ä»¶ä¸‹ï¼Œç ”ç©¶è€…è§€å¯Ÿåˆ°è‰¯å¥½çš„ç·šæ€§é—œä¿‚å’Œè¼ƒä½çš„æª¢æ¸¬é™ï¼Œé¡¯ç¤ºå‡ºé€™ç¨®æ–¹æ³•çš„æœ‰æ•ˆæ€§ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾æ˜¯ï¼Œç ”ç©¶è€…åœ¨18ç¨®éå¯é£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­æˆåŠŸæª¢æ¸¬åˆ°äº†è‘¡è„ç³–è˜¿è””ç¡«ç´ å’Œè˜¿è””ç¡«ç´ ï¼Œä¸¦ä¸”åœ¨æ·»åŠ æ¨£æœ¬çš„å›æ”¶ç‡ç¯„åœç‚º89.1%åˆ°109.3%ä¹‹é–“ï¼Œè®Šç•°ä¿‚æ•¸å°æ–¼6.9%ã€‚é€™è¡¨æ˜COF-Cysåœ¨ç·šå›ºç›¸èƒå–-è¶…é«˜æ•ˆæ¶²ç›¸è‰²è­œ-è³ªè­œè¯ç”¨çš„æ–¹æ³•åœ¨æª¢æ¸¬é€™äº›åŒ–åˆç‰©æ–¹é¢å…·æœ‰å¾ˆå¤§çš„æ½›åŠ›ï¼Œä¸¦å¯èƒ½ç‚ºæœªä¾†åŠŸèƒ½æ€§ç”¢å“çš„é–‹ç™¼æä¾›æœ‰åƒ¹å€¼çš„æ”¯æŒã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦å•Ÿç¤ºï¼Œå› ç‚ºè˜¿è””ç¡«ç´ å’Œå…¶å‰é«”åŒ–åˆç‰©åœ¨è¨±å¤šé†«ç™‚æ‡‰ç”¨ä¸­é¡¯ç¤ºå‡ºæ½›åŠ›ã€‚é€™äº›åŒ–åˆç‰©ä¸»è¦ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœï¼Œå¦‚é’èŠ±æ¤°èœï¼Œç„¶è€Œï¼Œé€™ä¹Ÿé™åˆ¶äº†å®ƒå€‘çš„é–‹ç™¼å’Œåˆ©ç”¨ã€‚å› æ­¤ï¼Œæ¢ç´¢å…¶ä»–æ¤ç‰©ä¾†æºçš„è˜¿è””ç¡«ç´ å’Œå…¶å‰é«”åŒ–åˆç‰©ï¼Œå¯èƒ½ç‚ºæœªä¾†çš„å¥åº·ç”¢å“é–‹ç™¼æä¾›æ–°çš„æ–¹å‘ï¼Œä¸¦æœ‰åŠ©æ–¼æå‡æˆ‘å€‘å°é€™äº›åŒ–åˆç‰©çš„èªè­˜ï¼Œé€²è€Œä¿ƒé€²å¥åº·å’Œé é˜²ç–¾ç—…çš„å¯èƒ½æ€§ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•å¾éå¯é£Ÿç”¨æ¤ç‰©ä¸­æª¢æ¸¬è˜¿è””ç¡«ç´ å’Œå…¶å‰é«”åŒ–åˆç‰©â€”â€”è‘¡è„ç³–è˜¿è””ç¡«ç´ ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•æœ‰æ•ˆåœ°å¾é€™äº›éå¯é£Ÿç”¨æ¤ç‰©ä¸­æå–å’Œæª¢æ¸¬é€™äº›æœ‰ç›Šçš„åŒ–åˆç‰©ï¼Œä¸¦è©•ä¼°å…¶åœ¨ä¸åŒæ¤ç‰©æ¨£æœ¬ä¸­çš„å­˜åœ¨æƒ…æ³ã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼æ“´å¤§æˆ‘å€‘å°é€™äº›åŒ–åˆç‰©çš„ä¾†æºäº†è§£ï¼Œé‚„å¯èƒ½ä¿ƒé€²å…¶åœ¨åŠŸèƒ½æ€§ç”¢å“ä¸­çš„æ‡‰ç”¨ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†ä¸€ç¨®æ°¨åŸºé…¸å…±åƒ¹æœ‰æ©Ÿæ¡†æ¶ï¼ˆCOF-Cysï¼‰ï¼Œä¸¦å°‡å…¶ç”¨ä½œåœ¨ç·šå›ºç›¸èƒå–çš„å¸é™„åŠ‘ï¼Œä»¥æª¢æ¸¬éå¯é£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­çš„è‘¡è„ç³–è˜¿è””ç¡«ç´ å’Œè˜¿è””ç¡«ç´ ã€‚ç ”ç©¶è€…ä½¿ç”¨å¯†åº¦æ³›å‡½ç†è«–åˆ†æäº†å¸é™„æ©Ÿåˆ¶ï¼Œç™¼ç¾å¸é™„ä¸»è¦æ˜¯é€ééœé›»ä½œç”¨å’Œæ°«éµé€²è¡Œçš„ã€‚åœ¨æœ€ä½³æ¢ä»¶ä¸‹ï¼Œç ”ç©¶è€…è§€å¯Ÿåˆ°è‰¯å¥½çš„ç·šæ€§é—œä¿‚å’Œè¼ƒä½çš„æª¢æ¸¬é™ï¼Œé¡¯ç¤ºå‡ºé€™ç¨®æ–¹æ³•çš„æœ‰æ•ˆæ€§ã€‚\n\nä¸»è¦ç™¼ç¾æ˜¯ï¼Œç ”ç©¶è€…åœ¨18ç¨®éå¯é£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­æˆåŠŸæª¢æ¸¬åˆ°äº†è‘¡è„ç³–è˜¿è””ç¡«ç´ å’Œè˜¿è””ç¡«ç´ ï¼Œä¸¦ä¸”åœ¨æ·»åŠ æ¨£æœ¬çš„å›æ”¶ç‡ç¯„åœç‚º89.1%åˆ°109.3%ä¹‹é–“ï¼Œè®Šç•°ä¿‚æ•¸å°æ–¼6.9%ã€‚é€™è¡¨æ˜COF-Cysåœ¨ç·šå›ºç›¸èƒå–-è¶…é«˜æ•ˆæ¶²ç›¸è‰²è­œ-è³ªè­œè¯ç”¨çš„æ–¹æ³•åœ¨æª¢æ¸¬é€™äº›åŒ–åˆç‰©æ–¹é¢å…·æœ‰å¾ˆå¤§çš„æ½›åŠ›ï¼Œä¸¦å¯èƒ½ç‚ºæœªä¾†åŠŸèƒ½æ€§ç”¢å“çš„é–‹ç™¼æä¾›æœ‰åƒ¹å€¼çš„æ”¯æŒã€‚",
    "fb_post": "æ ¹æ“šã€ŠMikrochimica actaã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± å¤§å®¶çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„æ—¥å¸¸é£²é£Ÿä¸­è—è‘—ä¸€äº›ç¥å¥‡çš„åŒ–åˆç‰©ï¼Œåƒæ˜¯è˜¿è””ç¡«ç´ ï¼Œé€™äº›æˆåˆ†ä¾†è‡ªæˆ‘å€‘ç†Ÿæ‚‰çš„é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœï¼Œå°å¥åº·å’Œç–¾ç—…é é˜²æœ‰è‘—ä¸å°çš„æ½›åŠ›ï¼ä¸éï¼Œé€™ç¯‡ç ”ç©¶è®“æˆ‘å€‘æ›´é€²ä¸€æ­¥ï¼Œæ¢ç´¢äº†å…¶ä»–éå¯é£Ÿç”¨æ¤ç‰©ä¸­çš„è˜¿è””ç¡«ç´ å’Œå®ƒçš„å‰é«”åŒ–åˆç‰©â€”â€”è‘¡è„ç³–è˜¿è””ç¡«ç´ ã€‚\n\né€™å€‹ç ”ç©¶çš„é‡é»æ˜¯ï¼šå¦‚ä½•å¾é‚£äº›æˆ‘å€‘ä¸å¸¸åƒçš„æ¤ç‰©ä¸­æå–å’Œæª¢æ¸¬é€™äº›æœ‰ç›Šçš„åŒ–åˆç‰©ã€‚ç ”ç©¶è€…å€‘åˆæˆäº†ä¸€ç¨®ç‰¹æ®Šçš„ææ–™ï¼Œä¾†å¹«åŠ©ä»–å€‘åœ¨å¯¦é©—ä¸­æª¢æ¸¬é€™äº›åŒ–åˆç‰©ï¼Œä¸¦ç™¼ç¾äº†æœ‰æ•ˆçš„æª¢æ¸¬æ–¹æ³•ã€‚æœ€ä»¤äººé©šè¨çš„æ˜¯ï¼Œä»–å€‘åœ¨18ç¨®éå¯é£Ÿç”¨æ¤ç‰©ä¸­æˆåŠŸæ‰¾åˆ°äº†é€™äº›åŒ–åˆç‰©ï¼Œå›æ”¶ç‡ä¹Ÿéå¸¸é«˜ï¼Œé¡¯ç¤ºå‡ºé€™ç¨®æ–¹æ³•çš„æ½›åŠ›ã€‚\n\nğŸ” ä¸»è¦ç™¼ç¾ï¼š\n1. æˆåŠŸæª¢æ¸¬åˆ°è‘¡è„ç³–è˜¿è””ç¡«ç´ å’Œè˜¿è””ç¡«ç´ ã€‚\n2. æä¾›äº†ä¸€ç¨®æ–°çš„æª¢æ¸¬æ–¹æ³•ï¼Œæœªä¾†å¯èƒ½æ‡‰ç”¨æ–¼åŠŸèƒ½æ€§ç”¢å“ã€‚\n3. æ“´å¤§äº†æˆ‘å€‘å°é€™äº›æœ‰ç›ŠåŒ–åˆç‰©ä¾†æºçš„äº†è§£ï¼\n\nè®“æˆ‘å€‘ä¸€èµ·æœŸå¾…é€™äº›ç ”ç©¶èƒ½ç‚ºæœªä¾†çš„å¥åº·ç”¢å“å¸¶ä¾†æ–°æ–¹å‘å§ï¼",
    "image_prompt": "Create an infographic that visually explains the experimental method and main results of a study on glucoraphanin and sulforaphane from non-edible plants. Use a flat design style with a white or light-colored background and soft colors. Include icons representing broccoli and sulforaphane, simplified illustrations of experimental subjects like humans or cells, arrows or flow lines indicating the steps of the experiment, and a section highlighting 'Main Results' with key findings such as detection success rates and potential applications.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41171476/"
  },
  {
    "id": "41246347",
    "title_en": "Sulforaphane in cancer precision medicine: from biosynthetic origins to multiscale mechanisms and clinical translation.",
    "pub_date": "2025",
    "journal": "Frontiers in immunology",
    "abstract_en": "Sulforaphane (SFN), an isothiocyanate derived from glucoraphanin in cruciferous vegetables, has evolved from a dietary antioxidant to a sophisticated multi-target agent in oncology. While its roles in nuclear factor erythroid 2-related factor 2 (Nrf2) activation and histone deacetylase (HDAC) inhibition are well-established, this review provides a novel synthesis by integrating disparate research scales-a multiscale perspective that spans from the genetic and epigenetic regulation of glucoraphanin biosynthesis in plants to SFN's recently elucidated effects on ferroptosis, cancer stem cells (CSCs), and the tumor immune microenvironment in humans. We critically evaluate how key host factors, such as gut microbiota composition and glutathione S-transferase (GST) polymorphisms, dictate SFN bioavailability and efficacy, thereby framing a precision nutrition paradigm for its application. Furthermore, we move beyond generic claims of synergy to detail SFN's specific mechanisms in enhancing conventional therapies, including the modulation of drug transporters and immune checkpoints. By integrating advances from plant biochemistry to molecular oncology, this review establishes an updated and mechanism-oriented framework for realizing SFN's compelling potential in cancer prevention and therapy through a precision medicine approach.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œè¿‘å¹´ä¾†è¢«èªç‚ºåœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­å…·æœ‰æ½›åœ¨çš„ä½œç”¨ã€‚é€™é …ç ”ç©¶çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé€éäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„é£²é£Ÿæ–¹å¼ä¾†é é˜²ç™Œç—‡ï¼Œä¸¦æ”¹å–„ç¾æœ‰çš„æ²»ç™‚æ–¹æ³•ã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼æå‡æˆ‘å€‘å°å¥åº·é£²é£Ÿçš„èªè­˜ï¼Œä¹Ÿå¯èƒ½ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„æ€è·¯ï¼Œè®“æˆ‘å€‘èƒ½å¤ æ›´ç²¾æº–åœ°é‡å°å€‹é«”éœ€æ±‚é€²è¡Œç‡Ÿé¤Šä»‹å…¥ã€‚",
    "para2": "é€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ çš„å¤šé‡ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡é ˜åŸŸçš„æ‡‰ç”¨ã€‚ç ”ç©¶è€…æ¢è¨äº†è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç—‡å¹¹ç´°èƒã€è…«ç˜¤å…ç–«å¾®ç’°å¢ƒä»¥åŠå…¶åœ¨ç´°èƒæ­»äº¡éç¨‹ä¸­çš„è§’è‰²ã€‚é€éæ•´åˆä¸åŒå±¤é¢çš„ç ”ç©¶ï¼Œé€™ç¯‡æ–‡ç« è©¦åœ–æä¾›ä¸€å€‹å…¨é¢çš„è¦–è§’ï¼Œè®“æˆ‘å€‘èƒ½å¤ æ›´æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©å­¸ç‰¹æ€§åŠå…¶åœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­çš„æ½›åŠ›ã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…æ¡ç”¨äº†å¤šå±¤æ¬¡çš„åˆ†ææ–¹æ³•ï¼Œå¾æ¤ç‰©çš„åŸºå› å’Œè¡¨è§€éºå‚³èª¿æ§é–‹å§‹ï¼Œæ¢è¨è˜¿è””ç¡«ç´ çš„åˆæˆéç¨‹ï¼Œä¸¦å»¶ä¼¸åˆ°å…¶åœ¨äººé«”ä¸­çš„ä½œç”¨ã€‚ç ”ç©¶ä¸­é‚„è€ƒæ…®äº†å®¿ä¸»å› ç´ ï¼Œä¾‹å¦‚è…¸é“å¾®ç”Ÿç‰©çµ„çš„çµ„æˆå’Œè°·èƒ±ç”˜è‚½S-è½‰ç§»é…¶çš„å¤šæ…‹æ€§ï¼Œé€™äº›å› ç´ å¯èƒ½å½±éŸ¿è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©åˆ©ç”¨åº¦å’Œç™‚æ•ˆã€‚é€™æ¨£çš„ç ”ç©¶è¨­è¨ˆæœ‰åŠ©æ–¼å»ºç«‹ä¸€å€‹ç²¾æº–ç‡Ÿé¤Šçš„æ¡†æ¶ï¼Œä»¥ä¾¿æ›´å¥½åœ°æ‡‰ç”¨è˜¿è””ç¡«ç´ æ–¼è‡¨åºŠã€‚",
    "para4": "ç ”ç©¶çš„ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨å¢å¼·å‚³çµ±æ²»ç™‚æ•ˆæœæ–¹é¢å…·æœ‰æ½›åŠ›ï¼Œå°¤å…¶æ˜¯åœ¨èª¿ç¯€è—¥ç‰©é‹è¼¸å’Œå…ç–«æª¢æŸ¥é»æ–¹é¢ã€‚é€™äº›çµæœå¼·èª¿äº†è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„å…·é«”ä½œç”¨æ©Ÿåˆ¶ï¼Œä¸¦ç‚ºæœªä¾†çš„ç ”ç©¶æä¾›äº†æ–°çš„æ–¹å‘ã€‚é›–ç„¶é€™äº›ç™¼ç¾ä»¤äººé¼“èˆï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶åœ¨è‡¨åºŠæ‡‰ç”¨ä¸­çš„å¯¦éš›æ•ˆæœã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œè¿‘å¹´ä¾†è¢«èªç‚ºåœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­å…·æœ‰æ½›åœ¨çš„ä½œç”¨ã€‚é€™é …ç ”ç©¶çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé€éäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„é£²é£Ÿæ–¹å¼ä¾†é é˜²ç™Œç—‡ï¼Œä¸¦æ”¹å–„ç¾æœ‰çš„æ²»ç™‚æ–¹æ³•ã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼æå‡æˆ‘å€‘å°å¥åº·é£²é£Ÿçš„èªè­˜ï¼Œä¹Ÿå¯èƒ½ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„æ€è·¯ï¼Œè®“æˆ‘å€‘èƒ½å¤ æ›´ç²¾æº–åœ°é‡å°å€‹é«”éœ€æ±‚é€²è¡Œç‡Ÿé¤Šä»‹å…¥ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ çš„å¤šé‡ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡é ˜åŸŸçš„æ‡‰ç”¨ã€‚ç ”ç©¶è€…æ¢è¨äº†è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç—‡å¹¹ç´°èƒã€è…«ç˜¤å…ç–«å¾®ç’°å¢ƒä»¥åŠå…¶åœ¨ç´°èƒæ­»äº¡éç¨‹ä¸­çš„è§’è‰²ã€‚é€éæ•´åˆä¸åŒå±¤é¢çš„ç ”ç©¶ï¼Œé€™ç¯‡æ–‡ç« è©¦åœ–æä¾›ä¸€å€‹å…¨é¢çš„è¦–è§’ï¼Œè®“æˆ‘å€‘èƒ½å¤ æ›´æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©å­¸ç‰¹æ€§åŠå…¶åœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­çš„æ½›åŠ›ã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…æ¡ç”¨äº†å¤šå±¤æ¬¡çš„åˆ†ææ–¹æ³•ï¼Œå¾æ¤ç‰©çš„åŸºå› å’Œè¡¨è§€éºå‚³èª¿æ§é–‹å§‹ï¼Œæ¢è¨è˜¿è””ç¡«ç´ çš„åˆæˆéç¨‹ï¼Œä¸¦å»¶ä¼¸åˆ°å…¶åœ¨äººé«”ä¸­çš„ä½œç”¨ã€‚ç ”ç©¶ä¸­é‚„è€ƒæ…®äº†å®¿ä¸»å› ç´ ï¼Œä¾‹å¦‚è…¸é“å¾®ç”Ÿç‰©çµ„çš„çµ„æˆå’Œè°·èƒ±ç”˜è‚½S-è½‰ç§»é…¶çš„å¤šæ…‹æ€§ï¼Œé€™äº›å› ç´ å¯èƒ½å½±éŸ¿è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©åˆ©ç”¨åº¦å’Œç™‚æ•ˆã€‚é€™æ¨£çš„ç ”ç©¶è¨­è¨ˆæœ‰åŠ©æ–¼å»ºç«‹ä¸€å€‹ç²¾æº–ç‡Ÿé¤Šçš„æ¡†æ¶ï¼Œä»¥ä¾¿æ›´å¥½åœ°æ‡‰ç”¨è˜¿è””ç¡«ç´ æ–¼è‡¨åºŠã€‚\n\nç ”ç©¶çš„ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨å¢å¼·å‚³çµ±æ²»ç™‚æ•ˆæœæ–¹é¢å…·æœ‰æ½›åŠ›ï¼Œå°¤å…¶æ˜¯åœ¨èª¿ç¯€è—¥ç‰©é‹è¼¸å’Œå…ç–«æª¢æŸ¥é»æ–¹é¢ã€‚é€™äº›çµæœå¼·èª¿äº†è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„å…·é«”ä½œç”¨æ©Ÿåˆ¶ï¼Œä¸¦ç‚ºæœªä¾†çš„ç ”ç©¶æä¾›äº†æ–°çš„æ–¹å‘ã€‚é›–ç„¶é€™äº›ç™¼ç¾ä»¤äººé¼“èˆï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶åœ¨è‡¨åºŠæ‡‰ç”¨ä¸­çš„å¯¦éš›æ•ˆæœã€‚",
    "fb_post": "æ ¹æ“šã€ŠFrontiers in immunologyã€‹æ–¼ 2025 å¹´ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“è˜¿è””è£¡é¢æœ‰ä»€éº¼ç§˜å¯†æ­¦å™¨å—ï¼Ÿå…¶å¯¦ï¼Œè˜¿è””ç¡«ç´ é€™ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œæœ€è¿‘åœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸Šå¼•èµ·äº†ä¸å°‘é—œæ³¨ï¼\n\né€™é …ç ”ç©¶ä¸»è¦æƒ³äº†è§£è˜¿è””ç¡«ç´ æ€éº¼å½±éŸ¿ç™Œç—‡ï¼Œç‰¹åˆ¥æ˜¯å®ƒå°ç™Œç—‡å¹¹ç´°èƒå’Œè…«ç˜¤å…ç–«ç’°å¢ƒçš„å½±éŸ¿ã€‚ç ”ç©¶è€…å€‘é€éå¤šå±¤æ¬¡çš„åˆ†æï¼Œå¾æ¤ç‰©çš„åŸºå› åˆ°äººé«”çš„ä½œç”¨ï¼Œæ·±å…¥æ¢è¨äº†å®ƒçš„åˆæˆéç¨‹ã€‚é‚„è€ƒæ…®äº†è…¸é“å¾®ç”Ÿç‰©çµ„ç­‰å› ç´ ï¼Œé€™äº›éƒ½å¯èƒ½å½±éŸ¿è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚\n\næœ€æœ‰è¶£çš„æ˜¯ï¼Œç ”ç©¶ç™¼ç¾è˜¿è””ç¡«ç´ å¯èƒ½å¢å¼·å‚³çµ±ç™Œç—‡æ²»ç™‚çš„æ•ˆæœï¼Œç‰¹åˆ¥æ˜¯åœ¨èª¿ç¯€è—¥ç‰©é‹è¼¸å’Œå…ç–«ç³»çµ±æ–¹é¢ã€‚é›–ç„¶é€™äº›çµæœå¾ˆä»¤äººæŒ¯å¥®ï¼Œä½†æˆ‘å€‘ä»éœ€æ›´å¤šç ”ç©¶ä¾†ç¢ºèªå®ƒçš„å¯¦éš›æ•ˆæœã€‚\n\nğŸ”‘é‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼ç™Œç—‡é é˜²å’Œæ²»ç™‚ã€‚\n2. ç ”ç©¶æ¢ç´¢äº†å®ƒåœ¨ç™Œç—‡å¹¹ç´°èƒå’Œå…ç–«ç³»çµ±ä¸­çš„ä½œç”¨ã€‚\n3. ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†é©—è­‰å…¶è‡¨åºŠæ‡‰ç”¨æ•ˆæœã€‚",
    "image_prompt": "Create a flat design infographic explaining the experimental methods and main results of the study on sulforaphane. Include simple illustrations of broccoli or symbols representing sulforaphane, simplified figures of experimental subjects like humans or cells, arrows or flow lines indicating the steps of the experiment, and a section highlighting the main results, such as protective effects or observed changes. Use a light-colored background with soft color tones.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç™Œç—‡ Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41246347/"
  },
  {
    "id": "41056875",
    "title_en": "Sulforaphane inhibits gastric cancer progression by regulating the YY1/PSMB8-AS1/miR-888-5p/SLC4A7 axis.",
    "pub_date": "2025 Oct",
    "journal": "Biochemical and biophysical research communications",
    "abstract_en": "Sulforaphane (SFN) plays a vital role in many types of cancer as a natural extract from plants. However, whether SFN can inhibit gastric carcinogenesis by regulating the lncRNA-miRNA-mRNA axis is unclear. In the current work, the significantly differentially expressed lncRNA PSMB8AS1 was obtained by performing high-throughput sequencing of gastric cancer cells treated with SFN. The qRT-PCR assay results confirmed the inhibitory effect of SFN on PSM8AS1. Subsequently, using gastric cancer data from TCGA and 11 pairs of clinical samples from gastric and paracancerous tissues, we found that PSMB8-AS1 was upregulated in gastric cancer, and high expression of PSMB8-AS1 was associated with low survival of patients with gastric cancer. MTT, cell colony formation, scratch healing, flow cytometry, and qRT-PCR assays showed that the knockdown of PSMB8-AS1 significantly reduced the proliferation and migration of gastric cancer cells as well as promoted apoptosis. Dual luciferase reporter gene and RNA immunoprecipitation (RIP) assay confirmed that PSMB8-AS1 can function as the molecular sponge for miR-888-5p. Meanwhile, bioinformatics analysis and dual-luciferase reporter gene assay showed that miR-888-5p regulates SLC4A7. Overexpression of miR-888-5p or knockdown of SLC4A7 reduced the proliferation and migration of gastric cancer cells. In addition, rescue experiments confirmed that the inhibitory effects of the knockdown of PSMB8-AS1 or the knockdown of SLC4A7 on the proliferation and migration of gastric cancer cells could be reversed by miR-888-5p inhibitor treatment. Subcutaneous tumor formation experiments in nude mice demonstrated that the tumor volume of nude mice transplanted with PSMB8-AS1-knockdown gastric cancer cells was significantly reduced compared with that of the control group. Transcription factors can usually bind to the promoter regions of lncRNAs and regulate the transcription of lncRNAs. We demonstrated through website prediction and experiments that SFN can inhibit the level of PSMB8-AS1 by regulating the transcription factor YY1. These results suggest that SFN inhibits gastric cancer growth through the YY1/PSMB8-AS1/miR-888-5p/SLC4A7 axis. Therefore, SFN might be a promising therapeutical agent for GC prevention and therapy.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨èƒƒç™Œçš„é˜²æ²»æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿ç¯€ç‰¹å®šçš„åˆ†å­è·¯å¾‘ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç™¼å±•ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­å¢åŠ é’èŠ±æ¤°èœç­‰å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é™ä½èƒƒç™Œçš„é¢¨éšªï¼Œé€²è€Œä¿ƒé€²æ•´é«”å¥åº·ã€‚é›–ç„¶é€™äº›çµæœä»¤äººé¼“èˆï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å¯¦éš›æ•ˆæœå’Œæ‡‰ç”¨ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½é€éèª¿ç¯€é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰èˆ‡å¾®å°RNAï¼ˆmiRNAï¼‰åŠä¿¡ä½¿RNAï¼ˆmRNAï¼‰ä¹‹é–“çš„ç›¸äº’ä½œç”¨ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç™¼ç”Ÿã€‚ç ”ç©¶è€…é—œæ³¨çš„æ˜¯ä¸€ç¨®åç‚ºPSMB8-AS1çš„lncRNAï¼Œä¸¦è©¦åœ–äº†è§£å…¶åœ¨èƒƒç™Œä¸­çš„è¡¨ç¾åŠå…¶å°ç™Œç´°èƒå¢æ®–å’Œé·ç§»çš„å½±éŸ¿ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…é¦–å…ˆå°æ¥å—è˜¿è””ç¡«ç´ è™•ç†çš„èƒƒç™Œç´°èƒé€²è¡Œé«˜é€šé‡æ¸¬åºï¼Œä»¥æ‰¾å‡ºè¡¨é”é¡¯è‘—ä¸åŒçš„lncRNAã€‚æ¥è‘—ï¼Œä½¿ç”¨qRT-PCRç­‰æ–¹æ³•ç¢ºèªè˜¿è””ç¡«ç´ å°PSMB8-AS1çš„æŠ‘åˆ¶æ•ˆæœã€‚ç ”ç©¶è€…é‚„åˆ†æäº†ä¾†è‡ªTCGAçš„èƒƒç™Œæ•¸æ“šåŠ11å°è‡¨åºŠæ¨£æœ¬ï¼Œç™¼ç¾PSMB8-AS1åœ¨èƒƒç™Œä¸­è¡¨é”ä¸Šèª¿ï¼Œä¸¦èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡æœ‰é—œè¯ã€‚éš¨å¾Œï¼Œé€²è¡Œäº†ä¸€ç³»åˆ—ç´°èƒå¯¦é©—ä¾†è©•ä¼°PSMB8-AS1çš„åŠŸèƒ½ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼ŒæŠ‘åˆ¶PSMB8-AS1çš„è¡¨é”å¯ä»¥é¡¯è‘—æ¸›å°‘èƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œä¸¦ä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾PSMB8-AS1èƒ½ä½œç‚ºmiR-888-5pçš„åˆ†å­æµ·ç¶¿ï¼Œä¸¦ä¸”miR-888-5pèƒ½èª¿æ§SLC4A7çš„è¡¨é”ã€‚é€²ä¸€æ­¥çš„å¯¦é©—é¡¯ç¤ºï¼Œéè¡¨é”miR-888-5pæˆ–æŠ‘åˆ¶SLC4A7éƒ½èƒ½æ¸›å°‘èƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éYY1/PSMB8-AS1/miR-888-5p/SLC4A7é€™ä¸€åˆ†å­è·¯å¾‘ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œé¡¯ç¤ºå‡ºå…¶ä½œç‚ºæ½›åœ¨æ²»ç™‚åŠ‘çš„å¯èƒ½æ€§ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨èƒƒç™Œçš„é˜²æ²»æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿ç¯€ç‰¹å®šçš„åˆ†å­è·¯å¾‘ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç™¼å±•ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­å¢åŠ é’èŠ±æ¤°èœç­‰å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é™ä½èƒƒç™Œçš„é¢¨éšªï¼Œé€²è€Œä¿ƒé€²æ•´é«”å¥åº·ã€‚é›–ç„¶é€™äº›çµæœä»¤äººé¼“èˆï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å¯¦éš›æ•ˆæœå’Œæ‡‰ç”¨ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½é€éèª¿ç¯€é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰èˆ‡å¾®å°RNAï¼ˆmiRNAï¼‰åŠä¿¡ä½¿RNAï¼ˆmRNAï¼‰ä¹‹é–“çš„ç›¸äº’ä½œç”¨ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç™¼ç”Ÿã€‚ç ”ç©¶è€…é—œæ³¨çš„æ˜¯ä¸€ç¨®åç‚ºPSMB8-AS1çš„lncRNAï¼Œä¸¦è©¦åœ–äº†è§£å…¶åœ¨èƒƒç™Œä¸­çš„è¡¨ç¾åŠå…¶å°ç™Œç´°èƒå¢æ®–å’Œé·ç§»çš„å½±éŸ¿ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…é¦–å…ˆå°æ¥å—è˜¿è””ç¡«ç´ è™•ç†çš„èƒƒç™Œç´°èƒé€²è¡Œé«˜é€šé‡æ¸¬åºï¼Œä»¥æ‰¾å‡ºè¡¨é”é¡¯è‘—ä¸åŒçš„lncRNAã€‚æ¥è‘—ï¼Œä½¿ç”¨qRT-PCRç­‰æ–¹æ³•ç¢ºèªè˜¿è””ç¡«ç´ å°PSMB8-AS1çš„æŠ‘åˆ¶æ•ˆæœã€‚ç ”ç©¶è€…é‚„åˆ†æäº†ä¾†è‡ªTCGAçš„èƒƒç™Œæ•¸æ“šåŠ11å°è‡¨åºŠæ¨£æœ¬ï¼Œç™¼ç¾PSMB8-AS1åœ¨èƒƒç™Œä¸­è¡¨é”ä¸Šèª¿ï¼Œä¸¦èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡æœ‰é—œè¯ã€‚éš¨å¾Œï¼Œé€²è¡Œäº†ä¸€ç³»åˆ—ç´°èƒå¯¦é©—ä¾†è©•ä¼°PSMB8-AS1çš„åŠŸèƒ½ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼ŒæŠ‘åˆ¶PSMB8-AS1çš„è¡¨é”å¯ä»¥é¡¯è‘—æ¸›å°‘èƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œä¸¦ä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾PSMB8-AS1èƒ½ä½œç‚ºmiR-888-5pçš„åˆ†å­æµ·ç¶¿ï¼Œä¸¦ä¸”miR-888-5pèƒ½èª¿æ§SLC4A7çš„è¡¨é”ã€‚é€²ä¸€æ­¥çš„å¯¦é©—é¡¯ç¤ºï¼Œéè¡¨é”miR-888-5pæˆ–æŠ‘åˆ¶SLC4A7éƒ½èƒ½æ¸›å°‘èƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éYY1/PSMB8-AS1/miR-888-5p/SLC4A7é€™ä¸€åˆ†å­è·¯å¾‘ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œé¡¯ç¤ºå‡ºå…¶ä½œç‚ºæ½›åœ¨æ²»ç™‚åŠ‘çš„å¯èƒ½æ€§ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBiochemical and biophysical research communicationsã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ‘€ è½èªªéè˜¿è””ç¡«ç´ å—ï¼Ÿå®ƒä¸åªæ˜¯è®“æˆ‘å€‘çš„èœè‰²æ›´ç¾å‘³ï¼Œé‚„å¯èƒ½å°å¥åº·æœ‰å¹«åŠ©å“¦ï¼é€™é …ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ å°èƒƒç™Œçš„å½±éŸ¿ï¼Œè©¦åœ–æ­é–‹å®ƒå¦‚ä½•å¹«åŠ©æˆ‘å€‘çš„èº«é«”ã€‚ç ”ç©¶è€…å€‘ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿æ•´ä¸€äº›ç´°èƒå…§çš„åˆ†å­è·¯å¾‘ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç™¼å±•ã€‚ \n\nä»–å€‘ç‰¹åˆ¥é—œæ³¨ä¸€ç¨®å«åšPSMB8-AS1çš„é•·éˆéç·¨ç¢¼RNAï¼ˆç°¡å–®ä¾†èªªï¼Œå°±æ˜¯ä¸€ç¨®ä¸æœƒè½‰è®Šæˆè›‹ç™½è³ªçš„RNAï¼‰ï¼Œä¸¦ç ”ç©¶å®ƒåœ¨èƒƒç™Œç´°èƒä¸­çš„è¡¨ç¾ã€‚é€šéå¯¦é©—ï¼Œç ”ç©¶è€…å€‘ç™¼ç¾ï¼Œç•¶æŠ‘åˆ¶PSMB8-AS1çš„è¡¨é”æ™‚ï¼Œèƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»æ˜é¡¯æ¸›å°‘ï¼Œç”šè‡³é‚„ä¿ƒé€²äº†ç´°èƒçš„å‡‹äº¡ã€‚ \n\né€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ æœ‰æ½›åŠ›æˆç‚ºå°æŠ—èƒƒç™Œçš„è¼”åŠ©æ²»ç™‚é¸æ“‡ï¼Œä½†é‚„éœ€è¦æ›´å¤šçš„ç ”ç©¶ä¾†ç¢ºèªï¼ \n\nğŸ”‘ ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼é™ä½èƒƒç™Œé¢¨éšªã€‚\n2. PSMB8-AS1åœ¨èƒƒç™Œç´°èƒä¸­è¡¨é”ä¸Šèª¿ï¼Œèˆ‡æ‚£è€…ç”Ÿå­˜ç‡æœ‰é—œã€‚\n3. æŠ‘åˆ¶PSMB8-AS1å¯æ¸›å°‘ç™Œç´°èƒå¢æ®–å’Œé·ç§»ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ çš„æ½›åœ¨ç™‚æ•ˆã€‚",
    "image_prompt": "Create a flat design infographic with a light background. Include symbols representing broccoli or sulforaphane. Simplified illustrations of experimental subjects like humans, animals, or cells. Use arrows or flow lines to indicate the experimental steps. Include a section labeled 'Key Results' highlighting protective effects or changes observed, such as reduced cancer cell proliferation and migration.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "èƒƒç™Œ Gastric Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41056875/"
  },
  {
    "id": "41235157",
    "title_en": "Novel magnolol-sulforaphane hybrids as potent antitumor agents: synthesis and biological characterization.",
    "pub_date": "2025 Oct",
    "journal": "RSC medicinal chemistry",
    "abstract_en": "The natural product-based hybrid strategy is a promising approach for innovative drug discovery. Leveraging the privileged architecture of sulforaphane-a prominent anticancer natural product-we engineered a novel library of magnolol-sulforaphane molecular hybrids for antitumor evaluation through a concise synthetic strategy for the pharmacophore of sulforaphane (SFN), culminating in the identification of CTNPC8 as a promising anticancer compound. Notably, CTNPC8 not only displays exceptional broad-spectrum anticancer activity with potency surpassing both parent compounds and cisplatin, but also exhibits potent <i>in vitro</i> efficacy against the challenging nasopharyngeal carcinoma (NPC) cell model. Mechanistic studies in nasopharyngeal carcinoma models reveal that CTNPC8 triggers mitochondrial-mediated apoptosis through regulating ROS generation and induces G<sub>2</sub>/M phase arrest. Transcriptomic profiling coupled with validation experiments reveals that CTNPC8 exerts its anti-NPC activity primarily by modulating the Akt/mTOR pathway. The present study provided a valuable strategy for discovering new antitumor agents through hybrid molecular design, nominating CTNPC8 as a promising hit compound for anti-NPC research.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€å€‹æœ‰è¶£çš„æ–¹å‘ï¼Œå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰å¹«åŠ©ã€‚ç ”ç©¶è€…å€‘æ¢ç´¢äº†å¦‚ä½•åˆ©ç”¨å¤©ç„¶ç”¢å“ä¾†é–‹ç™¼æ–°å‹æŠ—ç™Œè—¥ç‰©ï¼Œé€™ä¸åƒ…èƒ½å¤ ä¿ƒé€²ç™Œç—‡æ²»ç™‚çš„é€²æ­¥ï¼Œé‚„å¯èƒ½ç‚ºæœªä¾†çš„è—¥ç‰©ç™¼ç¾æä¾›æ–°çš„æ€è·¯ã€‚é€éé€™ç¨®æ–¹æ³•ï¼Œç§‘å­¸å®¶å€‘å¸Œæœ›èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹å¼ï¼Œç‰¹åˆ¥æ˜¯åœ¨é¢å°ä¸€äº›é›£ä»¥æ²»ç™‚çš„ç™Œç—‡æ™‚ï¼Œåƒæ˜¯é¼»å’½ç™Œç­‰ï¼Œé€™å°æ–¼æå‡æ‚£è€…çš„ç”Ÿæ´»å“è³ªå’Œç”Ÿå­˜ç‡æœ‰è‘—é‡è¦çš„æ„ç¾©ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯é‡å°æŠ—ç™Œè—¥ç‰©çš„é–‹ç™¼ï¼Œç‰¹åˆ¥æ˜¯é‡å°é¼»å’½ç™Œçš„æ²»ç™‚ã€‚ç ”ç©¶è€…å€‘é—œæ³¨çš„æ˜¯å¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶ç”¢ç‰©ï¼Œä¸¦çµåˆå…¶ä»–åŒ–åˆç‰©ï¼Œä¾†å‰µé€ å‡ºæ–°çš„åˆ†å­æ··åˆç‰©ï¼Œä»¥æœŸèƒ½æé«˜æŠ—ç™Œæ•ˆæœã€‚é€™é …ç ”ç©¶ä¸åƒ…æ¢è¨äº†æ–°åŒ–åˆç‰©çš„åˆæˆéç¨‹ï¼Œé‚„è©•ä¼°äº†å…¶åœ¨æŠ—è…«ç˜¤æ–¹é¢çš„æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯å°æ–¼é›£æ²»çš„é¼»å’½ç™Œç´°èƒæ¨¡å‹çš„å½±éŸ¿ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å€‘è¨­è¨ˆäº†ä¸€ç³»åˆ—çš„åˆ†å­æ··åˆç‰©ï¼Œé€™äº›æ··åˆç‰©æ˜¯ç”±è˜¿è””ç¡«ç´ å’Œå¦ä¸€ç¨®åŒ–åˆç‰©ï¼ˆmagnololï¼‰çµ„æˆçš„ã€‚ç ”ç©¶åœ˜éšŠé€²è¡Œäº†æŠ—è…«ç˜¤æ´»æ€§çš„è©•ä¼°ï¼Œä¸¦é¸æ“‡äº†CTNPC8ä½œç‚ºä¸€å€‹æœ‰å‰æ™¯çš„æŠ—ç™ŒåŒ–åˆç‰©ã€‚å¯¦é©—ä¸­ä½¿ç”¨äº†é¼»å’½ç™Œç´°èƒæ¨¡å‹ï¼Œä¸¦é€²è¡Œäº†æ©Ÿåˆ¶ç ”ç©¶ï¼Œä»¥äº†è§£CTNPC8å¦‚ä½•å½±éŸ¿ç´°èƒçš„ç”Ÿé•·å’Œæ­»äº¡æ©Ÿåˆ¶ã€‚é€™äº›ç ”ç©¶æ–¹æ³•åŒ…æ‹¬äº†ç´°èƒå¯¦é©—å’ŒåŸºå› è¡¨é”åˆ†æï¼Œæ—¨åœ¨æ­ç¤ºå…¶æŠ—ç™Œä½œç”¨çš„å…·é«”æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯CTNPC8é¡¯ç¤ºå‡ºå„ªç•°çš„æŠ—ç™Œæ´»æ€§ï¼Œç”šè‡³è¶…éäº†å…¶æ¯é«”åŒ–åˆç‰©å’Œé †é‰‘ã€‚ç ”ç©¶çµæœé¡¯ç¤ºï¼ŒCTNPC8èƒ½å¤ é€šéèª¿ç¯€æ´»æ€§æ°§çš„ç”Ÿæˆä¾†èª˜å°ç·šç²’é«”ä»‹å°çš„ç´°èƒå‡‹äº¡ï¼Œä¸¦ä½¿ç´°èƒé€²å…¥G2/MæœŸçš„åœæ»¯ã€‚æ­¤å¤–ï¼Œé€šéè½‰éŒ„çµ„åˆ†æå’Œé©—è­‰å¯¦é©—ï¼Œç ”ç©¶è€…å€‘ç™¼ç¾CTNPC8çš„æŠ—é¼»å’½ç™Œæ´»æ€§ä¸»è¦æ˜¯é€šéèª¿ç¯€Akt/mTORé€šè·¯ä¾†å¯¦ç¾çš„ã€‚é€™äº›çµæœç‚ºæœªä¾†æŠ—è…«ç˜¤è—¥ç‰©çš„è¨­è¨ˆæä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€å€‹æœ‰è¶£çš„æ–¹å‘ï¼Œå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰å¹«åŠ©ã€‚ç ”ç©¶è€…å€‘æ¢ç´¢äº†å¦‚ä½•åˆ©ç”¨å¤©ç„¶ç”¢å“ä¾†é–‹ç™¼æ–°å‹æŠ—ç™Œè—¥ç‰©ï¼Œé€™ä¸åƒ…èƒ½å¤ ä¿ƒé€²ç™Œç—‡æ²»ç™‚çš„é€²æ­¥ï¼Œé‚„å¯èƒ½ç‚ºæœªä¾†çš„è—¥ç‰©ç™¼ç¾æä¾›æ–°çš„æ€è·¯ã€‚é€éé€™ç¨®æ–¹æ³•ï¼Œç§‘å­¸å®¶å€‘å¸Œæœ›èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹å¼ï¼Œç‰¹åˆ¥æ˜¯åœ¨é¢å°ä¸€äº›é›£ä»¥æ²»ç™‚çš„ç™Œç—‡æ™‚ï¼Œåƒæ˜¯é¼»å’½ç™Œç­‰ï¼Œé€™å°æ–¼æå‡æ‚£è€…çš„ç”Ÿæ´»å“è³ªå’Œç”Ÿå­˜ç‡æœ‰è‘—é‡è¦çš„æ„ç¾©ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯é‡å°æŠ—ç™Œè—¥ç‰©çš„é–‹ç™¼ï¼Œç‰¹åˆ¥æ˜¯é‡å°é¼»å’½ç™Œçš„æ²»ç™‚ã€‚ç ”ç©¶è€…å€‘é—œæ³¨çš„æ˜¯å¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶ç”¢ç‰©ï¼Œä¸¦çµåˆå…¶ä»–åŒ–åˆç‰©ï¼Œä¾†å‰µé€ å‡ºæ–°çš„åˆ†å­æ··åˆç‰©ï¼Œä»¥æœŸèƒ½æé«˜æŠ—ç™Œæ•ˆæœã€‚é€™é …ç ”ç©¶ä¸åƒ…æ¢è¨äº†æ–°åŒ–åˆç‰©çš„åˆæˆéç¨‹ï¼Œé‚„è©•ä¼°äº†å…¶åœ¨æŠ—è…«ç˜¤æ–¹é¢çš„æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯å°æ–¼é›£æ²»çš„é¼»å’½ç™Œç´°èƒæ¨¡å‹çš„å½±éŸ¿ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å€‘è¨­è¨ˆäº†ä¸€ç³»åˆ—çš„åˆ†å­æ··åˆç‰©ï¼Œé€™äº›æ··åˆç‰©æ˜¯ç”±è˜¿è””ç¡«ç´ å’Œå¦ä¸€ç¨®åŒ–åˆç‰©ï¼ˆmagnololï¼‰çµ„æˆçš„ã€‚ç ”ç©¶åœ˜éšŠé€²è¡Œäº†æŠ—è…«ç˜¤æ´»æ€§çš„è©•ä¼°ï¼Œä¸¦é¸æ“‡äº†CTNPC8ä½œç‚ºä¸€å€‹æœ‰å‰æ™¯çš„æŠ—ç™ŒåŒ–åˆç‰©ã€‚å¯¦é©—ä¸­ä½¿ç”¨äº†é¼»å’½ç™Œç´°èƒæ¨¡å‹ï¼Œä¸¦é€²è¡Œäº†æ©Ÿåˆ¶ç ”ç©¶ï¼Œä»¥äº†è§£CTNPC8å¦‚ä½•å½±éŸ¿ç´°èƒçš„ç”Ÿé•·å’Œæ­»äº¡æ©Ÿåˆ¶ã€‚é€™äº›ç ”ç©¶æ–¹æ³•åŒ…æ‹¬äº†ç´°èƒå¯¦é©—å’ŒåŸºå› è¡¨é”åˆ†æï¼Œæ—¨åœ¨æ­ç¤ºå…¶æŠ—ç™Œä½œç”¨çš„å…·é«”æ©Ÿåˆ¶ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯CTNPC8é¡¯ç¤ºå‡ºå„ªç•°çš„æŠ—ç™Œæ´»æ€§ï¼Œç”šè‡³è¶…éäº†å…¶æ¯é«”åŒ–åˆç‰©å’Œé †é‰‘ã€‚ç ”ç©¶çµæœé¡¯ç¤ºï¼ŒCTNPC8èƒ½å¤ é€šéèª¿ç¯€æ´»æ€§æ°§çš„ç”Ÿæˆä¾†èª˜å°ç·šç²’é«”ä»‹å°çš„ç´°èƒå‡‹äº¡ï¼Œä¸¦ä½¿ç´°èƒé€²å…¥G2/MæœŸçš„åœæ»¯ã€‚æ­¤å¤–ï¼Œé€šéè½‰éŒ„çµ„åˆ†æå’Œé©—è­‰å¯¦é©—ï¼Œç ”ç©¶è€…å€‘ç™¼ç¾CTNPC8çš„æŠ—é¼»å’½ç™Œæ´»æ€§ä¸»è¦æ˜¯é€šéèª¿ç¯€Akt/mTORé€šè·¯ä¾†å¯¦ç¾çš„ã€‚é€™äº›çµæœç‚ºæœªä¾†æŠ—è…«ç˜¤è—¥ç‰©çš„è¨­è¨ˆæä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "fb_post": "æ ¹æ“šã€ŠRSC medicinal chemistryã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„æ—¥å¸¸é£²é£Ÿä¸­ç«Ÿç„¶éš±è—è‘—æŠ—ç™Œçš„æ½›åŠ›ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶èšç„¦æ–¼ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„å¤©ç„¶æˆåˆ†ï¼Œç§‘å­¸å®¶å€‘å¸Œæœ›é€éå®ƒä¾†é–‹ç™¼æ–°çš„æŠ—ç™Œè—¥ç‰©ï¼Œç‰¹åˆ¥æ˜¯é‡å°é›£æ²»çš„é¼»å’½ç™Œã€‚é€™é …ç ”ç©¶çš„åœ˜éšŠè¨­è¨ˆäº†ä¸€äº›ç”±è˜¿è””ç¡«ç´ å’Œå¦ä¸€ç¨®åŒ–åˆç‰©çµ„æˆçš„åˆ†å­æ··åˆç‰©ï¼Œç„¶å¾Œåœ¨å¯¦é©—å®¤ä¸­æ¸¬è©¦å®ƒå€‘å°ç™Œç´°èƒçš„å½±éŸ¿ã€‚çµæœé¡¯ç¤ºï¼Œé€™äº›æ··åˆç‰©ä¸­çš„ä¸€ç¨®ï¼Œåç‚ºCTNPC8ï¼Œå±•ç¾äº†å„ªç•°çš„æŠ—ç™Œæ´»æ€§ï¼Œç”šè‡³è¶…éäº†å‚³çµ±çš„åŒ–ç™‚è—¥ç‰©ï¼é€™è®“äººæ„Ÿåˆ°æŒ¯å¥®ï¼Œå› ç‚ºå®ƒå¯èƒ½ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„æ–¹å‘ã€‚  \n\né€™è£¡æœ‰å¹¾å€‹é‡é»æƒ³è·Ÿå¤§å®¶åˆ†äº«ï¼š  \n1. è˜¿è””ç¡«ç´ æœ‰æ½›åŠ›æˆç‚ºæ–°çš„æŠ—ç™Œè—¥ç‰©æˆåˆ†ã€‚  \n2. CTNPC8åœ¨å¯¦é©—ä¸­é¡¯ç¤ºå‡ºè¶…éå‚³çµ±è—¥ç‰©çš„æŠ—ç™Œæ•ˆæœã€‚  \n3. ç ”ç©¶æ­ç¤ºäº†CTNPC8å¦‚ä½•å½±éŸ¿ç™Œç´°èƒç”Ÿé•·ï¼Œé€™å°æœªä¾†çš„æ²»ç™‚æœ‰é‡è¦æ„ç¾©ã€‚",
    "image_prompt": "Create an infographic that explains the experimental methods and main findings of a study on a compound called 'CTNPC8' derived from sulforaphane. Use a flat design style with a white or light-colored background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like people or cells, and arrows or flow lines to indicate the steps of the experiment. Also, include a section that briefly highlights the main results, such as protective effects or changes observed.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "é¼»å’½ç™Œ Nasopharyngeal Carcinoma",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41235157/"
  },
  {
    "id": "41181585",
    "title_en": "Sulforaphane alleviates hepatocyte pyroptosis via activating Nrf2-HO-1 signaling during septic acute liver injury.",
    "pub_date": "2025",
    "journal": "Frontiers in pharmacology",
    "abstract_en": "Acute liver injury (ALI) caused by sepsis is a fatal disease with a high mortality rate and poor prognosis. Sulforaphane (SFN) is a natural isothiocyanate that has robust antioxidant and anti-inflammatory properties. The aim of this study was to identify the pharmacological effects and therapeutic mechanisms of SFN in lipopolysaccharide (LPS)-induced ALI. The role of SFN in ALI was investigated using a mouse model of LPS-induced ALI. Briefly, eighteen mice were divided into three groups: control, LPS, and LPS + SFN, which were intraperitoneally injected for 2Â days before LPS treatment. 24Â h after the LPS injection, blood and liver tissues were collected for further analysis. The hematoxylin and eosin (HE) staining showed a lot of visible necrosis areas, inflammatory cell infiltration, and congestion in liver. Meanwhile, Ly6G and F4/80 staining showed increased infiltration of neutrophils and macrophages in liver, these results indicated that LPS induced sever ALI. As inflammatory response plays a vital role in the pathogenesis of LPS-induced ALI, we detected the occurrence of pyroptosis in liver by ribonucleic acid (RNA) sequencing. The results showed that pyroptosis was significantly promoted by LPS, as indicated by gene ontology (GO) and kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analyses, revealing the activation of pyroptosis, interleukin (IL)-1 production, IL-18 production, and inflammatory signaling pathways. Then, we explored the effect of SFN on LPS-induced ALI. The results showed that SFN obviously reduced LPS-induced plasma alanine aminotransferase and aspartate aminotransferase level, pathological injuries and TdT-mediated dUTP nick-end labeling (TUNEL) positive cells, indicating protective effect of SFN on ALI. Furthermore, SFN also showed robust effect on LPS-induced inflammatory response in liver, as reflected by suppressing the infiltration of neutrophils and macrophages, and downregulating mRNA levels of C-X-C motif chemokine ligand 9, IL-6, monocyte chemoattractant protein-1, and tumor necrosis factor-Î± in liver of LPS treated mice. Furthermore, SFN blocked hepatocyte pyroptosis, and suppressed plasma IL-1Î² and IL-18 levels of LPS treated mice. Mechanistically, SFN selectively activated nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) signaling to mediate pyroptotic cell death. SFN also reversed the inhibited superoxide dismutase activity and induced malondialdehyde content in liver of LPS exposed mice. SFN ameliorated liver injury and inflammation during LPS-induced ALI by suppressing hepatocyte pyroptosis via the activation of Nrf2/HO-1 signaling. This study provides new evidence for the potential treatment of ALI with SFN.",
    "para1": "æ€¥æ€§è‚æå‚·ï¼ˆALIï¼‰æ˜¯ä¸€ç¨®ç”±æ•—è¡€ç—‡å¼•èµ·çš„è‡´å‘½ç–¾ç—…ï¼Œæ­»äº¡ç‡é«˜ä¸”é å¾Œä¸ä½³ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨é€™ç¨®æƒ…æ³ä¸‹çš„æ½›åœ¨ç™‚æ•ˆï¼Œå¯èƒ½ç‚ºæ”¹å–„è‚æå‚·çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚ç”±æ–¼è˜¿è””ç¡«ç´ å…·æœ‰å¼·å¤§çš„æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚ç‰¹æ€§ï¼Œäº†è§£å®ƒçš„ä½œç”¨æ©Ÿåˆ¶å¯èƒ½æœ‰åŠ©æ–¼é–‹ç™¼æ–°çš„æ²»ç™‚æ–¹æ³•ï¼Œé€²è€Œé™ä½æ€¥æ€§è‚æå‚·çš„æ­»äº¡ç‡ï¼Œæå‡æ‚£è€…çš„ç”Ÿæ´»å“è³ªã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„æ€¥æ€§è‚æå‚·çš„è—¥ç†æ•ˆæ‡‰åŠå…¶æ²»ç™‚æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯åœ¨æ•—è¡€ç—‡å¼•èµ·çš„æ€¥æ€§è‚æå‚·ä¸­ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ æ¸›è¼•è‚è‡Ÿçš„æå‚·ï¼Œä¸¦ä¸”å¦‚ä½•å½±éŸ¿ç›¸é—œçš„ç™¼ç‚åæ‡‰å’Œç´°èƒæ­»äº¡éç¨‹ã€‚",
    "para3": "å¯¦é©—ä¸­ä½¿ç”¨äº†å°é¼ æ¨¡å‹ä¾†æ¨¡æ“¬LPSå¼•èµ·çš„æ€¥æ€§è‚æå‚·ã€‚ç ”ç©¶åœ˜éšŠå°‡18éš»å°é¼ åˆ†ç‚ºä¸‰çµ„ï¼šå°ç…§çµ„ã€LPSçµ„å’ŒLPS + è˜¿è””ç¡«ç´ çµ„ã€‚åœ¨LPSè™•ç†å‰ï¼Œé€™äº›å°é¼ æ¥å—äº†ç‚ºæœŸå…©å¤©çš„è…¹è…”æ³¨å°„ã€‚LPSæ³¨å°„å¾Œ24å°æ™‚ï¼Œç ”ç©¶äººå“¡æ”¶é›†äº†å°é¼ çš„è¡€æ¶²å’Œè‚è‡Ÿçµ„ç¹”é€²è¡Œé€²ä¸€æ­¥åˆ†æï¼Œè§€å¯Ÿè‚è‡Ÿçš„ç—…ç†è®ŠåŒ–åŠç™¼ç‚åæ‡‰ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—é™ä½LPSå¼•èµ·çš„è¡€æ¼¿è½‰æ°¨é…¶æ°´å¹³åŠè‚è‡Ÿç—…ç†æå‚·ï¼Œé¡¯ç¤ºå‡ºå°æ€¥æ€§è‚æå‚·çš„ä¿è­·ä½œç”¨ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½æŠ‘åˆ¶LPSå¼•èµ·çš„ç™¼ç‚åæ‡‰ï¼Œæ¸›å°‘ä¸­æ€§ç²’ç´°èƒå’Œå·¨å™¬ç´°èƒçš„æµ¸æ½¤ï¼Œä¸¦é™ä½å¤šç¨®ç™¼ç‚å› å­çš„è¡¨é”ã€‚é€™äº›ç™¼ç¾è¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éæ¿€æ´»Nrf2/HO-1ä¿¡è™Ÿé€šè·¯ä¾†æŠ‘åˆ¶è‚ç´°èƒçš„ç„¦äº¡ï¼Œå¾è€Œæ”¹å–„LPSå¼•èµ·çš„è‚æå‚·å’Œç™¼ç‚æƒ…æ³ï¼Œç‚ºæ€¥æ€§è‚æå‚·çš„æ²»ç™‚æä¾›äº†æ–°çš„è­‰æ“šã€‚",
    "explanation_zh": "æ€¥æ€§è‚æå‚·ï¼ˆALIï¼‰æ˜¯ä¸€ç¨®ç”±æ•—è¡€ç—‡å¼•èµ·çš„è‡´å‘½ç–¾ç—…ï¼Œæ­»äº¡ç‡é«˜ä¸”é å¾Œä¸ä½³ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨é€™ç¨®æƒ…æ³ä¸‹çš„æ½›åœ¨ç™‚æ•ˆï¼Œå¯èƒ½ç‚ºæ”¹å–„è‚æå‚·çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚ç”±æ–¼è˜¿è””ç¡«ç´ å…·æœ‰å¼·å¤§çš„æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚ç‰¹æ€§ï¼Œäº†è§£å®ƒçš„ä½œç”¨æ©Ÿåˆ¶å¯èƒ½æœ‰åŠ©æ–¼é–‹ç™¼æ–°çš„æ²»ç™‚æ–¹æ³•ï¼Œé€²è€Œé™ä½æ€¥æ€§è‚æå‚·çš„æ­»äº¡ç‡ï¼Œæå‡æ‚£è€…çš„ç”Ÿæ´»å“è³ªã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„æ€¥æ€§è‚æå‚·çš„è—¥ç†æ•ˆæ‡‰åŠå…¶æ²»ç™‚æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯åœ¨æ•—è¡€ç—‡å¼•èµ·çš„æ€¥æ€§è‚æå‚·ä¸­ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ æ¸›è¼•è‚è‡Ÿçš„æå‚·ï¼Œä¸¦ä¸”å¦‚ä½•å½±éŸ¿ç›¸é—œçš„ç™¼ç‚åæ‡‰å’Œç´°èƒæ­»äº¡éç¨‹ã€‚\n\nå¯¦é©—ä¸­ä½¿ç”¨äº†å°é¼ æ¨¡å‹ä¾†æ¨¡æ“¬LPSå¼•èµ·çš„æ€¥æ€§è‚æå‚·ã€‚ç ”ç©¶åœ˜éšŠå°‡18éš»å°é¼ åˆ†ç‚ºä¸‰çµ„ï¼šå°ç…§çµ„ã€LPSçµ„å’ŒLPS + è˜¿è””ç¡«ç´ çµ„ã€‚åœ¨LPSè™•ç†å‰ï¼Œé€™äº›å°é¼ æ¥å—äº†ç‚ºæœŸå…©å¤©çš„è…¹è…”æ³¨å°„ã€‚LPSæ³¨å°„å¾Œ24å°æ™‚ï¼Œç ”ç©¶äººå“¡æ”¶é›†äº†å°é¼ çš„è¡€æ¶²å’Œè‚è‡Ÿçµ„ç¹”é€²è¡Œé€²ä¸€æ­¥åˆ†æï¼Œè§€å¯Ÿè‚è‡Ÿçš„ç—…ç†è®ŠåŒ–åŠç™¼ç‚åæ‡‰ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—é™ä½LPSå¼•èµ·çš„è¡€æ¼¿è½‰æ°¨é…¶æ°´å¹³åŠè‚è‡Ÿç—…ç†æå‚·ï¼Œé¡¯ç¤ºå‡ºå°æ€¥æ€§è‚æå‚·çš„ä¿è­·ä½œç”¨ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½æŠ‘åˆ¶LPSå¼•èµ·çš„ç™¼ç‚åæ‡‰ï¼Œæ¸›å°‘ä¸­æ€§ç²’ç´°èƒå’Œå·¨å™¬ç´°èƒçš„æµ¸æ½¤ï¼Œä¸¦é™ä½å¤šç¨®ç™¼ç‚å› å­çš„è¡¨é”ã€‚é€™äº›ç™¼ç¾è¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éæ¿€æ´»Nrf2/HO-1ä¿¡è™Ÿé€šè·¯ä¾†æŠ‘åˆ¶è‚ç´°èƒçš„ç„¦äº¡ï¼Œå¾è€Œæ”¹å–„LPSå¼•èµ·çš„è‚æå‚·å’Œç™¼ç‚æƒ…æ³ï¼Œç‚ºæ€¥æ€§è‚æå‚·çš„æ²»ç™‚æä¾›äº†æ–°çš„è­‰æ“šã€‚",
    "fb_post": "æ ¹æ“šã€ŠFrontiers in pharmacologyã€‹æ–¼ 2025 å¹´ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿè˜¿è””è£¡é¢æœ‰ä¸€ç¨®ç¥å¥‡çš„æˆåˆ†å«è˜¿è””ç¡«ç´ ï¼Œæœ€è¿‘çš„ç ”ç©¶ç™¼ç¾å®ƒå¯èƒ½å°æˆ‘å€‘çš„è‚è‡Ÿæœ‰ä¿è­·ä½œç”¨ï¼é€™ç¯‡ç ”ç©¶ä¸»è¦é—œå¿ƒçš„æ˜¯ï¼Œåœ¨æ•—è¡€ç—‡å¼•èµ·çš„æ€¥æ€§è‚æå‚·ä¸­ï¼Œè˜¿è””ç¡«ç´ èƒ½å¦æ¸›è¼•è‚è‡Ÿçš„æå‚·ï¼Œä¸¦ä¸”å¦‚ä½•å½±éŸ¿ç™¼ç‚åæ‡‰ã€‚ç ”ç©¶åœ˜éšŠä½¿ç”¨å°é¼ æ¨¡å‹ï¼Œå°‡å°é¼ åˆ†æˆä¸‰çµ„ï¼Œåˆ†åˆ¥æ˜¯å°ç…§çµ„ã€LPSçµ„ï¼ˆé€™æ˜¯ä¸€ç¨®å¼•èµ·è‚æå‚·çš„ç‰©è³ªï¼‰å’ŒLPS + è˜¿è””ç¡«ç´ çµ„ã€‚ç¶“éå¯¦é©—å¾Œï¼Œä»–å€‘ç™¼ç¾è˜¿è””ç¡«ç´ èƒ½é¡¯è‘—é™ä½è‚è‡Ÿçš„æå‚·ï¼Œé‚„èƒ½æŠ‘åˆ¶ç™¼ç‚åæ‡‰ï¼Œç”šè‡³æ¸›å°‘è¨±å¤šç™¼ç‚å› å­çš„è¡¨é”ã€‚é€™äº›çµæœè®“æˆ‘å€‘çœ‹åˆ°è˜¿è””ç¡«ç´ åœ¨æ€¥æ€§è‚æå‚·æ²»ç™‚ä¸­çš„æ½›åŠ›ï¼\n\nğŸ” ç ”ç©¶é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘æ€¥æ€§è‚æå‚·ã€‚  \n2. å®ƒèƒ½æŠ‘åˆ¶ç™¼ç‚åæ‡‰ï¼Œä¿è­·è‚è‡Ÿå¥åº·ã€‚  \n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†çš„è‚æå‚·æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ï¼",
    "image_prompt": "Create a flat design infographic on a light background that explains a research study about the effects of sulforaphane (found in broccoli and radishes) on acute liver injury. Include simplified illustrations of mice as experimental subjects, arrows or flow lines to show the experimental steps, and a section highlighting key results such as protective effects on the liver and reduction of inflammation. Use soft colors and clear visual elements to make the information easy to understand.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ€¥æ€§è‚æå‚· Acute Liver Injury",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41181585/"
  },
  {
    "id": "41099966",
    "title_en": "Sulforaphane improves exercise-induced NRF2 signaling in older adults: an in vivo-ex vivo approach.",
    "pub_date": "2025 Oct",
    "journal": "GeroScience",
    "abstract_en": "Redox signaling is a key mechanism of exercise-induced adaptation. However, studies have demonstrated impaired responses to acute exercise in older organisms. Adjunctive therapies to augment exercise effects may overcome these deficits. Sulforaphane (SFN), a phytochemical from cruciferous vegetables, stimulates NRF2. This study tested the hypothesis that combining acute exercise (in vivo stimulus) with ex vivo SFN treatment would induce greater NRF2 activation and signaling in older adults compared to either treatment alone. Twenty-five older adults (12 men, 13 women; mean age: 67â€‰Â±â€‰5Â years) performed 30-min cycling exercise (AET). Blood was drawn before and immediately after the AET to isolate PBMCs and incubate with and without SFN (5Â ÂµM) treatment (four conditions: DMSO (CON), SFN, exercise (EX), and EXâ€‰+â€‰SFN). PBMCs were harvested after 2-h or 5-h incubation for measures of NRF2 or gene expression for NQO1, HO-1, GR, and GCLC targets, respectively. All treatments (SFN, EX, EXâ€‰+â€‰SFN) increased NRF2 activation compared to CON (pâ€‰<â€‰0.05). The response to EXâ€‰+â€‰SFN was significantly greater than either SFN or EX alone (2.1-fold versus 1.5-fold, pâ€‰=â€‰0.01). SFN stimulation resulted in a significant upregulation of all four genes compared to control (pâ€‰<â€‰0.001). EXâ€‰+â€‰SFN treatment stimulated a greater increase in gene expression compared to EX (pâ€‰<â€‰0.05); however, SFN did not differ statistically from EXâ€‰+â€‰SFN, suggesting a possible ceiling effect of the SFN concentration in terms of gene expression. There were no significant sex differences in any of the responses. These data suggest that combining exercise with SFN may amplify the strength of NRF2/ARE redox signaling in older adults. ClinicalTrials.gov ID: NCT04848792.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯å°æ–¼å¹´é•·è€…ä¾†èªªã€‚éš¨è‘—å¹´é½¡å¢é•·ï¼Œèº«é«”å°é‹å‹•çš„åæ‡‰å¯èƒ½æœƒæ¸›å¼±ï¼Œé€™å¯èƒ½å½±éŸ¿åˆ°ä»–å€‘çš„å¥åº·ç‹€æ³ã€‚ç ”ç©¶æŒ‡å‡ºï¼Œé€éçµåˆé‹å‹•å’Œè˜¿è””ç¡«ç´ çš„æ²»ç™‚ï¼Œæˆ–è¨±èƒ½å¤ æ”¹å–„é€™ç¨®æƒ…æ³ï¼Œå¢å¼·èº«é«”çš„æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œé€²è€Œä¿ƒé€²å¥åº·ã€‚é€™å°æ–¼å¸Œæœ›ä¿æŒæ´»åŠ›å’Œå¥åº·çš„å¹´é•·è€…ä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨é‹å‹•èˆ‡è˜¿è””ç¡«ç´ çµåˆå°å¹´é•·è€…çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å¦‚ä½•å¢å¼·èº«é«”å…§éƒ¨çš„æŠ—æ°§åŒ–ä¿¡è™Ÿå‚³éã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¹´é•·è€…åœ¨é€²è¡Œæ€¥æ€§é‹å‹•å¾Œï¼Œèº«é«”çš„åæ‡‰æ˜¯å¦æœƒå—åˆ°å½±éŸ¿ï¼Œä»¥åŠæ˜¯å¦å¯ä»¥é€éè˜¿è””ç¡«ç´ çš„è¼”åŠ©æ²»ç™‚ä¾†æ”¹å–„é€™ç¨®åæ‡‰ã€‚é€™æ¨£çš„ç ”ç©¶æœ‰åŠ©æ–¼äº†è§£å¦‚ä½•æ›´æœ‰æ•ˆåœ°ä¿ƒé€²å¹´é•·è€…çš„å¥åº·ã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…æ‹›å‹Ÿäº†25ä½å¹´é•·è€…ï¼ˆ12ä½ç”·æ€§å’Œ13ä½å¥³æ€§ï¼Œå¹³å‡å¹´é½¡67æ­²ï¼‰ï¼Œè®“ä»–å€‘é€²è¡Œ30åˆ†é˜çš„é¨è‡ªè¡Œè»Šé‹å‹•ã€‚é‹å‹•å‰å¾Œï¼Œç ”ç©¶åœ˜éšŠæœƒæŠ½å–è¡€æ¶²ï¼Œä»¥åˆ†é›¢å¤–å‘¨è¡€å–®æ ¸ç´°èƒï¼ˆPBMCsï¼‰ï¼Œä¸¦å°‡é€™äº›ç´°èƒèˆ‡æˆ–ä¸èˆ‡è˜¿è””ç¡«ç´ é€²è¡ŒåŸ¹é¤Šã€‚ç ”ç©¶è¨­è¨ˆäº†å››ç¨®è™•ç†æ¢ä»¶ï¼Œåˆ†åˆ¥æ˜¯å°ç…§çµ„ã€è˜¿è””ç¡«ç´ çµ„ã€é‹å‹•çµ„å’Œé‹å‹•åŠ è˜¿è””ç¡«ç´ çµ„ï¼Œä¸¦åœ¨ä¸åŒçš„æ™‚é–“é»æ”¶é›†ç´°èƒä»¥æ¸¬é‡æŠ—æ°§åŒ–ç›¸é—œåŸºå› çš„è¡¨é”ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œæ‰€æœ‰è™•ç†çµ„ï¼ˆåŒ…æ‹¬è˜¿è””ç¡«ç´ ã€é‹å‹•å’Œé‹å‹•åŠ è˜¿è””ç¡«ç´ ï¼‰éƒ½æ¯”å°ç…§çµ„é¡¯è‘—æé«˜äº†æŠ—æ°§åŒ–ä¿¡è™Ÿçš„æ´»åŒ–ç¨‹åº¦ã€‚ç‰¹åˆ¥æ˜¯é‹å‹•åŠ è˜¿è””ç¡«ç´ çš„çµ„åˆï¼Œå…¶æ•ˆæœé¡¯è‘—å„ªæ–¼å–®ç¨çš„è˜¿è””ç¡«ç´ æˆ–é‹å‹•ï¼Œé¡¯ç¤ºå‡ºæ›´å¼·çš„æŠ—æ°§åŒ–åæ‡‰ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ çš„åˆºæ¿€ä¹Ÿé¡¯è‘—æå‡äº†å››å€‹ç›¸é—œåŸºå› çš„è¡¨é”ã€‚é€™äº›çµæœæš—ç¤ºï¼Œçµåˆé‹å‹•èˆ‡è˜¿è””ç¡«ç´ å¯èƒ½æœƒå¢å¼·å¹´é•·è€…çš„æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ•ˆæœã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯å°æ–¼å¹´é•·è€…ä¾†èªªã€‚éš¨è‘—å¹´é½¡å¢é•·ï¼Œèº«é«”å°é‹å‹•çš„åæ‡‰å¯èƒ½æœƒæ¸›å¼±ï¼Œé€™å¯èƒ½å½±éŸ¿åˆ°ä»–å€‘çš„å¥åº·ç‹€æ³ã€‚ç ”ç©¶æŒ‡å‡ºï¼Œé€éçµåˆé‹å‹•å’Œè˜¿è””ç¡«ç´ çš„æ²»ç™‚ï¼Œæˆ–è¨±èƒ½å¤ æ”¹å–„é€™ç¨®æƒ…æ³ï¼Œå¢å¼·èº«é«”çš„æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œé€²è€Œä¿ƒé€²å¥åº·ã€‚é€™å°æ–¼å¸Œæœ›ä¿æŒæ´»åŠ›å’Œå¥åº·çš„å¹´é•·è€…ä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨é‹å‹•èˆ‡è˜¿è””ç¡«ç´ çµåˆå°å¹´é•·è€…çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å¦‚ä½•å¢å¼·èº«é«”å…§éƒ¨çš„æŠ—æ°§åŒ–ä¿¡è™Ÿå‚³éã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¹´é•·è€…åœ¨é€²è¡Œæ€¥æ€§é‹å‹•å¾Œï¼Œèº«é«”çš„åæ‡‰æ˜¯å¦æœƒå—åˆ°å½±éŸ¿ï¼Œä»¥åŠæ˜¯å¦å¯ä»¥é€éè˜¿è””ç¡«ç´ çš„è¼”åŠ©æ²»ç™‚ä¾†æ”¹å–„é€™ç¨®åæ‡‰ã€‚é€™æ¨£çš„ç ”ç©¶æœ‰åŠ©æ–¼äº†è§£å¦‚ä½•æ›´æœ‰æ•ˆåœ°ä¿ƒé€²å¹´é•·è€…çš„å¥åº·ã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…æ‹›å‹Ÿäº†25ä½å¹´é•·è€…ï¼ˆ12ä½ç”·æ€§å’Œ13ä½å¥³æ€§ï¼Œå¹³å‡å¹´é½¡67æ­²ï¼‰ï¼Œè®“ä»–å€‘é€²è¡Œ30åˆ†é˜çš„é¨è‡ªè¡Œè»Šé‹å‹•ã€‚é‹å‹•å‰å¾Œï¼Œç ”ç©¶åœ˜éšŠæœƒæŠ½å–è¡€æ¶²ï¼Œä»¥åˆ†é›¢å¤–å‘¨è¡€å–®æ ¸ç´°èƒï¼ˆPBMCsï¼‰ï¼Œä¸¦å°‡é€™äº›ç´°èƒèˆ‡æˆ–ä¸èˆ‡è˜¿è””ç¡«ç´ é€²è¡ŒåŸ¹é¤Šã€‚ç ”ç©¶è¨­è¨ˆäº†å››ç¨®è™•ç†æ¢ä»¶ï¼Œåˆ†åˆ¥æ˜¯å°ç…§çµ„ã€è˜¿è””ç¡«ç´ çµ„ã€é‹å‹•çµ„å’Œé‹å‹•åŠ è˜¿è””ç¡«ç´ çµ„ï¼Œä¸¦åœ¨ä¸åŒçš„æ™‚é–“é»æ”¶é›†ç´°èƒä»¥æ¸¬é‡æŠ—æ°§åŒ–ç›¸é—œåŸºå› çš„è¡¨é”ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œæ‰€æœ‰è™•ç†çµ„ï¼ˆåŒ…æ‹¬è˜¿è””ç¡«ç´ ã€é‹å‹•å’Œé‹å‹•åŠ è˜¿è””ç¡«ç´ ï¼‰éƒ½æ¯”å°ç…§çµ„é¡¯è‘—æé«˜äº†æŠ—æ°§åŒ–ä¿¡è™Ÿçš„æ´»åŒ–ç¨‹åº¦ã€‚ç‰¹åˆ¥æ˜¯é‹å‹•åŠ è˜¿è””ç¡«ç´ çš„çµ„åˆï¼Œå…¶æ•ˆæœé¡¯è‘—å„ªæ–¼å–®ç¨çš„è˜¿è””ç¡«ç´ æˆ–é‹å‹•ï¼Œé¡¯ç¤ºå‡ºæ›´å¼·çš„æŠ—æ°§åŒ–åæ‡‰ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ çš„åˆºæ¿€ä¹Ÿé¡¯è‘—æå‡äº†å››å€‹ç›¸é—œåŸºå› çš„è¡¨é”ã€‚é€™äº›çµæœæš—ç¤ºï¼Œçµåˆé‹å‹•èˆ‡è˜¿è””ç¡«ç´ å¯èƒ½æœƒå¢å¼·å¹´é•·è€…çš„æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ•ˆæœã€‚",
    "fb_post": "æ ¹æ“šã€ŠGeroScienceã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿé‹å‹•å’Œè˜¿è””ç¡«ç´ çš„çµåˆï¼Œå¯èƒ½æ˜¯å¹«åŠ©å¹´é•·è€…ä¿æŒå¥åº·çš„ç§˜å¯†æ­¦å™¨ï¼ğŸ’ªğŸ¥¦\n\næœ€è¿‘æœ‰ä¸€é …æœ‰è¶£çš„ç ”ç©¶ï¼Œå°ˆæ³¨æ–¼å¹´é•·è€…çš„å¥åº·ç‹€æ³ã€‚éš¨è‘—å¹´é½¡å¢é•·ï¼Œæˆ‘å€‘çš„èº«é«”å°é‹å‹•çš„åæ‡‰æœƒè®Šå¾—æ¯”è¼ƒé²éˆï¼Œé€™å¯èƒ½æœƒå½±éŸ¿æˆ‘å€‘çš„å¥åº·ã€‚ç ”ç©¶è€…æƒ³çŸ¥é“ï¼Œé‹å‹•åŠ ä¸Šè˜¿è””ç¡«ç´ ï¼ˆä¾†è‡ªé’èŠ±æ¤°èœç­‰é£Ÿç‰©çš„ä¸€ç¨®å¤©ç„¶æˆåˆ†ï¼‰æ˜¯å¦èƒ½æ”¹å–„é€™ç¨®æƒ…æ³ã€‚\n\nç ”ç©¶ä¸­ï¼Œ25ä½å¹´é•·è€…åƒåŠ äº†30åˆ†é˜çš„é¨è‡ªè¡Œè»Šé‹å‹•ï¼Œä¸¦åœ¨é‹å‹•å‰å¾ŒæŠ½å–è¡€æ¶²ä¾†åˆ†æã€‚çµæœé¡¯ç¤ºï¼Œç„¡è«–æ˜¯å–®ç¨é‹å‹•é‚„æ˜¯æ­é…è˜¿è””ç¡«ç´ çš„çµ„åˆï¼Œéƒ½èƒ½é¡¯è‘—æé«˜èº«é«”çš„æŠ—æ°§åŒ–èƒ½åŠ›ã€‚ç‰¹åˆ¥æ˜¯é‹å‹•åŠ è˜¿è””ç¡«ç´ çš„çµ„åˆæ•ˆæœæœ€æ˜é¡¯ï¼Œé¡¯ç¤ºå‡ºæ›´å¼·çš„æŠ—æ°§åŒ–åæ‡‰ï¼\n\né€™é …ç ”ç©¶å‘Šè¨´æˆ‘å€‘ï¼š\n1. é‹å‹•å°å¹´é•·è€…çš„å¥åº·éå¸¸é‡è¦ã€‚\n2. è˜¿è””ç¡«ç´ å¯èƒ½å¢å¼·é‹å‹•çš„æ•ˆæœã€‚\n3. çµåˆé‹å‹•å’Œå¥åº·é£²é£Ÿï¼Œæˆ–è¨±èƒ½è®“å¹´é•·è€…æ›´æœ‰æ´»åŠ›ï¼\n\nè®“æˆ‘å€‘ä¸€èµ·é—œå¿ƒé•·è¼©çš„å¥åº·ï¼Œä¿æŒæ´»åŠ›å§ï¼âœ¨",
    "image_prompt": "Create an infographic that explains the experiment and main results of a study on the effects of exercise combined with sulforaphane on older adults. Use a simple and clear flat design style with a white or light-colored background and soft colors. Include illustrations of broccoli or sulforaphane, simplified representations of people or cells as experimental subjects, arrows or flow lines to indicate the experimental steps, and a section highlighting the main results, such as increased antioxidant activity.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41099966/"
  },
  {
    "id": "40763479",
    "title_en": "Sulforaphane modulates macrophage polarization via JAK1/STAT1 inhibition to promote tendon repair in tendinopathy.",
    "pub_date": "2025 Oct",
    "journal": "International immunopharmacology",
    "abstract_en": "Imbalanced M1/M2 macrophage polarization is central to tendinopathy pathogenesis. Sulforaphane (SFN), a natural compound with anti-inflammatory properties, may modulate macrophage polarization. This study utilized a collagenase-induced mouse model of tendinopathy to evaluate the therapeutic effects of local SFN administration on tendinopathy in vivo. Furthermore, the effects of SFN on macrophage polarization were investigated in vitro, and RNA sequencing was used to explore the mechanisms by which SFN regulates macrophage polarization in vivo. Finally, an ex vivo human pathological tendon culture system was employed to explore the therapeutic effects of SFN on tendinopathic lesions. In this study, we found that SFN modulated the polarization of M1 macrophages towards M2 macrophages, thereby effectively modulating the inflammatory response. RNA sequencing and Western blot analyses indicated that the effect of SFN was mediated through the JAK1/STAT1 signaling pathway. In a collagenase-induced mouse model of tendinopathy, local injection of SFN led to a significant improvement in tendon tissue structure, with the collagen matrix restoring its natural dense parallel arrangement. Furthermore, there was an increase in local M2 macrophages and a decrease in M1 macrophages, which promoted the resolution of inflammation. Finally, the immunomodulatory effect of SFN on macrophages was also validated in tendon tissue from patients with tendinopathy. SFN can effectively alleviate tendinopathy by promoting the polarization of M1 macrophages towards M2 macrophages, an effect achieved through the inhibition of the JAK1/STAT1 signaling pathway, thereby providing a promising therapeutic approach for the treatment of tendinopathy.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚Œè…±ç—…çš„æ²»ç™‚ä¸Šã€‚è‚Œè…±ç—…æ˜¯ä¸€ç¨®å¸¸è¦‹çš„é‹å‹•å‚·å®³ï¼Œé€šå¸¸ä¼´éš¨è‘—ç–¼ç—›å’ŒåŠŸèƒ½éšœç¤™ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éèª¿ç¯€å…ç–«ç´°èƒçš„æ¥µåŒ–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•ç‚ç—‡åæ‡‰ï¼Œé€²è€Œæ”¹å–„è‚Œè…±çš„å¥åº·ç‹€æ…‹ã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†åœ¨é é˜²å’Œæ²»ç™‚è‚Œè…±ç—…æ–¹é¢ï¼Œå¯èƒ½å¯ä»¥åˆ©ç”¨ä¸€äº›å¤©ç„¶åŒ–åˆç‰©ä¾†é”åˆ°æ›´å¥½çš„æ•ˆæœï¼Œé€™å°æ–¼é‹å‹•å“¡å’Œä¸€èˆ¬äººä¾†èªªéƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚",
    "para2": "é€™é …ç ”ç©¶ä¸»è¦é—œæ³¨çš„æ˜¯è˜¿è””ç¡«ç´ å°è‚Œè…±ç—…çš„æ²»ç™‚æ•ˆæœã€‚è‚Œè…±ç—…çš„ç™¼ç”Ÿèˆ‡å…ç–«ç³»çµ±ä¸­M1å’ŒM2å·¨å™¬ç´°èƒçš„æ¥µåŒ–å¤±è¡¡æœ‰é—œã€‚ç ”ç©¶è€…å¸Œæœ›é€éé€™é …ç ”ç©¶ï¼Œäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿é€™äº›å…ç–«ç´°èƒçš„æ¥µåŒ–ï¼Œä¸¦é€²ä¸€æ­¥æ¢è¨å…¶å°è‚Œè…±ç—…çš„æ½›åœ¨ç™‚æ•ˆã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼äº†è§£è‚Œè…±ç—…çš„ç—…ç†æ©Ÿåˆ¶ï¼Œä¹Ÿå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›æ–°çš„æ€è·¯ã€‚",
    "para3": "ç ”ç©¶ä¸­ä½¿ç”¨äº†ä¸€ç¨®ç”±è† åŸé…¶èª˜å°çš„è€é¼ æ¨¡å‹ä¾†æ¨¡æ“¬è‚Œè…±ç—…ï¼Œä¸¦è©•ä¼°å±€éƒ¨æ³¨å°„è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„åœ¨é«”å¤–å¯¦é©—ä¸­è§€å¯Ÿäº†è˜¿è””ç¡«ç´ å°å·¨å™¬ç´°èƒæ¥µåŒ–çš„å½±éŸ¿ï¼Œä¸¦åˆ©ç”¨RNAæ¸¬åºæŠ€è¡“æ¢è¨è˜¿è””ç¡«ç´ èª¿ç¯€å·¨å™¬ç´°èƒæ¥µåŒ–çš„æ©Ÿåˆ¶ã€‚æœ€å¾Œï¼Œç ”ç©¶è€…é‚„ä½¿ç”¨äº†äººé¡ç—…ç†è‚Œè…±çš„åŸ¹é¤Šç³»çµ±ï¼Œé€²ä¸€æ­¥é©—è­‰è˜¿è””ç¡«ç´ å°è‚Œè…±ç—…è®Šçš„ç™‚æ•ˆã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆèª¿ç¯€M1å·¨å™¬ç´°èƒå‘M2å·¨å™¬ç´°èƒçš„æ¥µåŒ–ï¼Œå¾è€Œæ¸›å°‘ç‚ç—‡åæ‡‰ã€‚RNAæ¸¬åºå’Œè¥¿æ–¹å°è·¡åˆ†æè¡¨æ˜ï¼Œé€™ä¸€æ•ˆæœæ˜¯é€šéæŠ‘åˆ¶JAK1/STAT1ä¿¡è™Ÿé€šè·¯ä¾†å¯¦ç¾çš„ã€‚åœ¨è† åŸé…¶èª˜å°çš„è€é¼ æ¨¡å‹ä¸­ï¼Œå±€éƒ¨æ³¨å°„è˜¿è””ç¡«ç´ é¡¯è‘—æ”¹å–„äº†è‚Œè…±çµ„ç¹”çµæ§‹ï¼Œæ¢å¾©äº†è† åŸåŸºè³ªçš„è‡ªç„¶æ’åˆ—ã€‚æ­¤å¤–ï¼Œå±€éƒ¨M2å·¨å™¬ç´°èƒçš„å¢åŠ å’ŒM1å·¨å™¬ç´°èƒçš„æ¸›å°‘ä¹Ÿä¿ƒé€²äº†ç‚ç—‡çš„ç·©è§£ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ åœ¨è‚Œè…±ç—…çš„æ²»ç™‚ä¸­å…·æœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚Œè…±ç—…çš„æ²»ç™‚ä¸Šã€‚è‚Œè…±ç—…æ˜¯ä¸€ç¨®å¸¸è¦‹çš„é‹å‹•å‚·å®³ï¼Œé€šå¸¸ä¼´éš¨è‘—ç–¼ç—›å’ŒåŠŸèƒ½éšœç¤™ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éèª¿ç¯€å…ç–«ç´°èƒçš„æ¥µåŒ–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•ç‚ç—‡åæ‡‰ï¼Œé€²è€Œæ”¹å–„è‚Œè…±çš„å¥åº·ç‹€æ…‹ã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†åœ¨é é˜²å’Œæ²»ç™‚è‚Œè…±ç—…æ–¹é¢ï¼Œå¯èƒ½å¯ä»¥åˆ©ç”¨ä¸€äº›å¤©ç„¶åŒ–åˆç‰©ä¾†é”åˆ°æ›´å¥½çš„æ•ˆæœï¼Œé€™å°æ–¼é‹å‹•å“¡å’Œä¸€èˆ¬äººä¾†èªªéƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨çš„æ˜¯è˜¿è””ç¡«ç´ å°è‚Œè…±ç—…çš„æ²»ç™‚æ•ˆæœã€‚è‚Œè…±ç—…çš„ç™¼ç”Ÿèˆ‡å…ç–«ç³»çµ±ä¸­M1å’ŒM2å·¨å™¬ç´°èƒçš„æ¥µåŒ–å¤±è¡¡æœ‰é—œã€‚ç ”ç©¶è€…å¸Œæœ›é€éé€™é …ç ”ç©¶ï¼Œäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿é€™äº›å…ç–«ç´°èƒçš„æ¥µåŒ–ï¼Œä¸¦é€²ä¸€æ­¥æ¢è¨å…¶å°è‚Œè…±ç—…çš„æ½›åœ¨ç™‚æ•ˆã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼äº†è§£è‚Œè…±ç—…çš„ç—…ç†æ©Ÿåˆ¶ï¼Œä¹Ÿå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›æ–°çš„æ€è·¯ã€‚\n\nç ”ç©¶ä¸­ä½¿ç”¨äº†ä¸€ç¨®ç”±è† åŸé…¶èª˜å°çš„è€é¼ æ¨¡å‹ä¾†æ¨¡æ“¬è‚Œè…±ç—…ï¼Œä¸¦è©•ä¼°å±€éƒ¨æ³¨å°„è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„åœ¨é«”å¤–å¯¦é©—ä¸­è§€å¯Ÿäº†è˜¿è””ç¡«ç´ å°å·¨å™¬ç´°èƒæ¥µåŒ–çš„å½±éŸ¿ï¼Œä¸¦åˆ©ç”¨RNAæ¸¬åºæŠ€è¡“æ¢è¨è˜¿è””ç¡«ç´ èª¿ç¯€å·¨å™¬ç´°èƒæ¥µåŒ–çš„æ©Ÿåˆ¶ã€‚æœ€å¾Œï¼Œç ”ç©¶è€…é‚„ä½¿ç”¨äº†äººé¡ç—…ç†è‚Œè…±çš„åŸ¹é¤Šç³»çµ±ï¼Œé€²ä¸€æ­¥é©—è­‰è˜¿è””ç¡«ç´ å°è‚Œè…±ç—…è®Šçš„ç™‚æ•ˆã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆèª¿ç¯€M1å·¨å™¬ç´°èƒå‘M2å·¨å™¬ç´°èƒçš„æ¥µåŒ–ï¼Œå¾è€Œæ¸›å°‘ç‚ç—‡åæ‡‰ã€‚RNAæ¸¬åºå’Œè¥¿æ–¹å°è·¡åˆ†æè¡¨æ˜ï¼Œé€™ä¸€æ•ˆæœæ˜¯é€šéæŠ‘åˆ¶JAK1/STAT1ä¿¡è™Ÿé€šè·¯ä¾†å¯¦ç¾çš„ã€‚åœ¨è† åŸé…¶èª˜å°çš„è€é¼ æ¨¡å‹ä¸­ï¼Œå±€éƒ¨æ³¨å°„è˜¿è””ç¡«ç´ é¡¯è‘—æ”¹å–„äº†è‚Œè…±çµ„ç¹”çµæ§‹ï¼Œæ¢å¾©äº†è† åŸåŸºè³ªçš„è‡ªç„¶æ’åˆ—ã€‚æ­¤å¤–ï¼Œå±€éƒ¨M2å·¨å™¬ç´°èƒçš„å¢åŠ å’ŒM1å·¨å™¬ç´°èƒçš„æ¸›å°‘ä¹Ÿä¿ƒé€²äº†ç‚ç—‡çš„ç·©è§£ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ åœ¨è‚Œè…±ç—…çš„æ²»ç™‚ä¸­å…·æœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ã€‚",
    "fb_post": "æ ¹æ“šã€ŠInternational immunopharmacologyã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„èº«é«”è£¡æœ‰ä¸€äº›å°å°çš„æˆ°å£«ï¼Œå°ˆé–€å°æŠ—ç‚ç—‡å’Œç–¼ç—›ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™å€‹å¤©ç„¶æˆåˆ†ï¼Œå¯èƒ½å°è‚Œè…±ç—…çš„æ²»ç™‚æœ‰å¹«åŠ©ï¼è‚Œè…±ç—…å¸¸è¦‹æ–¼é‹å‹•å“¡èº«ä¸Šï¼Œæœƒå°è‡´ç–¼ç—›å’Œæ´»å‹•ä¸ä¾¿ã€‚é€™é …ç ”ç©¶ç‰¹åˆ¥é—œæ³¨è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿æˆ‘å€‘å…ç–«ç³»çµ±ä¸­çš„ç´°èƒï¼Œå°¤å…¶æ˜¯å·¨å™¬ç´°èƒã€‚ç ”ç©¶è€…å€‘ä½¿ç”¨äº†å°é¼ æ¨¡å‹ï¼Œé€éå±€éƒ¨æ³¨å°„è˜¿è””ç¡«ç´ ä¾†è§€å¯Ÿæ•ˆæœï¼Œé‚„é€²è¡Œäº†ç´°èƒå¯¦é©—ä¾†äº†è§£å®ƒçš„ä½œç”¨æ©Ÿåˆ¶ã€‚çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ å¹«åŠ©èª¿ç¯€å…ç–«ç´°èƒçš„å¹³è¡¡ï¼Œæ¸›å°‘ç‚ç—‡åæ‡‰ï¼Œä¸¦æ”¹å–„è‚Œè…±çš„å¥åº·ã€‚é€™äº›ç™¼ç¾è®“æˆ‘å€‘å°æœªä¾†çš„è‚Œè…±ç—…æ²»ç™‚å……æ»¿æœŸå¾…ï¼\n\nâœ¨ é‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è‚Œè…±ç—…çš„ç—‡ç‹€ã€‚\n2. å®ƒé€éèª¿ç¯€å…ç–«ç´°èƒä¾†æ¸›å°‘ç‚ç—‡ã€‚\n3. é€™äº›ç ”ç©¶çµæœç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›äº†æ–°æ€è·¯ï¼",
    "image_prompt": "Create an infographic that explains the experimental methods and main results of a study on the effects of sulforaphane on tendon disease. Use a simple and clear style with a white or light-colored background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like humans, animals, or cells, and arrows or flow lines showing the experimental steps. Add a section that highlights the main results, such as protective effects or changes observed.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚Œè…±ç—… Tendinopathy",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40763479/"
  },
  {
    "id": "41060333",
    "title_en": "Sulforaphane from broccoli, an epigenetic modulator in cancer cells.",
    "pub_date": "2025 Oct",
    "journal": "Discover oncology",
    "abstract_en": "The consumption of cruciferous vegetables offers several health benefits due to some of their compounds. Sulforaphane (SFN), a compound found in cabbage and broccoli, has received special attention in recent years due to its anticancer activities. The main objective of this systematic review is to examine the epigenetic and genetic effects of SFN on cancers (in vitro and in vivo) which contribute to its anticancer activities. We only analyzed studies that combined its epigenetic effects and anticancer activities due to the multitude of studies on SFN over the past few years. We found that SFN is able to regulate epigenetic mechanisms and promote the prevention and treatment of several cancers. Definitely, it prevents tumor growth and acts as a histone deacetylase (HDAC) inhibitor, a DNA methyltransferase (DNMT) inhibitor, and a microRNA regulator in several cancers. These epigenetic regulations lead indirectly to a hyperregulation or deregulation of the expression of genes involved in carcinogenesis. SFN hasn't any major epigenetic effect on normal cells. This review revealed that the anticancer activities attributable to SFN are largely related to its ability to modulate cancer cell epigenome. These capabilities to modulate the epigenome make SFN a promising anticancer agent with significant therapeutic potential.",
    "para1": "é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„æ”å–å°å¥åº·æœ‰è¨±å¤šå¥½è™•ï¼Œé€™ä¸»è¦ä¾†è‡ªæ–¼å®ƒå€‘æ‰€å«çš„æŸäº›åŒ–åˆç‰©ã€‚ç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ ï¼Œè¿‘å¹´ä¾†å› å…¶æŠ—ç™Œæ´»æ€§è€Œå—åˆ°å»£æ³›é—œæ³¨ã€‚é€™é …ç ”ç©¶çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé€éå¢åŠ é€™é¡è”¬èœçš„æ”å–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é é˜²æŸäº›ç™Œç—‡ï¼Œä¸¦ä¿ƒé€²å¥åº·ã€‚é›–ç„¶é€™äº›ç ”ç©¶çš„çµæœé¡¯ç¤ºè˜¿è””ç¡«ç´ åœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸Šæœ‰æ½›åŠ›ï¼Œä½†æˆ‘å€‘ä»éœ€è¬¹æ…çœ‹å¾…ï¼Œå› ç‚ºé€™ä¸¦ä¸ä»£è¡¨å®ƒèƒ½å¤ å®Œå…¨æ²»ç™’ç™Œç—‡æˆ–å–ä»£å‚³çµ±æ²»ç™‚æ–¹æ³•ã€‚",
    "para2": "é€™é …ç³»çµ±æ€§å›é¡§çš„ä¸»è¦ç›®çš„æ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ç™Œç—‡çš„è¡¨è§€éºå‚³å’Œéºå‚³å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ å¦‚ä½•é€éèª¿ç¯€åŸºå› è¡¨é”ä¾†å½±éŸ¿ç™Œç—‡çš„ç™¼å±•ï¼Œä¸¦ä¸”å°ˆæ³¨æ–¼å…¶è¡¨è§€éºå‚³æ•ˆæ‡‰èˆ‡æŠ—ç™Œæ´»æ€§ä¹‹é–“çš„é—œè¯ã€‚ç”±æ–¼éå»å¹¾å¹´æœ‰å¤§é‡é—œæ–¼è˜¿è””ç¡«ç´ çš„ç ”ç©¶ï¼Œé€™é …å›é¡§ç‰¹åˆ¥åˆ†æäº†é‚£äº›åŒæ™‚æ¢è¨å…¶è¡¨è§€éºå‚³æ•ˆæ‡‰å’ŒæŠ—ç™Œä½œç”¨çš„ç ”ç©¶ã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…åˆ†æäº†å¤šé …é—œæ–¼è˜¿è””ç¡«ç´ çš„ç ”ç©¶ï¼Œé€™äº›ç ”ç©¶åŒ…æ‹¬äº†é«”å¤–ï¼ˆin vitroï¼‰å’Œé«”å…§ï¼ˆin vivoï¼‰çš„å¯¦é©—ã€‚ç ”ç©¶è€…è‘—é‡æ–¼è˜¿è””ç¡«ç´ å¦‚ä½•èª¿ç¯€è¡¨è§€éºå‚³æ©Ÿåˆ¶ï¼Œä¸¦ä¿ƒé€²ç™Œç—‡çš„é é˜²å’Œæ²»ç™‚ã€‚é€™äº›ç ”ç©¶çš„å°è±¡åŒ…æ‹¬ç™Œç´°èƒå’Œæ­£å¸¸ç´°èƒï¼Œä¸¦æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨ä¸åŒç™Œç—‡é¡å‹ä¸­çš„ä½œç”¨ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ èª¿ç¯€è¡¨è§€éºå‚³æ©Ÿåˆ¶ï¼Œä¸¦åœ¨å¤šç¨®ç™Œç—‡ä¸­ä¿ƒé€²é é˜²å’Œæ²»ç™‚ã€‚å®ƒè¢«ç™¼ç¾èƒ½å¤ æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸¦ä½œç‚ºçµ„è›‹ç™½å»ä¹™é†¯åŒ–é…¶ï¼ˆHDACï¼‰æŠ‘åˆ¶åŠ‘ã€DNAç”²åŸºè½‰ç§»é…¶ï¼ˆDNMTï¼‰æŠ‘åˆ¶åŠ‘å’Œå¾®å°RNAèª¿ç¯€å› å­ã€‚é€™äº›è¡¨è§€éºå‚³èª¿æ§é–“æ¥å½±éŸ¿äº†èˆ‡ç™Œç—‡ç™¼ç”Ÿç›¸é—œåŸºå› çš„è¡¨é”ã€‚ç„¶è€Œï¼Œè˜¿è””ç¡«ç´ å°æ­£å¸¸ç´°èƒä¸¦æ²’æœ‰é¡¯è‘—çš„è¡¨è§€éºå‚³å½±éŸ¿ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„æŠ—ç™Œæ´»æ€§èˆ‡å…¶èª¿ç¯€ç™Œç´°èƒè¡¨è§€åŸºå› çµ„çš„èƒ½åŠ›å¯†åˆ‡ç›¸é—œï¼Œé¡¯ç¤ºå‡ºå…¶ä½œç‚ºæŠ—ç™ŒåŠ‘çš„æ½›åŠ›ã€‚",
    "explanation_zh": "é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„æ”å–å°å¥åº·æœ‰è¨±å¤šå¥½è™•ï¼Œé€™ä¸»è¦ä¾†è‡ªæ–¼å®ƒå€‘æ‰€å«çš„æŸäº›åŒ–åˆç‰©ã€‚ç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ ï¼Œè¿‘å¹´ä¾†å› å…¶æŠ—ç™Œæ´»æ€§è€Œå—åˆ°å»£æ³›é—œæ³¨ã€‚é€™é …ç ”ç©¶çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé€éå¢åŠ é€™é¡è”¬èœçš„æ”å–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é é˜²æŸäº›ç™Œç—‡ï¼Œä¸¦ä¿ƒé€²å¥åº·ã€‚é›–ç„¶é€™äº›ç ”ç©¶çš„çµæœé¡¯ç¤ºè˜¿è””ç¡«ç´ åœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸Šæœ‰æ½›åŠ›ï¼Œä½†æˆ‘å€‘ä»éœ€è¬¹æ…çœ‹å¾…ï¼Œå› ç‚ºé€™ä¸¦ä¸ä»£è¡¨å®ƒèƒ½å¤ å®Œå…¨æ²»ç™’ç™Œç—‡æˆ–å–ä»£å‚³çµ±æ²»ç™‚æ–¹æ³•ã€‚\n\né€™é …ç³»çµ±æ€§å›é¡§çš„ä¸»è¦ç›®çš„æ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ç™Œç—‡çš„è¡¨è§€éºå‚³å’Œéºå‚³å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ å¦‚ä½•é€éèª¿ç¯€åŸºå› è¡¨é”ä¾†å½±éŸ¿ç™Œç—‡çš„ç™¼å±•ï¼Œä¸¦ä¸”å°ˆæ³¨æ–¼å…¶è¡¨è§€éºå‚³æ•ˆæ‡‰èˆ‡æŠ—ç™Œæ´»æ€§ä¹‹é–“çš„é—œè¯ã€‚ç”±æ–¼éå»å¹¾å¹´æœ‰å¤§é‡é—œæ–¼è˜¿è””ç¡«ç´ çš„ç ”ç©¶ï¼Œé€™é …å›é¡§ç‰¹åˆ¥åˆ†æäº†é‚£äº›åŒæ™‚æ¢è¨å…¶è¡¨è§€éºå‚³æ•ˆæ‡‰å’ŒæŠ—ç™Œä½œç”¨çš„ç ”ç©¶ã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…åˆ†æäº†å¤šé …é—œæ–¼è˜¿è””ç¡«ç´ çš„ç ”ç©¶ï¼Œé€™äº›ç ”ç©¶åŒ…æ‹¬äº†é«”å¤–ï¼ˆin vitroï¼‰å’Œé«”å…§ï¼ˆin vivoï¼‰çš„å¯¦é©—ã€‚ç ”ç©¶è€…è‘—é‡æ–¼è˜¿è””ç¡«ç´ å¦‚ä½•èª¿ç¯€è¡¨è§€éºå‚³æ©Ÿåˆ¶ï¼Œä¸¦ä¿ƒé€²ç™Œç—‡çš„é é˜²å’Œæ²»ç™‚ã€‚é€™äº›ç ”ç©¶çš„å°è±¡åŒ…æ‹¬ç™Œç´°èƒå’Œæ­£å¸¸ç´°èƒï¼Œä¸¦æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨ä¸åŒç™Œç—‡é¡å‹ä¸­çš„ä½œç”¨ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ èª¿ç¯€è¡¨è§€éºå‚³æ©Ÿåˆ¶ï¼Œä¸¦åœ¨å¤šç¨®ç™Œç—‡ä¸­ä¿ƒé€²é é˜²å’Œæ²»ç™‚ã€‚å®ƒè¢«ç™¼ç¾èƒ½å¤ æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸¦ä½œç‚ºçµ„è›‹ç™½å»ä¹™é†¯åŒ–é…¶ï¼ˆHDACï¼‰æŠ‘åˆ¶åŠ‘ã€DNAç”²åŸºè½‰ç§»é…¶ï¼ˆDNMTï¼‰æŠ‘åˆ¶åŠ‘å’Œå¾®å°RNAèª¿ç¯€å› å­ã€‚é€™äº›è¡¨è§€éºå‚³èª¿æ§é–“æ¥å½±éŸ¿äº†èˆ‡ç™Œç—‡ç™¼ç”Ÿç›¸é—œåŸºå› çš„è¡¨é”ã€‚ç„¶è€Œï¼Œè˜¿è””ç¡«ç´ å°æ­£å¸¸ç´°èƒä¸¦æ²’æœ‰é¡¯è‘—çš„è¡¨è§€éºå‚³å½±éŸ¿ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„æŠ—ç™Œæ´»æ€§èˆ‡å…¶èª¿ç¯€ç™Œç´°èƒè¡¨è§€åŸºå› çµ„çš„èƒ½åŠ›å¯†åˆ‡ç›¸é—œï¼Œé¡¯ç¤ºå‡ºå…¶ä½œç‚ºæŠ—ç™ŒåŠ‘çš„æ½›åŠ›ã€‚",
    "fb_post": "æ ¹æ“šã€ŠDiscover oncologyã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ ä½ çŸ¥é“é’èŠ±æ¤°èœä¸åƒ…å¥½åƒï¼Œé‚„å°å¥åº·æœ‰å¤§å¹«åŠ©å—ï¼Ÿæœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆé–€æ¢è¨äº†è˜¿è””ç¡«ç´ é€™å€‹ç¥å¥‡çš„æˆåˆ†ï¼\n\né€™é …ç ”ç©¶ä¸»è¦é—œå¿ƒè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç—‡çš„ç™¼å±•ï¼Œç ”ç©¶è€…å€‘é€éåˆ†æè¨±å¤šå¯¦é©—ï¼Œæƒ³äº†è§£å®ƒæ˜¯æ€éº¼èª¿ç¯€åŸºå› è¡¨é”çš„ï¼Œä¸¦ä¸”çœ‹çœ‹é€™è·ŸæŠ—ç™Œæ´»æ€§æœ‰ä»€éº¼é—œè¯ã€‚\n\nç ”ç©¶ä¸­ï¼Œç§‘å­¸å®¶å€‘é€²è¡Œäº†é«”å¤–å’Œé«”å…§çš„å¯¦é©—ï¼Œè§€å¯Ÿäº†è˜¿è””ç¡«ç´ å°ç™Œç´°èƒå’Œæ­£å¸¸ç´°èƒçš„å½±éŸ¿ã€‚ä»–å€‘ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å¯ä»¥å¹«åŠ©é é˜²å’Œæ²»ç™‚å¤šç¨®ç™Œç—‡ï¼Œä¸¦ä¸”èƒ½å¤ æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼ä¸éï¼Œé€™ä¸¦ä¸ä»£è¡¨è˜¿è””ç¡«ç´ èƒ½å–ä»£å‚³çµ±æ²»ç™‚ï¼Œå¤§å®¶é‚„æ˜¯è¦ä¿æŒè¬¹æ…å“¦ã€‚\n\nğŸ” é€™è£¡æœ‰å¹¾å€‹é‡é»è®“ä½ çŸ¥é“ï¼š\n1. è˜¿è””ç¡«ç´ èƒ½èª¿ç¯€ç™Œç´°èƒçš„åŸºå› è¡¨é”ï¼Œæœ‰åŠ©æ–¼æŠ—ç™Œã€‚\n2. å®ƒå°æ­£å¸¸ç´°èƒçš„å½±éŸ¿ä¸å¤§ï¼Œä¸»è¦é‡å°ç™Œç´°èƒã€‚\n3. å¢åŠ é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„æ”å–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼å¥åº·å’Œç™Œç—‡é é˜²ï¼",
    "image_prompt": "Create a flat design infographic that explains the experimental methods and main results of a study on sulforaphane. Include simple icons representing broccoli or sulforaphane, simplified representations of experimental subjects like humans, animals, or cells. Use arrows or flow lines to indicate the steps of the experiment. Add a section that clearly states the main results, such as protective effects and changes observed in cancer cells.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "ç™Œç—‡ Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41060333/"
  },
  {
    "id": "40553560",
    "title_en": "Antibacterial effects of sulforaphane - AÂ phytonutrient derived from broccoli asÂ promising candidate in the combat ofÂ bacterial infections.",
    "pub_date": "2025 Oct",
    "journal": "European journal of microbiology & immunology",
    "abstract_en": "Bacterial pathogens, particularly antibiotic-resistant strains may constitute major challenges for the successful treatment of infected patients. Therefore, novel antibiotics or alternative, antibiotics-independent compounds with antimicrobial properties such as phytonutrients are needed. Our systematic literature review summarizes current knowledge on antibacterial effects of sulforaphane (SFN) in vitro and in vivo, including human studies. The isothiocyanate SFN is abundant in plants from the BrassicaceaeÂ family including broccoli. The 28 reports reviewed herein revealed that SFN i.) exerted antimicrobial effects against a variety of Gram-positive and Gram-negative bacteria; ii.) counteracted distinct virulence factors such as biofilm formation and toxin production (e.g. Shiga toxin); iii.)Â enhanced antibacterial immune cell responses mounting in anti-oxidant and anti-inflammatory actions thereby supporting bacterial killing and dampening inflammatory cell and tissue damage; iv.) prevented from aspirin-induced small intestinal cell injury; and v.) alleviated Helicobacter pylori-induced gastritis. In conclusion, given its antibacterial, immune-modulatory, and disease-alleviating effects, SFN constitutesÂ a promising alternative antibiotic-independent candidate for the treatment of bacterial infections, warranting further consideration in clinical trials.",
    "para1": "åœ¨ç•¶ä»Šé†«ç™‚ç’°å¢ƒä¸­ï¼ŒæŠ—ç”Ÿç´ æŠ—è—¥æ€§èŒæ ªçš„å‡ºç¾å°æ–¼æ²»ç™‚æ„ŸæŸ“ç—…äººé€ æˆäº†é‡å¤§æŒ‘æˆ°ã€‚å› æ­¤ï¼Œå°‹æ‰¾æ–°çš„æŠ—ç”Ÿç´ æˆ–å…¶ä»–ä¸ä¾è³´æŠ—ç”Ÿç´ çš„æŠ—å¾®ç”Ÿç‰©åŒ–åˆç‰©è®Šå¾—è¶Šä¾†è¶Šé‡è¦ã€‚é€™é …ç ”ç©¶æä¾›äº†æœ‰é—œè˜¿è””ç¡«ç´ çš„æŠ—èŒæ•ˆæœçš„æœ€æ–°è³‡è¨Šï¼Œé€™å¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰è‘—é‡è¦çš„å•Ÿç¤ºï¼Œå°¤å…¶æ˜¯åœ¨å°æŠ—æŠ—è—¥æ€§ç´°èŒæ–¹é¢ã€‚é€éäº†è§£é€™äº›å¤©ç„¶åŒ–åˆç‰©çš„æ½›åŠ›ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ¡ˆï¼Œæ¸›å°‘å°å‚³çµ±æŠ—ç”Ÿç´ çš„ä¾è³´ï¼Œé€²è€Œæ”¹å–„å…¬å…±å¥åº·ç‹€æ³ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰åœ¨æŠ—èŒæ–¹é¢çš„æ•ˆæœã€‚ç ”ç©¶è€…å€‘é—œæ³¨é€™ç¨®ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘æ¤ç‰©çš„åŒ–åˆç‰©ï¼Œç‰¹åˆ¥æ˜¯å®ƒåœ¨å°æŠ—å„ç¨®ç´°èŒæ„ŸæŸ“æ–¹é¢çš„æ½›åŠ›ã€‚é€éç³»çµ±æ€§çš„æ–‡ç»å›é¡§ï¼Œç ”ç©¶è€…å€‘æ•´ç†äº†ç›®å‰å°æ–¼è˜¿è””ç¡«ç´ çš„æŠ—èŒæ•ˆæœçš„äº†è§£ï¼ŒåŒ…æ‹¬åœ¨é«”å¤–å’Œé«”å…§çš„ç ”ç©¶çµæœï¼Œä¸¦ä¸”æ¶µè“‹äº†äººé¡ç ”ç©¶çš„è³‡æ–™ï¼Œé€™ä½¿å¾—ç ”ç©¶çš„çµæœæ›´å…·åƒè€ƒåƒ¹å€¼ã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…å€‘å›é¡§äº†28ç¯‡ç›¸é—œæ–‡ç»ï¼Œé€™äº›æ–‡ç»æ¢è¨äº†è˜¿è””ç¡«ç´ çš„æŠ—èŒæ•ˆæœã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬åˆ†æä¸åŒçš„å¯¦é©—è¨­è¨ˆï¼Œé€™äº›è¨­è¨ˆæ¶µè“‹äº†é«”å¤–å¯¦é©—å’Œå‹•ç‰©å¯¦é©—ï¼Œç”šè‡³åŒ…æ‹¬äººé¡çš„è‡¨åºŠç ”ç©¶ã€‚é€™äº›ç ”ç©¶ä¸»è¦é›†ä¸­åœ¨è˜¿è””ç¡«ç´ å°æ–¼å¤šç¨®é©è˜­æ°é™½æ€§å’Œé™°æ€§ç´°èŒçš„å½±éŸ¿ï¼Œä»¥åŠå®ƒå¦‚ä½•å½±éŸ¿ç´°èŒçš„æ¯’åŠ›å› å­å’Œå…ç–«åæ‡‰ç­‰æ–¹é¢ï¼Œå¾è€Œæä¾›äº†ä¸€å€‹å…¨é¢çš„è¦–è§’ä¾†ç†è§£é€™ç¨®åŒ–åˆç‰©çš„æ½›åŠ›ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å°å¤šç¨®ç´°èŒå…·æœ‰æŠ—èŒæ•ˆæœï¼Œä¸¦èƒ½å¤ æŠ‘åˆ¶ç´°èŒçš„æ¯’åŠ›å› å­ï¼Œä¾‹å¦‚ç”Ÿç‰©è†œå½¢æˆå’Œæ¯’ç´ ç”¢ç”Ÿã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½å¢å¼·å…ç–«ç´°èƒçš„æŠ—èŒåæ‡‰ï¼Œä¸¦å…·æœ‰æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ä½œç”¨ï¼Œé€™äº›éƒ½å¯èƒ½æœ‰åŠ©æ–¼ç´°èŒçš„æ¸…é™¤åŠæ¸›å°‘ç‚ç—‡å¼•èµ·çš„ç´°èƒå’Œçµ„ç¹”æå‚·ã€‚ç ”ç©¶é‚„æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ é é˜²é˜¿æ–¯åŒ¹æ—å¼•èµ·çš„å°è…¸ç´°èƒæå‚·ï¼Œä¸¦ç·©è§£ç”±å¹½é–€èºæ—‹æ¡¿èŒå¼•èµ·çš„èƒƒç‚ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ æ˜¯ä¸€å€‹æœ‰å‰æ™¯çš„æŠ—èŒæ›¿ä»£åŠ‘ï¼Œå€¼å¾—åœ¨è‡¨åºŠè©¦é©—ä¸­é€²ä¸€æ­¥æ¢è¨ã€‚",
    "explanation_zh": "åœ¨ç•¶ä»Šé†«ç™‚ç’°å¢ƒä¸­ï¼ŒæŠ—ç”Ÿç´ æŠ—è—¥æ€§èŒæ ªçš„å‡ºç¾å°æ–¼æ²»ç™‚æ„ŸæŸ“ç—…äººé€ æˆäº†é‡å¤§æŒ‘æˆ°ã€‚å› æ­¤ï¼Œå°‹æ‰¾æ–°çš„æŠ—ç”Ÿç´ æˆ–å…¶ä»–ä¸ä¾è³´æŠ—ç”Ÿç´ çš„æŠ—å¾®ç”Ÿç‰©åŒ–åˆç‰©è®Šå¾—è¶Šä¾†è¶Šé‡è¦ã€‚é€™é …ç ”ç©¶æä¾›äº†æœ‰é—œè˜¿è””ç¡«ç´ çš„æŠ—èŒæ•ˆæœçš„æœ€æ–°è³‡è¨Šï¼Œé€™å¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰è‘—é‡è¦çš„å•Ÿç¤ºï¼Œå°¤å…¶æ˜¯åœ¨å°æŠ—æŠ—è—¥æ€§ç´°èŒæ–¹é¢ã€‚é€éäº†è§£é€™äº›å¤©ç„¶åŒ–åˆç‰©çš„æ½›åŠ›ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ¡ˆï¼Œæ¸›å°‘å°å‚³çµ±æŠ—ç”Ÿç´ çš„ä¾è³´ï¼Œé€²è€Œæ”¹å–„å…¬å…±å¥åº·ç‹€æ³ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰åœ¨æŠ—èŒæ–¹é¢çš„æ•ˆæœã€‚ç ”ç©¶è€…å€‘é—œæ³¨é€™ç¨®ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘æ¤ç‰©çš„åŒ–åˆç‰©ï¼Œç‰¹åˆ¥æ˜¯å®ƒåœ¨å°æŠ—å„ç¨®ç´°èŒæ„ŸæŸ“æ–¹é¢çš„æ½›åŠ›ã€‚é€éç³»çµ±æ€§çš„æ–‡ç»å›é¡§ï¼Œç ”ç©¶è€…å€‘æ•´ç†äº†ç›®å‰å°æ–¼è˜¿è””ç¡«ç´ çš„æŠ—èŒæ•ˆæœçš„äº†è§£ï¼ŒåŒ…æ‹¬åœ¨é«”å¤–å’Œé«”å…§çš„ç ”ç©¶çµæœï¼Œä¸¦ä¸”æ¶µè“‹äº†äººé¡ç ”ç©¶çš„è³‡æ–™ï¼Œé€™ä½¿å¾—ç ”ç©¶çš„çµæœæ›´å…·åƒè€ƒåƒ¹å€¼ã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…å€‘å›é¡§äº†28ç¯‡ç›¸é—œæ–‡ç»ï¼Œé€™äº›æ–‡ç»æ¢è¨äº†è˜¿è””ç¡«ç´ çš„æŠ—èŒæ•ˆæœã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬åˆ†æä¸åŒçš„å¯¦é©—è¨­è¨ˆï¼Œé€™äº›è¨­è¨ˆæ¶µè“‹äº†é«”å¤–å¯¦é©—å’Œå‹•ç‰©å¯¦é©—ï¼Œç”šè‡³åŒ…æ‹¬äººé¡çš„è‡¨åºŠç ”ç©¶ã€‚é€™äº›ç ”ç©¶ä¸»è¦é›†ä¸­åœ¨è˜¿è””ç¡«ç´ å°æ–¼å¤šç¨®é©è˜­æ°é™½æ€§å’Œé™°æ€§ç´°èŒçš„å½±éŸ¿ï¼Œä»¥åŠå®ƒå¦‚ä½•å½±éŸ¿ç´°èŒçš„æ¯’åŠ›å› å­å’Œå…ç–«åæ‡‰ç­‰æ–¹é¢ï¼Œå¾è€Œæä¾›äº†ä¸€å€‹å…¨é¢çš„è¦–è§’ä¾†ç†è§£é€™ç¨®åŒ–åˆç‰©çš„æ½›åŠ›ã€‚\n\nä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å°å¤šç¨®ç´°èŒå…·æœ‰æŠ—èŒæ•ˆæœï¼Œä¸¦èƒ½å¤ æŠ‘åˆ¶ç´°èŒçš„æ¯’åŠ›å› å­ï¼Œä¾‹å¦‚ç”Ÿç‰©è†œå½¢æˆå’Œæ¯’ç´ ç”¢ç”Ÿã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½å¢å¼·å…ç–«ç´°èƒçš„æŠ—èŒåæ‡‰ï¼Œä¸¦å…·æœ‰æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ä½œç”¨ï¼Œé€™äº›éƒ½å¯èƒ½æœ‰åŠ©æ–¼ç´°èŒçš„æ¸…é™¤åŠæ¸›å°‘ç‚ç—‡å¼•èµ·çš„ç´°èƒå’Œçµ„ç¹”æå‚·ã€‚ç ”ç©¶é‚„æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ é é˜²é˜¿æ–¯åŒ¹æ—å¼•èµ·çš„å°è…¸ç´°èƒæå‚·ï¼Œä¸¦ç·©è§£ç”±å¹½é–€èºæ—‹æ¡¿èŒå¼•èµ·çš„èƒƒç‚ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ æ˜¯ä¸€å€‹æœ‰å‰æ™¯çš„æŠ—èŒæ›¿ä»£åŠ‘ï¼Œå€¼å¾—åœ¨è‡¨åºŠè©¦é©—ä¸­é€²ä¸€æ­¥æ¢è¨ã€‚",
    "fb_post": "æ ¹æ“šã€ŠEuropean journal of microbiology & immunologyã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ ä½ çŸ¥é“å—ï¼Ÿå…¶å¯¦æˆ‘å€‘çš„é¤æ¡Œä¸Šå¯èƒ½éš±è—è‘—å°æŠ—ç´°èŒçš„ç§˜å¯†æ­¦å™¨ï¼æœ€è¿‘çš„ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰é€™ç¨®ä¾†è‡ªé’èŠ±æ¤°èœç­‰è”¬èœçš„å¤©ç„¶åŒ–åˆç‰©ï¼Œå°æŠ—ç´°èŒçš„æ•ˆæœéå¸¸å€¼å¾—é—œæ³¨ï¼\n\né€™é …ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ å¦‚ä½•å¹«åŠ©æˆ‘å€‘å°æŠ—æŠ—è—¥æ€§ç´°èŒï¼Œé€™äº›ç´°èŒå°å‚³çµ±æŠ—ç”Ÿç´ å·²ç¶“ä¸å†æ•æ„Ÿï¼Œè®“æ²»ç™‚æ„ŸæŸ“è®Šå¾—å›°é›£ã€‚ç ”ç©¶è€…å€‘å›é¡§äº†28ç¯‡ç›¸é—œæ–‡ç»ï¼Œåˆ†æäº†ä¸åŒçš„å¯¦é©—è¨­è¨ˆï¼ŒåŒ…æ‹¬é«”å¤–å¯¦é©—å’Œå‹•ç‰©å¯¦é©—ï¼Œç”šè‡³é‚„æœ‰ä¸€äº›äººé¡çš„è‡¨åºŠç ”ç©¶ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æŠ‘åˆ¶ç´°èŒçš„ç”Ÿé•·ï¼Œé‚„èƒ½æ¸›å°‘ç´°èŒç”¢ç”Ÿçš„æ¯’ç´ ï¼Œå¢å¼·æˆ‘å€‘å…ç–«ç³»çµ±çš„åæ‡‰ï¼Œç”šè‡³å°æŠ—ç”±å¹½é–€èºæ—‹æ¡¿èŒå¼•èµ·çš„èƒƒç‚ï¼é€™äº›ç™¼ç¾è®“è˜¿è””ç¡«ç´ æˆç‚ºä¸€å€‹æœ‰å‰æ™¯çš„æŠ—èŒæ›¿ä»£åŠ‘ï¼Œæœªä¾†å¯èƒ½åœ¨è‡¨åºŠè©¦é©—ä¸­ç™¼æ®é‡è¦ä½œç”¨ã€‚\n\nğŸ” ç¸½çµä¾†èªªï¼š\n1. è˜¿è””ç¡«ç´ ä¾†è‡ªé’èŠ±æ¤°èœç­‰è”¬èœï¼Œå°æŠ—ç´°èŒæœ‰æ½›åŠ›ã€‚\n2. èƒ½æŠ‘åˆ¶ç´°èŒçš„æ¯’ç´ ç”¢ç”Ÿï¼Œå¢å¼·å…ç–«åæ‡‰ã€‚\n3. å¯èƒ½æˆç‚ºæŠ—è—¥æ€§ç´°èŒçš„æ›¿ä»£æ²»ç™‚é¸æ“‡ï¼",
    "image_prompt": "Create a simple and informative infographic that explains the experimental methods and main results of a study on sulforaphane (SFN) from broccoli. Use flat design style with a white or light-colored background and soft colors. Include symbols of broccoli or sulforaphane, simplified illustrations of experimental subjects (like humans, animals, or cells), arrows or flow lines to indicate experimental steps, and a section highlighting the main results, such as protective effects and changes observed.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "å¹½é–€èºæ—‹æ¡¿èŒæ„ŸæŸ“ Helicobacter pylori Infection",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40553560/"
  },
  {
    "id": "40597512",
    "title_en": "In vitro gastrointestinal digestion of broccolis sprout extract: Impact on the bioaccesibility of sulforaphane and total phenolic.",
    "pub_date": "2025 Oct",
    "journal": "Food research international (Ottawa, Ont.)",
    "abstract_en": "Broccoli sprout extract is rich in phenolic compounds and sulforaphane (SFN) and the gastrointestinal digestion process can affect the bioaccessibility of these substances. This study aimed to evaluate the antioxidant capacity and the content of total phenolic compounds (TPC) and SFN in broccoli sprout extract before and during in vitro gastrointestinal digestion (GID). The antioxidant capacity was determined using different assays (FRAP, ABTS and DPPH), and the TPC and sulforaphane content was measured using the Folin-Ciocalteu method and high performance liquid chromatography (HPLC), respectively. The in vitro digestion analyses followed the INFOGEST 2.0 protocol. Additionally, microbiological characterization and chemical composition analysis of broccoli sprouts were conducted. The microbiological analyses indicated that the sprouts were safe for consumption, with high amounts of TPC, antioxidant capacity, and SFN content. The TPC content decreased significantly (pÂ <Â 0.001) after GID, from 1740.0Â Î¼gÂ eq. GAE/g before digestion to 536.5Â Î¼gÂ eq. GAE/g in the gastric phase and 211.0Â Î¼gÂ eq. GAE/g in the enteric phase. The antioxidant capacity also decreased significantly after simulated digestion compared to initial values. A lower (pÂ <Â 0.001) SFN content was identified in the gastric phase (18.6Â mg/g) compared to the intestinal phase (27.8Â mg/g), although both showed lower SFN levels than the undigested sample, which contained 72.2Â mg/g of SFN. In conclusion, simulated digestion significantly reduced the amount of TPC and SFN, likely due to degradation or biotransformation of the compounds under digestion conditions.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é’èŠ±æ¤°èœèŠ½æå–ç‰©ä¸­æ‰€å«çš„æŠ—æ°§åŒ–åŠ‘å’Œè˜¿è””ç¡«ç´ ã€‚é€™äº›æˆåˆ†å¯èƒ½å°æˆ‘å€‘çš„èº«é«”æœ‰ç›Šï¼Œä½†åœ¨æ¶ˆåŒ–éç¨‹ä¸­ï¼Œå®ƒå€‘çš„å¯ç”¨æ€§æœƒå—åˆ°å½±éŸ¿ã€‚äº†è§£é€™äº›æˆåˆ†åœ¨æ¶ˆåŒ–éç¨‹ä¸­çš„è®ŠåŒ–ï¼Œèƒ½å¹«åŠ©æˆ‘å€‘æ›´å¥½åœ°é¸æ“‡é£Ÿç‰©ï¼Œå¾è€Œæå‡å¥åº·ï¼Œä¸¦å¯èƒ½åœ¨æŸäº›ç–¾ç—…çš„é é˜²ä¸Šç™¼æ®ä½œç”¨ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨é’èŠ±æ¤°èœèŠ½æå–ç‰©åœ¨æ¨¡æ“¬èƒƒè…¸é“æ¶ˆåŒ–éç¨‹ä¸­çš„æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œä»¥åŠå…¶ç¸½é…šé¡åŒ–åˆç‰©å’Œè˜¿è””ç¡«ç´ çš„å«é‡è®ŠåŒ–ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯é€™äº›æœ‰ç›Šæˆåˆ†åœ¨æ¶ˆåŒ–éç¨‹ä¸­æ˜¯å¦æœƒè¢«é™è§£æˆ–è½‰åŒ–ï¼Œå¾è€Œå½±éŸ¿å®ƒå€‘çš„å¥åº·æ•ˆç›Šã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é’èŠ±æ¤°èœèŠ½æå–ç‰©ï¼Œä¸¦ä¾æ“šINFOGEST 2.0å”è­°é€²è¡Œäº†æ¨¡æ“¬èƒƒè…¸é“æ¶ˆåŒ–åˆ†æã€‚ä»–å€‘ä½¿ç”¨ä¸åŒçš„æ¸¬è©¦æ–¹æ³•ä¾†è©•ä¼°æŠ—æ°§åŒ–èƒ½åŠ›ï¼ŒåŒ…æ‹¬FRAPã€ABTSå’ŒDPPHç­‰ï¼Œä¸¦é€šéFolin-Ciocalteuæ–¹æ³•å’Œé«˜æ•ˆæ¶²ç›¸è‰²è­œï¼ˆHPLCï¼‰ä¾†æ¸¬é‡ç¸½é…šé¡åŒ–åˆç‰©å’Œè˜¿è””ç¡«ç´ çš„å«é‡ã€‚æ­¤å¤–ï¼Œé‚„é€²è¡Œäº†é’èŠ±æ¤°èœèŠ½çš„å¾®ç”Ÿç‰©ç‰¹æ€§å’ŒåŒ–å­¸æˆåˆ†åˆ†æï¼Œä»¥ç¢ºä¿å…¶å®‰å…¨æ€§ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œæ¨¡æ“¬æ¶ˆåŒ–éç¨‹é¡¯è‘—é™ä½äº†é’èŠ±æ¤°èœèŠ½æå–ç‰©ä¸­çš„ç¸½é…šé¡åŒ–åˆç‰©å’Œè˜¿è””ç¡«ç´ å«é‡ã€‚ç ”ç©¶çµæœæŒ‡å‡ºï¼Œåœ¨æ¶ˆåŒ–éç¨‹ä¸­ï¼Œç¸½é…šé¡åŒ–åˆç‰©çš„å«é‡å¾æ¶ˆåŒ–å‰çš„1740.0 Î¼g eq. GAE/gé™è‡³èƒƒç›¸çš„536.5 Î¼g eq. GAE/gå’Œè…¸ç›¸çš„211.0 Î¼g eq. GAE/gï¼ŒæŠ—æ°§åŒ–èƒ½åŠ›ä¹Ÿé¡¯è‘—ä¸‹é™ã€‚æ­¤å¤–ï¼Œèƒƒç›¸ä¸­çš„è˜¿è””ç¡«ç´ å«é‡ç‚º18.6 mg/gï¼Œè€Œè…¸ç›¸ç‚º27.8 mg/gï¼Œå…©è€…å‡ä½æ–¼æœªæ¶ˆåŒ–æ¨£æœ¬çš„72.2 mg/gï¼Œé€™è¡¨æ˜æ¶ˆåŒ–éç¨‹å¯èƒ½å°è‡´é€™äº›åŒ–åˆç‰©çš„é™è§£æˆ–è½‰åŒ–ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é’èŠ±æ¤°èœèŠ½æå–ç‰©ä¸­æ‰€å«çš„æŠ—æ°§åŒ–åŠ‘å’Œè˜¿è””ç¡«ç´ ã€‚é€™äº›æˆåˆ†å¯èƒ½å°æˆ‘å€‘çš„èº«é«”æœ‰ç›Šï¼Œä½†åœ¨æ¶ˆåŒ–éç¨‹ä¸­ï¼Œå®ƒå€‘çš„å¯ç”¨æ€§æœƒå—åˆ°å½±éŸ¿ã€‚äº†è§£é€™äº›æˆåˆ†åœ¨æ¶ˆåŒ–éç¨‹ä¸­çš„è®ŠåŒ–ï¼Œèƒ½å¹«åŠ©æˆ‘å€‘æ›´å¥½åœ°é¸æ“‡é£Ÿç‰©ï¼Œå¾è€Œæå‡å¥åº·ï¼Œä¸¦å¯èƒ½åœ¨æŸäº›ç–¾ç—…çš„é é˜²ä¸Šç™¼æ®ä½œç”¨ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨é’èŠ±æ¤°èœèŠ½æå–ç‰©åœ¨æ¨¡æ“¬èƒƒè…¸é“æ¶ˆåŒ–éç¨‹ä¸­çš„æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œä»¥åŠå…¶ç¸½é…šé¡åŒ–åˆç‰©å’Œè˜¿è””ç¡«ç´ çš„å«é‡è®ŠåŒ–ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯é€™äº›æœ‰ç›Šæˆåˆ†åœ¨æ¶ˆåŒ–éç¨‹ä¸­æ˜¯å¦æœƒè¢«é™è§£æˆ–è½‰åŒ–ï¼Œå¾è€Œå½±éŸ¿å®ƒå€‘çš„å¥åº·æ•ˆç›Šã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é’èŠ±æ¤°èœèŠ½æå–ç‰©ï¼Œä¸¦ä¾æ“šINFOGEST 2.0å”è­°é€²è¡Œäº†æ¨¡æ“¬èƒƒè…¸é“æ¶ˆåŒ–åˆ†æã€‚ä»–å€‘ä½¿ç”¨ä¸åŒçš„æ¸¬è©¦æ–¹æ³•ä¾†è©•ä¼°æŠ—æ°§åŒ–èƒ½åŠ›ï¼ŒåŒ…æ‹¬FRAPã€ABTSå’ŒDPPHç­‰ï¼Œä¸¦é€šéFolin-Ciocalteuæ–¹æ³•å’Œé«˜æ•ˆæ¶²ç›¸è‰²è­œï¼ˆHPLCï¼‰ä¾†æ¸¬é‡ç¸½é…šé¡åŒ–åˆç‰©å’Œè˜¿è””ç¡«ç´ çš„å«é‡ã€‚æ­¤å¤–ï¼Œé‚„é€²è¡Œäº†é’èŠ±æ¤°èœèŠ½çš„å¾®ç”Ÿç‰©ç‰¹æ€§å’ŒåŒ–å­¸æˆåˆ†åˆ†æï¼Œä»¥ç¢ºä¿å…¶å®‰å…¨æ€§ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œæ¨¡æ“¬æ¶ˆåŒ–éç¨‹é¡¯è‘—é™ä½äº†é’èŠ±æ¤°èœèŠ½æå–ç‰©ä¸­çš„ç¸½é…šé¡åŒ–åˆç‰©å’Œè˜¿è””ç¡«ç´ å«é‡ã€‚ç ”ç©¶çµæœæŒ‡å‡ºï¼Œåœ¨æ¶ˆåŒ–éç¨‹ä¸­ï¼Œç¸½é…šé¡åŒ–åˆç‰©çš„å«é‡å¾æ¶ˆåŒ–å‰çš„1740.0 Î¼g eq. GAE/gé™è‡³èƒƒç›¸çš„536.5 Î¼g eq. GAE/gå’Œè…¸ç›¸çš„211.0 Î¼g eq. GAE/gï¼ŒæŠ—æ°§åŒ–èƒ½åŠ›ä¹Ÿé¡¯è‘—ä¸‹é™ã€‚æ­¤å¤–ï¼Œèƒƒç›¸ä¸­çš„è˜¿è””ç¡«ç´ å«é‡ç‚º18.6 mg/gï¼Œè€Œè…¸ç›¸ç‚º27.8 mg/gï¼Œå…©è€…å‡ä½æ–¼æœªæ¶ˆåŒ–æ¨£æœ¬çš„72.2 mg/gï¼Œé€™è¡¨æ˜æ¶ˆåŒ–éç¨‹å¯èƒ½å°è‡´é€™äº›åŒ–åˆç‰©çš„é™è§£æˆ–è½‰åŒ–ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFood research international (Ottawa, Ont.)ã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘åƒçš„é£Ÿç‰©è£¡æœ‰äº›æˆåˆ†åœ¨æ¶ˆåŒ–å¾Œå¯èƒ½æœƒè®Šå¾—ä¸ä¸€æ¨£ï¼Œé€™å¯å½±éŸ¿æˆ‘å€‘çš„å¥åº·å“¦ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆé–€æ¢è¨é’èŠ±æ¤°èœèŠ½æå–ç‰©ä¸­çš„æŠ—æ°§åŒ–åŠ‘å’Œè˜¿è””ç¡«ç´ ï¼Œé€™äº›æˆåˆ†å°æˆ‘å€‘çš„èº«é«”æœ‰ç›Šï¼Œä½†åœ¨æ¶ˆåŒ–éç¨‹ä¸­å®ƒå€‘æœƒç™¼ç”Ÿè®ŠåŒ–ã€‚\n\né€™é …ç ”ç©¶çš„é‡é»æ˜¯çœ‹çœ‹é’èŠ±æ¤°èœèŠ½æå–ç‰©åœ¨æ¨¡æ“¬èƒƒè…¸é“æ¶ˆåŒ–éç¨‹ä¸­ï¼ŒæŠ—æ°§åŒ–èƒ½åŠ›å’Œæœ‰ç›Šæˆåˆ†çš„è®ŠåŒ–ã€‚ç ”ç©¶äººå“¡æ¡ç”¨äº†å¤šç¨®æ–¹æ³•ä¾†è©•ä¼°é€™äº›æˆåˆ†çš„è®ŠåŒ–ï¼Œä¸¦ç¢ºä¿å®ƒå€‘çš„å®‰å…¨æ€§ã€‚\n\nçµæœé¡¯ç¤ºï¼Œæ¨¡æ“¬æ¶ˆåŒ–éç¨‹ä¸­ï¼Œé’èŠ±æ¤°èœèŠ½æå–ç‰©ä¸­çš„ç¸½é…šé¡åŒ–åˆç‰©å’Œè˜¿è””ç¡«ç´ çš„å«é‡éƒ½é¡¯è‘—ä¸‹é™ã€‚é€™æ„å‘³è‘—ï¼Œæ¶ˆåŒ–éç¨‹å¯èƒ½æœƒå°è‡´é€™äº›æœ‰ç›Šæˆåˆ†çš„é™è§£æˆ–è½‰åŒ–ï¼Œå½±éŸ¿åˆ°æˆ‘å€‘çš„å¥åº·æ•ˆç›Šã€‚\n\nğŸ” ä¸»è¦ç™¼ç¾ï¼š\n- æ¶ˆåŒ–éç¨‹ä¸­ï¼ŒæŠ—æ°§åŒ–èƒ½åŠ›é¡¯è‘—ä¸‹é™ã€‚\n- ç¸½é…šé¡åŒ–åˆç‰©å’Œè˜¿è””ç¡«ç´ çš„å«é‡æ¸›å°‘ã€‚\n- äº†è§£é€™äº›è®ŠåŒ–æœ‰åŠ©æ–¼æˆ‘å€‘é¸æ“‡æ›´å¥åº·çš„é£Ÿç‰©ï¼",
    "image_prompt": "Create a flat design infographic illustrating the experiment and main results of a study on broccoli sprout extract. Include symbols for broccoli and sulforaphane, simplified icons representing human or animal subjects, arrows or flow lines to indicate experimental steps, and a section labeled 'Main Results' showing the decrease in antioxidant capacity and beneficial compounds during digestion.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40597512/"
  }
]